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GLOSSARY OF TERMS1 
 
Additive – substance contained in a tobacco product, its unit packet or its outside packaging with the 
exception of tobacco leaves and other natural or unprocessed parts of tobacco plants. 
 
Characterising flavour -  a distinguishable aroma or taste other than tobacco, resulting from an additive 
or combination of additives, including but not limited to  fruit, spice, herb, alcohol, candy, menthol or 
vanilla observable before or upon intended use of the tobacco product; 
 
'Cheap whites / illicit whites' - cigarettes produced (often legitimately) in their country of origin at very 
low cost, destined to be illicitly sold in other jurisdictions and not respecting the legal requirements in the 
jurisdiction of destination. 
 
Chewing tobacco - a smokeless tobacco product exclusively designed for the purpose of chewing. 
 
Cigar - a roll of tobacco consumed via a combustion process and further defined in Article 4(1) of 
Council Directive 2011/64/EU of 21 June 2011 on the structure and rates of excise duty applied to 
manufactured tobacco.  
 
Cigarette  – a roll of tobacco consumed via a combustion process and further defined in Article 3(1) of 
Council Directive 2011/64/EU. 
 
Cigarillo – a small type of cigar with a diameter of up to 8 mm.  
 
Contraband - products which have been diverted into illicit trade, not respecting the legal requirements in 
the jurisdiction of destination. 
 
Counterfeit –brand protected products which have been falsified without consent of the brand owner and 
are not respecting the legal requirements in the jurisdiction of destination.   
Electronic cigarette (Electronic Nicotine Delivery Systems, ENDS) – electronic device typically 
consisting of a mouth piece (containing an electronic evaporator) and a cartridge (typically replaceable) 
and designed to deliver nicotine to the lung through inhalation of a mixture of air & vapours into the 
respiratory system. 
 
Factory manufactured cigarette (FMC) – a cigarette, produced by a tobacco manufacturer, capable of 
being smoked as such.  
 
FCTC commitments –political commitments to implement the non-binding guidelines developed under 
the FCTC to assist Parties in meeting their implementation obligations under the FCTC. 
 
FCTC obligations – obligations to implement the legally binding FCTC and the Illicit Trade Protocol . 
 
Flavouring – an additive that imparts aroma and/or taste. 
 
Herbal products for smoking – a product based on plants or herbs which contains no tobacco and is 
consumed via a combustion process.  
 
Ingredient – an additive, tobacco (leaves and other natural, processed or unprocessed parts of tobacco 
plants including expanded and reconstituted tobacco), as well as any substance present in a finished 
tobacco product including paper, filter, inks, capsules and adhesives.   
Illicit trade – any practice or conduct prohibited by law and which relates to production, shipment, 
receipt, possession, distribution, sale or purchase, including any practice or conduct intended to facilitate 
such activity.    
 
Nasal tobacco - a smokeless tobacco product consumed via the nose. 
 
                                                 
1 The purpose of this glossary is to provide the reader with a better understanding of the terms used in the document. 
It should in no way prejudge the terminology defined in the legal proposal.  
  
Nicotine containing products (NCP) – a product usable for consumption by final consumers via 
inhalation, ingestion or in other forms and to which nicotine is either added during the manufacturing 
process or self-administered by the user before or during consumption.  
 
Nicotine Replacement Therapies (NRT) - remedial administration of nicotine to the body by means 
other than tobacco, usually authorised under the pharmaceutical legislation as part of smoking cessation. 
Common forms of nicotine replacement therapy are nicotine patches and nicotine gum.  
 
Novel tobacco product - a tobacco product other than a cigarette, roll-your-own tobacco, pipe tobacco, 
water-pipe tobacco, cigar, cigarillo, chewing tobacco, nasal tobacco or tobacco for oral use placed on the 
market after entry into force of the Directive. 
 
Pipe tobacco – tobacco consumed via a combustion process and exclusively designed for the purpose of 
being used in a pipe. 
 
Plain packaging – full standardisation of the packages, including brand- and product names printed in a 
mandated size, font and colour on a given place of the package; standardised package colour; standardised 
size and appearance of the package; display of required (textual and pictorial) health warnings and other 
legally mandated product information, such as tax-paid stamps and marking for traceability and security 
purposes.  
 
Promotional / Misleading element – any element promoting a tobacco product by a means that is false, 
misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, 
hazards or emissions, any element suggesting that a tobacco product is less harmful than others or has 
vitalising, energetic or other positive health effects, any element referring to flavour or taste or the absence 
thereof, or any elements resembling a food product. Such elements can take the form (but are not limited 
to) texts, signs, pictures or other graphical elements, references to natural or biological characteristics or to 
certain flavours or flavourings or other additives, inserts and other additional material, e.g. adhesive 
labels, stickers, onserts, scratch-offs, sleeves. 
 
Roll-your own tobacco (RYO) – tobacco which can be used for making cigarettes by final consumers or 
retail outlets.  
 
Smokeless tobacco products (STP) – a tobacco product not involving a combustion process, including 
tobacco for oral use. 
 
Tobacco for oral use/oral tobacco - all products for oral use, except those intended to be inhaled or 
chewed, made wholly or partly of tobacco, in powder or in particulate form or in any combination of those 
forms, particularly those presented in sachet portions or porous sachets. 
 
Traditional use – Continuous use of a smokeless tobacco product in a Member State or part thereof for at 
least 30 years.  
  
 
MAIN REPORTS/STUDIES USED FOR THE IMPACT ASSESSMENT 
 
 
• First Report on the Application of the Tobacco Products Directive. COM(2005) 339 final (First 
Application Report 2005) 
• Second Report on the Application of the Tobacco Products Directive. COM(2007) 754 final 
(Second application Report 2007): 
http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/tobacco_products_en.p
df 
• Report on the public consultation on the possible revision of the Tobacco Products Directive 
2001/37/EC, European Commission, Health and Consumer Directorate-General, July 2011 
(Public consultation Report 2011): 
http://ec.europa.eu/health/tobacco/consultations/tobacco_cons_01_en.htm 
• Commission Staff Working Document of 23.11.09: Report on the Implementation of the Council 
Recommendation of 2 December 2002 on the prevention of smoking and on initiatives to improve 
tobacco control (2003/54/EC) (Commission Staff Working Document 2009): 
http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/tobacco_report09_en.p
df   
• SCENIHR. Health effects of smokeless tobacco products. 6 February 2008 (SCENIHR 2008): 
http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_013.pdf 
• SCENIHR. Addictiveness and attractiveness of Tobacco Additives. 12 November 2010 
(SCENIHR 2010): 
http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_031.pdf 
• Special Eurobarometer 332; 2010 (Eurobarometer 2010):  
http://ec.europa.eu/health/tobacco/docs/ebs332_en.pdf 
• Special Eurobarometer 385, 2012 (Eurobarometer 2012) : 
http://ec.europa.eu/health/eurobarometers/index_en.htm 
• GHK. A study on liability and the health costs of smoking (2008/C6/046) as revised 2012 (GHK 
2012): http://ec.europa.eu/health/tobacco/docs/tobacco_liability_en.pdf 
• Rand Europe. Assessing the impacts of revising the Tobacco Products Directive. TR-823-EC. 
September 2010 (RAND 2010): http://ec.europa.eu/health/tobacco/docs/tobacco_ia_rand_en.pdf 
• Rand Europe. Availability, accessibility, usage & regulatory environment for novel & emerging 
tobacco, nicotine or related products. Rand Europe. 2012 (RAND 2012)  
• Matrix insight. Economic analysis of the EU market of tobacco, nicotine & related products 2012 
(Matrix 2012) 




Directive 2001/37/EC of the European Parliament and of the Council on the approximation of 
the laws, regulations and administrative provisions of the Member States concerning the 
manufacture, presentation and sale of tobacco products (Tobacco Products Directive, 
hereafter TPD), was adopted on 5 June 2001.2  
 
More than ten years have passed since the adoption of the TPD. In line with market, scientific 
and international developments it has become necessary to update and complete the TPD. A 
revision is explicitly foreseen in Article 11 of the current TPD and was repeatedly called for 
by the Council and the European Parliament3. The initiative to revise the TPD is included in 
the Commission's Work Plan 2012.4  
 
The overall objective of the revision is to improve the functioning of the internal market. In 
particular, the proposal aims to: 
 
 Update already harmonised areas to overcome Member States' obstacles to bring 
their national legislations in line with new market, scientific and international 
developments.5  
 
 Address product related measures not yet covered by the TPD insofar as 
heterogeneous development in Member States has led to, or is likely to lead to, 
fragmentation of the internal market.6  
 
 Ensure that certain provisions of the TPD are not circumvented by placing on the 
market of products not compliant with the TPD.7 
 
It is also important to ensure a harmonised implementation of FCTC obligations and a 
consistent approach to non-binding FCTC commitments if there is a risk of diverging national 
transposition. 
 
In line with Article 114(3) TFEU a high level of health protection has been taken as a basis 
for this impact assessment when choosing between different policy options. In this context, 
the revision seeks to regulate tobacco products in a way that reflects their specific 
characteristics (nicotine has addictive properties) and the negative consequences of their 
                                                 
2 OJ L 194, 18.7.2001, p. 26–35 
3 Council Recommendation of 30 November 2009 on smoke-free environments; Council Conclusions of 1-2 
December 2011 on prevention, early diagnosis and treatment of chronic respiratory diseases in children; EP 
resolution of 15 September 2011 on European Union position and commitment in advance to the UN high-level 
meeting on the prevention and control of non-communicable diseases; EP Resolution of 24 October 2007 on the 
Green Paper 'Towards a Europe free from tobacco smoke: policy options at EU level; EP Resolution of 26 
November 2009 on smoke free environments. 
4Annex 1 to the Commission work programme 2012 – forthcoming initiatives 2012. COM(2011)777 final.  
 http://ec.europa.eu/atwork/programmes/docs/cwp2012_annex_en.pdf (accessed 28 Nov 2012). 
5  Without an update, Member States cannot, for example, increase the size of the health warnings, change their 
location of the package or replace the display of tar, nicotine and carbon monoxide levels.  
6 For example, at this stage, eight Member States have adopted pictorial health warnings and the regulations of 
ingredients differ between Member States. 
7 For example, measures on cross-border distance sales and traceability will facilitate legal activity and thus 
prevent sale of tobacco products not complying with the TPD (e.g. health warnings and ingredients). 
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consumption (health risks such as various cancer types, cardiovascular problems, increased 
risk of blindness, impotence, lower fertility, impact on the unborn child etc.). Their treatment 
costs more than 25 bEUR per year. Furthermore, tobacco is the most significant cause of 
premature deaths in the EU, responsible for almost 700,000 deaths every year (see section 
2.1.2). The revision focuses on initiation of tobacco consumption, in particular by young 
people, taking into account that 70% of the smokers start before the age of 18 and 94% before 
the age of 25 years8. This is also reflected in the selection and focus of the policy areas 
proposed and the products primarily targeted (FMC, RYO and STP).  
 
From a broader perspective, the revision will contribute to the overall aim of the EU to 
promote the well-being of its people (TEU Article 3) and the Europe 2020 strategy as keeping 
people healthy and active longer, and helping people to prevent avoidable diseases and 
premature death, will have a positive impact on productivity and competitiveness. An 
unintended, but welcome side effect of the measures against trade of products not complying 
with the requirements of the TPD might be that the tax revenues of Member States are better 
protected as the products often also circumvent national tax legislations. 
 
The revision of the TPD focuses on five policy areas: (1) STP9 and extension of the product 
scope (i.e. NCP and herbal products for smoking), (2) packaging & labelling, (3) 
ingredients/additives, (4) cross-border distance sales and (5) traceability and security features. 
When preparing this impact assessment report economic, legal and scientific considerations 
were taken into account. Particular attention was given to the Fundamental Rights Charter and 
international obligations (FCTC, WTO-TRIPS, TBT).10 
This impact assessment report presents the analysis and all relevant results of the impact 
assessment work. Due to space limitations, citations are limited to key publications and, as 
appropriate, relevant studies illustrating the current evidence base. More detailed information 
and supporting materials are also included in the five technical annexes accompanying the 
main report. The first four annexes provide more detailed information on stakeholders' views, 
the tobacco market, the regulatory framework and the assessment criteria used when assessing 
the impacts as well as scoring tables. Annex 5 outlines the socio economic impacts and 
explains in detail how a reduction in tobacco consumption will impact on stakeholders 
(indirect impacts).  
 
1.2. APPLICATION, IMPLEMENTATION AND ENFORCEMENT OF THE CURRENT TPD 
AND NOTIFICATIONS FROM MEMBER STATES 
1.1.1. Content of the existing TPD 
The existing TPD was adopted to recast two previous internal market Directives.11 According 
to its Article 1, the TPD aims at approximating certain national rules regarding tobacco 
products, e.g. tar, nicotine and carbon monoxide (TNCO), health warnings, ingredients and 
misleading description of tobacco products. The current TPD is limited to products 
containing tobacco (i.e. NCPs and herbal products for smoking are not subject to the TPD). It 
applies to all categories of tobacco: FMC, RYO, pipe tobacco, cigars, cigarillos, STP and 
other forms of tobacco.   
                                                 
8 Eurobarometer 2012 
9 This includes also novel tobacco products which are primarily expected to fall within the category of STP. 
10 Commission Staff Working Paper. Operational Guidance on taking account of Fundamental Rights in 
Commission Impact Assessments, SEC(2011)567 final, Brussels, 6.5.2011 
11 Directives 89/622EEC and 90/239/EEC 
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Article 3 of the TPD sets the maximum levels for tar, nicotine and carbon monoxide 
(TNCO) and Article 4 explains how the TNCO levels should be measured. Regarding 
ingredients, Article 6 foresees reporting obligations for the industry (including available data 
on toxicology and addictiveness). Article 12 invites the Commission to submit a common list 
of ingredients authorised for tobacco products. The Commission has not suggested such a list 
taking into account a shift in regulatory priorities, including in the context of the FCTC and 
the adoption of partial guidelines on ingredients related to attractiveness.  
 
Article 5 contains labelling requirements. It stipulates that all tobacco products except STP 
must carry a general health warning, (e.g. "Smoking kills"), covering not less than 30% of the 
front side, and a specific text warning (e.g. "Smoking causes fatal lung cancer"), covering not 
less than 40% of the back side.12 The TPD also requires that all STP carry a health warning 
("This tobacco product can damage your health and is addictive."). Moreover, the TPD 
empowers the Commission to adopt rules for the use of additional pictorial warnings that 
Member States have to comply with if they decide to require those warnings. In addition, the 
packages should display the levels of tar, nicotine and carbon monoxide (TNCO). Article 7 of 
the TPD prohibits the use of trademarks and texts suggesting that a particular product is less 
harmful than others (e.g. "mild" or "light"). To ensure product identification and traceability, 
the tobacco products should be marked by batch numbering enabling the place and time of 
manufacture to be determined (Article 5 (9) TPD). The Commission was invited to provide 
technical details, but has not responded to the invitation in the light of new international 
developments the Commission concluded that the information on time and location of 
manufacturing was not sufficient to ensure full traceability and reduce illicit trade effectively.  
 
Article 8 prohibits the placing on the market of oral tobacco (snus) outside Sweden.  
 
Articles 9, 10 and 11 of the TPD contain comitology provisions and reporting obligations. 
Article 13 sets out the conditions under which Member States can take stricter provisions.  
1.1.2. Application of the TPD 
Article 11 of the current TPD requires that the Commission reports regularly on the 
application of the Directive. Two such reports have been issued, a first one in July 2005 and a 
second one in November 2007.13 Subsequent reports were not issued in the light of the 
pending revision/impact assessment process.  
 
The First Report on the Application of the TPD concluded that the Commission should 
consider further the development of labelling, such as the wider use of quit line telephone 
numbers. As regards reporting of ingredients, it was stressed that Article 6 on the reporting of 
ingredients needs to be developed, that information transmitted from the industry varies 
greatly and that there is lack of capacity to analyse the data.  
 
In its Second Report on the Application of the TPD, the Commission concluded that it 
should examine the possibilities with regard to an increased size of the warnings, mandatory 
pictorial warnings on both sides of the packets and the replacement of TNCO levels by other 
information. The Commission also stressed that it should explore the possibilities of generic 
                                                 
12 For Member States having more than one official language, the warnings should be increased to 32-35% and 
45-50%. Commission Directive 2012/9/EU, updating text warnings has been adopted on 7 March 2012: 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:069:0015:0016:EN:PDF (accessed 28 Nov 
2012) A revision of the pictorial warnings is planned for 2013. 
13 First Application Report 2005, Second Application Report 2007  
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standardised packaging. As regards reporting of ingredients, the report refers to the wish from 
a number of Member States and the industry to make the formats developed on a voluntary 
basis compulsory throughout the EU. In terms of oral tobacco, it was concluded that the 
scientific opinion on the health effects of STP (SCENIHR 2008)14 should form the scientific 
basis for any future risk management decision of the Commission. In addition, it was 
concluded in the report that new tobacco and/or nicotine products should be studied with a 
view to ensure proper regulation. Both reports have provided input to the current impact 
assessment. Both reports also covered Article 12 of the TPD on ingredients. For the reasons 
outlined above, not concrete follow-up was given to this provision.  
1.1.3. Implementation of the TPD 
Member States have transposed the existing TPD and the Commission has used its powers to 
adopt rules for the use of colour photographs and other illustrations and to amend the textual 
health warnings in line with scientific and technical progress.15 However, the Commission has 
not made use of its powers to adopt measures for identification and traceability purposes nor 
has the Commission responded to the invitation from legislators to develop a common list of 
ingredients. 
1.1.4. Enforcement of the TPD and legal challenges 
In general, enforcement of the TPD has not been seen as a problem and only a limited 
number of infringement procedures have been launched. However, the current TPD is unclear 
as regards to the level of harmonisation. While Article 5(5) allows Member States a degree of 
discretion to adapt the labelling of tobacco products to the requirement of public health 
protection, Article 13(1) stipulates that they cannot, for considerations relating to health 
warnings, prohibit or restrict the import of tobacco products complying with the TPD 
provisions. This Article has been subject to several consultations of the Commission's Legal 
Service.16 The current situation implies that Member States are allowed to take certain 
actions, but only for domestically produced products while they cannot impose the same 
requirements on imported products.17 This does not make sense in a globalised market such as 
the tobacco market and - taking in account the significant cross border trade - can easily result 
in production moving to countries where less stringent rules are required. Only a revision can 
address these shortcomings. In addition, the development of the internet as a distribution 
channel for tobacco products and the definition of “oral tobacco” represent particular 
challenges in terms of enforcement.18 Also the current requirement for rotation of the health 
warnings has been subject to different interpretation and needs to be clarified.  
 
The current TPD has been subject to several legal challenges since its entering into force. In 
2001 British American Tobacco (BAT) and Imperial Tobacco, initiated legal proceedings in 
the British Courts on the validity and interpretation of the Directive. The case was referred to 
                                                 
14 SCENIHR 2008  
15 Commission Decisions 2003/641, C(2005) 1452 final, C(2006) 1502 final, Commission Directive 2012/9/EU 
16 Two judgments concerning the previous tobacco labelling Directive 89/622 also addresses Member States' 
possibilities of imposing stricter national rules: C-222/91 Ministero delle Finanze and Ministero della Sanità v 
Philip Morris Belgium SA and others. European Court reports 1993 Page I-03469 and The Queen v Secretary of 
State for Health, ex parte Gallaher Ltd, Imperial Tobacco Ltd and Rothmans International Tobacco (UK) Ltd, 
European Court reports 1993 Page I-03545 
17 See, with reference to the previous tobacco labelling Directive 89/622, case C-222/91, Ministero delle Finanze 
and Ministero della Sanità v Philip Morris Belgium SA and others, [1993] ECR I-03469 and C-11/92, The 
Queen v Secretary of State for Health, ex parte Gallaher Ltd, Imperial Tobacco Ltd and Rothmans International 
Tobacco (UK) Ltd, [1993] ECR I-03545. 
18 See for internet: Commission Staff Working Document 2009.  STP: see problem identification, section 2.2.1.  
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the ECJ (Case 491/01).19 The companies argued that the legal basis for the directive (Article 
95 TEC, current article 114 TFEU) was inadequate, because it was a public health measure 
being introduced as an internal market measure. The companies also argued that the 
introduction of Article 133 TEC as a second legal basis invalidated the directive. The 
principles of proportionality and subsidiarity were also claimed to have been infringed. They 
also argued that the labelling provisions for yields and larger health warnings, and the ban on 
misleading descriptors breached trade mark and intellectual property rights, as well as being 
an infringement of the obligation to give reasons. In 2002, the Court upheld the validity of the 
Directive and confirmed the validity of its provisions.20   
 
The directive’s ban on the marketing of certain types of oral tobacco (snus) has also been 
challenged (Cases C-434/02 and C- 210/03).21 These challenges were brought by Swedish 
Match, a manufacturer of oral tobacco (snus), against the UK government, and a German 
wholesaler who brought a case against the German government. They claimed that the 
directive was in breach of the rules laid down in Articles 95, 133 and 253 TEC. A claim was 
also made that the ban on oral tobacco was a breach of the principle of subsidiarity. They also 
alleged the directives' provision to constitute a restriction as referred to in Articles 28 and 29 
TEC which prohibits quantitative restrictions in trade between Member States. One of the 
claimants also alleged that the ban was in breach of the principle of the freedom to pursue an 
occupation. Also in this case, the Court rejected the arguments and upheld the validity of the 
directive.  
1.1.5. Notifications 
A large number of notifications under Directive 98/34/EC22 have been received from Member 
States in the area of tobacco including on pictorial health warnings, the maximum number of 
FMC sticks in the package, display of quit lines on the package, regulations on ingredients 
and rules for herbal products for smoking. In addition, fourteen RAPEX notifications have 
been received so far regarding electronic cigarettes (17 December 2012).23  
 
1.3. CONSULTATIONS, EXPERTISE AND OTHER INPUT 
Stakeholder consultations 
A public consultation was held between 24 September and 17 December 2010. The 
Commission received more than 85,000 contributions from a wide range of stakeholders. 
Citizen contributions accounted for 96% of the survey response, 57% of which are 
“duplicate”/repeated responses24 which appear to be the result of several citizen mobilisation 
                                                 
19  Case  C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) 
Ltd and Imperial Tobacco Ltd. [2002] ECR I-11453.  
20 The Court found, however, that Article 95 TEC was the only appropriate legal base, but that the addition of 
Article 133 TEC as a legal base was not a reason for declaring the Directive invalid.    
21 Case C-210/03 The Queen, on the application of: Swedish Match AB and Swedish Match UK Ltd v Secretary 
of State for Health. [2004] ECR I-11893. 
22 Directive 98/34/EC of the European Parliament and of the Council of 22 June 1998 laying down a procedure 
for the provision of information in the field of technical standards and regulations, OJ L 204, 21.7.1998, p. 37–
48 
23 RAPEX is the EU rapid alert system that facilitates the rapid exchange of information between Member States 
and the Commission on measures taken to prevent or restrict the marketing or use of products posing a serious 
risk to the health and safety of consumers with the exception of food, pharmaceutical and medical devices: 
http://ec.europa.eu/consumers/dyna/rapex/rapex_archives_en.cfm (accessed 28 Nov 2012). 
24 A response considered “duplicate” in the public consultation was a response fulfilling the following criteria: 1. 
At least six responses containing the same text. 2. Text box containing more than three words. 3. Text box not 
containing text directly copied from the consultation document.   
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campaigns that took place in some Member States.25 The actions and efforts of these 
campaigns seem to have affected the overall quantitative data of the public consultation, 
which indicates that most of the citizens responding to the consultation were against changes 
to the TPD. This outcome deviates significantly from the latest Eurobarometer survey,26 
published in May 2012. Unlike public consultations, it is important to note that respondents in 
a Eurobarometer survey are selected randomly. Member States representatives and - even 
more so - health NGOs favour the introduction of strict tobacco control measures, while 
tobacco industry and retailers are against some of the stricter measures (for more details, see 
Annex 1 and separate sections under the assessment of each policy area). A report presenting 
the outcome of the consultation was published on 27 July 2011 and contributions have been 
published online.27  
 
Targeted discussions with stakeholders took place throughout the revision process. A first 
exchange of views with health NGOs, tobacco- and pharmaceutical industries took place on 3 
and 4 December 2009 and on 19 and 20 October 2010 and discussions with NGOs, growers, 
FMC producers, other tobacco producers, distributors of tobacco products and upstream 
suppliers of tobacco products have continued throughout 2011 and 2012.28A number of 
written contributions were also received, which were carefully considered in assessing the 
impacts of different policy options. In particular, the criticism received in relation to the 
external study from RAND Europe (see below) was taken into account. Alternative data 
submitted by stakeholders was also carefully studied. The Commissioner for Health and 
Consumer Policy met with Health NGOs and economic stakeholders in February-March 
2012.29 The revision of TPD has also been discussed regularly in the TPD Regulatory 
Committee from 2009 to 2012.30  
 
The policy area "traceability and security features" was added to the revision in response to 
concerns put forward by some stakeholders that the selling of contraband and counterfeit 
products not complying with the requirements of TPD is already today a significant 
problem.31 For the purpose of this Directive the main concerns associated with illicit products 
is that these products are non-compliant with the safeguards of the TPD. A more detailed 
summary of stakeholders' positions in the context of the consultations can be found in Annex 
1.  
 
Inter Service Steering Group (ISSG) 
An Inter Service Steering Group (ISSG) was established in March 2009 to support the work 
of DG SANCO. The following services were invited: SG, SJ, AIDCO, AGRI, COMP, DEV, 
EAC, ECFIN, ECHO, ELARG, EMPL, ENTR, ENV, MARE, INFSO, JLS, JRC, MARKT, 
                                                 
25 For example, a campaign was organised by a group representing over 75% of Italian Tobacconists (European 
Voice, 10 February, 2011). This action was followed by over 30,000 submissions, including 99% duplicate 
responses from Italy 
26 Eurobarometer 2012  
27 Public Consultation Report 2011. In addition to the contributions received on-line, the contributions received 
through other formats from 20 Member States at the level of Governments or ministries as well as from two 
EFTA/EEA countries have been published on the same web site.  
28 Minutes for stakeholder meetings can be found at http://ec.europa.eu/health/tobacco/events/index_en.htm#anchor4 
(accessed 28 Nov 2012). 
29 Idem.  
30 The minutes from the meetings can be found at: 
http://ec.europa.eu/health/tobacco/events/index_en.htm#anchor0  (accessed 28 Nov 2012). 
31 It is important to underline that the preferred policy options do not – in the assessment of the Commission – 
lead to increased illicit trade. On the other hand, illicit trade accounts already for 8,25% of the current 
consumption (Euromonitor data as presented in Matrix 2012). 
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OLAF, REGIO, RELEX, RTD, TAXUD, TRADE and TREN.32 The Group held 8 meetings: 
5 March 2009, 26 November 2009, 2 July 2010, 18 April 2011, 3 October 2011, 1 March 
(information meeting and hand-out of draft Impact Assessment Report), 12 March 2012 and 
19 July 2012. A meeting with associated services also took place on 30 November to present 
the legal proposal in the context of the inter-service consultation.   
 
Expertise and input 
A number of external studies have been commissioned to provide input to this impact 
assessment. First, a study on liability and the health costs of smoking was presented in 
December 2009. This study provided valuable input as far as the socioeconomic impacts of 
tobacco control policies are concerned. An updated version of this study was prepared in 
2012.33 Second, a study assessing the impacts of revising the TPD was presented in 
September 2010.34 This report (by RAND Europe) was criticised by many stakeholders for its 
actual and perceived inaccuracies. In this respect, it is important to stress that this study has 
provided input to, but has not formed the exclusive basis of this impact assessment. The 
information was verified on the basis of other sources. Third, a study on novel and emerging 
tobacco, nicotine or related products was commissioned in 2010.35 Fourth, a study on the 
economics of the EU market of tobacco, nicotine and related products was commissioned in 
September 2011 to fill some remaining data gaps.36  
 
The Commission’s independent Scientific Committee on Emerging and Newly Identified 
Health Risks (SCENIHR) has presented two opinions relevant to the impact assessment: one 
on smokeless tobacco in February 2008 and one on additives in tobacco products in 
November 2010.37  
 
Finally, the Eurobarometer surveys conducted in October 2009 and February 2012 have 
been used to provide better insight on tobacco and nicotine use in the EU and on attitudes 
towards tobacco control policies.38 In particular the last Eurobarometer showed increased 
public support for the policy measures envisaged in this impact assessment. 
Invitations from European Parliament and the Council 
Since October 2007, the European Parliament has repeatedly called on the Commission to 
present a proposal for an amendment of the TPD and consider measures on ingredients and 
sales arrangements.39 A large number of questions on the TPD revision have also been 
received from the European Parliament during the past years. 
 
The Council has twice invited the Commission to consider strengthening the tobacco control 
legislation and, in this context, to consider product related measures aimed at reducing the 
                                                 
32 Some of the DGs have changed since the launch of the ISSG 
33 GHK 2012  
34 Rand 2010  
35 Rand 2012   
36 Matrix 2012  
37 SCENIHR 2008, SCENIHR 2010 
38 Eurobarometer 2010, Eurobarometer 2012   
39 Resolution of 24 October 2007 on the Green Paper 'Towards a Europe free from tobacco smoke: policy 
options at EU level'. (2007/2105) 
 http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+P6-TA-2007-0471+0+DOC+XML+V0//EN (accessed 28 Nov 2012). 
 Resolution of 26 November 2009 on smoke-free environments. (2009/2751) 
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2009-100  (accessed 28 Nov 2012). 
 Resolution of 15 September 2011 on European Union position and commitment in advance to the UN high-level meeting on the prevention 
and control of non-communicable diseases. 2011/2802 
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&reference=P7-TA-2011-0390&language=EN  (accessed 28 Nov 2012). 
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attractiveness and addictiveness of tobacco products and to analyse the legal issues and the 
evidence base for the impact of plain packaging, including its effect on the functioning of the 
internal market.40 
 
1.4. IMPACT ASSESSMENT BOARD 
A first version of this impact assessment report was submitted to the Impact Assessment 
Board (IAB) on 21 March 2012. On 18 April 2012 DG SANCO representatives had a meeting 
with the Board and the written opinion of the Board was received on 20 April 2012. The 
opinion concluded that the draft report required further work and asked for resubmission. A 
second version was submitted to the Board in June 2012. The second opinion of the Board, of 
12 July 2012, did not request a resubmission but made some further recommendations on how 
to improve it. The opinion criticised in particular the evidence base for the policy areas 
"display at PoS" and "STP", which were subsequently dropped/amended. The table below sets 
out the main comments of the second opinion of the Impact Assessment Board and describes 
how they have been reflected in this revised version of the report.    
 
Main comments from the IAB Revision of the draft IA Report 
1. Better present the problem:  
-Present separately problems related to effectiveness, 
implementation, enforcement and currently non-harmonised 
areas. 
-Demonstrate recourse to Article 114 for non-harmonised 
areas, in particular for limitation of promotion at the PoS. 
-Clarify compatibility between inequality in health and 
Member States' competences in defining their health policies.  
 
 
-Clearer references to effectiveness, implementation, enforcement 
and non-harmonised issues were introduced in the problem 
identification (2.2.1-2.2.5).  
-Internal market justifications were better explained under the 
problem identification (2.2.1-2.2.5). The policy areas on PoS and 
TVM were discarded (4.1). The preferred policy option for STP 
was amended. The section on the legal basis (2.4.1) was reviewed. 
-The references to equality were replaced by references to the 
objectives of Article 3 TEU (promote the well-being of its people) 
where relevant (for ex. 2.2). Health inequalities were, however, 
maintained as assessment criteria.  
2. Develop a robust baseline scenario:  
-Explain foreseeable national actions in the context of FCTC. 
-Analyse further the likely take-up of STP, better explain 
circumvention possibilities of oral tobacco and acknowledge 
the uncertainty in relation to STP.  
-National actions in the context of FCTC have been further 
explained under the baseline scenario (2.3.2). 
-The likely take-up of STP is described under the baseline 
scenario (2.3.3) and assessment of option 1(5.2.1). Circumvention 
is described in 2.2.1.  
3. Better demonstrate the proportionality of policy options 
-Present measures going beyond current TPD and FCTC. 
-Discuss a wider range of discarded options. 
-Justify STP, NCP and cross-border distance sale preferred 
options and alternative ban-options. 
-Explain STP derogation, TVM verification and traceability 
obligations. 
 
-A clarification of the options status in comparison with the 
current TPD and FCTC has been introduced in a table on TPD and 
FCTC commitments in Annex 3 (3.2).  
-A number of discarded options have been added to section 4.  
-The preferred option on cross-border distance sales have been 
further justified (5.5.4). New preferred options have been 
identified for STP (regulation of chewing and nasal tobacco, 
notification of novel tobacco products and maintaining the ban on 
oral tobacco, see 5.2.1), NCP (all NCP above a certain nicotine 
threshold are subject to the medicinal products legislation, see 5.2.2). 
-The definition of traditional use in the glossary was revised, but 
no longer part of preferred option (5.2.1). The policy area on 
TVM was discarded (4.1). Traceability obligations in the context 
of FCTC were clarified in section 2.1.4 and Annex 3.   
4. Improve the assessment of impacts:  
-Better explain persisting divergences, in particular on 
ingredients. 
-Present discounted values. 
-Assess administrative costs for internet notifications. 
-Divergences were better explained, for example under 5.4 on 
ingredients.  
-Discounted values are presented in section 5.7.2 and Annex 5. 
-Administrative costs for internet notifications are better 
explained under 5.5.1. 
                                                 
40 Council Recommendation of 30 November 2009 on smoke-free environments. 2009/C 296/02.  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:296:0004:0014:EN:PDF  (accessed 28 Nov 2012). Council conclusions 
on Prevention, early diagnosis and treatment of chronic respiratory diseases in children. 16709/11.  
http://register.consilium.europa.eu/pdf/en/11/st16/st16709.en11.pdf  (accessed 28 Nov 2012). 
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-Breakdown of overall health impacts. 
-Show where evidence is inconclusive. 
-Acknowledge trade-offs between internal market and health. 
 
-Breakdown of health impacts are presented in more details under 
section 5.7 intro. 
-Evidence was reinforced and the conclusions to be drawn 
revisited, see for ex. STP baseline (2.3.3), plain packaging (5.3.3) 
and NCP impacts (5.7 intro)   
-Trade-offs are further clarified in the table under 6.1 
 
2. PROBLEM DEFINITION 
2.1. MARKET DESCRIPTION 
1.1.6. Tobacco products market  
 
a)  Supply side 
The total value of the tobacco market at retail level, including taxes and excise duties, is 136,5 
bEUR and the market currently consists of five main categories of products41: 1) Factory 
manufactured cigarettes (FMC), 2) Roll-your own tobacco (RYO), 3) Pipe tobacco, 4) Cigars 
and cigarillos and 5) Smokeless tobacco products (STP) (oral, chewing and nasal tobacco). 
The value and volume of sales as well as manufacturing methods and consumption patterns 
differ significantly between the product categories. 





















FMC represent almost 90% (121,3 bEUR) of the total tobacco market value and despite a 
decline in sales volumes over the last ten years, the overall market value has increased 
consistently over the same period. This is mainly due to the tax increases and continuous 
development of premium brands sold at higher prices. FMC manufacturing is increasingly in 
the hands of four large multinational companies (PMI, BAT, JT and IT) accounting for 
around 90% of the EU FMC market. 
 
The FMC production is also highly concentrated in geographical terms, with only a few 
Member States (the United Kingdom, Netherlands and Germany) accounting for more than 
                                                 
41 This categorisation is in line with the Commission's merger practice. It is important to underline that the notion 
of a market in this impact assessment is not based on competition law terminology.  
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50% of the total EU production.42 American Blend (using a mixture of Burley, Oriental and 
Virginia leaves) accounts for 76% of the FMC market.43  
 
The RYO market has increased significantly in recent years and accounts today for about 
6,8% (9,3 bEUR) of the total tobacco market. This market is also characterised by strong 
presence of the four biggest FMC manufacturers (70% of the market), but to a lesser extent 
than FMC. The markets for pipe tobacco, cigars, and cigarillos are considerably smaller. 
These products as well as chewing and nasal tobacco products are to a large extent 
manufactured by SMEs.44 The pipe tobacco and the cigar markets have been continuously 
declining in the last decade. The increase in cigarillo sales was partly driven by flourishing 
sales of so called eco-cigarillos which are not typical cigarillos and were recently re-classified 
as cigarettes.45 The STP market is dominated by oral tobacco (snus) and concentrated to 
Sweden, the only Member State where the marketing of this product is allowed.46 Chewing 
and nasal tobacco account for less than 0.1% of the total tobacco market and sales are 
concentrated to about 12 companies, mostly SMEs, who also sell other tobacco products.47 
Recent years have seen an increasing interest from bigger cigarette manufacturers to enter the 
STP market.48 Novel categories of tobacco products are currently being developed but they 
are not yet placed on the EU market.49 Most of these products are expected not to involve a 
combustion process and therefore would fall in the product category of STP.    
 
Figure 2:  Market value and volume 2000-2010 












FMC 90.7 121.3  +33.8 793.7 bs 608.8 bs  -23.3 
RYO 4.2 9.3 +123 53.1 tt 75.5 tt +42.2 
Pipe 0.576 0.480 -17 6.33 tt 4.03 tt -36 
Cigars/cigarillos50 4.62 4.65  +0.6 7.81 bs 9.92 bs  +27 
STP51  0.48  0.83 +73 5,3  5.9 +10 
Source: Euromonitor. Nominal prices 
 
In terms of market development, a significant diversification of products has taken place in 
recent years. For example, the main manufacturer of oral tobacco (snus) increased its portfolio 
from 22 to 180 brands between 2002 and 2008,52 distinctive flavoured FMC such as "pina 
colada" and "chocolate" have been put on the market53 and FMC with new technology 
                                                 
42 Eurostat 2008/2009 
43 Euromonitor 2010 (Matrix 2012) 
44 European Smoking Tobacco Industry: Facts & Figures for DG Sanco, ESTA 2011-2012, ECMA, European 
Cigar Manufacturers Association, Facts and Figures 
45 Directive 2010/12/EC on the structure and rates of excise duty applied on manufactured tobacco. Germany and 
Hungary have been granted transitional periods until 2014.  
46 Marketing of oral tobacco is banned according to Article 8 of the current TPD and has been banned since 
1992. Sweden and Norway were granted a permanent derogation from the ban received in their Accession 
Treaty; OJ C 241, 29.8.1994 (see article 151 and Annex XV thereof)  
47 European Smoking Tobacco Industry Facts & Figures for DG SANCO, ESTA 2011-2012 
48 In February 2009, Swedish Match entered a joint venture with Philip Morris International. The second largest 
producer of oral tobacco in Sweden, Fiedler and Lundgren, became part of the British American Tobacco Group in 
2008. 
49 DG SANCO's meeting with PMI, 8 March 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20120308_mi_en.pdf (accessed 28 Nov 2012). 
50 This covers also "eco-cigarillos" exempted from the definitions for cigars and cigarillos through Directive 
2010/12/EC on the structure and rates of excise duty applied on manufactured tobacco. 
51 The data is limited to chewing tobacco in Denmark and Slovenia and oral and nasal tobacco (according to 
Euromonitor terminology snuff) in Germany, Sweden and Denmark 
52 Swedish Match magazine Inside #2 from May 2008  
53 Matrix 2012 
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including capsules filled with flavourings embedded in the filter have been introduced in 
many Member States.54 New market strategies have also been developed, in particular as a 
result of the tobacco advertising ban/restrictions in Member States, including innovative 
packaging and promotion at point of sale.55  
 
Illicit trade in FMC currently accounts for 8.25 % of total trade in the EU and is estimated to 
increase by 1 % per year in the next five years.56 Three broad categories exist: contraband, 
counterfeit and cheap whites/illicit whites (see glossary). Typically, these products do not 
comply with the safeguards of the TPD.   
 
In terms of employment, there were 48,500 persons employed in tobacco manufacturing in 
the EU in 2009.57 In addition to this, Eurostat data indicates that there are 86,113 farmers.58 In 
2010, there were almost 100 first processors59 of tobacco in the EU located close to the 
growers’ areas, while the market of second processors60 is in the hands of two global players61 
with similar market shares. 45,900 persons are employed in wholesale.62 The retail sector 
differs widely between Member States, but according to the European retailer association 
(CEDT), there are almost 990,000 premises selling tobacco in the EU and around 230,000 of 
these are specialised shops which usually generate 45-50% of their turnover from tobacco.63  
 
As far as raw tobacco is concerned, the EU was a net importer of around 430,000 tonnes 
(about 2/3 of the quantity needed) in 2010.64 The EU tobacco production amounted to 
294,000 tonnes. The production is often limited to small regions, very specialised and with 
large family labour requirements. Despite the fact that Virginia is the leading tobacco variety 
(46% of the EU production), most of the EU tobacco farmers (81%) are involved in labour 
intensive Burley and Oriental farming which is used in American blend cigarettes.65 
According to tobacco producers, adding certain substances, including sugar, is indispensable 
for the use of these tobacco varieties. This is because these varieties lose their sugar content 
during the drying process whereas other varieties (such as Virginia) keep it.  
 
A number of upstream actors other than farmers and processors are also involved in the 
tobacco manufacturing process. These include suppliers of ingredients, cigarette papers, filters 
                                                 
54 German Cancer Research Center (DKFZ). Menthol Capsules in Cigarette Filters – Increasing the 
Attractiveness of a Harmful Product. Heidelberg: DKFZ; 2012. 
55 Cancer Research UK. The packaging of tobacco products. Stirling: Centre for Tobacco Control Research, 
University of Stirling; 2012. Harper T. Why the tobacco industry fears point of sale display bans. Tob Control 
2006;15(3):270-1. 
56 Euromonitor data presented in Matrix 2012. According to OLAF indications, the ratio between categories of 
illicit trade is 30 % contraband, 50 % counterfeit and 20 % illicit whites (for definitions, see glossary).   
57 Eurostat.  http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Tobacco_processing_statistics_-
_NACE_Rev._1.1  (accessed 6 Nov 2012)  
58 Economic stakeholders UNITAB and COPA estimate a number of 400.000 workers involved in growing in 
total (including family and seasonal working force.)  
59 The first processors collect the raw tobacco cured by farmers and make a first process before selling it to the 
industry producing FMC, cigars or manufactured tobacco. DG AGRI 
60 The second processors subsequently purchase, process, blend, pack, store and ship tobacco to meet each 
specifications of manufacturers of FMC and other tobacco products. DG AGRI 
61 Alliance One Int. and Universal Corporation 
62 Eurostat 2010. Bulgarian farmers represent 50% of the EU tobacco farmers, followed by Poland and Greece 
(both 17%) 
63 Tobacco Retailers Figures. CEDT (Confédération Européenne des Détaillants en Tabac). Sent to DG SANCO 
in January 2012 
64 Eurostat 2010 
65 Nomisma. The cultivation of tobacco in the European Union and the impact deriving from changes in 
Directive 2001/37/EC. Analyses of socio-economic impact. October 2010.  
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and packaging (see also figure 3). Based on industry reported data, the total value of those 




Figure 3: Composition of a FMC 
 
Source: Background to Cigarette Manufacturing and Use of Additives. 
Prepared by Philip Morris International Management S.A. 8 January 2010 
 
The multinational dimension of the tobacco market combined with the geographic 
concentration of manufacturers and growers results in significant cross-border trade, both 
within the EU and with third countries. About 268,000 tonnes of raw tobacco were subject to 
internal trade between Member States in 2010 and the overall value of manufactured tobacco 
products traded across Member States' borders in 2010 was 9.5 bEUR.66 Figure 4 illustrates 
the main intra-EU flows in the production of American blend cigarettes. 
 
Figure 4: Trade flows between tobacco-growing, tobacco-producing and tobacco-consuming countries67 











Romania, Hungary, Greece, 
Lithuania, Netherlands, 
Portugal, Czech Republic, 
Italy




EU 26 (all countries but the 
United Kingdom)
 
More than one third of tobacco products manufactured within the EU are sold across 
borders.68 Figure 5 illustrates intra EU trade in tobacco, following the categories used by 
Eurostat.   
 
                                                 
66 Eurostat (Procom) 2008 
67 Matrix 2012 based on information from the industry 
68 As indicated in Annex 5, the total value of the FMC and RYO is 18 bEUR (ex-manufacture price). Almost 8 
bEUR (see figure 5) is subject to intra EU trade.  





Figure 5: Intra-EU trade in tobacco 2010 




Cigarettes (containing tobacco) 
 6.591 3,427,689 
Cigars, Cheroots and Cigarillos  
(containing tobacco) 0.644 68,641 
Cigars, Cheroots, Cigarillos and Cigarettes  
of tobacco substitutes 0.004 1,864 
Smoking Tobacco (whether or not containing  
tobacco substitutes in any proportion) 1.058 970,327 
Manufactured Tobacco, Extracts  
and Essences, N.E.S. 0.279 639,322 
Total Manufactured Tobacco (whether or not  
containing tobacco substitutes) 8.576 5,107,843 
Source: Eurostat intra-EU trade figures  
 
As regards trade between the EU and third countries, the total import to the EU of 
manufactured tobacco is less than 200mEUR, whilst the export of FMC and other 
manufactured tobacco products outside the EU accounts for 2.5 bEUR, i.e. a positive trade 
balance of 2.3 bEUR. On the other hand, import of unmanufactured tobacco (both raw and 
processed) counts for 2.17 bEUR, while the export accounts for 670 mEUR, what results in a 
trade deficit of 1.5 bEUR.  For more details on the tobacco market and the manufacturing 
process, see Annex 2. 
b) Demand side  
According to the latest Eurobarometer 28 % of all EU citizens and 29 % of young people 
(aged 15-24 years) smoked in 2012.69 FMC is the most widely used tobacco product. 70% of 
the smokers start before the age of 18 and 94% under the age of 25. The overall smoking 
prevalence differs widely between Member States and ranges from 13% to 40%. Menthol 
cigarettes account in the EU, for approximately 4% of the EU market, ranging from 25% in 
Finland to 0.1% in Greece. Cigars and pipes are smoked far less than FMC and tend to be 
smoked occasionally rather than daily and mostly by older individuals. STP use is most 
common in Sweden, where around 12% of the population uses STP (mainly oral 
tobacco/snus) on a regular basis, compared to 2% or less in other EU countries where 
marketing of oral tobacco is banned, but chewing and nasal tobacco is allowed. The figure is 
higher if one considers all citizens who have at least tried STP. Chewing tobacco appears to 
have most users in Denmark and nasal tobacco is mainly used in Germany. Some industry 
players see a significant growth potential for STP as well as NCP, also in the light of smoke 
free environments. Figure 6 indicates the trends in smoking prevalence 2006-2012 and STP 
use 2009-2012.  
 
Figure 6: Smoking Prevalence 2006-2012 and STP use 2009-2012 
  
                                                 
69 Eurobarometer 2012  
STP 2009 2012 
Regular Users Na 1% 
EU 27 6% 7% 
DK 12% 15% 
Proportion 
who have 
tried STP FI 20% 13% 
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Smoking tobacco 2006 2009 2012 
 Smokers 32% 29% 28% 
FMC  79% 80% 
RYO  15% 20% 




daily Pipe  1% 1% 
 
Source: Eurobarometer  
 
More than six out of ten smokers in the EU have tried to quit, with two out of ten in the 
previous twelve months.70 Personal health concerns are the main motivation to quit. While the 
number of smokers in the EU, and with this also the smoking prevalence, has decreased in the 
past decades, some Member States have seen an upwards trend in young people since 2005. 
The Health Behaviour in School-aged Children (HBSC) study of WHO Europe from 2012 
indicates an increase in smoking prevalence in 14 Member States for 15 year old boys and in 
nine Member States for 15 year old girls. 71 
 
According to the 2012 Eurobarometer,72 smokers and non-smokers commonly perceive FMC 
with lower tar or nicotine levels to be less harmful. The most important factor in choosing a 
FMC brand is the taste of tobacco (84%), followed by the brand itself (69%) and price (65%), 
but packaging (23%) and specific tastes (such as menthol, spicy, fruity or sweet) (32%) are 
also important. Peer group pressure/behaviour is obviously the most important factor for 
smoking initiation. EU citizens, including smokers, are largely and increasingly in favour of 
various tobacco control measures. For example, three out of four citizens support putting 
pictorial health warnings on all tobacco product packages. A third of smokers and ex-smokers 
also say that health warnings had an impact on their attitudes and behaviours towards 
smoking. 
 
Most EU citizens who smoke or have smoked purchase regularly their cigarettes in a 
specialised tobacco shop (37%), from a newsagent (26%) a supermarket (22%) or a 
convenience store (20%). 10% of EU citizens purchase their tobacco from TVM (mounting to 
15% in Member States where TVM were accessible). Only 10 EU citizens in 100 report that 
they have purchased tobacco products in a country other than their country of residence in the 
past 12 months.73 Cross border purchases via the internet are also limited (according to self-
reporting). However, taking into account the increased use of e-commerce in other sectors, it 
appears likely that the market segment will grow.  
1.1.7. The role of tobacco in the society  
Tobacco is a legal product on the EU’s internal market, but is no ordinary commodity in the 
sense that it is the largest avoidable health threat in the EU, responsible for almost 700,000 
deaths in the EU each year (see Annex 5). Moreover, millions of people in the EU suffer from 
one or more of the six main disease categories associated with smoking: 1) Bronchitis and 
other lower respiratory infections, 2) Chronic obstructive pulmonary diseases, 3) Stroke, heart 
attacks, arterial obstructions (especially in the legs) and other cardiovascular diseases, 4) 
                                                 
70 Eurobarometer 2012 
71 Currie C, Zanotti C, Morgan A, Currie D, de Looze M, Roberts C, et al., eds. Social determinants of health 
and well-being among young people. Health Behaviour in School-aged Children (HBSC) study: international 
report from the 2009/2010 survey. Copenhagen: WHO Regional Office for Europe; 2012. Prevalence increased 
for boys in: AT, CZ, FR, HE, HU, IT, LV, LT, LU, PT, RO, SK, ES and SE. Prevalence increased for girls in: 
CZ, HU, IT, LT, RO, SK, SI, ES and SE. 
72 Eurobarometer 2012  
73 Idem. 
SE 39% 44% 
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Asthma, 5) Lung cancers and 6) Other cancers, such as pancreas, oesophagus, and stomach. 
Studies show that around 50% of smokers die prematurely and if they do so they die on 
average 14 years earlier. In addition, smokers have more life years that are characterised by 
serious disease.74 
 
In addition to measures at EU and international level, strong tobacco control policies are 
pursued by Member States to address the harmful effects of tobacco and to protect public 
health. It is commonly agreed among tobacco control regulators that only a comprehensive set 
of continuously updated and adapted measures (e.g. price/taxation, smoke-free environments, 
advertising bans, labelling, ingredients regulations, information campaigns) is effective to 
reduce smoking prevalence over time, including reduced uptake among young people.  
 
Tobacco consumption also has important economic implications for society and is associated 
with important expenditures/costs. Annual EU public healthcare expenditure on treating 
smoking attributable diseases is estimated around 25.3 bEUR and society loses 8.3 bEUR per 
annum due to productivity losses (including early retirements/deaths and absenteeism) linked 
to smoking. In addition, if monetised, the life years lost due to smoking correspond to 517 
bEUR every year. Figure 7 summarizes the costs associated with smoking in table format. 
 
Figure 7: Costs associated with smoking in EU27 in mEUR 
Monetary value of life 
years lost 
Smoking induced 
health care costs  




516,713 25,300 6,081 2,162
 
On the other hand, revenue from excise duty on the sale of tobacco product in the EU 
exceeded 79 bEUR in 2010, contributing to almost 3% of the total Government revenue.75 For 
more detailed information on economic impacts on the society, see Annex 5 (A5.2.3).  
1.1.8. Non-tobacco products  
Nicotine Containing Products (NCP) 
In addition to the traditional tobacco market, recent years have seen the emergence of new 
nicotine containing products (NCP) marketed primarily as consumer/leisure products. 
Electronic cigarettes appear to be the most commonly available type.  
 
The EU electronic cigarette industry is still quite fragmented and the absence of reliable 
trade statistics makes it difficult to summarise and analyse in terms of market size and value.76 
However, it can be concluded that the market is growing rapidly. An electronic cigarette 
supplier has estimates that the current value of the German market is around 100 mEUR and 
that the total value of the EU27 e-cigarette market (including devices and refills) is between 
400 and 500 mEUR.77 The Electronic Cigarette Industry Trade Association (ECITA) 
                                                 
74 Bronnum-Hansen H, Juel K. Abstention from smoking extends life and compresses morbidity: a population 
based study of health expectancy among smokers and never-smokers in Denmark. Tobacco Control 2001; 10: 
273-8. Nusselder WJ, Looman CW, Marang-van de Mheen PJ, van de Mheen H, Mackenbach JP. Smoking and 
the compression of morbidity. J Epid Comm Health 2000; 54: 566-74. Klijs B, Mackenbach JP, Kunst AE. 
Obesity, smoking, alcohol consumption and years lived with disability: a Sullivan life table approach. BMC 
Public Health 2011; 11:378. 
75 EC, DG Taxud. 2010 For the purpose of this impact assessment, VAT has been excluded from the analysis as 
money not spent on tobacco will be spent on other goods attracting VAT. In this respect, any measure should be 
VAT neutral. 
76 See Matrix 2012 
77 Matrix 2012   
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estimates that they represent 60-70% of the volumes sold on the UK market and reports that 
the market is growing 20-30% monthly.78  
 
The EU market is mainly composed of distributors rather than manufacturers and dominated 
by small enterprises, although there is a growing interest from bigger cigarette manufacturers 
(including the big four FMC producers) to enter the market.79    
 
Most of electronic cigarettes are produced in China. Once imported into the EU, they are 
subject to significant cross-border trade. For example, in the Netherlands vendors of 
electronic cigarettes are reported to operate as a hub, reselling most of the electronic cigarettes 
they import from China to the rest of Europe. Around 20% of their sales are internal to the 
Dutch market, while around 60% are sold to German vendors and the remaining 20% to 













Figure 8: Value chain of the e-cigarette market in Europe  
                                                 
78 DG SANCO meeting with ECITA, 20 June 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20120703_mi_en.pdf (accessed 28 Nov 2012).  
79 Niconovum. Press Room. Helsingborg; Niconovum; 2012. http://www.niconovum.se/Press.aspx (accessed 28 
Nov 2012)., Thomas R. Cigarette giant to offer ‘safer alternative.’ England and Wales: Nicoventures; 2011. 
http://www.nicoventures.co.uk/Content/Downloads/august-2011/PM_Aug_p2.PDF (accessed 28 Nov 2012). 
80 Matrix 2012. Based on information from the Dutch e-cigarette consumer association. 
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Source: Matrix Insight  
 
As for the demand side, the current use of NCP is growing quickly. 7% of EU citizens have 
reported in the latest Eurobarometer that they have at least tried electronic cigarettes.81 In the 
UK an increase in the number of electronic cigarette owners has been estimated from a small 
number in 2006 to over 1 million by 2013.  
 
Figure 9: Projected growth in the UK market for e cigarettes 
 
Source: Matrix insight 2012 
 
Electronic cigarettes are widely advertised on the internet. A study monitoring Google search 
queries from January 2008 to September 2012 reported that online interest in electronic 
cigarettes has surpassed that of oral tobacco (snus) and nicotine replacement therapies.82   
 
                                                 
81 Eurobarometer 2012  
82 Ayers JW, Ribisl KM, Brownstein JS. Tracking the rise in popularity of electronic nicotine delivery systems 
(electronic cigarettes) using search query surveillance, Am J Prev Med, 2011; 40(4):448-453. 
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Electronic cigarettes are most often marketed by their producers as an alternative to FMC 
rather than a smoking cessation aid.83 There are limited data available at this stage why people 
use electronic cigarettes. However, according to a recent survey among electronic cigarette 
users in Poland, most used the product primarily to quit smoking or to reduce harm associated 
with smoking (both 41%).84 An online survey of more than 3500 e-cigarette smokers found 
that the vast majority of respondents were using e-cigarettes to quit smoking or reduce their 
smoking (92%) and a large proportion felt these products were less toxic than traditional 
tobacco products (84%).85 These studies are well in line with information received from the 
Electronic Cigarette Industry Trade Association (ECITA), namely that the “vast majority of 
consumers” use e-cigarettes as a harm reduction alternative to smoking/a substitute for 
FMC/for smoking cessation purposes and that many use them to get around smoke-free 
environments (including lorry drivers).86 Due to the high numbers of possible flavours, 
ECITA has also reported that e-cigarettes would be used as a “fun product” (annual “vape 
festivals”).87 In terms of age of the users, ECITA has stated that statistics show that the 
proportion of users under 20 is low but they cannot exclude that young people or minors 
might use the products, although they believe that the comparatively high start-up costs, 
together with a lack of peer pressure would make this unlikely.88 The previously mentioned 
Polish survey also found that one in five young people had tested electronic cigarettes.89 As 
explained in subsequent sections of this report, the regulatory framework for electronic 
cigarettes and other NCP is complex and varies between Member States and a number of 
health and safety concerns are associated with the products. NCP other than electronic 
cigarettes appear, at this stage, to be less common on the EU market.  
  
Herbal products for smoking 
Euromonitor data indicate that herbal cigarettes were sold in significant amounts in seven 
Member States over the period 2000-2010. The overall size of the market grew from around 
40.6 million units in 2000 to 50 million units in 2010, an increase of around 23%.90 These 
products are often marketed as "healthier" and natural products with "no additives", which 
gives the impression that these products are not harmful.91  
                                                 
83 Products marketed as smoking cessation aid would fall under the pharmaceutical framework and would need a 
prior authorization before being put on the market. ECITA explicitly advises its members to refrain from claims 
such as "quitting smoking" or satisfying cravings" (MOCK Audit Report shared with DG SANCO).  
84 Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and 
benefits: An Internet survey. Drug Alcohol Rev 2012. 
85 Etter JF, Bullen, C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. 
Addiction 2011; 106: 2017–28. 
86 DG SANCO meeting with ECITA, 20 June 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20120703_mi_en.pdf (accessed 28 Nov 2012). 
87 Idem. 
88 Idem. 
89 Goniewicz ML, Zielinska-Danch W. Electronic cigarette use among teenagers and young adults in Poland. 
Pediatrics 2012;130(4):e879-85. 
90 Matrix 2012 
91 Honeyrose. Stop smoking. Ipswich: Honeyrose Products Ltd; 2012. http://www.honeyrose.co.uk/stop.html  
(accessed 28 Nov 2012). Holland and Barrett. Herbal cigarettes. Nuneaton: Holland and Barrett; 2012. 
http://www.hollandandbarrett.com/pages/categories.asp?cid=313 (accessed 28 Nov 2012). 
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1.1.9. Regulatory framework 
2.1.1.1. Tobacco control in the EU   
Since the 1980s, there have been legislative initiatives in the EU to ensure harmonised 
product regulation for tobacco whilst also ensuring a high level of health protection. Today, 
the TPD constitutes, together with the Tobacco Advertising Directive from 2003,92 the key 
legislation in the field of tobacco in the EU. The content of the current TPD is described in 
section 1.2. The Tobacco Advertising Directive bans all forms of cross-border advertising in 
printed media, information society services, radio and sponsorships of events. 
 
These two main Directives are complemented by two non-binding Council 
Recommendations: one on the prevention of smoking and on initiatives to improve tobacco 
control from 2003 and one on smoke-free environments from 2009.93  
 
Awareness-raising activities are also important instruments in EU’s tobacco control policy. 
The current campaign (Ex-smokers are Unstoppable) was launched on 16 June 2011 to 
encourage young adults in the 25 to 34 age group to stop smoking. The previous campaign, 
"HELP – For a life without tobacco ", which ran from 2005 to 2010, was focused on smoking 
prevention, cessation, and passive smoking, targeting young Europeans between 15 and 25 
years of age. 
 
Measures to regulate and control tobacco are not only initiatives by DG SANCO. Tobacco is 
a cross-cutting issue which affects numerous policy areas. High taxes on tobacco products are 
generally seen as a very effective means to reduce tobacco use, with a particularly big impact 
on young people and people with lower incomes. Council Directive 2011/64/EU amends the 
structure and rates of excise duty on manufactured tobacco in the EU and in this context more 
convergence and further increases of tobacco taxes can be expected in the EU. The European 
Anti-Fraud Office (OLAF) investigates cases of illicit tobacco trade, which deprive 
Governments of significant tax revenues and undercut the prices charged by legal traders. In 
the area of advertising, the Audiovisual Media Services Directive 94 complements the EU 
legislation on tobacco advertising, by providing a ban on all forms of audiovisual commercial 
communications, including product placement as regards tobacco. Direct tobacco subsidies to 
growers were once an important but controversial part of the EU's agricultural policy. They 
have now been phased out, but were partially replaced by other subsidies. The Commission 
(DG EMPL) is also considering measures addressing the risks of employees arising from 
exposure to environmental tobacco smoke at the workplace. 
 
The EU also works with international partners to reduce the consumption of tobacco 
worldwide, including in the context of the WHO Framework Convention on Tobacco Control 
(FCTC) (see 2.1.4.2).    
 
All the instruments described in this section are mutually reinforcing and play an important 
role in the comprehensive tobacco control policy. 
                                                 
92 Directive 2003/33/EC of the European Parliament and of the Council of 26 May 2003 on the approximation of 
the laws, regulations and administrative provisions of the Member States relating to the advertising and 
sponsorship of tobacco products 
93 Council Recommendation 2003/54 of 2 December 2002 on the prevention of smoking and on initiatives to 
improve tobacco control and Council Recommendation of 30 November 2009 on smoke-free environments, 
(2009/C 296/02) 
94 OJ L 95/1 of 15.4.2010 
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WHO FCTC (in force since 
2005) 
-demand reduction  
-supply reduction  
 
Illicit Trade Protocol  (adopted 
in Nov. 2012) 
-comprehensive supply chain 
provisions (including global 
tracking and tracing)  
 
FCTC guidelines 
-Protection from commercial and 
other vested interests 
-Protection from exposure to 
tobacco smoke 
-Product content regulation and 
disclosures 
-Packaging and labelling 
-Education & communication 
-Advertising & sponsorship 
-Demand reduction & cessation 
-Guiding principles and 




Figure 10: Tobacco control in the EU  
 
 
2.1.1.2. Obligations in the context of the WHO FCTC  
The WHO Framework Convention on Tobacco Control (FCTC) was adopted by the World 
Health Assembly in May 2003 and is the first ever international treaty on public health 
developed in response to the globalisation of tobacco consumption. The FCTC includes both 
demand reduction provisions (such as price and tax measures, protection from exposure to 
tobacco smoke, content and disclosure of tobacco products, packaging and labelling, 
education and communication, advertising, promotion and sponsorship) and supply reduction 
provisions (such as illicit trade, sales to and by minors and support for economically viable 
alternative activities).  
 
The FCTC is a legally binding instrument which needs to be implemented and enforced by all 
Parties having ratified the Convention (so far over 170 countries across the world), including 
the EU and its Member States. At the time of the final approval of the FCTC it was 
considered that both the EU and Member States have competence in certain areas covered by 
the Convention (mixed agreement) and need to work together on the uniform application.95 A 
legally binding Illicit Trade Protocol based on Article 15 of the FCTC was adopted by the 
Conference of the Parties to the FCTC in November 2012. The EU and the Member States are 
expected to become Parties to this new instrument (as is the case for the FCTC). The core 
provisions of the protocol relate to the control of the supply chain for tobacco products 
through notably licensing (or equivalent approval), due diligence, record keeping, control of 
                                                 
95 See Council Decision concerning the conclusion of the WHO Framework Convention on Tobacco Control 
(2004/513/EC), recital 4. See also Annex II thereof referring to Community competence in areas covered by 
Community legislation, including TPD. 
Council Recommendations: 
-Smoke Free Environment (2009) 
-Prevention of smoking and initiatives to improve tobacco control (2003) 
Tobacco control in other policy areas : 
- Tobacco taxation 
- Illicit trade in tobacco 
- Audiovisual media 
Tobacco Products Directive 
(2001)  
- health warnings  
- ban misleading descriptors 
- ingredients reporting 
-maximum TNCO limits 
Advertising Directive (2003)  
-bans cross-border advertising 
in printed media, radio and on-
line services 
-bans cross-border sponsorship  
Awareness campaigns: 
-Ex-smokers are Unstoppable (2011) 
-HELP – For a life without tobacco (2005-2010) 
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duty free sales, of internet sales and of free zones and a tracking and tracing system. Seven 
sets of guidelines have also been adopted (by consensus) to assist Parties in meeting their 
implementation obligations under the FCTC (figure 11). The guidelines, while not legally 
binding, give an indication of Parties' political commitments under the FCTC. In general, the 
guidelines are more far reaching than the FCTC and reflect scientific developments in tobacco 
control. For the purpose of this impact assessment, a distinction has been made between the 
binding “FCTC obligations” and the political “commitments” contained in the guidelines.   
 
For the purpose of the revision of the TPD, it is relevant to distinguish between the following 
categories of obligations and commitments stemming from the FCTC:  
 
1. Harmonised areas at EU level: obligations at EU level stemming from the legally 
binding FCTC: 
The EU (as Party to the FCTC) has an international law obligation to ensure that the 
TPD provisions comply with the FCTC. Member States are bound by the TPD and 
cannot take action at national level. The Illicit Trade Protocol will also be a legally 
binding Treaty once adopted and entered into force. However it is not further 
considered in the context of this Impact Assessment. 
 
2. Harmonised areas at EU level: commitments at EU level stemming from the non-
binding FCTC guidelines: 
The EU should ensure that TPD reflects new developments based on scientific facts 
and internationally agreed product standards (TPD Article 11). Member States are 
bound by the TPD (where it allows no discretion to the Member States) and cannot 
take action at national level. 
 
3. Non-harmonised areas at EU level: obligations stemming from the legally binding 
FCTC: 
The EU and its Member States are legally bound by the FCTC obligations and shall 
work together to ensure uniform application/avoid fragmentation of the internal 
market.  
 
4. Non-harmonised areas at EU level: commitments stemming from the non-binding 
FCTC guidelines  
The EU and the Member States have expressed their (political) support for the FCTC 
guidelines, but have no legal obligations to implement them. EU action is justified if 
divergent implementation in Member States leads to (or is likely to lead to) 
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Figure 11: Obligations in the context of FCTC in harmonised and non-harmonised areas 
 
1. TPD harmonised areas: 
Obligations stemming 
from the FCTC: 
  
FCTC Art 11: Health warnings 
should be 50% or more, but not 
less than 30%  
FCTC Art 15: Full traceability  
 
2. TPD harmonised 
areas: Commitments 
stemming from FCTC 
guidelines (GL): 
 
GL Art 11: Health warnings 
more than 50%  
-Pictorial health warnings on 
both sides of the packets  
-Removal of TNCO display  
3. TPD non-harmonised 
areas: Obligations 
stemming from the 
FCTC: 
 
FCTC Art 9 and 10: Effective 
ingredients regulation and 
measures for disclosure  
FCTC Art 11:No misleading 
package promotion  
FCTC Art 16: No small packages  
FCTC Art 16:TVM not accessible 
to minors   
4. TPD non-harmonised 
areas: Commitments 
stemming from the 
FCTC guidelines (GL): 
GL Art 9 and 10: Restriction/ban 
on "attractive" ingredients  
GL Art 11: Cessation 
information on the packages 
-Consider the adoption of plain 
packaging 
GL Art.13: -Consider the 
adoption of plain packaging 
-TVM ban  
-PoS display ban  
-Internet sale ban   
 
 
Annex 3 gives a more detailed description of developments and plans in Member States as 
well as the links between the TPD and FCTC (A.3.2). 
 
2.2. PROBLEM IDENTIFICATION  
Market developments, such as the appearance of new products (e.g. electronic cigarettes) 
and new market strategies (e.g. appealing packages and flavoured tobacco products) have 
taken place in recent years. The same is true for scientific development (e.g. SCENIHR 
opinions). In terms of international obligations, the FCTC was concluded after the adoption 
of the current TPD, which was later supplemented by guidelines. In particular the guidelines 
leave Member States with substantial discretion in terms of implementation. This could lead 
to heterogeneous development in Member States and have a negative effect on the internal 
market, in general, and, in particular, in Commission legislative proposal in the field of 
internal market . 
 
The lack of EU action negatively affects EU citizens in terms of premature mortality, 
expensive health care treatment and inadequate consumer information. This is not in line with 
the overall aim of the EU to promote the wellbeing of its people (TEU Article 3) nor with 
TFEU Articles 168(1) and 114(3) which foresee a high level of health protection in all EU 
policies and activities.  
 
Economic stakeholders have referred to some shortcomings with the current TPD (e.g. on 











EU action to 
prevent 
fragmentatio
n of the 
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market if 
there is a risk 
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implementati
on.   
EU to ensure that 
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are implemented.  
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application. EU 
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fragmentation of 
the internal 
market caused by 
divergent 
implementation.   
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are not against a revision of the TPD if it improves the functioning of the internal market.96 
The industry has also drawn the attention of the Commission to the risks associated with 
increased illicit trade. However, in general, the industry does not support further 
harmonisation, possibly in the fear of stricter regulation ("high level of public health"), 
although one company interviewed in the context of the revision stated that a single regulation 
on ingredients across EU might be less expensive than the continuous adaptation to national 
provisions, as long as the regulation is proportionate and science based.97 The tobacco 
industry, in particular Swedish Match, has also asked for the lifting of the ban on oral 
tobacco. They strongly oppose measures such as plain packaging and display ban at point of 
sale (PoS). The health NGOs, on the other hand called for stricter measures in particular with 
respect to labelling and ingredients. They requested that the ban on oral tobacco (snus) is not 
lifted and that stricter measures for chewing and nasal tobacco are introduced. They also 
called for strict regulation of NCP and supported measures against illicit/non-compliant 
products. For further details, see Annex 1.  
 
1.1.1. Problem 1: Smokeless tobacco and extension of the product scope  
a) Smokeless tobacco products (STP) 
Within the category of STP, the placing on the marketing of oral tobacco was banned in the 
EU in 1992 and this ban was maintained in the TPD in 2001 to stop the expansion of a 
product considered harmful to health, attractive to young people and new on the markets of all 
Member States.98  Before the ban, Member States had started to take individual action, which 
in 1992 was replaced by action at the Community level. The producers of oral tobacco argue 
that the ban on oral tobacco is no longer appropriate. The health NGOs and most Member 
States are of a different view. This section also raises the question whether the current 
labelling requirements for all STP (Art 5(4) TPD) and ingredients regulation (reporting) are 
still adequate/sufficient, taking into account the high number of new products which are now 
marketed/attractive to young people. 
• Effectiveness of the current TPD  
General problems related to all STP 
The current regulation of STP does not effectively address recent and foreseeable 
market developments. When the current regulation on STP (including the ban on oral 
tobacco) was introduced in 1992 and confirmed in 2001, chewing and nasal tobacco products 
were seen as traditional products on a declining market with virtually no market outside 
certain socio-professional groups (seafarers, miners and sectors of the army) and regions.99 
The situation has somewhat changed since the current TPD was adopted. Recent years have 
seen an increase in the sale of chewing tobacco as well as a modest increase in sale of nasal 
tobacco on the main markets concerned.100 Chewing and nasal tobacco products are subject to 
                                                 
96 Minutes from the meeting with FMC manufacturers, 2 December 2011: 
http://ec.europa.eu/health/tobacco/events/index_en.htm#anchor4 (accessed 28 Nov 2012). 
97 Matrix 2012 
98 OJ L 158. 11.06.1992. p30-33/ Council Directive 92/41/EEC on 15 May 1992 amending Directive 
89/622/EEC on the approximation of the laws, regulations and administrative provisions of the Member States 
concerning the labelling of tobacco products. See whereas clauses. Sweden has an exemption from the ban 
granted in its Accession Treaty (see article 151 and Annex XV thereof)), OJ C 241, 29.8.1994. 
99 OJ C 150 E. 30.5.2006. p 43-51. COM (1999) 594 final. 16.11.1999. Proposal for a Directive of the European 
Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the 
Member States concerning the labelling of tobacco products. See explanatory memorandum. 
100 Euromonitor data indicates an increase in the sale of chewing tobacco from 4 tons to 14.2 tons between 2000 
and 2010 in Denmark. Sales of nasal tobacco in Germany saw a small decrease in the beginning of the century, 
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cross-border trade, including via the internet, meaning that they can reach new user groups 
and new geographical markets.101 However, one chewing tobacco manufacturer has reported a 
greater potential for growth as more restrictions are put in place for smoking tobacco products 
as STP provides an alternative to be used where smoking is not allowed.102  The production 
method (partly done by hand) of traditional chewing tobacco and the relative expensiveness of 
the products is also an important factor in determining the market potential.  
 
In addition, there has been an important product development in STP (both as regards 
chewing and nasal tobacco and as regards oral tobacco limited to the Swedish market). As 
indicated in the market description (section 2.1.1), the main manufacturer of oral tobacco 
(snus) increased its portfolio from 22 to 180 brands between 2002 and 2008.103 New market 
strategies target consumers outside the distinctive population groups who traditionally used 
these products, including young people. For example, there are STP available which are 
especially developed for modern taste or a younger generation. STP with characterising 
flavours (including chewing tobacco with tropical or bergamot flavours, nasal tobacco with 
peanut butter or cheese and bacon flavour and oral tobacco with elderflower and rhubarb 
taste) are put on the market and nasal tobacco has recently been promoted at youth parties 
throughout Germany. The packaging and labelling has also become more attractive masking 
the health risks associated with these products. In this light some Member States have taken 
action and banned STP all together leading to discrepancy between national markets (see 
Annex 3). The accession country Iceland is also reflecting about the introduction of a ban on 
chewing and nasal tobacco.104   
 
The current labelling requirements for STP (oral, nasal and chewing tobacco) do not 
adequately inform consumers about the adverse health effects of STP. In particular, the 
current warnings lack visibility as they are required on one side of the package only and are 
often placed on the bottom of the packet.105 One of the countries (Norway) responding to the 
public consultation has argued that the current health warning on STP (including oral 
tobacco) is outdated, insufficient and needs to be strengthened. However, Norway cannot take 
action at national level due to the current TPD requirements (TPD Article 5(4)) which applies 
to this country through the EEA Agreement.106   
In terms of health, there are considerable differences between various types of STP, but 
all STP contain nicotine and are addictive. While according to a relatively recent SCENIHR 
opinion (2008) STP are less harmful than for example FMC, the report also concluded that 
STP are not harmless. This is in line with the assessment of IARC, that has classified STP as 
carcinogenic to humans. These products contain carcinogenic substances, albeit at different 
levels, and are associated with a number of adverse health effects. The health effects, 
                                                                                                                                                        
but the trend has reversed in recent years, from 168 tons 2008 to 170 tons in 2011. (Matrix 2012).  The trend in 
chewing tobacco is fully in line with data reported by one manufacturer of chewing tobacco. Other stakeholders 
involved in chewing and nasal tobacco were not able to provide the Commission with specific data showing the 
development of the market from 2000 to 2010 despite several reminders.  
101 There are no exact figures on cross-border trade in STP trade available, but indications that such trade exists 
are available on a number of websites.  
102 SANCO meeting with Oliver Twist, 19 July 2012. 
103 Swedish Match magazine Inside #2 from May 2008 
104 Fontaine P. Ban on snuff a possibility. The Reykavik Grapevine 2012 Jul 17. 
http://grapevine.is/News/ReadArticle/Ban-On-Snuff-A-Possibility (accessed 28 Nov 2012). 
105 Swedish National Institute of Public Health (FHI). Public Consultation. Possible revision of the Tobacco 
products directive. Ostersund: FHI; 2010. http://www.fhi.se/Documents/Om-oss/remisser/2010/Remissyttrande-
tobacco-products-directiveVERK-2010-546.pdf (accessed 28 Nov 2012). 
106 Comment on the Consultation on the possible Revision of the Tobacco Products Directive 2001/37/EC by the 
Norwegian ministry of Health and Care Services, December 2010. 
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including findings from more recent studies, are further developed in section 5.2.1, assessing 




Oral tobacco (snus) 
There are divergent views among stakeholders whether the current ban of placing on 
the market of oral tobacco is justified and whether the ban should be maintained, 
extended to other STP or lifted. Economic stakeholders, in particular those producing oral 
tobacco (snus), like Swedish Match, and citizens responding to the public consultation have 
argued that the ban of oral tobacco is no longer justified considering that oral tobacco is less 
harmful than FMC and also less harmful than other STP (chewing and nasal tobacco) which 
are not banned. These stakeholders also claim that oral tobacco can be used for smoking 
cessation. Other stakeholders, including most Member States and health NGOs, have 
defended the current ban and/or argued for an extension of the ban to all STP. The main 
arguments from these stakeholders relate to concerns about the harmful health effects of STP, 
the risk of STP as a gateway to FMC consumption and the risk of dual use (i.e. consumption 
of both cigarettes and snus). It was also argued that all STP need to be banned while these 
products still have relatively limited market shares as the supply of novel forms of STP is 
likely to increase. Respondents within this category also pointed to the fact that STP cannot 
be seen as an effective substitute for FMC.  
 
The main producer of oral tobacco in the EU, has also claimed that the different treatment of 
oral tobacco and chewing tobacco is discriminatory. The producer has pointed to the huge 
marketing potential for oral tobacco (snus) outside Sweden and indicated that the current ban 
is equal to a hypothetical annual loss in export revenues to at least 3 bEUR and in the most 
optimistic scenario the market could even reach 9 bEUR per year.107 The marketing potential 
for oral tobacco has increased significantly in recent years as STP is a means to consume 
tobacco/nicotine in public places where smoking is forbidden. Manufacturing of some other 
STP requires manual labour which significantly limits the growth potential. Also, this type of 
STP is produced by a very limited number of SMEs who do not have the market power to 
export into new markets where the products have no traditional use.     
 
The authorities of the autonomous Finnish island Ǻland have argued in their submission to 
the public consultation on the revision of the Tobacco Products Directive (TPD) that the 
current ban on oral tobacco distorts competition. Ships under Swedish flag would be allowed 
to sell oral tobacco (snus), whilst vessels under the flags of Finland or Åland serving the same 
routes would not be allowed to do so.108  
 
Novel tobacco products 
The STP market development is not limited to conventional oral, chewing and nasal tobacco 
products. There are also important developments in other novel tobacco products, often 
claimed to be less harmful than FMC and targeted to consumers who cannot or will not cease 
                                                 
107 Swedish Match power point, 15 December 2011 
108 Any differential treatment, however, is an effect of the exemption rather than the ban. See the Courts 
reasoning in Case C-434/02 Arnold André GmbH & Co. KG v Landrat des Kreises Herford [2004] ECR I-
11825, p 41 
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smoking.109 The tobacco industry seems to see a very significant potential in this new product 
development.110 Like for other the STP, the question is whether these products can act as 
entry gates into tobacco consumption, in particular among young people, or whether these 
products prevent established smokers from quitting (dual use). The expected development in 
consumption of STP in the absence of further EU action is explored under section 2.3 
(Baseline scenario).    
• Enforcement of the current TPD 
The current regulation of STP based on the mode of consumption of different STP 
categories is sometimes unclear and can facilitate circumvention of the current legislation. 
In particular, it may encourage STP manufacturers to market their products as chewing 
tobacco (allowed) instead of tobacco to be sucked (banned as oral tobacco). For example, the 
instruction on how to use a product marketed as a chewing tobacco found on an internet store 
refers to the placing “under your upper lip and keep in place for 5 minutes to a few hours 
according to your convenience", which describes a sucking and not a chewing mode of use. 
 
It has been reported that the current ban of placing on the market of oral tobacco has 
also led to some enforcement difficulties. A recent study concludes that many internet 
retailers of Swedish oral tobacco (snus) target non-Swedish customers and that ordering oral 
tobacco from EU Member States other than Sweden is quick and straight forward despite the 
current ban. Out of 43 test purchases in 10 Member States, 41 were successfully made.111 The 
availability of oral tobacco through internet throughout the EU was also pointed out in the 
Commission report on Sweden's implementation of measures necessary to ensure that oral 
tobacco is not placed on the market in other Member States.112 Further action might be 
warranted on this issue upon receipt of supplementary information. 
 
b) Nicotine containing products (NCP) 
Electronic cigarettes and other NCP for leisure purposes did not exist when the current TPD 
was adopted in 2001. This raises the question whether there is a need for action and if so how 
these products should be treated. 
• Implementation of the current legal framework for NCP  
About half of the Member States have reported that they consider electronic cigarettes and 
other NCP as medicinal products by function, even if they are not presented as smoking 
cessation aid but rather as alternative to cigarettes (leisure products). One third have said they 
have no specific regulation in place which means that the General Product Safety Directive113 
applies and a minority of the Member States have chosen to ban these products or apply 
certain provisions that are used for tobacco products (for further details, see Annex 3, 
A.3.1.1.2.). So far, no electronic cigarette has been authorised in the EU under the 
pharmaceutical regulation, but at least one application has been submitted and others are 
                                                 
109 Minutes from SANCO's meeting with Philip Morris International, 8 March 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20120308_mi_en.pdf 
110 See for ex. Thompson C. BAT invests in a smokeless future. Financial Times 2012 Sept 30, where it is 
reported that the market for tobacco alternatives (including non-combustible cigarettes and nicotine inhalers) 
could count for as much as 40% of BAT's revenues – which were £15bn in 2011 – in 20 years time.   
111 Peeters S, Gilmore AB. How online sales and promotion of snus contravenes current European Union 
legislation. Tob Control 2012. 
112 COM (2010) 399 final Report from the Commission to the Council on the implementation of the Kingdom of 
Sweden of the measures necessary to ensure that oral tobacco is not placed on the market in other Member 
States. 29.7.2010.  
113 Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001 on general product safety 
     27 
foreseen.114 The increasing market volume (section 2.1.3) and cross-border trade together 
with the different legislations in Member States affects negatively the functioning of the 
internal market. It contributes to legal uncertainty for manufacturers and distributors and 
may also negatively affect consumer confidence in the internal market, in particular 
considering the safety concerns related to NCP (see figure 12). It also prevents NCP from 
moving freely across borders as manufacturers and distributors are required to comply with 
many different legal systems. Member States have expressed an urgent need for orientation 
from the Commission as to which legislation applies to electronic cigarettes.115  
 
Nicotine replacement products (NRTs) considered as medicinal products need to undergo 
strict marketing authorisation procedures and if other NCP can reach the market without such 
authorisation, it could lead to an unjustified advantage undermining a level playing field. 
The pharmaceutical industry has argued in favour of regulating NCP (some of them in the 
context of the pharmaceutical legislation and others by including them in the scope of the 
TPD), while Electronic Cigarettes Industry Trade Association (ECITA) representing primarily 
vendors of electronic cigarettes in the UK has argued that these products do not need to be 
further regulated (see Annex 1).  
 
The current fragmented situation is a result of various efforts in Member States to respond to 
health concerns associated with NCP. The Commission has, so far, received fourteen 
notifications concerning (refill) liquids for electronic cigarettes via the RAPEX system, 
indicating serious health risks for consumers (17 December 2012).116 The serious health risks 
were due to the toxicity of nicotine and misleading presentation, for example labelling 
referring to fruit.  
 
Nicotine is a toxic and addictive substance.117 Acute nicotine poisoning has occurred in 
children who accidentally ingest nicotine and the safety of heavy or long terms use are not 
(yet) known.118 Cartridges are sometimes sold in containers with minimal protection against 
tampering, opening by children etc. Ingestion of a single replacement cartridge is very likely 
to be lethal and users have reported leakage when replacing cartridges, suggesting that the 
quality of cartridges themselves is highly variable. A study of five different brands of 
electronic cigarette also found that most brands' cartridges were poorly constructed and 
leaked.119 
 
                                                 
114 Information about one application. It has also been reported in media that at least one of the big FMC 
manufacturers is preparing for an application: Thomas R. Cigarette giant to offer ‘safer alternative.’ England and 
Wales: Nicoventures; 2011. http://www.nicoventures.co.uk/Content/Downloads/august-2011/PM_Aug_p2.PDF 
(accessed 28 Nov 2012). 
115 See European Commission. Orientation note. Electronic cigarettes and the EC legislation. Brussels: EC; 2008. 
http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/orientation_0508_en.pdf (accessed 28 
Nov 2012). 
116 DG Health and Consumers. Rapid Alert System for non-food products posing a serious risk (RAPEX). 
Brussels: DG SANCO; 2012. http://ec.europa.eu/consumers/safety/rapex/index_en.htm  
117 Nicotine is classified as a dangerous substance in Directive 67/548/EEC. 
118 Connolly GN, Richter P, Aleguas A Jr, Pechacek TF, Stanfill SB, Alpert HR. Unintentional child poisonings 
through ingestion of conventional and novel tobacco products. Pediatrics 2010; 125(5):896-9. See: BBC News. 
Gateshead doctor calls for research into 'e-cigarettes.' England: BBC; 2011. http://www.bbc.co.uk/news/uk-
england-12887335 (accessed 28 Nov 2012). A British doctor has called for more research on the risks of 
electronic cigarettes after a patient died of lung disease following heavy use of these products. The Electronic 
Cigarette Industry Trade Association claims, however, that 100% of users are former smokers and any lung 
damage observed in patients will have been the results of traditional cigarette use 
119 Trtchounian A, Talbot P. Electronic nicotine delivery systems: is there a need for regulation? Tobacco 
Control 2010; 20:47–52. 
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Studies of the nicotine content of cartridges have shown significant differences between 
labelled and true levels of nicotine cartridges and refill solutions.120 Analyses of electronic 
cigarette samples conducted by the US Food and Drug Administration (FDA) have shown 
detectable levels of known carcinogens and toxic chemicals; including diethylene glycol, 
tobacco-specific nitrosamines and tobacco specific impurities.121 A recent study has found 
immediate adverse physiologic effects (changes in the lung function) after short terms use 
which is similar to some of the effects associated with tobacco smoking.122 Another recent 
study concludes that ‘passive vaping’ must be expected from the consumption of e-cigarettes 
due to prominent components in the gas-phase, including 1,2-propanediol, 1,2,3-propanetriol, 
diacetin, flavorings, and traces of nicotine.123  
 
Some NCP also appear to be subject to vivid and innovative marketing, which could 
attract young people in particular. For example, e-cigarettes are available in a range of 
flavours, including coffee and cherry and a "smart pack" is being introduced that vibrates and 
flashes a blue light when a user is within 50 feet of someone with another "smart pack". The 
popularity of electronic cigarettes was also confirmed in a recent Polish survey which found 
that one in five young people had tested electronic cigarettes. 124 ECITA on the other hand 
claims that consumers are mainly established smokers using the product for cessation and 
reduction purposes.125 
 
At this stage the evidence on the effectiveness of electronic cigarettes in smoking cessation is 
inconclusive.126 As indicated, most users of electronic cigarettes seem to use them for 
cessation/reduction purposes, but the industry association, ECITA, explicitly advices its 
members to refrain from such claims as it could trigger application of medicinal products 
regulation (see section 2.1.3.). There are also some concerns that electronic cigarettes and 
other NCP can take advantage from national smoke-free environment policies,127 in particular 
as the products are often promoted as an alternative to smoking which allows smokers to keep 
up nicotine addiction in situations where smoking is prohibited. Electronic cigarettes can also 
become a starter/re-starter product attractive to young people or former smokers.128 However 
                                                 
120 Goniewicz ML, Kuma T, Gawron M, Knysak J, Kosmider L. Nicotine Levels in Electronic Cigarettes. 
Nicotine Tob Res 2012. 
121 US Food and Drug Administration (FDA). Evaluation of e-cigarettes. St Louis, MO: FDA, USDHHS; 2009. 
US Food and Drug Administration (FDA). Summary of Results: Laboratory Analysis of Electronic Cigarettes. 
US: FDA; 2009. Knysak J, Gawron M, Goniewicz ML, Kurek J, Kosmider L, Sobczak A. Determination of 
formaldehyde in aerosol from electronic cigarettes using derivatization and solid phase extraction followed by 
liquid chromatography, Abstract from 14th young scientists conference on chemistry, 18-21 March 2012, 
Rostock, Germany. p.95.  
122 Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term 
pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled 
nitric oxide. Chest 2012; 141(6):1400-6. 
123 Schripp T, Markewitz D, Uhde E, Salthammer T. Does e-cigarette consumption cause passive vaping?  
Indoor Air 2012.  
124 Goniewicz ML, Zielinska-Danch W. Electronic cigarette use among teenagers and young adults in Poland. 
Pediatrics 2012;130(4):e879-85. 
125 Minutes from SANCO's meeting with ECITA, 20 June 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20120703_mi_en.pdf (accessed 28 Nov 2012). 
126 Etter JF, Bullen C, Fouris AD, Laugesen M, Eisenberg T. Electronic nicotine delivery systems: a research 
agenda. Tob Control 2011; 20:243-8. 
127 World Health Organization (WHO) Study Group on Tobacco Product  Regulation. Report on the Scientific 
Basis of Tobacco Product Regulation. WHO Technical Report Series, no. 955. Geneva: WHO; 2010. Yamin CK, 
Bitton A, Bates DW. E-cigarettes: a rapidly growing Internet phenomenon. Ann Intern Med 2010 Nov 2;153(9): 
607-9. 
128 Cobb NK, Abrams DB.  E-cigarette or Drug-Delivery Device? Regulating Novel Nicotine Products. N Engl J 
Med 2011; 365(3):193-5. 
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there are some studies being published that highlight the electronic cigarettes' potential as a 
smoking cessation aid. 129 
 
• Enforcement of the current legal framework for NCP 
The current uncertainty in relation to the legal classification of NCP makes enforcement 
difficult and contributes to circumvention. It also undermines reaching a level playing 
field and leads to an unjustified differential treatment of different types of products containing 
nicotine. Today, there are two categories of products containing nicotine available on the 
market: NCP placed on the market without any prior control and NRT (Nicotine Replacement 
Therapies) which have been subject to a strict (and relatively costly) risk/benefit analysis and 
approved as medicinal products.  
 
As illustrated under the market description (section 2.1.3), most electronic cigarettes are 
presented as alternatives to FMC rather than smoking cessation aids. It appears that the 
products are presented in this way in order to avoid the relatively burdensome authorisation 
procedure applicable to medicinal products.130   
 
Regardless of the presentation of the NCP, a product which may be used to modify 
physiological functions falls under the definition of medicinal products by function and needs 
to be authorised under this framework before being put on the market. The pharmacological 
effects of nicotine in NRTs are well documented. Nicotine attaches itself to receptors in the 
brain and has a long tradition of use in NRTs to reduce craving and help people stop 
smoking.131 
 
Moreover, electronic cigarettes without prior authorisation appear to be available also in 
Member States which have reported that they consider them as medicinal products or prohibit 
marketing.132 According to ECITA, regulatory agencies struggle to provide monitoring and 
enforcement in regulating the electronic cigarette industry.133  
 
c)  Herbal products for smoking 
• Fragmentation of the internal market 
Herbal products for smoking, e.g. tobacco- and nicotine-free cigarettes and herbal fillings of 
water-pipes, fall outside the current scope of the TPD and are currently not subject to 
harmonised rules in the EU. This raises the question whether these products – considering 
their similarities with tobacco products – should be regulated in the revised TPD. Herbal 
products for smoking are subject to many different regulatory regimes in Member States. 
About half of the Member States have no specific regulation in place, while two Member 
States do not allow these products, one Member State has labelling requirements in place and 
                                                 
129 Caponnetto P, Polosa R, Russo C, Leotta C, Campagna D.  Successful smoking cessation with electronic 
cigarettes in smokers with a documented history of recurring relapses: a case series. J Med Case Rep 2011 Dec 
20;5(1):585. Etter JF, Bullen C. Saliva cotinine levels in users of electronic cigarettes. Eur Respir J. 2011. Polosa 
R, Caponnetto P, Morjaria JB, Papale G, Campagna D, Russo C. Effect of an electronic nicotine delivery device 
(e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health 
2011;11:786. 
130 For example, ECITA recommends to its members to stay out of medical claims as this could render the 
product illegal (material provided to DG SANCO).   
131 Nicotine patches, sprays, inhalers and chewing gums have already been authorized as medicinal products. 
132 See for example Minutes of SANCO's meeting with ECITA on 20 June 2012 reporting about two members in 
Greece despite the ban on such products in Greece (see Annex 3: 
http://ec.europa.eu/health/tobacco/docs/ev_20120703_mi_en.pdf 
133 Electronic Cigarette Industry Trade Association (ECITA). Quarterly Update, June 2012. UK: ECITA; 2012. 
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the remaining Member States have other rules (see Annex 3, A.3.1.1.1). This negatively 
affects the cross border trade in these products, which appears to be quite significant 
considering that many products are marketed and sold on-line.134 Manufacturers and retailers 
need to be familiar with and keep up to date with many different legal situations in all 
Member States. The free movement of goods and consumer confidence in the internal market 
cannot be secured in this case as the health requirements differ significantly from one 
Member States to another. 
 
The divergent actions taken by Member States are a result of health concerns related to these 
products. Herbal products for smoking have not been extensively studied from a 
scientific/health perspective but it is generally acknowledged that inhalation of smoke of any 
kind can pose a health risk. This is also the reason for Member States' actions in this area. 
Evidence suggests that the combustion of these products produces a level of carbon monoxide 
similar to tobacco cigarettes as well as other toxic substances such as tar.135 On the other 
hand, these products do not contain nicotine and may therefore not be associated with the 
same risk of addictiveness.136 It is of particular concern that these products are often perceived 
as harmless or less harmful by consumers. This perception is reinforced by the current 
marketing of herbal products for smoking as "healthier" and "natural products without 
additives".137 
 
A particularly worrying trend in this context is the increase in water-pipe (sisha) smoking 
among young people.138 The content of the water-pipe filling is often unclear and sometimes 
herbal filling is used which does not contain tobacco.139 Water-pipe smoking as such is also 
often perceived as a less harmful activity than traditional tobacco smoking. As indicated, this 
is expected to trigger further actions at national level in the years to come.   
1.1.2. Problem 2: Packaging and labelling 
The type, size and location of health warnings as well as the display of TNCO levels are 
already subject to harmonised provisions in the current TPD (see figure 12). However, it 
might be necessary to update these rules to bring them in line with international, market and 
scientific development. 
 
• Effectiveness of the current TPD 
The current provisions on packaging and labelling are no longer in line with scientific 
evidence and commitments in the context of the FCTC. For example, the current 
obligation to print the TNCO yields on the package have been shown to be potentially 
misleading, as it makes people believe that some products are less risky to their health.140 
                                                 
134 No exact figures are available, but herbal cigarettes are sold on line 
135 Groman E, Bernhard G, Blauensteiner D, Kunze U. A harmful aid to stopping smoking. Lancet 1999; 
353(9151):466-7. 
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Scientific evidence also suggests that bigger pictorial pictures on both sides are more effective 
than text-only warnings on a range of outcomes, including being a deterrent for new 
smokers141 and a means to increase cessation among current smokers.142 In particular, they 
increase smokers' and potential consumers' awareness of warnings, knowledge and credibility 
of health risks, depth of processing and also cessation behaviours such as forgoing FMC, quit 
intentions and actual quitting.143 Thus, the current TPD provisions in this area are not as 
effective as they could be.  
 
Figure 12: Comparison between harmonised TPD provisions and FCTC guidelines in the area of packaging & 
labelling  
Current TPD Articles 5 and 7 Article 11 FCTC and Guidelines for implementing 
Articles 11 and 13 FCTC 
Text warnings not less than 30% + 40% of both sides 
(Art 5(5)). For Member States having more than one 
official language, the warnings should be increased to 
32-35% and 45-50%.   
Health warnings shall be large, clear, visible and 
legible and should be 50% or more of the principal 
display areas but not less than 30% (FCTC Art 11b(iii) 
and (iv)) 
Health warnings should be more than 50% of the 
display areas (GL Art 11) 
Member States may introduce pictorial warnings on 
one side of the package (Art 5(3))  
Parties should consider pictorial health warnings on 
both principal display areas. (GL Art 11)  
Mandatory display of TNCO levels on the package 
(Art 5(1))  
Parties should prohibit the display of figures for 
emission yields such as TNCO. (GL Art 11) 
Ban on misleading product descriptions (Art 7)    Packaging, individual cigarettes or other tobacco 
products should carry no advertising or promotion, 
including design features that make products attractive. 
(GL Art 13) 
 
Some of the current packet shapes make it difficult to effectively display health 
warnings affecting negatively the visibility and legibility of the warning. This is 
particularly the case for very narrow (including “lip-stick” shaped) packets which distorts text 
and picture warnings.144  
 
Use of colours and other design features on packages and tobacco products undermines 
the effectiveness of the ban on misleading descriptors in Article 7 of the current TPD. 
                                                                                                                                                        
Monograph no. 13. Bethesda, MD: National Cancer Institute, 2001. Brown A, McNeill A, Mons U, Guignard R. 
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Addiction 2008; 103:1562-71.  Créatec+. Quantitative Study of Canadian Youth Smokers and Vulnerable Non-
Smokers: Effects of Modified Packaging Through Increasing the Size of Warnings on Cigarette Packages. 
Montreal: Créatec+; 2008. (Report for Health Canada). Shanahan P, Elliott D. Evaluation of the Effectiveness of 
the Graphic Health Warnings on Tobacco Product Packaging 2008. Canberra: Australian Government 
Department of Health and Ageing; 2009. 
142 Hammond D. Health warning messages on tobacco products: a review. Tob Control 2011; 20:327-3. Thrasher 
JF, Rousu MC, Hammond D, Navarro A, Corrigan J. Estimating the impact of pictorial health warnings and 
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102:41– 8.  
143 Hammond D. Health warning messages on tobacco products: a review. Tob Control 2011; 20:327-3. 
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Since the adoption of the current TPD, misleading descriptors such as “light, “mild” and 
ultra” has been replaced by the use of colours which can be misleading and give the 
impression that some products are less harmful than others (for example gold and white is 
used to indicate 'light' FMC).145 Recent studies have demonstrated that packages have the 
potential to mislead smokers and potential consumers and present them with an erroneous 
comfort about the risk of smoking.146 For instance, FMC packets featuring the descriptors 
'slim' ot 'extra-slim' were rated significantly more appealing than packets witout those 
descriptors.147 In another study of young adults, so-called 'super-slim' 'parfume type' FMC 
packagets were associated with femininity, elegance, slimness and reduced harm.148  
 
Likewise, the shapes (e.g. slim) and colours (e.g. pink, black, denim blue) of individual FMC 
can mislead consumers by creating e.g. the impression of harmlessness.149 A study found that 
smokers of 'slim' FMC were more likely to believe that some FMC could be less harmful and 
that their own brand might be a little less harmful.150 A recent study in young Australian 
adults has shown that characteristics of the cigarette stick affect smokers' perceptions of the 
attributes of cigarettes.151 Some packages make different types of health claims by conveying 
the impression that a product has health benefits as it contains fruits, vitamins or is associated 
with energy. Other packages claim that FMC contain “no additives” or are “natural”, which 
can lead to misperceptions that certain products are less harmful.  
   
• Enforcement of the current TPD 
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Article 5(5) of the current TPD allows Member States to impose stricter labelling measures 
for domestically produced products, but Member States can only impose stricter rules on 
imported products.152 This can lead to market distortion and the industry could 
circumvent strict domestic measures by shifting production to other Member States.  
 
• Currently not fully harmonised aspects of packaging and labelling 
Some of the not fully harmonised aspects of packaging and labelling are subject to important 
disparities between national regulations. For example, pictorial health warnings are already in 
use in eight Member States, two Member States will use them from 2013 onwards while the 
remaining seventeen Member States for the moment require textual warnings only (see Annex 
3). In addition, Member States apply different rules on the package size/minimum number of 
FMC per package and different rules on display of cessation services on the packages. The 
choice of pictures used also varies from one Member State to another. At least one Member 
State (France) bans promotional elements on the package as part of its advertising ban, whilst 
technical discussions are taking place in a few Member States as regards promotional 
elements, including FMC and smoke appearance.153 As described under section 2.3, the 
disparities are expected to grow in coming years.  
 
The heterogeneous development in Member States is closely linked to the legal obligations 
and political commitments in the context of the FCTC (see figure 13). The FCTC provides a 




Figure 13: Political commitments stemming from FCTC guidelines in areas not fully harmonised by the TPD 
 
FCTC and its guidelines (GL)  Situation in Member States  
Each Party should endeavour to prohibit the sale of 
FMC individually or in small packets. (FCTC Article 
16) 
Fourteen Member States specify a minimum package 
size of twenty FMC: AT, CZ, DK, EE, FI, FR, EL, IE, 
LU, LT, PL, PT, RO, ES 
Four Member States specify a minimum package of 
nineteen FMC: DE, HU, NL, SE 
One Member State has a minimum package size of 10: 
UK 
One Member States requires FMC to be sold in 
packages of 10 or 20: IT   
Two Member States prohibit the sale of single FMC: 
LV, SI 
Parties should consider pictorial health warnings on 
both principal display areas. (GL Article 11) 
Pictorial health warnings (on one side) in use in eight 
Member States: BE, RO, UK, LV, FR, MT, ES and 
DK (in IE and HU starting in 2013) 
Health warnings and messages should in addition to 
harmful effects address advice on cessation (GL 
Article 11) 
Four Member States have mandatory references to 
cessation services displayed on the packages: BE, FR, 
NL, SI 
Nine Member States have references to cessation 
services included in some warnings: AT, DK, DE, HU, 
IE, LV, PL, SE, UK 
Parties should consider adopting measures to restrict 
or prohibit the use of logos, colours, brand images or 
promotional information on, packaging other than 
-Public consultation in UK. (16 April -10 August 
2012)154 
-Statement of BE Health Minister in the parliament.155 
                                                 
152 Of course, if a measure is outside the scope of the current TPD Member States are entitled to impose stricter 
rules (even restricting cross-border trade), if the measure can be justified under Art.36 TFEU. 
153 ITC Project. ITC France National Report. Waterloo, CA and Paris: University of Waterloo, Institut national 
de prévention et d’éducation pour la santé (INPES), Institut national du cancer (INCa), and Observatoire français 
des drogues et des toxicomanies (OFDT); 2009. 
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brand names and product names displayed in standard 
colour and font size (plain packaging) (GL Article  11) 
Parties should consider adopting plain packaging 
requirements to eliminate the effects of advertising and 
promotion on packaging. (GL Article 13) 
-Proposal by FR MP in report to the FR Health 
Minister (February 2012).156 
-Informal discussions in FI.   
 
Parties should prohibit or restrict ingredients that have 
colouring properties in tobacco products. (GL Article 9 
and 10) 
-At least BE bans an ingredient capable of colouring 
the smoke blue (see Annex 3).   
 
Discrepancies between national legislations in product related areas are liable in themselves to 
constitute obstacles to the free movement of goods.157 In this concrete case, the diversity 
between national legislations obliges the tobacco industry to be familiar with and adapt to 
multiple national legislations and possibly produce different labels and different packages for 
different markets.  
 
The fact that the industry has not explicitly requested the harmonisation should not be 
misunderstood to suggest that the problem does not exist. It could rather be a sign that the 
industry might expect a harmonisation at a higher level ("high level of public health"). SME's 
could be more open to harmonisation as they have less resources to adapt to diverging 
legislation and harmonisation would thus facilitate their ambition to expand their activities 
beyond their home markets.158 At least one of four big tobacco manufacturers has also 
indicated that it has no major concerns regarding the introduction of mandatory pictures, 
TNCO replacement and cessation services displayed on the packages if appropriate space is 
given for trademarks.159 Other manufacturers have been less explicit. 
 
For Member States, the current lack of harmonisation represents a lost opportunity to fully 
benefit from common solutions across the EU as Member States will have to come up with 
their own solutions to address scientific, market and international developments.  
 
The divergent labelling schemes in Member States also mean an unnecessary burden for 
economic stakeholder in terms of compliance costs (e.g. familiarisation, multiple adaptations 
to national measures and different product lines for different countries) (see section 5.1).   
1.1.3. Problem 3: Ingredients 
The current TPD foresees reporting obligations in a non-harmonised format and invites the 




                                                                                                                                                        
154 UK Department of Health (UK DoH). Consultation on standardised packaging of tobacco products. London: 
DoH; 2012. 
155 Commission de la Santé publique, de l'Environnement et du Renouveau de la Société. Report of the health 
commission of 19th January 2011. Brussels: Chambre des représentants de Belgique; 2011. p 29-31. 
http://www.lachambre.be/doc/CCRI/pdf/53/ic096.pdf  (accessed 28 Nov 2012).  
156 Yves Bur. Propositions pour une nouvelle politique de lutte contre le tabac. Rapport au Ministre du Travail, 
de l'Emploi et de la Sante. Paris: 2012. See also: Chantry C. Nouveau plan antitabac: ce que prépare le 
gouvernement. Paris: Le Parisien; 2012. http://www.leparisien.fr/economie/nouveau-plan-antitabac-ce-que-
prepare-le-gouvernement-05-09-2012-2151462.php  (accessed 28 Nov 2012). 
157 C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) Ltd 
and Imperial Tobacco Ltd.[2001] ECR I-11453, p 64 
158 See section 5.1 and the reference to the statement of one company that ingredients legislation across EU 
might be less expensive than if actions are taken at Member State level, Matrix 2012. 
159 Minutes from the meeting with FMC manufacturers, 2 December 2011: 
http://ec.europa.eu/health/tobacco/events/index_en.htm#anchor4 (accessed 28 Nov 2012). 
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• Effectiveness of the current TPD 
Despite its mandatory character, the ingredients reporting set out in Article 6 of the current 
TPD is not working effectively. This was emphasised by economic (and other) stakeholders in 
the context of the public consultation of the TPD (see Annex 1) and also highlighted in the 
Second Application Report. Despite the publication of the EU guide on harmonised reporting 
format160 and the development of an electronic tool for data submission (EMTOC161), 
different reporting formats are still used for reporting of ingredients. This makes it difficult 
for manufacturers and importers to provide requested information and for Member 
States to fulfil the reporting obligations set out in the current TPD. It also makes it difficult 
for the Commission to analyse the reported data.  
 
Manufacturers also have concerns about confidential business information and there is no 
uniform and reliable basis to inform consumers on the content of tobacco products. Finally, 
disparities in the current reporting system makes it burdensome for Member States and the 
Commission to compare, analyse and draw conclusions from the data received.  
 
b) Ingredients regulation 
• Currently non-harmonised aspects of ingredients 
In the absence of a common ingredients regulation, Member States have adopted different 
approaches. Four Member States have introduced positive lists indicating additives allowed 
to be used in tobacco products, one has introduced a negative list that restricts specific 
additives from being included in tobacco products and five have a combination. One Member 
State has maintained a voluntary agreement with the manufacturers (see Annex 3, 3.1.2.2). 
The EU has no regulatory power within the current TPD to harmonise these national lists and 
thus prevent obstacles to the internal market.162 Most of these national regulations appear to 
be rather old and based on food legislation. However, there is a growing tendency in Member 
States to regulate ingredients, in particular as regards additives attractive to young people. 
One key example is the French regulation, fixing maximum levels for additives that impart a 
sweet or fruity/acid taste to FMC (e.g. vanilla). This has led to the reformulation or removal 
of certain products on the French market. In the aftermath, the same products were also 
altered in the other EU markets. Lithuania bans clove, vanilla plant and a number of other 
additives (see Annex 3.1.3.2). Another example is the different approaches as regards to 
additives added to the filter of FMC (e.g. menthol burst-capsule which allows a smoker to 
activate the menthol flavour whenever he/she wishes to do so). These new products are 
allowed in a number of Member States, while authorisation has been refused in other Member 
States (Germany, Belgium) (see Annex 3, A.3.1.3). The lack of a harmonised approach on 
additives affects the functioning of the internal market and prevents free movement of 
products across the EU. Manufacturers have to produce different products for different 
markets. 
 
                                                 
160 European Commission. Practical guide on reporting on tobacco ingredients. Brussels: European Commission; 
2007. http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/practical_guidance_en.pdf 
(accessed 28 Nov 2012). 
161 EMTOC (Electronic Model Tobacco Control) is a European web application which enables safe submission 
of the lists of tobacco ingredients to the concerned authorities. It was funded from the Health Programme by the 
European Executive Agency for Health and Consumers (EAHC) (60%) and a consortium of 13 Member States 
(40%). 
162 Article 12 of the current TPD invites the Commission to propose a common list taking into account inter alia 
addictiveness.  
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As outlined under the baseline scenario (section 2.3), the heterogeneous development on the 
internal market is expected to increase further in coming years in the absence of a 
common EU approach. The expected development in Member States is not only based on the 
FCTC guidelines, but also on scientific progress and development of the market.  
 
A significant number of scientific studies show that certain tobacco additives make FMC 
more appealing. The WHO Study Group on Tobacco Product Regulation summarises the 
international public health knowledge about flavourings added to FMC and other tobacco 
products and their attractiveness to young and older smokers.163 The Commission’s 
independent Scientific Committee on Emerging and Newly Identified Health Risks 
(SCENIHR) concludes, in its Opinion of 2010, that the use of fruit and candy flavourings in 
high amounts seems to favour smoking initiation by young people.164 It is also suggested that 
some additives decrease the harshness and increase the smoothness of the smoke. This also 
applies to menthol FMC, which show increased use in some Member States, e.g. Germany 
where the market share of menthol FMC more than doubled in the past ten years, from 1.3 to 
3%.165 
 
In terms of market development, additives are added to tobacco products which will make 
them more palatable and capable of misleading consumers to believe that they are less 
harmful or have some beneficial effects. For example, spices and herbs can also be used to 
improve the palatability.166 As mentioned above, another recent development is FMC 
containing a burst capsule that enhances menthol (or other) flavour when squeezed and turn a 
FMC from non-menthol to a menthol FMC.167 Colouring agents are another way of enticing 
young people. Both pink and black coloured FMC are available on the market and a tobacco 
company recently wanted to use an additive which would colour the smoke blue.168 Various 
additives have been used in tobacco products to help create the misleading impression that 
such products have health benefits, present reduced health hazards or increase mental 
alertness and physical performance.169 For example, an oral tobacco product containing 
caffeine, taurine and guarana as well as baking soda claimed to help to keep the teeth white 
are available. 19% of EU citizens (smokers and non-smokers) believe that some FMC, e.g. 
those with menthol or other taste/flavour (spice, sweet, fruit) or those without additives or 
labelled as “organic” or “natural” are less harmful than others which is not the case.170 There 
is also a trend in several countries to use products labelled “without additives”.171 The tobacco 
industry has expressed doubts whether a ban on certain fruit and candy flavoured products, 
such as pina colada and strawberry, would affect smoking behaviour, but showed some 
understanding for the need of further regulation.172 
 
 
                                                 
163 World Health Organization (WHO) Study Group on Tobacco Product  Regulation.  Candy flavoured tobacco 
products: Research needs and regulatory recommendations. The Scientific Basis of Tobacco Product Regulation, 
WHO Technical Report Series no. 945. Geneva: WHO; 2007. p.25-42.  
164 SCENIHR 2010  
165 German Cancer Research Center (DKFZ). Menthol Capsules in Cigarette Filters – Increasing the 
Attractiveness of a Harmful Product. Heidelberg: DKFZ; 2012. 
166 WHO FCTC guidelines for the implementation of Article 9 and 10. 
167 German Cancer Research Center (DKFZ). Menthol Capsules in Cigarette Filters – Increasing the 
Attractiveness of a Harmful Product. Heidelberg: DKFZ; 2012. 
168 Annex 3 (3.1.3). See also: De Standaard. Belgium. 5 December 2011. 
169 WHO FCTC guidelines for the implementation of Article 9 and 10 
170  Eurobarometer 2012  
171 SCENIHR 2010  
172 Minutes from the meeting with FMC manufacturers, 2 December 2011: 
http://ec.europa.eu/health/tobacco/docs/ev_20121202_mi_en.pdf (accessed 28 Nov 2012). 
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Finally, it should be noted that tobacco additives also transform tobacco smoke into an even 
more complex chemical mixture and thereby may further increase the carcinogenic and 
harmful effects of tobacco. Additives that facilitate deeper inhalation (e.g. menthol) or 
inhibit the metabolism of nicotine may enhance the addictiveness of nicotine indirectly.173 A 
review made of nearly 600 additives to FMC suggests that more than 100 are known to “have 
pharmacological actions that camouflage the odour of environmental tobacco smoke emitted 
from FMC, enhance or maintain nicotine delivery, could increase the addictiveness of FMC, 
and mask symptoms and illnesses associated with smoking behaviours.”174 The less aversive, 
cooler and milder smoke seems to improve the experience of smoking and facilitate smoking 
initiation. On the basis of an extensive review of all available information, the US FDA 
Tobacco Products Scientific Advisory Committee confirmed in 2011 that the evidence was 
sufficient to conclude that it is more likely than not that the availability of menthol cigarettes 
increases the likelihood of experimentation and regular smoking beyond.175 However, as 
mentioned previously (section 1.2) international work on ingredients has, so far, focused on 
attractiveness and the FCTC guidelines adopted in November 2010 do not address toxicity 
and addictiveness. However, work has been initiated in the areas of addictiveness and toxicity 
and it is expected that guidelines will be developed for these issues in coming years.     
In the absence of a harmonised approach under the current situation, Member States are faced 
with unnecessary administrative burden in terms of finding their own solutions on how to 
implement the FCTC guidelines and adapt national legislations to the above mentioned 
market and scientific developments. They cannot fully benefit from the economy of scale 
associated with one common solution across the EU and enforcement of national rules is 
becoming more burdensome. In addition, economic stakeholders are/would be faced with 
unnecessary compliance costs in terms of country specific familiarisation, reformulations of 
tobacco products and different production lines for different Member States (see section 
5.1).176  
1.1.4. Problem 4: Cross-border distance sales 
 
Cross-border distance sales of tobacco products fall outside the scope of the current TPD. 
According to Council Recommendation 2003/54, Member States are recommended to restrict 
tobacco distance sales for general retail. The FCTC guidelines for implementing Article 13 
recommend Parties to ban internet sales. The Protocol on Illicit Trade recommends regulating 
cross-border internet sales.   
 
Cross-border distance sales of tobacco implies a risk of circumvention of the safeguards 
of the TPD. Typically, tobacco products sold on the internet do not comply with the 
provisions of TPD, which means that consumers do not benefit from safeguards of the TPD 
(e.g. health warnings and ingredients). Legal cross-border internet sale of tobacco products 
also makes very little sense as taxes have to be paid, by the vendor, in the country of the buyer 
(i.e. no tax savings can be made by the buyer).177 Given the characteristics of the tobacco 
market, most tobacco products are also available on the domestic market. If the taxes in the 
                                                 
173 SCENIHR 2010  
174 Rabinoff  MD, Caskey N, Rissling A, Park C. Pharmacological and Chemical Effects of Cigarette Additives. 
Am J Public Health 2007; 97:1981-91.  
175 Tobacco Products Scientific Advisory Committee (TPSAC). Menthol Cigarettes and Public Health: Review 
of the Scientific Evidence and Recommendations.  Rockville, MD: US Food and Drug Administration; 2011. 
176 Matrix 2012. Summary of industry responses to questionnaire.   
177 Article 36 of Directive 2008/118 on excise duty of tobacco indicates that in the case of cross border sale, the 
excise duty have to be paid for in the country of destination. However, from a perspective of a consumer, cross-
border purchase makes primarily sense when the consumer avoids the higher excise duties in the country of 
destination.  
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country of destination are not paid consumers gets access to this product below the price level 
considered appropriate by the country of destination.   
 
• Circumvention of the TPD and problems related to enforcement  
The lack of effective common rules on cross-border distance sales of tobacco products 
increases the volume of tobacco products circulating on the internal market without 
complying with the TPD provisions (e.g. on health warnings, ingredients and ban on the 
placing on the market of oral tobacco). This is particularly the case under the current situation 
where internet sale of tobacco products is expected to increase in coming years (see section 
2.1.1) and also taking into consideration that legal cross-border internet sales of tobacco 
products make very little sense as described above.  
 
The difficulties to enforce the ban of placing on the market of oral tobacco are further 
described in section 2.2.1. 
 
In a report from 2009 on the implementation of the Recommendation 2003/54, the 
Commission also concluded that, despite the overall satisfactory transposition, the area of 
distance sale of tobacco represent particular challenges and problems as far as 
enforcement is concerned.178  
 
In addition to the non-compliance with the TPD provisions, many of the sites offering tobacco 
products on-line do not have information as regards sales to minors and have no system in 
place to verify the age of the purchaser.179 In this context, it should be noted that age limits, 
between 16 and 18 years, for purchasing of tobacco are in place in all Member States (see 
Annex 3, A.3.1.4).  
Access to tobacco on the internet is therefore easier and cheaper than from other sources. 
Internet sales of tobacco also often imply illegal advertising.180  
 
As illustrated in Annex 3 (3.1.4), nine Member States do not allow internet sale of tobacco 
while some others have no restrictions in place.181 Among those Member States, some 
(including France and Lithuania) have introduced outright ban on this type of sale. Others 
(including Austria, Bulgaria, Hungary, Latvia and Spain) only grant licences or permission to 
sell tobacco through other sales channels. Several other Member States have different 
restrictions in place as far as internet sale of tobacco is concerned. The restrictions range from 
licensing of the internet retailer, to age limits and advertising bans. The different regulatory 
schemes in Member States and the lack of any common rules make it difficult for Member 
States to enforce their national legislation. This is particularly the case given the cross-
border dimension of this type of sales and the fact that the economic operators (retailers) 
compete on the same virtual market and offer their products to consumers regardless of their 
locations.  
 
• Impact on the internal market 
                                                 
178 Commission Staff Working Document of 23.11.09: Report on the Implementation of the Council 
Recommendation of 2 December 2002 on the prevention of smoking and on initiatives to improve tobacco 
control (2003/54/EC); 
http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/tobacco_report09_en.pdf 
179 Williams RS, Ribisl KM, Feighery EC. Internet cigarette vendors' lack of compliance with a California state 
law designed to prevent tobacco sales to minors. Arch Pediatr Adolesc Med 2006; 160(9):988-9. 
180 Peeters S, Gilmore AB. How online sales and promotion of snus contravenes current European Union 
legislation. Tob Control 2012. 
181 AT, BG, ES, FR, HU, IT, LT, LV and SK do not allow internet sale of tobacco. 
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As described above, illegal cross-border distance sales of tobacco undermine the application 
of the provisions contained in the TPD, e.g. on health warnings and ingredients.  
 
The steady increase in (illegal) cross-border internet sales also reduce the legal movement of 
goods both within and between Member States and makes it more difficult for legal business 
(traditional retailers) to compete on the market.  
 
1.1.5. Problem 5: Traceability and security features 
• Implementation of the current TPD 
 
Illicit trade in FMC currently accounts for 8.25 % of total trade in the EU and is estimated to 
increase by 1 % per year in the next five years.182  The negative impact of illicit trade is 
manifold for the legal supply chain, consumers and Member States. From the perspective of 
TPD, the main concern is that the safeguards of the TPD are not respected by illicit products 
(e.g. health warnings in the correct language). For Member States, the loss in tax revenues (10 
bEUR per year according to OLAF)183 is certainly also a major concern. The main 
beneficiaries are criminals and the organised crime. The main categories of illicit products are 
contraband (i.e. products which have been diverted into illicit trade, not respecting the legal 
requirements in the jurisdiction of destination), counterfeit (i.e. brand protected products 
which have been falsified without consent of the brand owner and are not respecting the legal 
requirements in the jurisdiction of destination) and illicit/“cheap” whites (i.e. products  
produced (often legitimately) in their country of origin at very low cost, destined to be 
smuggled into other jurisdictions and not respecting requirements in the jurisdiction of the 
destination). According to According to OLAF indications, the ratio between these categories 
is 30 % contraband, 50 % counterfeit and 20 % illicit whites.   
 
The current TPD contains, as part of its Article 5(9) the possibility to introduce provisions on 
traceability and product identification, but so far no effective implementation has taken 
place. In particular, the Commission has not used the power in Article 5(9) to adopt technical 
measures related to traceability and identification. A major reason for this delay was that since 
2000 the concepts of traceability have been discussed internationally in the development of 
Article 15 FCTC and later on in the negotiations of the Illicit Trade Protocol based on Article 
15 FCTC. It would therefore not appear useful if the Commission made use of the powers 
under Article 5(9) TPD at this stage, as the current provision does not provide for a fully-
fledged traceability concept and is thus no longer state of the art. The currently foreseen batch 
marking is only one element for achieving traceability and control of the supply chain. 
Already the FCTC goes further and stipulates that each unit package has to be marked in 
order to determine the origin and the point of diversion and to monitor, document and control 
the movement of tobacco products and their legal status. As regards Article 5 (9) TPD, in the 
absence of the adoption of an implementing measure, Member States are, in principle, unable 
to take actions unilaterally, while being obliged by the FCTC. Taking into account that a very 
significant part of FMC and RYO are traded across EU borders (2.1.1), an EU wide system 
would clearly provide added value.  
 
                                                 
182 Euromonitor data presented in Matrix 2012. According to OLAF indications, the ratio between categories of 
illicit trade is 30 % contraband, 50 % counterfeit and 20 % illicit whites (for definitions, see glossary).   
183 OLAF. Huge Illegal Cigarette Factory in Poland Raided. Brussels: OLAF; 2011. 
http://ec.europa.eu/anti_fraud/media-corner/press-releases/press-releases/2011/20110315_01_en.htm (accessed 
28 Nov 2012). 
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• Enforcement of the TPD 
Typically, illicit trade products (both contraband and counterfeit) do not comply with the 
TPD.  This undermines the enforcement of the Directive and thus the effectiveness of the 
internal market in legal tobacco products. Sales of products not complying with TPD mean 
that the consumers do not benefit from the safeguards in form of the appropriate labelling 
(e.g. text warnings in a different language), or ingredients control.  
 
In terms of traceability, there is currently no level playing field for economic operators 
on the internal market. The four largest tobacco manufacturers have concluded legally 
binding agreements with the EU and the participating Member States ('the agreements'),184 
including provisions on tracking and tracing, but other manufacturers and importers do not 
have similar legal obligations to control the supply chain through tracking and tracing.  
 
It is highly likely that Member States will also consider additional measures in terms of 
security features to act against counterfeit and empower consumers to verify the authenticity 
of the product concerned. Article 15 FCTC contains obligations in this regard, but without a 
common EU approach Member States are expected to take different approaches. Such 
heterogeneous development will have a negative impact on the internal market and 
prevent free movement of products.  
 
2.3. BASELINE SCENARIO  
This section describes how the tobacco market is expected to evolve in the coming years if no 
changes are made to the TPD. In this respect it is first important to underline that the current 
difficulties in terms of implementation, application and enforcement of the current TPD (see 
section 1.2) would persist under the baseline scenario.  
1.1.6. Development of the market 
As mentioned in the market description (section 2.1) significant development and 
diversification have taken place on the tobacco market in recent years. This development 
towards further fragmentation of the internal market is expected to continue under the 
baseline scenario.  
 
The rapid development of the traditional STP (oral, chewing and nasal) market is likely to 
continue under the baseline scenario (new brands, new flavours, new attractive packaging). 
The development of novel tobacco products is also a priority for FMC manufacturers and this 
market is expected to increase significantly.185 In addition, the development of tobacco-free 
products, such as NCP (notably electronic cigarettes) described in the market description 
section, 2.1.3) is expected to continue and even intensify.186 One of the main drivers for this 
trend is the implementation of smoke-free environments and tobacco control measures in the 
Member States.  
 
                                                 
184 Anti-Contraband and Anti-Counterfeit Agreement and General Release with Philip Morris (2004), 
Cooperation Agreement with Japan Tobacco (2007), Cooperation Agreement with British American Tobacco 
(2010) and Mutual Cessation Agreement with Imperial Tobacco (2010). The agreements start to expire as of 
2016.   
185 Minutes from SANCO's meeting with Philip Morris International, 8 March 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20120308_mi_en.pdf (accessed 28 Nov 2012). 
 See also: BAT. Harm reduction. London: BAT; 2012. http://www.bat.com/harmreduction (accessed 28 Nov 
2012). 
186 SANCO discussion with an e-cigarette manufacturer, July 2012. SANCO meeting with ECITA, 20 June 
2012: http://ec.europa.eu/health/tobacco/docs/ev_20120703_mi_en.pdf (accessed 28 Nov 2012).  
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Also the new marketing strategies for tobacco for smoking are expected to continue. This 
applies in particular to innovative and appealing tobacco packaging (e.g. new "lip stick" 
packets with slim FMC). The development is even expected to aggravate under the baseline 
scenario, especially following stricter advertising regimes in Member States and taking into 
consideration that packaging constitutes an important factor in choosing a FMC brand 
(23%).187 
 
Moreover, further market development as regards ingredients for combusted tobacco is 
expected to continue in coming years, in particular in light of the recent development of 
distinctive flavoured tobacco products (see section 2.1.1). The various patents required by 
tobacco industry to embed flavourings in the filter are also an indication of further 
development in this regard.188 Increased sale of menthol FMC can also be expected under the 
baseline scenario and these products are likely to be most popular among young people. The 
market share of menthol FMC has more than doubled in Germany in the past ten years, from 
1.3 to 3%.189 In the United States, menthol FMC sales have remained stable as cigarette sales 
have decreased and the share of menthol brands is higher in new adolescent smokers, who 
have been smoking for less than one year, than for those who have smoked for more.190  
1.1.7. Development in Member States 
2.3.1.1. Already harmonised areas  
In areas already covered by harmonisation, Member States would be prevented under the 
baseline scenario from taking actions to maintain or strengthen a high level of health 
protection.  
2.3.1.2. Non-harmonised areas 
In reaction to the market developments outlined above, some Member States have already 
taken actions and more are likely to follow (see sub-sections under 2.2 and Annex 3). Member 
States will also adapt to scientific progress and international development, e.g. implement 
the FCTC and its guidelines.   
 
Although the FCTC provides good orientations, it leaves significant discretion to Member 
States on how to implement the Convention and guidelines in terms of content and time. For 
example, the Convention refers to health warnings of a certain size (50% or more but not less 
than 30%) and effective ingredients regulation. However, the Convention itself does not 
specify how and where to place the warnings on the packets, nor which ingredients should be 
addressed by the regulation. The guidelines are a bit more specific and more far reaching, but 
also they give some discretion to Member States and they are not legally binding. Whilst 
some Member States are expected to take actions to implement fully also the non-binding 
guidelines, others are likely to be less ambitious in this respect. The legal obligations 
stemming from FCTC are also different from obligations based on an EU Directive in the 
sense that the enforcement mechanisms are different. Whilst a failure to implement an EU 
                                                 
187 Eurobarometer 2012 
188 German Cancer Research Center (DKFZ). Menthol Capsules in Cigarette Filters – Increasing the 
Attractiveness of a Harmful Product. Heidelberg: DKFZ; 2012. 
189 Giovino GA, Sidney S, Gfroerer JC, O'Malley PM, Allen JA, Richter PA et al. Epidemiology of menthol 
cigarette use. Nicotine Tob Res 2004;Suppl 1:S67-81 German Cancer Research Center (DKFZ). Menthol 
Capsules in Cigarette Filters – Increasing the Attractiveness of a Harmful Product. Heidelberg: DKFZ; 2012. 
190 Kreslake JM, Wayne GF, Connolly GN. The menthol smoker: tobacco industry research on consumer sensory 
perception of menthol cigarettes and its role in smoking behavior. Nicotine Tob Res 2008; 10:705-15. 
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Directive may lead to infringements procedures, settlement of the disputes in the context of 
FCTC leaves more flexibility to Parties (FCTC Article 27 refers to negotiations or any other 
peaceful means of their choice). Also this can affect the implementation of the FCTC. In light 
of this, further discrepancies can be expected under the baseline scenario.  
 
More specifically, in the areas of STP, NCP and herbal products for smoking, it can be 
expected that Member States continue to take unilateral actions to address the market 
development described above. For example, some Member States can be expected to react to 
the development of flavoured STP and implement the FCTC guidelines on Articles 9 and 10 
which recommend banning additives capable of making these products more attractive or of 
misleading consumers to believe they are less harmful or have health benefits. Some Member 
States are also likely act to ensure maximum effect of their smoke-free environment policies. 
Although it is difficult to predict the exact shape and timing of these actions, it appears certain 
that they will consist of divergent approaches reinforcing the already existing discrepancies.  
 
Also in the area of packaging and labelling, the disparities are expected to grow in coming 
years as Member States continue to take further measures, e.g. to adopt pictorial health 
warnings, introduce cessation information and/or further standardise tobacco packaging in 
line with the guidelines for implementing Articles 11 and 13 of the FCTC. In the context of 
the public consultation on the TPD, five Member States who have not yet adopted pictorial 
health warnings nevertheless supported such a proposal at the EU level.191 It is likely that at 
least some of them will go forward at national level in the absence of a common EU 
approach. The UK Government launched a public consultation on plain packaging on 16 
April 2012 and appears to be the most advanced in terms of considering the full 
standardisation of the package,192 but reflections on plain packaging are also on-going at 
various levels in some other Member States, including Belgium, Finland and France (see 
Annex 3, A.3.1.2.2). Member States' interest in plain packaging is also reflected in a Council 
Recommendation from 2009 inviting the Commission to analyse the legal issues and the 
evidence base for the impact of plain packaging, including its effect on the functioning of the 
internal market.193  
 
In order to comply with their obligations under FCTC (see Annex 3, A.3.1.3.1), Member 
States have already different measures in place and are likely to adopt rules on ingredients 
unilaterally in the years to come, in particular to address the attractiveness of tobacco products 
and considering the market development in recent years with more flavoured tobacco 
products being placed on the market. At least one Member State has declared that it will 
discuss a national ban on “candy-cigarettes” if no action is taken at EU level.194 A majority of 
Member States also supports some kind of regulation in the context of the public consultation 
(see Annex 1, section A1.2.2). It is also likely that Member States will seek inspiration from 
other jurisdictions. A number countries around the world have taken measures (e.g. Canada 
and Brazil banning in principle all additives and US banning characterising flavours).195  
 
                                                 
191 AT, FI, LV, PL and SI.   
192 UK Department of Health (UK DoH). Consultation on standardised packaging of tobacco products. London: 
DoH; 2012. 
193 Council Recommendation of 30 November 2009 on smoke-free environments. 2009/C 296/02.  
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:296:0004:0014:EN:PDF (accessed 28 Nov 
2012). 
194 DK political agreement between the Government and the Alliance of 21 April 2012 
195 Canada has an exemption for menthol and Brazil accepts sugar up to a certain level. US bans cigarettes with 
characterising flavours other than tobacco or menthol, including strawberry, grape, orange, clove, cinnamon, 
pineapple, vanilla, coconut, licorice, cocoa, chocolate, cherry or coffee  
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Finally, Member States are expected to further develop their legislation in order to address 
easy access to and visibility of tobacco, including through the internet. In this case the FCTC 
plays an important role as well as the enforcement difficulties faced by Member States under 
the current situation (e.g. age limits for purchasing of tobacco).  
1.1.8. The demand side  
The overall smoking prevalence has decreased significantly in the EU in recent decades.196 
Whilst Euromonitor predicts also some moderate decline in consumption (decrease in volume 
sales) in the years to come it cannot be assumed that this predicted decrease will in reality 
continue in the absence of new adjusted tobacco control measures.197 Firstly, the decline was 
the effect of a concerted and comprehensive tobacco control policy consisting of a broad 
range of measures used in a complementary manner and where new elements have been 
constantly introduced. This includes the adoption of the FCTC, increases in tobacco taxation, 
bans on tobacco advertising, restrictions on sales to minors, comprehensive laws on smoke-
free environments, health warnings on tobacco packages, awareness raising campaigns as well 
as measures adopted in other policy areas (see section 2.1.4). In the absence of further tobacco 
control measures at EU level, it is likely that the trend in prevalence would revert, at least in 
those Member States not taking actions under the baseline scenario. In any case, even if some 
Member States take stronger actions on their own initiative, this would create a patchwork of 
legislations interfering with the internal market.   
 
Secondly, market developments in terms of packaging, ingredients, new products and sales 
strategies have the potential of misleading consumers, undermining awareness of health risks 
and encouraging (in particular) young people to take up smoking. This has been demonstrated 
in the problem identification above (section 2.2.1-2.2.5) for each of the relevant policy areas, 
including references to scientific evidence. Over time, this could encourage young people to 
take up smoking and prevent current smokers from quitting. Whilst the latest Eurobarometer 
showed a welcome decline in smoking prevalence amongst young people, studies from the 
WHO showed that several Member States have seen an increase in smoking prevalence 
among youth since 2005.198  
 
Based on this it is assumed that the overall smoking prevalence will remain at the current 
level if no EU action is taken. The precise prediction of the baseline is, however, of limited 
relevance for this impact assessment as the impact of all measures is expressed in relative 
terms, i.e. if the consumption/prevalence were to decrease as predicted by Euromonitor, the 
proposed measures would accelerate the decrease. If, on the other hand, the consumption were 
to remain stable, it could decrease thanks to the envisaged measures. 
 
Consumption of STP is expected to increase under the baseline scenario in light of new 
product developments and the introduction of smoke-free environments in more and more 
Member States.199 This prediction is also shared by one of the chewing tobacco manufacturers 
who sent information to the Commission in the context of the revision of the TPD. The same 
                                                 
196 According to 2012 Eurobarometer survey, smoking prevalence was 28% in the EU-25 (excluding RO and 
BU) and 27% in EU-15. This is considerably less than 32% in 2006 (EU-25), respectively 39% in 2002 (EU-15).  
The volume of the EU-27 cigarettes market in 2010 was 608.8 bn sticks, what represents a decline of 23.3% in 
comparison to 2000, when 793.7 bn sticks were sold across the EU. 
197 Matrix 2012. 
198 Currie C, Zanotti C, Morgan A, Currie D, de Looze M, Roberts C, et al., eds. Social determinants of health 
and well-being among young people. Health Behaviour in School-aged Children (HBSC) study: international 
report from the 2009/2010 survey. Copenhagen: WHO Regional Office for Europe; 2012. Eurobarometer 2012  
199 Despite repeated efforts to gather reliable statistics from the industry (European Associations and larger 
producers such as Pöchl) no information could be obtained.  
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manufacturer also confirmed that multinational tobacco companies' engagement in the STP 
segment is likely to lead to greater awareness of STP in general. Moreover, reports from other 
jurisdictions also suggest an upwards trend in STP worldwide. Use of nasal tobacco in Iceland 
has increased significantly from 11.7 tons in 2003 to 30.2 tons in 2011.200 New STP products 
have also been introduced on the US market, including dissolvable STP resembling candies.  
There is not conclusive evidence as regards the substitution between STP (including 
novel non-combusted tobacco products) and smoking products and it is therefore not 
possible to draw any firm conclusion whether the expected increase in STP use will have an 
impact on the smoking prevalence. STP can, indeed, be used by current smokers, e.g. to 
reduce consumption or in any effort to quit, but at the same time and as illustrated above, STP 
can attract young people who do not yet smoke and who do not intend to take up smoking 
(entry gate). STP can also prevent people from effectively quitting (dual use). The issue of 
substitution will be further explored in section 5.1.1.    
The lack of visible health warnings on STP under the current TPD (see 2.2.1) could also 
undermine consumers' and potential consumers' awareness of the adverse health effects of 
STP and thus lead to higher uptake of these products.  
  
2.4. EU BASIS TO ACT 
This section includes a general assessment of the relevant legal basis, subsidiarity and 
proportionality. The proportionality is further examined as part of the assessment and 
comparison of policy options (section 5).  
 
Compliance with fundamental right has also been ensured throughout the document. The 
proposal affects the freedom of economic operators to conduct business (Article 16) as well as 
their freedom of expression and information (Article 11) and right to property (Article 17) but 
the obligations imposed on manufacturers, importers and distributors of tobacco products are 
necessary to improve the functioning of the internal market while ensuring a high level of 
health protection. 
1.1.9. Legal basis 
The current TPD is based on Article 95 TEC (now Article 114 TFEU).201 The choice of the 
legal base has been confirmed by the Court of Justice of the European Union (hereinafter: 
"the Court").202 The same legal basis is appropriate for revising the TPD. Article 114(1) 
TFEU empowers the European Parliament and the Council to adopt measures for the 
approximation of the provisions laid down by law, regulation or administrative action in 
Member States which have as their object the establishment and functioning of the internal 
market. According to Article 114(3) TFEU, the Commission should aim at ensuring a high 
level of health protection in its proposal envisaged in paragraph 1 of Article 114.  
 
It follows from the case law that measures adopted on the basis of Article 114 TFEU must 
genuinely have as their object the improvement of the conditions for the establishment and 
functioning of the internal market. A mere finding of disparities between national rules is not 
                                                 
200 Information received from the Icelandic Ministry of Welfare, July 2012. 
201 In addition to Article 95 TEC the TPD was also adopted on the basis of Article 133 TEC. Case:  C-491/01 
The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) Ltd and Imperial 
Tobacco Ltd. [2001] ECR I-11453, the Court found, however, that Article 95 TEC was the only appropriate legal 
base, but that the addition of Article 133 TEC as a legal base was not a reason for declaring the Directive invalid. 
202 C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) Ltd 
and Imperial Tobacco Ltd.[2001] ECR I-11453 
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sufficient to justify having recourse to Article 114 TFEU.203 At the same time it is settled 
case-law that recourse to Article 114 TFEU as a legal basis is possible if the aim is to prevent 
the emergence of future obstacles to trade resulting from divergent development of national 
laws. The emergence of such obstacles must be likely and the measures in question must be 
designed to prevent the discrepancies.204 The (existing or likely) disparity must have (actually 
or probably) the effect of creating an obstacle to trade, by preventing a product or service 
from moving freely within the Union,205 or by appreciably distorting competition on the 
internal market.  
 
The Court has held that, provided that the conditions for recourse to Article 114 TFEU are 
fulfilled, the legislature cannot be prevented from relying on that legal basis on the ground 
that public health protection is a decisive factor in the choices to be made.206 On the contrary, 
priority must be given to measures ensuring a high level of health protection.   
 
In line with the jurisprudence of the Court, the following situations of relevance for this 
impact assessment can be distinguished, under which harmonisation based on Article 114 is 
justified:   
 
1. There is an existing level of harmonisation which needs an update in light of 
scientific and international developments.207  This is the case for display of TNCO 
levels, the size of the warnings and certain aspects of traceability features. The current 
legislation needs to be updated to take into account new evidence.  
 
2. For product specific measures the decisive question is whether there are 
discrepancies between national legislations impacting on the marketing of products 
across borders or whether there is a sufficient likelihood that such discrepancies will 
appear in the future. Measures related to scope, labelling and ingredients typically fall 
within this category. It follows from jurisprudence that these types of product 
requirements are in themselves liable, in the absence of harmonisation at EU level, to 
constitute obstacles to the free movement of goods. 208 
 
3. Even a measure not directly aimed at improving the conditions for the functioning of 
the internal market can be adopted under Article 114 if its purpose is to ensure that 
certain provisions concerning the internal market are not circumvented.209 This is 
                                                 
203 C-376/98 Federal Republic of Germany v European Parliament and Council of the European Union. [2000] 
ECR I-08419, p 84 and C-380/03 Federal Republic of Germany v European Parliament and Council of the 
European Union [2006] ECR I-11573, p 37 
204 C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) Ltd 
and Imperial Tobacco Ltd.[2001] ECR I-11453, p 61, C-380/03 Federal Republic of Germany v European 
Parliament and Council of the European Union [2006] ECR I-11573, p 38 and C-58/08 The Queen, on the 
application of Vodafone Ltd and Others v Secretary of State for Business, Enterprise and Regulatory Reform. 
[2010] ECR I-04999, p 33 
205 Cases, C-371/98, The Queen v Secretary of State for the Environment, Transport and the Regions, ex parte 
First Corporate Shipping Ltd, interveners: World Wide Fund for Nature UK (WWF) and Avon Wildlife Trust. 
[2000], p I-09235, para 84. C-380/03, Federal Republic of Germany v European Parliament and Council of the 
European Union.[2006], p I-11573, para 37.  
206 C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) Ltd 
and Imperial Tobacco Ltd.[2001] ECR I-11453, para 62 
207 Idem, para 77-79 
208 Idem, para 64 
209 Case  C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) 
Ltd and Imperial Tobacco Ltd.[2001] ECR I-11453, p 82-83 
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particularly relevant for the areas on cross-border distance sales and tracking, tracing 
and security features in this impact assessment. 
  
4. A ban of a product can also, under specific circumstances, be adopted on the basis of 
Article 114.210  In the case of oral tobacco, the Court confirmed the validity of the  ban 
taking into consideration that national legislations were divergent and were therefore 
such as to constitute obstacles to the free movement of goods, the product (oral 
tobacco) was new on the market and could be attractive to young people. The Court 
also found the ban on oral tobacco proportionate due to the harmful effects, the 
uncertainty of oral tobacco as a substitute for cigarettes, the addictive and toxic 
characters of nicotine, oral tobacco's danger to young people and the novelty of the 
product. 211  
1.1.10. Subsidiarity 
In accordance with the principle of subsidiarity, the Union shall act only if and in so far as the 
objectives of the proposed action cannot be sufficiently achieved by the Member States, either 
at central level or at regional or local level, but can rather be better achieved at Union level 
(Article 5(3) TEU).  
 
As indicated above, some of the areas included in this impact assessment are already covered 
by the current TPD, but need to be updated in accordance with market, scientific and 
international developments. Due to the harmonisation which already exists, Member States 
are prevented / limited from acting unilaterally. For example, Member States are not allowed 
to remove the display of tar, nicotine and carbon monoxide (TNCO) levels or choose to put 
the pictorial health warning on the most visible side of the package and they have limited 
competence in terms of traceability. Only a common approach is possible to update these 
provisions. 
 
Other areas relevant for this impact assessment are subject to different approaches in 
Member States which have led to obstacles to the functioning of the internal market. For 
example, in policy areas labelling and ingredients, the heterogeneous situations in Member 
States have resulted in a situation where the industry has to produce different product lines for 
different markets. Even more disparity is expected in coming years when Member States 
implement the FCTC obligations and commitments. Only a harmonised approach at EU-level 
can remove obstacles to cross-border trade. Only a harmonised approach would ensure that 
industry is not obliged to adapt at different times to 27 national regimes. 
 
Finally, in some areas it would be very difficult for a Member State to act unilaterally due 
to the difficulties to enforce such an action when other Member States have different rules. 
For example, it appears almost impossible for a Member State to enforce restrictions on 
tobacco internet sales if such sales are unregulated in other Member States. The current 
Council Recommendation 2003/54/EC does not indicate how tobacco distance sale should be 
regulated and the challenge related to enforcement was outlined in the Commission’s Staff 
Working Document from 2009 on the implementation of the Recommendation. A legally 
binding and EU wide measure in the framework of the revision of the TPD would therefore 
produce clear benefits. The same holds true for the EU system for tracking and tracing, when 
tobacco products regularly move across borders.  
 
                                                 
210 For example Case C-434/02 Arnold André GmbH & Co. KG v Landrat des Kreises Herford [2004] ECR I-
11825 
211 Case C-434/02 Arnold André GmbH & Co. KG v Landrat des Kreises Herford [2004] ECR I-11825 
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EU action would also contribute to greater consistency, both between and within Member 
States, and a higher level of legal certainty, for example in the area of NCP where the legal 
situation is complex and unclear, which undermines the level playing field.  
1.1.11. Proportionality 
Under the principle of proportionality, the content and form of the Union action shall not 
exceed what is necessary to achieve the objectives of the Treaty (Article 5(4) TEU). In the 
area of health, the Court has held that the EU legislature must be allowed broad discretion 
and the legality of a measure can be affected only if the measure is manifestly inappropriate 
having regard to the objective which the competent institution is seeking to pursue.212 The 
revision shall aim at providing an appropriate level of margin for implementation by the 
Member States and it must fully respects responsibilities of the Member States to organise, 
finance and deliver health services and medical care. 
 
3. POLICY OBJECTIVES 
 
Overall objectives 
The overall objective of the revision is to improve the functioning of the internal market, 
while ensuring a high level of health protection. In terms of internal market, the proposal 
aims to: 
 
1. Update already harmonised areas to overcome Member States' obstacles to bring 
their national legislations in line with new market, scientific and international 
developments.213  
 
2. Address product related measures not yet covered by the TPD insofar as 
heterogeneous development in Member States has led to, or is likely to lead to, 
fragmentation of the internal market.214  
 
3. Ensure that certain provisions of the TPD are not circumvented by placing on the 
market of products not compliant with the TPD.215 
 
It is also important to ensure a harmonised implementation of international obligations 
following from the WHO Framework Convention on Tobacco Control (FCTC), which is 
binding for the EU and all Member States, and a consistent approach to non-binding FCTC 
commitments, if there is a risk of diverging national transposition.  
 
                                                 
212 See C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco (Investments) 
Ltd and Imperial Tobacco Ltd.[2001] ECR I-11453, p 123 
213 Without an update, Member States cannot, for example, increase the size of the health warnings, change their 
location of the package or replace the display of tar, nicotine and carbon monoxide levels. For example, at this 
stage, eight Member States have adopted pictorial health warnings and the regulations of ingredients differ 
between Member States. 
214 For example, at this stage, eight Member States have adopted pictorial health warnings and the regulations of 
ingredients differ between Member States. For example, measures on cross-border distance sales and traceability 
will facilitate legal activity and thus prevent sale of tobacco products not complying with the TPD (e.g. health 
warnings and ingredients). 
215 For example, measures on cross-border distance sales and traceability will facilitate legal activity and thus 
prevent sale of tobacco products not complying with the TPD (e.g. health warnings and ingredients). 
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The revision will contribute to the overall aim of the EU to promote the well-being of its 
people (TEU Article 3). The proposal should contribute to the Europe 2020 strategy in so far 
as keeping people healthy and active longer will have a positive impact on productivity and 
competitiveness. The revision should also fully respect the EU Charter on Fundamental 
Rights.  
 
Specific and operational objectives 
 
Specific objectives Operational objectives (PA=Policy Area) 
A To remove obstacles to cross-border trade and ensure 
a level playing field for manufacturers and other 
economic operators 
1. remove unjustified differential treatment between products (PA1a, b, 3)  
2. facilitate a level playing field for economic actors in the field of STP, 
NCP and herbal products for smoking (PA1), for retailers involved in 
cross-border distance sale (PA4) and traceability and security features 
(PA5) 
3. remove national disparities and ensure a harmonised approach in 
packaging & labelling and ingredients (PA1, 2,3) and traceability and 
security features (PA5) 
B To reduce the administrative burden for economic 
actors and public authorities due to the complexity of 
the current TPD and remaining disparities in 
legislations  
1. unify the rules on labelling and ingredients and establish one single 
format for ingredients reporting (PA1, PA2, PA3) 
2. facilitate market surveillance of Member States and improve the overall 
enforceability, including by reducing the number of  products on the 
market which do not comply with TPD specifications (PA 1a, 3, 4, 5) 
 
Choosing between options 
A high level of health protection has been considered when choosing between different 
policy options. In this context, the revision seeks to regulate tobacco products in a way that 
reflects their characteristics and negative impact on health, e.g. by ensuring that the 
ingredients and packaging of the products do not encourage or facilitate initiation by young 
people. 216 The focus on young people is also reflected in the selection of the policy options 
and the products primarily targeted (FMC, RYO and STP). In addition, the revision should 
create conditions which allow all citizens across the EU to take informed decisions about the 
products, based on accurate information on the health consequences of consuming tobacco 
products. Finally, all smokers should benefit from measures contained in the TPD (e.g. health 
warnings and ingredients regulation). 217  
 
Specific considerations Operational considerations (PA=Policy Area) 
C To provide a high level of protection to citizens 
throughout the EU  
1. regulate the placing on the market of hazardous and potentially hazardous 
products (PA1, 3) 
2. remove from the market products which are particularly attractive, in 
particular to young people, because of their appearance or taste/smell (PA1, 
2, 3) 
3. assist consumers to verify the authenticity of tobacco products and protect 
them against non-complying  supply (PA5) 
4. inform the consumer, through the labelling, about the harmful effects of 
tobacco and related products and remove misleading information (PA1, 2) 
5. reduce easy availability and access of tobacco and related products in the 
interest of protecting vulnerable groups, in particularly young people (PA1a, 
c, 4, 5) 
6. ensure that consumers across the EU benefit from a minimum level of 
protection when purchasing tobacco products (e.g. health warnings and 
ingredients control) and reduce the appeal of cheaply available illicit tobacco 
products to protect vulnerable groups. (PA4, 5) 
                                                 
216 Riordan M. The path to smoking addiction starts at very young ages. Washington, DC: Campaign for 
Tobacco-Free Kids; 2009. http://www.tobaccofreekids.org/research/factsheets/pdf/0127.pdf (accessed 28 Nov 
2012). 
217 An unintended, but welcome side effect of the measures against illicit trade is that it protects tax revenues of 
Member States 
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4. POLICY OPTIONS 
 
A number of factors have been taken into consideration when identifying the policy 
options, most prominently the benefits for the internal market and its main stakeholders 
(industry, suppliers, distributors, consumers, NGOs and Governments), international 
obligations and commitments (notably FCTC and its guidelines), and the EU Charter on 
Fundamental Rights. The views put forward by stakeholders have been carefully considered. 
Reference is also made to the criteria contained in Annex 4. Some general comments are 
necessary upfront.  
 
The role of public health 
While all options identified seek to improve the functioning of the internal market, the 
protection of public health has played a key role in designing/shaping the policy options. 
This follows from the Commission’s duty to ensure a high level of health protection in its 
proposals and is logical considering that the national legislations, which the revised TPD 
seeks to harmonise, have been adopted in order to protect public health.   
 
The relation to FCTC 
The table in section 3.2 of Annex 3 sets out the relation between the current TPD obligations, 
obligations stemming from FCTC, commitments in the context of FCTC guidelines as well as 
the preferred policy options. 
 
The products primarily targeted 
The policy options identified in this impact assessment cover in principle all tobacco 
products. However, in the policy areas on packaging & labelling (PA2), ingredients (PA3), 
and traceability & security features (PA5), stricter rules will - in a first stage - apply only to 
FMC, RYO and STP and other products will be exempted. The products initially exempted 
will continue to be subject to current TPD requirements. This means that the identified 
options primarily target large manufacturers of FMC and RYO and exempt the SMEs and 
micro-enterprises involved in the manufacturing of pipe tobacco and cigars.218 This reasoning 
is based on a proportionality assessment, taking into account the interest of these economic 
stakeholders, their marketing mainly towards adult consumers and the focus of this report on 
regulating tobacco products in such a way that they do not appeal to underage citizens. 
However, for policy area 5 (traceability and security features) the exemption is only of a 
temporary nature (longer transitional period) and for the other concerned policy areas the 
exemption will be removed if the consumption trend changes and consumption in young 
people increases significantly.  
 
The level of harmonisation 
In general, the policy options foresee full harmonisation, but obviously Member States are 
allowed to maintain or introduce stricter national measures in areas not covered by the 
harmonisation provided that national rules are compatible with the Treaty, in particular with 
the principle of free movement of goods. The Directive also foresees the possibility for 
Member States to maintain or introduce stricter measures in areas falling within the scope of 
                                                 
218 It should be noted, however, that also in the FMC, RYO and STP segment, some smaller manufacturers will 
be affected by the proposal.  
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the Directive provided that the measures are notified to and approved by the Commission 
which will assess if they are necessary, proportionate and non-discriminatory taking into 
account the high level of harmonisation achieved by the Directive. 
 
Delegated and implementing powers 
Delegated and implementing powers are foreseen to allow for an appropriate reaction to 
market, scientific and international developments, to amend or supplement the basic act and to 
give effect or shape the rules laid down in the basic act. The exact scope of these two 
categories of acts is further defined in the legislative proposal and the nature of the power is 
clearly defined in each case and linked to strict conditions in order to ensure legal certainty 
and respect the institutional division of tasks. Delegated/implemented powers are foreseen in 
the following situations:  
• Establish rules for the use of health warnings, unique identifiers and security 
features and adapt health warnings to technical and scientific developments. 
• Establish further rules for the shape and size of unit packets. 
• Setting/adapting maximum yields for emissions and their measurement methods. 
• Establish the format of ingredients reporting. 
• Remove from the market of tobacco products with characterising flavours and 
products with increased toxicity or addictiveness levels.  
• To remove the exemption for products other than FMC and RYO as regards the 
labelling and other than FMC, RYO and STP as regards ingredients.  
 
Subsequent impact assessments for implementing measures and delegated acts will be carried 
out as appropriate and in line with the Impact Assessment guidelines.219  
 
4.1. DISCARDED POLICY AREAS  
A number of additional policy areas were considered at an earlier stage of the impact 
assessment, but these were subsequently rejected.  
 
Firstly, regulation of toys and sweets resembling tobacco was considered at one stage. This 
suggestion has not been retained in the impact assessment as it was concluded in an early 
stage that the TPD is not the most adequate instrument to deal with these products.  
 
Secondly, the introduction of manufacturer liability for the financing of all health costs 
arising from tobacco consumption was proposed by the European Parliament in its 
resolution from 2007. Full implementation of the "polluter pays principle" was assessed in the 
external study produced by RAND Europe in September 2010.220 An external study on 
liability and the health costs of smoking was also commissioned to examine this proposal in 
more detail.221 However, the proposal has not been assessed further in the context of this 
impact assessment in the light of subsidiarity and legal considerations.  
 
Thirdly, a total ban of all tobacco products was discarded without further analysis. Despite 
the harmful effects of tobacco consumption, this option was not considered feasible. A total 
ban on tobacco products would lead to unreasonable compliance costs and not have the 
                                                 
219 European Commission. Impact Assessment guidelines. Brussels: European Commission; 2009.  
http://ec.europa.eu/governance/impact/commission_guidelines/docs/iag_2009_en.pdf (accessed 28 Nov 2012).  
220 Rand 2010  
221 GHK 2012  
     51 
desired effect of stopping the use of tobacco in the EU. An illegal market would most likely 
appear, in particular considering that 28% of EU citizens currently smoke.   
 
Fourthly, the approximation of Member States' legislations on Tobacco Vending Machines 
(TVM) was considered in the impact assessment process and public consultation. This policy 
area was discarded given subsidiarity concerns and taking into account the already good 
progress in this area following the Council Recommendation 2003/54 and the FCTC 
provisions and guidelines. Thirteen Member States have banned TVM, while all remaining 
Member States have put in place some kind of restrictions to limit access to young people 
under the legal age for purchasing.222 For more information about FCTC obligations and 
commitments as well as national legislations see Annex 3 (A.3.1.4.2).   
 
Fifthly, the approximation of Member States' legislations in the area of tobacco display at 
point of sale (PoS) was considered in the impact assessment process and the public 
consultation. Also this policy area was discarded due to subsidiarity concerns as well as the 
limited support from Member States at this point in time. For further information on 
international commitments and regulations in Member States, see Annex 3 (A.3.1.4.2). 
 
4.2. PROBLEM 1A – SMOKELESS TOBACCO PRODUCTS (STP)  
For STP, the main issues are how to effectively regulate the products (including oral tobacco, 
chewing and nasal tobacco as well as novel non-combustible tobacco products), which 
develop rapidly (labelling and ingredients) and which are addictive products with adverse 
health effects (although less harmful than FMC), taking into account the growth potential 
(smoke-free environments)) and the current differential treatment between oral tobacco (snus) 
and other STP. The following options were considered:  
 
• Option 0: No change  
Status quo means:  
a) Oral tobacco is banned (except for Sweden which has an exemption but needs to respect 
labelling requirements, i.e. health warnings, and ingredients reporting).  
b) Placing on the market of chewing and nasal tobacco is allowed subject to labelling 
requirements (health warning) and ingredients reporting.  
c) Placing on the market of novel forms of STP is allowed subject to labelling requirements 
(health warnings) and ingredients reporting.  
• Option 1: Lift the ban on oral tobacco and subject all STP to stricter labelling and 
ingredients regulation 
a) The current ban on oral tobacco is lifted and these products can be placed on the market 
subject to stricter labelling and ingredients requirements (e.g. health warnings on both sides of 
the package and a ban of products with characterising flavour (glossary) and increased 
toxicity or addictiveness).223    
b) The placing on the market of chewing and nasal tobacco continues to be allowed, but 
subject to the same rules on labelling and ingredients as set out under a.  
c) Placing on the market of novel tobacco products (glossary) continues to be allowed subject 
to the same rules on labelling and ingredients as set out under a.  
 
                                                 
222 Some of the national systems might be confronted with enforcement challenges. 
223 The product regulation developed under this option could be inspired by the voluntary industry standards 
already used for snus, the Gothia Tek standards. Rutqvist LE, Curvall M, Hassler T, Ringberger T, Wahlberg I. 
Swedish snus and the GothiaTek standard. Harm Reduct J  2011; 8:11. 
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Delegated/implementing power to adapt health warnings, act on products with characterising 
flavours on products with increased toxicity or addictiveness and to regulate additives that 
cause a characterising flavour.    
 
• Option 2: Maintain the ban on oral tobacco, subject all novel tobacco products to a 
notification obligation and all STP to stricter labelling and ingredients regulation 
a) The current ban on oral tobacco is maintained (except for Sweden which has an 
exemption), but oral tobacco needs to comply with stricter labelling and ingredients regulation 
(e.g. health warnings on both sides of the package and a ban of products with characterising 
flavours and increased toxicity or addictiveness).  
b) The placing on the market of chewing and nasal tobacco continues to be allowed, subject to 
the same rules as set out under a. A clearer definition of chewing tobacco is inserted in the 
TPD.   
c) A notification obligation is introduced for novel tobacco products (glossary) and a report 
on the market development in these products will be issued by the Commission five years 
after the transposition of the TPD. Novel tobacco products placed on the market must respect 
the rules on labelling (health warnings on both sides) and ingredients regulation (ban on 
products with characterising flavours).    
Delegated/implementing power as in option 1.  
 • Option 3: Maintain the ban on oral tobacco, restrict the sale of other STP to areas 
of traditional use only and subject all STP to stricter labelling and ingredients rules 
a) The current ban on oral tobacco is maintained (except for Sweden which has an 
exemption), but oral tobacco needs to comply with stricter labelling and ingredients regulation 
(e.g. health warnings on both sides of the package and a ban on products with characterising 
flavours and increased toxicity or addictiveness).  
b) The placing on the market of chewing and nasal tobacco is banned unless traditionally used 
(glossary) in Member States. The placing on the market of traditionally used STP is limited to 
the relevant territory/Member State and must comply with the same labelling and ingredients 
requirements as set out under a. Member States will have to prove traditional use and notify to 
the Commission. 
c) The placing on the market of novel tobacco products is banned.   
Delegated/implementing power as in option 1. 
• Option 4: Ban all STP with the exception of oral tobacco in Sweden which would be 
subject to stricter labelling and ingredients rules   
a) The current ban on oral tobacco is maintained (except for Sweden which has an 
exemption) 
b) The placing on the market of chewing and nasal tobacco is banned given their 
circumvention potential, in particular as regards chewing tobacco.  
c) The placing on the market of novel tobacco products is banned.   
• Discarded options: 
An alternative option would have been to lift the ban of placing on the market of oral tobacco 
without suggesting any regulation. However, this option was not considered viable as it would 
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mean lifting a ban for a product with adverse health properties without adequate 
control/limits. This option was not suggested by any of the stakeholders. 
 
Another option which was discarded was to introduce a new authorisation regime for novel 
tobacco products. Apart from the very significant burden for the evaluating and authorising 
bodies (either at national or EU level) and possibly new structures to be set up, more 
information is needed about these products as well as expected overall health effects, 
including on non-smokers, young people and people who would otherwise had quit tobacco 
consumption altogether.  
 
4.3. PROBLEM 1B – NICOTINE CONTAINING PRODUCTS (NCP)  
The main issue is how to effectively regulate NCP considering the heterogeneous 
development in Member States. Also, the addictive nature of NCP, health and safety concerns 
and uncertainty, growth potential (smoke-free environments) and market development 
(labelling and ingredients) need to be considered. 
• Option 0: No change  
Status quo means: The TPD remains limited to tobacco products. NCP remain subject to the 
General Product Safety Directive,224 or other more specific legislations. 
• Option 1: Subject NCP to labelling and ingredients requirement under TPD  
NCP placed on the market are subject to adapted health warnings, ingredients reporting and a 
prohibition to place on the market NCP with characterising flavours (glossary). 
Delegated/implementing power to adapt health warnings and act on products with 
characterising flavours, on products with increased toxicity or addictiveness and to regulate 
additives that cause characterising flavours.  
• Option 2: Establish a new authorisation scheme for NCP 
Only NCP that have been authorised under a new authorisation procedure (risk/benefit 
analysis) set up under TPD are allowed to be placed on the market. Otherwise, placing on the 
market of NCP is prohibited. The authorisation procedure would also cover labelling and 
additives control. 
 
• Option 3: Subject NCP over a certain nicotine threshold to the medicinal products' 
legislation and the remaining NCP to labelling requirements 
NCP with a nicotine level over a certain threshold may only be placed on the market if they 
have been authorised as medicinal products on the basis of their quality, safety and efficacy, 
and with a positive risk/benefit balance under the medicinal products legislation.225 NCP with 
nicotine levels below this threshold will be subject to an adapted health warning. The nicotine 
threshold identified under this policy option should be established by considering the nicotine 
content of medicinal products (NRTs) for smoking cessation which have already received a 
market authorisation under the medicinal products' legislation.   
 
Delegated/implementing power to adapt the health warning and the identified nicotine 
threshold taking into account scientific and technical developments. 
                                                 
224 Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001 on general product 
safety, OJ L 11, 15.1.2002, p. 4–17 
225 Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community 
code relating to medicinal products for human use. OJ L 311, 28.11.2001, p. 67, as last amended by Directive 
2011/62/EU, OJ L 174, 1.7.2011, p. 74 
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• Option 4: Subject all NCP to the medicinal products' legislation 
Only NCP that are authorised as medicinal products on the basis of their quality, safety and 
efficacy, and with a positive risk/benefit balance are allowed to be placed on the market. 
Otherwise, the placing on the market of NCP is prohibited. The authorisation procedure is 
described under option 3.    
• Discarded option 
Development of minimum safety standards for NCP under the General Product Safety 
Directive226 was not considered to address the health problems identified. Safety standards 
developed under this Directive and referenced in the Official Journal provide that products 
complying with the standards are presumed to be safe. However, since nicotine is toxic and 
addictive, it is impossible to set safety standards for products releasing nicotine. A safety 
standard under the General Product Safety Directive could therefore not fulfil its objective. 
Another option would have been to update the orientation note on electronic cigarettes from 
2008,227 but considering the non-binding character of such a document and the need for a 
clear legal framework, this option has been discarded.   
4.4. PROBLEM 1C – HERBAL PRODUCTS FOR SMOKING  
The main concern related to herbal products for smoking is the different regulatory 
approaches in Member States. Also, the misperception of adverse health effects needs to be 
taken into account.  
 
• Option 0: No change  
Status quo means: TPD remains limited to tobacco products. Herbal products for smoking 
remain unregulated or subject to different national regulations. 
• Option 1: Subject all herbal products for smoking to labelling requirements under 
TPD 
Adapted health warnings are required for herbal products for smoking. 
Delegated/implementing power to adapt the warnings.   
• Option 2: Phase out the placing on the market of herbal products for smoking 
Placing on the market of herbal products for smoking is phased out.  
• Discarded option 
An alternative option would have been to regulate the content of these products. However, 
this option was discarded as not relevant for the main problem identified.  
                                                 
226 Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001 on general product 
safety, OJ L 11, 15.1.2002, p. 4–17 
227 European Commission. Orientation note. Electronic cigarettes and the EC legislation. Brussels: EC; 2008. 
http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/orientation_0508_en.pdf (accessed 28 
Nov 2012). 
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4.5. PROBLEM 2 – PACKAGING AND LABELLING228  
The main issues are that some of the current provisions are outdated (e.g. size of the warnings, 
display of quantitative TNCO-values) and that there is heterogeneous development in 
Member States (e.g. pictorial warnings). There is also a need to implement FCTC obligations 
and commitments, to address the potential of packaging and labelling to mislead consumers 
and encourage people to start or maintain smoking.  
• Option 0: No change 
Status quo means: Current labelling rules are maintained, i.e. a general text warning of not 
less than 30% and an additional text warning of not less than 40%.229  Member States can 
choose to use a combined warning (picture and additional text warning) instead of the 
additional text warning (40%). Delegated/implementing power to adapt the additional health 
warnings.230  
• Option 1: Mandatory enlarged picture warnings 
Combined warnings (picture plus text) of 75%231 displayed on both sides of the packages of 
tobacco products, presented in rotation. TNCO levels on the packages are replaced with 
descriptive information on content, emissions and risks. Display of cessation information (e.g. 
quit-lines, websites) is added to the packages.  
 
Tobacco products other than FMC and RYO are exempted (current TPD rules apply). 
Delegated/implementing power to remove/extend the exemption for these products if there is 
a change of circumstances and to adapt the health warnings.  
• Option 2: Option 1 plus harmonise certain aspects of packets and prohibit 
promotional and misleading elements232  
Option 1 plus:  
1) The tobacco labelling and packaging and the tobacco product itself shall not include any 
promotional and misleading elements (e.g. misleading colours, symbols, slim FMC),  
2) setting certain requirements for packages (e.g. cuboid shape, minimum number of and 
FMC per package) as well as for the size of the warnings  
 
Member States are allowed to regulate the area not regulated by the TPD or other Union 
legislation, including adopting provisions providing full standardisation of packaging of 
tobacco products (i.e. plain packaging) as far as these provisions are compatible with the 
Treaty. The Commission will report on experiences gained with respect to surfaces not 
governed by the TPD five years after the transposition of the TPD.  
 
For Point 2) Tobacco products other than FMC and RYO are exempted (current TPD rules 
apply). Delegated/implementing power to remove the exemption for these products if there is 
a change in circumstances.    
• Option 3: Option 2 plus full plain packaging   
Option 2 plus: standardised colour, font, size and position of brand name and brand variant on 
packages (plain packaging) and a readable health warning on each FMC stick.  
 
                                                 
228 For STP, NCP and herbal products for smoking, see problem 1a, 1b, and 1c 
229 Required increase of the size if more than one official language (32-35% and 45-50%) 
230 Procedures foreseen in current TPD 
231 The size of the health warning proposed is based on scientific evidence and international developments. 
232 For definition, see glossary 
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Other tobacco products than FMC and RYO will be exempted from the requirements (current 
TPD rules apply). Delegated/implementing power to remove the exemption if there is a 
change in circumstances.  
• Discarded policy option 
An additional option which was considered in an earlier stage of the impact assessment was to 
introduce health warnings on pipes and water-pipes as such. This option was not considered 
appropriate within this revision.   
 
4.6. PROBLEM 3 – INGREDIENTS233 
The main problems are the lack of a harmonised reporting format resulting in additional 
burden for all stakeholders involved, the heterogeneous development in Member States in 
terms of ingredients regulation (toxicity, addictiveness, attractiveness) and the need to 
implement FCTC obligations and commitments. Also, the potential of certain tobacco 
products to mislead consumers and encourage people to take up or maintain smoking should 
be considered.  
• Option 0: No change 
Status quo means: Current mandatory reporting without common format. No common 
ingredients regulation beyond toxicity and addictiveness reporting. 
• Option 1: Common reporting format on a voluntary basis. Prohibit toxic, addictive 
and attractive additives in tobacco products. 
Member States are free to decide whether they oblige manufacturers to report additives in 
tobacco products. If Member States decide to make the reporting obligatory, the common 
reporting format must be used. Member States shall prohibit additives based on the general 
criteria toxicity, addictiveness and attractiveness.    
• Option 2: Mandatory reporting in harmonised format. Prohibit tobacco products 
with characterising flavours and products with increased toxicity or addictiveness.  
Manufacturers are obliged to electronically report ingredients (glossary) of tobacco products 
in accordance with a common format and provide supporting data (e.g. marketing reports). 
Fees charged by Member States for handling the information submitted to them shall not 
exceed the cost attributable to those activities. Placing on the market of new or modified 
tobacco products must not take place before the submission of ingredients data. Reported 
data, excluding confidential information, is published. Delegated/implementing power to 
specify the reporting format.  
 
Tobacco products with characterising flavours (glossary) are prohibited (this is similar to the 
US model). Test panels assist in the decision making process. Additives associated with 
energy and vitality (e.g. caffeine and taurine) or creating the impression that products have 
health benefits (e.g. vitamins) are prohibited. No flavourings are allowed in filters, papers or 
packages. Tobacco products with increased toxicity or addictiveness shall not be placed on 
the market. Member States shall remove from the market tobacco products that include 
ingredients not complying with REACH. Delegated/implementing power to set limits for 
additives imparting a characterising flavour, toxicity and addictiveness.     
 
                                                 
233 For STP, NCP and herbal products for smoking, see problem 1a, 1b and 1c.  
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Tobacco products other than FMC, RYO and STP (i.e. cigars, cigarillos and pipes) are 
exempted from the prohibition of products with characterising flavour and the prohibition of 
additives associated with energy and vitality or health benefits. Delegated/implementing 
powers to remove the exemption for these products are foreseen if there is a substantial 
change of circumstances.      
 
This approach is similar to the US approach. 
• Option 3: Mandatory reporting in harmonised format. Prohibit all additives not 
essential for manufacturing.   
Ingredients reporting as in option 2. In terms of ingredients regulation, all additives in tobacco 
products, except those essential for manufacturing are prohibited. Maximum limits are set for 
sugar and sweeteners. 
Other tobacco products than FMC, RYO and STP are exempted from the ingredients 
regulation. Delegated/implementing power to remove the exemption for these products if 
there is a change of circumstances.   
 
This option is similar to legislations in Canada and Brazil.  
• Discarded options 
An alternative approach would have been to develop a common list of ingredients based on 
addictiveness and toxicity as foreseen in the current TPD (Articles 6 and 12). This would have 
responded to the concerns expressed by the European Parliament in its Resolution from 
October 2007.234 However, as explained in previous sections, at this stage scientific and 
international progress has primarily been achieved in terms of attractiveness rather than 
addictiveness and toxicity. Therefore, this approach was not considered, but should rather be 
seen as a measure to be taken at a later stage/over time.  
 
4.7. PROBLEM 4 – CROSS-BORDER DISTANCE SALES OF TOBACCO PRODUCTS 
Cross-border distance sales of tobacco products undermine the safeguards/full effect of the 
TPD provisions (labelling, ingredients, ban on oral tobacco) and encourages illicit cross-
border trade (legal purchasing via the internet makes little sense).235 There is also a need to 
implement FCTC obligations and commitments. Finally, it facilitates access for young people. 
 
• Option 0: No change 
Status quo means: Regulation is left to Member States. Council Recommendation 2003/54 
applies, i.e. recommendation to restrict tobacco distance sales for general retail.  
• Option 1: Notification and age verification system  
Retailers of tobacco products intending to engage in cross-border distance sales shall notify 
their cross-border activities to the Member States where the company has its seat and where it 
intends to sell. Member States may require the retailer to appoint a natural person, who 
ensures compliance with the TPD of products delivered to customers in Member States 
concerned. Mandatory age verification mechanism is foreseen.  
• Option 2: Prohibit cross-border distance sales of tobacco products 
                                                 
234 Resolution of 24 October 2007 on the Green Paper 'Towards a Europe free from tobacco smoke: policy 
options at EU level'. (2007/2105) 
235 Council Directive 2008/118/EC of 16.12.2008, OJ 9/12 of 14.1.2009 
     58 
Cross-border distance sales of tobacco products are prohibited in the EU.  
 
4.8. PROBLEM 5 – TRACEABILITY AND SECURITY FEATURES 
The main problem in this area is that illicit products (estimated 8.25 % of the market with 
increasing tendency236) undermine the safeguards/full effect of the TPD provisions (labelling, 
ingredients). The current TPD provisions are incomplete, do not provide for a fully-fledged 
traceability system, and consumers have difficulties to verify the authenticity of tobacco 
products. There are also obligations as regards the fight against illicit products stemming from 
the FCTC (Article 15).  
• Option 0: No change 
The legally binding Agreements between the four biggest FMC manufacturers and the EU and 
Member States would continue to apply (until potential expiry as of 2016).237 Equivalent 
measures would not be in place for tobacco manufacturers without Agreement. The EU could 
adopt measures only on batch numbering (TPD Article 5(9)).  
• Option 1: EU tracking and tracing system 
An EU tracking and tracing system at packet level for tobacco products throughout the supply 
chain (excluding retail) is introduced. Tobacco manufacturers shall conclude contracts with 
independent third parties that provide data storage capacities for such system ensuring full 
transparency and accessibility by Member States at all times. Tobacco products other than 
FMC and RYO are granted a transitional period of five years. 
 
Delegated/implementing power to adopt technical specification to ensure compatibility 
between the systems used. 
• Option 2: Tracking and tracing system, complemented by security features 
Option 1 plus: security features against counterfeiting and against illicit/cheap whites 
(glossary) on all tobacco products (e.g. holograms). Tobacco products other than FMC and 
RYO are granted a transitional period for five years. Delegated/implementing power to adopt 
technical specifications for the security features. 
5. ANALYSIS OF IMPACTS 
In accordance with the Commission's impact assessment guidelines,238 this impact assessment 
analyses the likely impacts of identified policy options. As the overall objective of revising 
the TPD is to ensure a good functioning of the internal market while ensuring a high level of 
health protection, the focus of the analysis is on economic-, social and health impacts. 
Environmental impacts have been considered to be less significant and are therefore not 
specifically referred to in this section. The assessment criteria (listed in Annex 4) have been 
identified based on the specific objectives and health considerations set in chapter 3. Some 
additional comments are warranted upfront.  
 
                                                 
236 Euromonitor as presented by Matrix 2012.  
237 The European Union and  all Member States have signed legally binding and enforceable  agreements 
with  PMI (2004) and JTI (2007) and the European Union and 26 Member States have signed agreements with 
BAT and ITL  (2010) 
238 European Commission. Impact Assessment guidelines. Brussels: European Commission; 2009.  
http://ec.europa.eu/governance/impact/commission_guidelines/docs/iag_2009_en.pdf (accessed 28 Nov 2012). 
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Effectiveness, efficiency and coherence 
The comparison of policy options and the identification of preferred options are based on the 
general evaluation criteria effectiveness (the extent to which options achieve the objectives of 
the proposal), efficiency (the extent to which objectives can be achieved for a given level of 
resources/at least cost) and coherence (the extent to which options are coherent with the 
overarching objectives of EU policy).  
 
Data collection 
Collecting data and presenting it in a coherent form was a challenge when preparing this 
report. Data has been collected/received a.o. from NGOs, industry, external consultants, 
scientific studies, Member States, other Commission services and publicly accessible 
information. When, despite these efforts, information was considered inadequate, information 
from other comparable sectors were used.239 The analysis was complemented by qualitative 
assessments. Some stakeholders did not provide the information as requested or not in the 
format requested. Sometimes it was also difficult to reconcile publicly available data (e.g. 
Eurostat) with information received from the economic stakeholders. The data sets received 
from industry were also not always fully coherent (here an effort was made to reconcile the 
data to the extent possible). In order to ensure overall quality some of the key data was 
verified with the associated services (e.g. on tax revenues) and the industry (e.g. on turnover 
generated with tobacco products and the value chain by various stakeholders (farmers, 
upstream suppliers, tobacco industry, downstream distributors). Finally, information on the 
illicit part of the market is by definition difficult to establish in a robust form taking into 
account the nature of these activities.  
 
Direct impacts 
This impact assessment distinguish between direct impacts associated with the implantation 
of the options for the stakeholders' one-off and on-going costs and indirect impacts associated, 
in particular, with their effect on revenues. As for the direct costs for the economic 
stakeholders, five main cost categories have been identified and considered throughout the 
impact assessment: 1) familiarisation with the requirement of the new regulation, 2) 
redesign/reformulation of the package/product, 3) acquisition of new equipment (e.g. printing 
equipment), 4) costs for disposal of old stocks and equipment (e.g. printing equipment) and 5) 
variable/on-going costs (e.g. changes in types and quantities of material to be used). The 
estimation of the direct cost factor 1-4 has also been used as an indicator for the functioning 
of the internal market, i.e. the preferred option should normally lead to reduced compliance 
costs compared to the status quo, as economic stakeholders can adapt to EU provisions (as 
nationally implemented) in one go compared to consecutive changes at national level leading 
to diverging set of rules. For Governments, direct impacts are also estimated, e.g. in terms of 
administrative burden associated with the options.  
 
Indirect impacts 
The indirect impacts affect both the economic stakeholders (industry concerned, 
upstream/downstream actors, others) and Governments. Economic stakeholders are impacted 
in terms of revenue/profit and in terms of employment. In particular as regards employment, 
an input/output model was used which describes that money not spent on tobacco would be 
spent on other sectors. The expected main gain for Governments/society is the improvement 
of public health (gained life years). This impact has been monetised in line with the 
                                                 
239 For ex., see: Matrix 2012: "Industry has been able to provide limited data to demonstrate how particular 
regulatory change has impacted across the value chain in terms of costs or sales. The majority of evidence 
provided was indicative or too general."  
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Commission’s impact assessment guidelines.240 In addition, the impacts on health care costs, 
reduced absenteeism and tax revenues are addressed. The calculations are based on an 
expected consumption drop of 2% within five years after the transposition.241 The indirect 
impacts are further described in section 5.7 and Annex 5. 
  
SMEs 
When analysing the impacts, specific considerations have been given to SMEs and micro-
enterprises both in identifying the policy options and assessing their impacts. A summary of 
the impact on SMEs is set out in section 6.2.2.  
 
Stakeholders’ comments and concerns have also been carefully considered throughout the 
document, as illustrated by separate sections under each policy area describing the views 
expressed by key stakeholders, integration of key comments or essential points, and a detailed 
description in Annex 1.   
 
The text is divided in five subsections following the five identified policy areas (STP and 
extension of the product scope, packaging & labelling, ingredients, cross-border distance sales 
and traceability & security features). Assessment of impacts, comparison of policy options 
and presentation of a preferred option will thereafter be undertaken separately for each of the 
policy areas. Scoring tables for the different policy areas can be found in Annex 4. A general 
conclusion presenting the overall combined preferred options can be found in section 6.1. 
5.1. ASSESSMENT OF POLICY OPTION 0: NO CHANGE 
5.1.1. Economic impacts  
Internal market 
The increasing divergence between Member States' legislations under the baseline scenario 
leads to further fragmentation of the internal market. Given the significant amount of cross-
border trade in tobacco and related products (section 2.1), this will negatively affect cross-
border trade and undermine the level playing field for the economic actors involved.242  
 
Direct impacts 
More fragmentation of the internal market leads to higher costs for economic stakeholders 
to comply with different national measures. In general, a qualitative description of the various 
cost categories suggests that the compliance costs under option 0 (consecutive national 
changes) are expected to be higher than if a harmonised approach across the EU was taken.  
 
Following the cost categories identified above, the direct economic impact (compliance costs) 
can be described according to the table below. Categories 1-4 refer to one-off costs, while 
category 5 is a variable/on-going cost. 
 
                                                 
240 For each life year, a value of 52,000 EUR is assumed.  
241 For further information on how this drop was estimated, see Annex 5.  
242 In certain areas Member States cannot adapt their legislation due to existing level of harmonisation. Also, 
there is a risk that the safeguards of the Directive are undermined by non-compliant products. 
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Cost category (compliance cost) Description  
1. Familiarisation with the requirements of the new 
regulation. 
Economic stakeholders need to monitor 27 different legal 
systems and get familiar with all unilateral changes adopted by 
Member States.243 This can also include seeking legal advice.  
2. Redesign/reformulation of the package/product Economic stakeholders need to adapt to unilateral changes 
adopted by Member States. This also includes testing and 
legal/marketing/scientific advice. Stakeholders also have to 
adapt production lines to comply with different national 
legislations.  
3. Acquisition of new equipment Economic stakeholders may need to buy new equipment (e.g. 
printing equipment) to comply with national measures.  
4. Costs for disposal of old stocks and equipment Cost for the disposal of stocks can normally be disregarded 
provided sufficient transposition periods are granted.  
5. Variable/on-going costs Economic stakeholders might have to change the types and 
quantities of material to be used in the manufacturing process. 
This could be either a cost (e.g. more expensive ink) or a saving 
(e.g. less ingredients to be used) and is proportionate to the 
volume of sale.  
 
The approach can be exemplified for the area of labelling, ingredients and traceability and 
security features. For estimations of costs, see impact assessment sections 5.2-5.6.  
 
Indirect impacts 
As far as indirect impacts (linked to consumption) are concerned, the impact on companies' 
revenues under the baseline scenario is expected to be neutral. This is based on the estimated 
stagnation of smoking consumption/prevalence (see above under baseline scenario, 2.3.3). 
 
Also Governments' monetised value of public health, the tax revenues, health care costs and 
productivity losses are linked to the consumption/prevalence forecast. As mentioned in 
section 2.1.2, approximately 25 bEUR are currently spent every year to treat smoking related 
diseases and 8.3 bEUR are lost annually on productivity losses. From an economic point of 
view, the baseline scenario constitutes a missed opportunity for Governments to further 
reduce costs. From a macro-economic point of view, taxes are not a cost (taxes just reallocate 
revenues from economic stakeholders to the Government), but obviously reduced taxes have 
an impact on Government revenues. 
 
Consumers 
Under option 0, industry would have an incentive to present consumers with a larger choice 
of products.244 Consumers would also be subject to new innovative marketing, likely to target 
young consumers in particular and there would be a lack of protective measures.245 No 
particular impact is foreseen as far as the price is concerned. Consumers would also be 
exposed to serious health risks due to a lack of harmonised standards for some of the 
products, including STP, NCP and herbal products for smoking. The supply of illicit tobacco 
products would continue to be of (increasing) safety concern and to undermine tobacco 
control measures intended to protect consumers. In addition, as indicated in the problem 
identification, certain aspects of packaging & labelling, as well as certain ingredients may 
have the capacity to mislead consumers. 
                                                 
243 It could be noted that a UK administrative burden exercise estimated the costs attributed to familiarisation and 
understanding of the food labelling regulation as 13% of all administrative costs across food legislation, see FSA 
(2006), "Food Standards Agency: Administrative Burdens Measurements Exercise: Final Report", June 2006 
244 In the light of existing entry barriers it might not be easy, in particular for SMEs to enter the market in a 
sustainable manner with new brands. 
245 See for ex. Cancer Research UK. The packaging of tobacco products. Stirling: Centre for Tobacco Control 
Research, University of Stirling; 2012. 
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International 
In terms of international impact, under option 0, the EU does not fully comply with its 
international obligations/non-binding commitments (FCTC)246 and lags behind other 
jurisdictions (including Canada, Australia and the US) in many of the areas covered by this 
impact assessment, including labelling and ingredients.  
5.1.2. Social impacts  
The specific impact on employment is estimated under option 0 following the consumption 
forecast foreseen under the baseline scenario (section 2.3.3) (including redistribution effects). 
This is without prejudice to further consolidation and automatisation of production methods 
which can be expected and that would potentially entail employment cuts. In terms of 
equality, option 0 has negative consequences on young people in particular. As illustrated in 
the problem definition, many of the products on the market currently target young people. 
This is true both for STP, NCP and herbal products for smoking, but also for FMC marketed 
in appealing packages or with flavours particularly attractive to young people. Due to the 
price structure RYO are also attractive for young people. The targeting of young people is 
expected to continue in coming years.   
5.1.3. Health impacts  
As outlined above, under the baseline scenario (section 2.3.2), Member States would be 
prevented from taking unilateral actions in areas already harmonised in the TPD, notably 
as regards the size and placement of the health warnings, the removal of misleading TNCO 
levels and in the area of traceability. This is unsatisfactory from a public health point of view 
and is not in line with the obligation to ensure a high level of health protection in all policies 
and activities (TFEU Articles 168 and 114). The high level of premature mortality and 
morbidity would prevail (see section 2.1.2). 
 
5.2. SMOKELESS TOBACCO PRODUCTS AND EXTENSION OF THE PRODUCT SCOPE 
1.1.12. Smokeless tobacco products (STP)  
5.2.1.1. PO1: Lift the ban on oral tobacco and subject all STP to stricter labelling 
and ingredients regulation   
a) The current ban on oral tobacco is lifted and these products can be placed on the market 
subject to stricter labelling and ingredients requirements (e.g. health warnings on both sides of 
the package and a ban of products with characterising flavour (glossary) and increased 
toxicity or addictiveness).   
b) The placing on the market of chewing and nasal tobacco continues to be allowed, but 
subject to the same rules on labelling and ingredients as set out under a.  
c) Placing on the market of novel tobacco products (glossary) continues to be allowed subject 
to the same rules on labelling and ingredients as for oral tobacco.  
 
Delegated/implementing power to adapt health warnings, act on products with characterising 
flavours on products with increased toxicity or addictiveness and to regulate additives that 
cause a characterising flavour.    
                                                 
246 For ex. FCTC refers to effective legislation regulating the content of tobacco products, marking of all tobacco 
packages in order to determine the origin and health warnings of 50% or more (but no less than 30%). 
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Economic impacts 
Option 1 would allow the placing on the market of oral tobacco (snus) in the EU and remove 
the current differential treatment between different types of STP. However, when the ban on 
oral tobacco was introduced in 1992, three Member States had already adopted national bans. 
It is likely that, at the very least, these Member States will wish to maintain their approach, in 
particular when considering that most of the Member States responding to the public 
consultation explicitly supported keeping the ban on oral tobacco (Annex 1). This could 
negatively affect the functioning of the internal market if it reintroduces the fragmentation of 
the market that existed before 1992. Moreover, it is difficult to draw any firm conclusion on 
the effectiveness on STP in smoking cessation (see below under health impacts). In regional 
terms, option 1 would have a positive impact on the Finnish island Ǻland which claims being 
subject to unequal treatment under the current situation (section 2.2.1).  
 
The most important impact for the economic stakeholders is that of increased sales of oral 
tobacco following the lifting of the ban, in particular as this product is new to the EU market 
(except for Sweden) and is potentially attractive to new customers, including young people.247 
Smoke-free environments are a key driver for this expected growth. It is not possible to 
quantify the expected increase in sales as it is very difficult to foresee how new and 
unexplored markets would react to this product. The oral tobacco producer, Swedish Match, 
has indicated that the sale of oral tobacco in the EU could potentially generate gross profits to 
the retail sector in the amount of 3-9 bEUR.248 Chewing and nasal tobacco producers are 
likely to be confronted with decreased or stagnating sales in the light of increased competition 
from oral tobacco and a reduced product portfolio (no STP with characterising flavours, 
additional health warning).249 The same could be true for producers of NRT, FMC and RYO 
if oral tobacco is – as claimed by Swedish Match - used for smoking cessation purposes. 
However, the evidence to that end is not compelling (see also below on health impacts). Also, 
products claiming to assist smokers to quit smoking would require authorisation as medicinal 
products.  
 
All STP producers would be faced with limited additional compliance costs in terms of the 
required additional health warnings and the restrictions in terms of ingredients (ban on STP 
with characterising flavours).250 On the other hand, an EU based approach is still cheaper than 
consecutive changes at national level. Additional compliance costs would consist of 
familiarisation and understanding of the new requirements, redesign of the packages and 
reformulation of the products.251 The industry has estimated the medium range cost for 
changing the labelling to 6,000 EUR per SKU, although this can vary from company to 
company.252 As regards reformulation, an important market development has taken place in 
STP (including oral tobacco) in recent years. Many products are presented with characterising 
                                                 
247 This presupposes that potentially reduced sales in Sweden due to labelling and ingredients regulation are 
compensated through increased sales outside Sweden. 
248 Swedish Match, power point from 15 December 2011. See also Swedish Retail Institute (HUI). Snus in the 
EU The potential economic impact of snus on retail taxes and employment in the EU. Stockholm: HUI; 2010. 
The lower estimate is based on the assumption that only former smokers would use snus while the higher 
estimate ("normal consumption scenario") is based on additional recruitment of new users. The calculation does 
not take into account a corresponding drop in FMC sale. 
249 Currently there is a growth potential for STP in the light of smoke-free environments, see option 1. 
250 As previously explained a common EU approach is expected to be beneficial compared to consecutive 
amendments of national legislations. 
251 Additional costs for changing in printing, packaging and production equipment as well as disposal of existing 
stocks could be removed if sufficient transposition periods are given.   
252 European Smoking Tobacco Industry, facts and figures for DG SANCO, ESTA 2011-2012 
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flavours, including raspberry/pepper and rhubarb/ginger.253 These products would have to be 
reformulated or withdrawn from the market. While chewing and nasal tobacco producers are 
often SMEs, they typically also sell other tobacco products,254 making them less vulnerable.  
 
Overall, it is expected that the costs linked to compliance with the suggested product 
standards would be significantly surpassed by the overall increased sales following the lifting 
of the ban on oral tobacco and thus result in positive economic impact for the oral tobacco 
industry. Significant product development in novel STP products claimed to imply a lower 
risk than FMC is also expected under option 1 (see 2.2.1).255    
 
As there are no harmonised excise duties on STP in the EU, the impacts on governments in 
terms of tax incomes would vary among Member States. Governments would be confronted 
with some additional health risks/costs (see below under health impacts). Overall a broader 
range of products would be available to EU consumers (including oral tobacco also outside 
Sweden). However, the option would impact negatively on consumer protection due to the 
health risks referred to below under health impacts. Prohibiting STP with characterising 
flavours would be in line with the FCTC guidelines on ingredients. Lifting the ban on oral 
tobacco would not be in line with the WHO recommendation from 1988 that "countries with 
no established smokeless tobacco habit should consider a ban on the manufacture, 
importation, sale and promotion of smokeless tobacco products before they are introduced to 
market or become established habit”.256  
Social impacts 
Option 1 would result in increased employment in STP overall, mainly benefitting the oral 
tobacco industry (Swedish Match as leading actor) which would have the possibility to 
explore new markets. It is also expected that the big FMC manufacturers will use this 
opportunity to enter the STP market on a large scale (further reinforcing this on-going trend). 
On the other hand, some negative impacts are expected as far as chewing and nasal tobacco 
employment is concerned following increased competition from oral tobacco. In terms of 
equality, the already on-going targeting of young people would continue under option 1, but 
the attractiveness of the products would be reduced under option 1 due to stricter measures on 
labelling and ingredients.  
Health impacts 
Studies show that STP are less hazardous to health than FMC257 and even option 1 would 
prevent STP with increased toxicity or addictiveness to enter the market.  
 
                                                 
253 Swedish Match magazine Inside #2 from May 2008 reports that Swedish Match portfolio has grown from 22 
products in 2002 to 180 varieties in 2008 and that 14 new products are launched every year. New tastes flavours 
have been marketed in recent years, including raspberry/pepper (2011), mint/vanilla (2011), rhubarb/ginger 
(2010).  
254 European Smoking Tobacco Industry: Facts & Figures for DG Sanco, ESTA 2011-2012 
255 For example, the US market has seen a diversification of STP in recent years, including marketing of 
“dissolvable” tobacco products often sold in brightly coloured packaging an in an appearance similar to candy: 
Krisberg K. New types of smokeless tobacco present growing risks for youth: Survey: Products mistaken for 
candy. The Nation's Health 2010; 40:1-14. http://thenationshealth.aphapublications.org/content/40/6/1.2.full 
(accessed 28 Nov 2012). 
256 World Health Organization (WHO). Smokeless tobacco control. Report of a WHO Study Group. Geneva: 
WHO; 1998. 
257 Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, et al. The relative risks of a low-
nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. 
Cancer Epidemiol Biomarkers Prev 2004;13(12):2035-42. 
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Therefore, for individuals who replace FMC entirely with STP the overall benefits would 
outweigh the risks although full abstention from tobacco use would be the most beneficial. 
The overall health impacts on the population at EU level under option 1 would, however, 
largely depend on how the EU market reacts on the introduction of oral tobacco and in 
particular if this measure would contribute to reducing the number of smokers in the EU 
(substitution) or if it would rather increase the overall tobacco use contribute to initiation and 
undermine tobacco cessation efforts.  
 
Health effects of STP 
In terms of health, all STP tobacco products contain nicotine and are addictive. They also 
contain carcinogenic substances, including tobacco specific N-nitrosamines (TSNA) and 
polycyclic aromatic hydrocarbons (PAH). The Scientific Committee on Emerging and Newly 
Identified Health Risks (SCENIHR) concluded, in its opinion on 6 February 2008, that STP in 
all its forms can cause cancer (with the pancreas as a main target organ) and are addictive.258 
The International Agency for Research on Cancer (IARC) has also classified smokeless 
tobacco as "carcinogenic to humans”.259 A study on smokeless tobacco and cancer from 2008 
concludes that the cancer risk of smokeless tobacco users is probably lower than that of 
smokers but higher than that of non-tobacco users.260  
 
There are many forms of smokeless tobacco products, which differ considerably in their 
composition and toxic potential. Some chewing tobacco products, in particular some products 
used by the South Asian community in the UK, according to a recent study, contain a wide 
range of toxic substances, such as tobacco-specific nitrosamines (TNSA) chromium, nickel 
and lead.261 During the last two decades, the level of tobacco-specific nitrosamines (TNSA), 
the major group of carcinogens in smokeless tobacco, has been considerably lowered in some 
STP, including Swedish oral tobacco (snus).262 This means that the adverse health effects of 
snus might differ from other non-combustible tobacco products. However, it does not mean 
that snus or any other oral tobacco product is safe or harmless. Products with lower levels of 
carcinogenic tobacco-specific nitramines (TNSA) have also been on the market for too short 
time for any convincing support in favour of the presence or absence of a lower cancer risk. 
The WHO Study Group on Tobacco Product Regulation concludes in its report from 2009 
that existing evidence has not established that lowering TSNA or PAH levels in smokeless 
tobacco will lower cancer risks.263 
 
The link between STPs and pancreatic cancer has been discussed by the research community 
in recent years. Based on a number of case-control and cohort studies, the two authoritative 
international research groups SCENIHR and IARC have concluded that there is sufficient 
                                                 
258 SCENIHR, 2008 
259 International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic 
Risks to Humans. Volume 89: Smokeless Tobacco and some Tobacco-specific N-nitrosamines. Lyon: IARC 
Press; 2007. International Agency for Research on Cancer (IARC). A Review of Human Carcinogens: Personal 
Habits and Indoor Combustions. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: 
Volume 100E. Lyon: IARC Press; 2012. 
260 Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008; 9(7):667-75. 
261 Longman JM, Pritchard C, McNeill A, Csikar J, Croucher RE. Accessibility of chewing tobacco products in 
England. J Public Health (Oxf) 2010;32(3):372-8. 
262 Rutqvist LE, Curvall M, Hassler T, Ringberger T, Wahlberg I. Swedish snus and the GothiaTek standard. 
Harm Reduct J  2011; 8:11. 
263 World Health Organization (WHO) Study Group on Tobacco Product  Regulation. Report on the Scientific 
Basis of Tobacco Product Regulation. WHO Technical Report Series, no. 955. Geneva: WHO; 2010. 
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evidence that STPs cause pancreatic cancer in humans.264 A recent case-control study 
suggests, however, that there is no significant association between pancreatic cancer and 
smokeless tobacco.265 The discrepant results of this study with other case-control studies have 
been questioned by a number of researchers calling for a cautious interpretation in view of 
existing strong cohort data supporting an association between STP and risk of pancreatic 
cancer.266    
 
Risk of oral cancer have been found for various smokeless tobacco products, including some 
of the chewing tobacco products (e.g. areca nut and betel quid) used by ethnic minorities in 
the UK.267 There are also suggestions that nasal tobacco increases the risk of certain cancers, 
e.g. oral cancers.268 The risk for oral cancer is less clear as regards Swedish oral tobacco 
(snus).269   
 
SCENIHR concluded in 2008 that published studies support a causal role of STP in the 
etiology of oesophageal cancer.270 According to IARC, there is now sufficient evidence that 
there is a causal association between smokeless tobacco and oesophageal cancer.271 
 
In addition, there is evidence for an increased risk of fatal myocardial infarction among STP 
users.272 Hansson concluded in a study from February 2012 that current snus users had a 
higher probability of dying from acute myocardial infarction (AMI) as compared to non-users, 
and that this increase may be explained in confounding factors, although a small increased 
risk of sudden death from AMI among snus users cannot be ruled out.273   
 
Some data also indicate that STP use is associated with several pregnancy complications, 
including pre-term birth, intrauterine growth restriction, placenta abruption and still birth.274  
                                                 
264Alguacil, J and Silverman, DT. Smokeless and other non cigarette tobacco use and pancreatic cancer: A case-
control study based on direct interviews. Cancer Epidemiol Biomarkers Prev 2004; 13:55–8. Boffetta P, Aagnes 
B, Weiderpass E, Andersen A. Smokeless tobacco use and the risk of cancer of the pancreas and other organs. 
Int J Cancer 2005; 114(6):992-5. Cogliano V, Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F. Smokeless 
tobacco and tobacco-related nitrosamines. Lancet Oncol 2004; 5(12):708. Luo J, Ye W, Zendehdel K, Adami J, 
Adami HO, Boffetta P, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and 
pancreas in male construction workers: a retrospective cohort study. Lancet 2007;369(9578):2015-20. Secretan 
B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens--Part E: 
tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10(11):1033-4. 
265 Bertuccio P, La Vecchia C, Silverman DT, Petersen GM, Bracci PM, Negri E, et al. Cigar and pipe-smoking 
smokeless tobacco use and pancreatic cancer: an analysis from the International pancreatic Cancer Case-Control 
Consortium (PanC4). Ann Oncol 2011; 22(6):1420-6. 
266 Nyrén O, Lambe M, Ye W, Adami HO. Are cohort data on smokeless tobacco use and pancreatic cancer 
confounded by alcohol use? Ann Oncol 2011; 22(8):1930-1; author reply 1931-2. 
267 Action on Smoking and Health (ASH). ASH Fact sheet: Tobacco and ethnic minorities. London: ASH; 2011. 
268 SCENIHR  2008  
269 Idem 
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271 International Agency for Research on Cancer (IARC). A Review of Human Carcinogens: Personal Habits and 
Indoor Combustions. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 100E. 
Lyon: IARC Press; 2012. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of 
human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 
10(11):1033-4. 
272 SCENIHR 2008. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: 
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In conclusion, despite differences in composition and carcinogenic potential, there is scientific 
evidence that all STPs are addictive and harmful to health. As shown above, some of the 
epidemiological data are questioned by studies (partly sponsored by the industry) inconsistent 
but this does not put into question the overall conclusion. In any event it justifies the 
application of the precautionary principle, i.e. it justifies not allowing market entry of 
products, which are addictive and harmful.275   
 
Cessation, initiation, dual-use 
In terms of substitution, some studies suggest that oral tobacco (snus) can play a role in 
smoking cessation276 or that oral tobacco users are more likely to quit smoking than users of 
medicinal smoking cessation products.277 Most of the studies are based on observational data, 
which makes it difficult to draw reliable conclusions as to the relative effectiveness of 
smokeless tobacco in smoking cessation.278 On the other hand, a randomised controlled trial 
showed that use of STP in cessation did not have any long-terms efficacy.279 Swedish Match 
recently sponsored two clinical trials comparing the effectiveness between oral tobacco (snus) 
and placebo products in smoking cessation in Serbia and the US.280 The studies suggest that 
smokers using Swedish snus were 2-3 times more likely to quit smoking than those using 
placebo-products. However, the studies took place over a relatively short time (24 and 28 
weeks) and it is impossible to say whether the relatively few people quitting smoking in these 
studies would have done so also without oral tobacco or also, or even more, with the 
                                                                                                                                                        
Stirling: UK Centre for Tobacco Control Studies (UKCTCS); 2010. Wikström AK, Stephansson O, Kieler H, 
Cnattingius S. Snuff during pregnancy no risk-free alternative to smoking. [in Swedish] (Snus under graviditet ar 
inget riskfritt alternativ till rokning.) Lakartidningen 2011;108(29-31):1430-3.  
275 Swedish National Institute of Public Health (FHI). Public Consultation. Possible revision of the Tobacco 
products directive. Ostersund: FHI; 2010. http://www.fhi.se/Documents/Om-oss/remisser/2010/Remissyttrande-
tobacco-products-directiveVERK-2010-546.pdf (accessed 28 Nov 2012). 
276 Royal College of Physicians (RCP). Harm reduction in nicotine addiction: helping people who can’t quit. A 
report by the Tobacco Advisory Group of the Royal College of Physicians. London: RCP, 2007. Scheffels J, 
Lund KE, McNeill A. Contrasting snus and NRT as methods to quit smoking. an observational study. Harm 
Reduct J 2012; 9:10. 
277 Lund KE, McNeill A, Scheffels J. The use of snus for quitting smoking compared with medicinal products. 
Nicotine Tob Res. 2010 Aug;12(8):817-22. Lund KE, Scheffels J, McNeill A. The association between use of 
snus and quit rates for smoking: results from seven Norwegian cross-sectional studies. Addiction 
2011;106(1):162-7. Ramstrom LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in 
Sweden. Tob control 2006; 15(3): 210-214. Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Lim SS. 
Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007; 
369(9578):2010-4. 
These findings are challenged by Barrett SP, Campbell ML, Temporale K, Good KBP. The acute effect of 
Swedish-style snus on cigarette craving and self-administration in male and female smokers. Human 
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Kotlyar M, Hertsgaard LA, Lindgren BR, Jensen JA, Carmella SG, Stepanov I et al. Effect of oral snus and 
medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer 
Epidemiol Biomarkers Prev 2011; 20(1):91-100 found that Camel Snus and Taboka use was not superior to 
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assistance of NRT.281 In this context it should also be considered that 2/3-3/4 of smokers quit 
un-aided.282  
 
Sweden's low smoking prevalence in combination with the availability of oral tobacco (snus) 
is sometimes referred to as an indication of snus as an effective cessation method and there 
are some data indicating that snus has been used by Swedish smokers as an alternative to 
smoking.283 On the other hand, SCENIHR concluded in 2008 that the overall smoking 
prevalence in Norway, as well as in young Norwegians, had decreased at the same rates in 
men and women during the last decade, whereas a marked increase in oral tobacco (snus) use 
during this time period has only occurred in young men.284 In California, both the prevalence 
of smoking and smokeless tobacco use have decreased concurrently.285 Some countries which 
have invested heavily in preventive measures have also managed to reduce smoking rates 
without the availability of STP.286 These data imply that the association between patterns of 
STP tobacco use and smoking cessation differs between populations and is likely to be 
affected by cultural, societal and other factors. In this context, SCENIHR has concluded 
that it is not possible to extrapolate the trends in prevalence of smoking and use of oral 
tobacco from countries where oral tobacco is available to EU-countries where oral tobacco is 
not currently available.287 This is highly relevant, as the sale of the product cannot be limited 
to people who wish to stop smoking, unless the product is a medicinal product available only 
on prescription. 
 
Option 1 is also expected to result in uptake of STP use among individuals (including among 
young people) who would otherwise not have used tobacco. A survey undertaken by the 
Swedish National Institute of Public Health reveals that four out of ten oral tobacco (snus) 
users started using tobacco with oral tobacco.288 In Norway, recruitment of oral tobacco (snus) 
users among young people, including recruitment of those with no previous experience of 
smoking, is increasing.289 Results from cross-sectional studies from Norway show that over 
40% of young people (16-20 years old) of daily snus users had no previous smoking 
                                                 
281 The Fagerstrom study (2011) reported that only 4% (5 persons) abstained from week 6-28. 
282 Chapman S, MacKenzie R. The Global Research Neglect of Unassisted Smoking Cessation: Causes and 
Consequences. PLoS Med 2010;7(2):e1000216. 
283 Stenbeck M, Hagquist C, Rosén M. The association of snus and smoking behaviour: a cohort analysis of 
Swedish males in the 1990s. Addiction 2009;104(9):1579-85. See also SCENIHR 2008 although SCENIHR also 
concludes that it is not clear whether or by how much the availability of snus has influenced smoking prevalence. 
284 This conclusion by SCENIHR is based on Norwegian data up until 2006. Data after 2006, however, indicates 
a significant increase of oral tobacco (snus) uptake also among women: 
http://www.helsedirektoratet.no/folkehelse/tobakk/tall-og-undersokelser/snus/Sider/unge-snuser.aspx (accessed 
28 Nov 2012). Scheffels (2012) also concludes that Norwegian men frequently use snus as a method for quitting 
smoking whereas women are more likely to use NRT.        
285 SCENIHR 2008 
286 Holm LE, Fisker J, Larsen BI, Puska P, Halldórsson M. Snus does not save lives: quitting smoking does! Tob 
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287 SCENIHR 2008 
288 Holm LE, Fisker J, Larsen BI, Puska P, Halldórsson M. Snus does not save lives: quitting smoking does! Tob 
Control 2009;18(4):250-1. See also Swedish Retail Institute (HUI). Potential savings on social costs by the use 
of Swedish snus as a harm reduction device in the EU: HUI; 2010. In this study, 5 million new snus users are 
estimated if snus was allowed in the EU.  
289 According to SSB Statistics Norway responsible for coordinating all official statistics in Norway, use of oral 
tobacco (snus) has increased from 9% to 25% among men 16-24 years old from 2001-2011 and from almost not 
measureable figures to 11% for women in the same age group.: 
http://www.ssb.no/english/subjects/03/01/royk_en/ and http://www.helsedirektoratet.no/folkehelse/tobakk/tall-
og-undersokelser/snus/Sider/unge-snuser.aspx (accessed 28 Nov 2012). Lund KE. A tobacco-free society or 
tobacco harm reduction? Which objective for the remaining smokers in Scandinavia? SIRUS Report 6/2009. 
Oslo: Norwegian Institute for Alcohol and Drug Research (SIRUS); 2009.  
     69 
experience.290 Considering the current marketing strategies described under the problem 
identification (e.g. STP with distinctive tastes) and the obvious interest of the industry to 
recruit new users, a non-negligible uptake rate is expected under option 1. Smoke-free 
environment also play an important role in this respect.   
 
Although there is currently limited evidence regarding novel STP, which are yet to be 
marketed to consumers, there may also be a risk of uptake of these products among new users 
and smokers who would otherwise have quit smoking altogether. Despite the claim that these 
products are reduced risk products, they are addictive and harmful to health. As BAT states on 
their web site: "Cigarette smoking is a cause of serious and fatal diseases and the only way to 
avoid the health risks associated with tobacco products is to not use them."291 
    
There is also uncertainty as regards STPs' potential as a "gateway" to future smoking. 
Evidence from the US indicates that oral tobacco use may lead to subsequent FMC smoking, 
while some Swedish data do not support this hypothesis.292 The SCENIHR opinion of 
February 2008 suggests caution in translating these data.293  
 
Moreover, there is a risk of "dual use". One study of snus as a cessation method found that 
20% of unsuccessful quitters continued to use snus on a daily basis (dual use).294 A recent 
Norwegian study has also found that around 30% of daily snus users were smoking at least 
occasionally.295  Oral tobacco (snus) use in early adolescence has also been associated with 
increased risk of taking up occasional smoking in addition to snus in late adolescence.296 
There is also a risk that consumers taking up STP will become chronic users.297 
 
Finally, there is a risk under option 1 that lifting the ban on oral tobacco could have a negative 
impact on overall tobacco control policies. Norway has in its response to the public 
consultation on the TPD pointed to difficulties from a communication point of view of 
advocating non-use of oral tobacco (snus) among young people and at the same time 
advocating the use of the same product as a smoking cessation tool for another group.298 The 
same is true for other types of STP, including novel non-combustible products. In addition, 
the introduction of oral tobacco could potentially weaken cessation policies, in particular as it 
would allow people to keep up their nicotine addiction in situations where smoking is not 
allowed (e.g. smoke-free environments) and subsequently resume smoking.  
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Summarising the findings on oral tobacco, it is not possible at this stage to draw the 
conclusions oral tobacco is an effective smoking cessation aid in the long term. Any impacts 
therefore on smoking-related diseases remain uncertain under option 1. On the other hand, it 
is likely that new oral tobacco users would be recruited under option 1 who would otherwise 
not have used tobacco (entry gate) and current smokers who would otherwise have quit using 
tobacco altogether might switch to oral tobacco or use both products (dual use). This would 
lead to increased adverse health effects (see section 2.2.1). In this light, it appears difficult to 
reconcile lifting the ban with the precautionary principle.   
   
5.2.1.2. PO2: Maintain the ban on oral tobacco, subject all novel tobacco products to 
a notification obligation and all STP to stricter labelling and ingredients 
regulation  
a) The current ban on oral tobacco is maintained (except for Sweden which has an 
exemption), but oral tobacco needs to comply with stricter labelling and ingredients regulation 
(e.g. health warnings on both sides of the package and a ban of products with characterising 
flavours and increased toxicity or addictiveness).  
b) The placing on the market of chewing and nasal tobacco continues to be allowed, subject to 
the same rules as set out under a. A clearer definition of chewing tobacco is inserted.  
c) A notification obligation is introduced for novel tobacco products (glossary) and a report 
on the market development in these products will be issued by the Commission five years 
after the transposition of the TPD. Novel tobacco products placed on the market must respect 
the rules on labelling (health warnings on both sides) and ingredients regulation (ban on 
products with characterising flavours).    
Delegated/implementing power as in option 1.  
Economic impacts 
This option would contribute to a more homogenous development in terms of labelling and 
ingredients regulation of all STP. The insertion of a clearer definition of chewing tobacco 
(compared to tobacco products for oral used) would increase legal certainty and prevent 
circumvention of the TPD provisions. Compared to the baseline scenario, option 2 is 
considered to have a positive impact on the internal market. The differential treatment in 
terms of regional impact on Ǻland would remain neutral under option 2, i.e. ships under 
Swedish flag would be allowed to sell tobacco whilst vessels under the flags of Finland and 
Ǻland serving the same routes would not be allowed to do so. However, this differential 
treatment is an effect of the Swedish exemption on oral tobacco rather than the ban itself.299 
The differential treatment of oral tobacco and other forms of STP would also persist, as oral 
tobacco producers would not have the option to expand sales outside Sweden, but as the Court 
ruled, the differential treatment was justified in 2001. The underlying analysis has not 
changed.  
 
The impact in terms of compliance costs for the economic stakeholders involved in STP 
manufacturing would be similar to the once described under option 1, i.e. costs linked to the 
change of labelling and possible reformulation of additives. Option 2 also implies an 
obligation for manufacturers to report novel tobacco products prior to their placing on the 
market. The notification would also be accompanied by available scientific and market studies 
                                                 
299 This is also in line with the Courts reasoning in Case C-434/02 Arnold André GmbH & Co. KG v Landrat des 
Kreises Herford [2004] ECR I-11825, p 41  
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as well as other available and relevant information, including risk/benefit analyses of the 
products. This obligation would imply an additional burden for manufacturers intending to 
place novel tobacco products on the market. However, the burden is considered limited as it 
focus on already available information and information already required under the ingredients 
reporting requirements (policy area 3). In terms of indirect costs linked to consumption, the 
sale of oral tobacco would remain limited to Sweden and the sales potential to other Member 
States allowed for under option 1 cannot be explored under this option. The prohibition of 
STP with characterising flavours would also affect negatively sales of STP as well as the 
increased labelling requirements providing consumers with more visible information about 
the health risks associated with the products.    
 
The administrative burden for Member States of introducing a notification obligation for 
novel tobacco products under option 2 would be limited, if any. Option 2 would also result in 
reduction of the tax income for Governments following the drop in STP consumption, but 
they are expected to benefit from better health outcomes.300 EU consumers would have a 
more limited choice of STP than today due to the ban on STP with characterising flavours, 
but in particular young potential consumers could be better protected against initiation and 
better informed. The ban on STP with characterising flavours would be in line with FCTC 
guidelines on ingredients (also covering STP). Overall the option would lead to a consistent 
approach for all tobacco products that are likely to be used by young people (tobacco 
consumption initiation). 
Social impacts 
Option 2 would have some limited negative impact on employment due to the forecasted 
reduction in use and also because no new STP with characterising flavours attractive to young 
people could be developed. For the chewing and nasal tobacco industry, this would 
particularly affect certain regions where chewing and nasal tobacco products currently are 
produced (mainly in Germany, Denmark, Belgium and Poland). This negative impact, 
however, is more limited than the impact under option 4 as the products could still remain on 
the market. Overall, it is expected that some redistribution will take place as money not spent 
on STP is spent on other economic activities (see reasoning in Annex 5).  
 
Option 2 would remove the current targeting of young people and thus contribute to increased 
equality. It is not expected to impact on specific population groups using STP.   
Health impacts 
Under option 2, chewing and nasal tobacco would lose part of their current appeal and the 
future development of STP with distinctive tastes or aroma would be prohibited. Option 2 
would result in decreased use of STP. Also the additional health warning would reduce the 
appeal of these products and better inform consumers. As in option 1, option 2 would also 
prevent STP with increased toxicity or addictiveness to be placed on the market. Under option 
2, Member States would be placed in a better position to monitor market developments with 
regard to novel STP.    
 
                                                 
300 Member States would also have to ensure that sales are limited to territory, i.e. they would have to prohibit 
cross-border distance sales. Taking into account that the number of traditional STP is limited, the administrative 
burden for enforcement is limited.  
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5.2.1.3. PO3: Maintain the ban on oral tobacco, restrict the sale of other STP to 
areas of traditional use only and subject all STP to stricter labelling and 
ingredients rules  
a) The current ban on oral tobacco is maintained (except for Sweden which has an 
exemption), but oral tobacco needs to comply with stricter labelling and ingredients regulation 
(e.g. health warnings on both sides of the package and a ban on products with characterising 
flavours and increased toxicity or addictiveness).  
b) The placing on the market of chewing and nasal tobacco is banned unless traditionally used 
(glossary) in Member States. The placing on the market of traditionally used STP is limited to 
the relevant territory/Member State and must comply with the same labelling and ingredients 
rules as set out under a. Member States will have to prove traditional use and notify to the 
Commission. 
c) The placing on the market of novel tobacco products is banned.   
Delegated/implementing power as in option 1. 
Economic impacts 
Option 3 would impact positively on the internal market by removing current regulatory 
disparities for chewing & nasal tobacco and by ensuring equal treatment between different 
STP. It would reduce the growth potential (e.g. smoke-free environments) of STP with 
adverse health effects and prevent the launch of novel tobacco products with adverse health 
effects.  
 
The impact for the economic stakeholders would be that the sale of oral tobacco would 
remain limited to Sweden (having an exemption from the ban) and the sale of other STP 
would be limited to Member States with traditional use. All STP industries would have to 
comply with stricter rules on labelling (an additional health warning to be added to the 
packages) and on ingredients (prohibit STP with characterising flavours). The compliance 
costs would be linked to the change of labelling and possible reformulation of additives. 
Again, an EU approach is more cost effective than consecutive changes at national level. The 
companies affected are mainly SMEs although they are also involved in other tobacco 
products,301 which means that most of them would not have to exit the market altogether. The 
negative impact would be further reduced by allowing Member States exemptions for 
traditionally used STP.  
 
Option 3 would result in reduction of the tax income for Governments following the drop in 
STP consumption, but they would benefit from better health outcomes.302 EU consumers 
would have a more limited choice of STP than today due to the ban on STP with 
characterising flavours but in particular young (potential) consumers would be protected 
and/or at least better informed . In terms of international impacts, option 3 could have some 
negative impact on international trade due to the current import of certain STP from third 
countries (e.g. import for ethnic minorities). However, considering that chewing and nasal 
tobacco products count for less than 0,1% of the total tobacco market, this impact is 
considered limited. Also, the exemption of traditional use could apply. The ban on STP with 
characterising flavours would be in line with FCTC guidelines on ingredients (also covering 
STP). Overall the option would lead to a consistent approach for all products that are likely to 
be used by young people (tobacco consumption initiation). 
                                                 
301 European Smoking Tobacco Industry, facts and figures for DG SANCO, ESTA 2011-2012 
302 Member States would also have to ensure that sales are limited to territory, i.e. they would have to prohibit 
cross-border distance sales. Taking into account that the number of traditional STP is limited, the administrative 
burden for enforcement is limited.  
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Social impacts 
Option 3 would have some negative impacts on employment due to the forecasted reduction 
in use and also because no new STP with characterising flavours attractive to young people 
could be developed. For the chewing and nasal tobacco industry, this would particularly affect 
certain regions where chewing and nasal tobacco products currently are produced (mainly in 
Germany, Denmark, Belgium and Poland). This negative impact is mitigated by the fact that 
most of these manufacturers are also involved in the production of other tobacco products as 
well and that Member States can ask for derogations for traditionally used STP for their own 
territory. In macroeconomic terms the potentially negative impact will be linked to the size of 
the operators concerned and the expected derogations. Overall, it is expected that some 
redistribution will take place as money not spent on STP is spent on other economic activities 
(see reasoning in Annex 5).  
 
Option 3 would remove the current targeting of young people and thus contribute to increased 
equality. The option could impact on certain ethnic minority groups using specific chewing 
tobacco products (gutkha, zarda, khaini) if Member States do not ask for an exemption of 
these products.  
Health impacts 
Under option 3, chewing and nasal tobacco would lose part of their current appeal and the 
significant market potential of novel STP would be supressed. Option 3 would result in 
decreased use of STP and remove the circumvention potential that certain STP have following 
the ban of oral tobacco. The option also has the potential of impacting positively on smoking 
cessation by motivating current smokers to free themselves from nicotine addiction altogether 
rather than using STP in environments where smoking is not allowed. Also Member States 
exempting STP for traditional use, the ban on products with characterising flavour and the 
additional health warning would reduce the appeal of these products and better inform 
consumers. In terms of toxicity and addictiveness, reference is made to options 1 and 2.   
5.2.1.4. PO4: Ban all STP with the exception of oral tobacco in Sweden which would 
be subject to stricter labelling and ingredients rules   
a) The current ban on oral tobacco is maintained (except for Sweden which has an exemption) 
b) The placing on the market of chewing and nasal tobacco is banned given their 
circumvention potential, in particular as regards chewing tobacco.  
c) The placing on the market of novel tobacco products is banned.   
Economic impacts 
Similarly to option 2, option 4 would remove the legal uncertainty as to the classification of 
STP, which is currently based on the mode of use (“sucking” vs “chewing”). Option 4 would 
thus prevent circumvention of the ban by products which are comparable (see section 2.2.1). 
This would improve the effectiveness of the TPD and thus impact positively on the internal 
market. It would also remove the growth potential (e.g. smoke-free environments) of 
products with adverse health effects and prevent innovation and launch of novel STP, 
including non-combustible tobacco products claimed to be less harmful than traditional FMC. 
The impact on Ǻland would be similar to options 2 and 3.  
 
The compliance costs for economic stakeholders involved in oral tobacco would mean some 
costs for complying with labelling and ingredients regulation while the actual sales of oral 
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tobacco in Sweden could continue.  For chewing and nasal tobacco, it is expected to result in 
negative impact as all STP are prohibited under this option. This negative impact would 
exceed the impact outlined under options 2 and 3. For novel tobacco products, the effects of 
options 3 and 4 are identical.   
 
Option 4 would result in reduction of the tax income for Governments following the 
estimated drop of chewing and nasal tobacco use. The administrative burden would be 
limited. EU consumers outside Sweden would have no access to STP (except for private 
import, but excluding purchases via internet). In terms of international impacts, option 4 could 
have some negative impact on international trade due to the current import of certain STP 
from third countries. However, considering that chewing and nasal tobacco products count for 
less than 0,1% of the total tobacco market, this impact would be limited.   
Social impacts 
Employment in oral tobacco would somewhat decrease compared to the baseline scenario, 
while a negative impact is expected for the chewing and nasal tobacco following the ban of 
these products. This would particularly affect certain regions where chewing and nasal 
tobacco products currently are produced (mainly in Germany, Denmark, Belgium and 
Poland). This negative impact is mitigated by the fact that most of these manufacturers are 
involved in the production of other tobacco products as well.303 In macroeconomic terms the 
potentially negative impact will be linked to the size of the operators concerned. As option 4 
(opposite to option 3) does not allow derogations for traditionally used STP, the impact on 
economic stakeholders would be more important under option 3. The option would also have 
a negative impact in terms of innovation of novel STP products. Overall, it is expected that 
some redistribution will take place as money not spent on STP is spent on other economic 
activities (see reasoning in Annex 5).  
 
In terms of equality, option 4 would remove the current targeting of young people. It would 
also impact negatively on certain ethnic minority groups using specific chewing tobacco 
products (gutkha, zarda, khaini).  
Health impacts 
A ban of all STP would remove access to STP (except for oral tobacco in Sweden) and thus 
result in less adverse health effect linked to STP use.  
5.2.1.5. The views of stakeholders 
The tobacco industry (including the STP industry) has expressed support for lifting the 
current ban on oral tobacco and subject all STP to product standards which already apply to 
oral tobacco (snus). In this context it has been argued that the current ban on oral tobacco is 
discriminatory, that oral tobacco is less harmful than FMC and other STP and could help 
current smokers quitting. Sweden (and the Finnish island Ǻland) is also in favour of lifting the 
current ban on oral tobacco (snus), while most of the other Member States have expressed 
support for keeping the current ban or extend it to all STP (see Annex 1).304 On the other 
hand, the Swedish National Institute of Public Health supports keeping the ban on oral 
tobacco with the argument that the introduction of every new tobacco product on the EU 
                                                 
303 European Smoking Tobacco Industry, facts and figures for DG SANCO, ESTA 2011-2012 
304 Member States (including Sweden's) positions can be found on the public consultation web site: 
http://ec.europa.eu/health/tobacco/consultations/tobacco_cons_01_en.htm (accessed 28 Nov 2012). The Swedish 
position has also been reiterated in a letter from the Minister of Trade on 14 December 2010. The Swedish 
Ministers for Children and the Elderly and for Trade also asks for a uniform and responsible regulation covering 
all tobacco products in a letter of 24 October 2012.    
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market increases the dependency and all forms of tobacco is damaging to health.305 Also 
health NGOs have argued in favour of keeping/extending the current ban on oral tobacco. One 
FMC manufacturer has also suggested a new legal framework for regulating potentially 
reduced harm products.306  
5.2.1.6. Comparing the options and preferred option 
In terms of effectiveness,307 options 1, 3, and 4 would formally ensure equal treatment of all 
STP categories (chewing, nasal, oral) in terms of placing the products on the market, but these 
options do not take into account the significant differences between the products, e.g. in terms 
of consumption patterns and growth potential.308 Accordingly, options 1, 3 and 4 do result in 
the achievement of policy objectives A1 and A2. The ban on STP with characterising flavours 
under option 2 would contribute to a consistent approach for all tobacco products capable of 
encouraging young people to take up smoking because of their distinct taste or flavour. This 
would partly contribute to objectives A1 and A2 (equal treatment and level playing field).  
Options 1-3 would all contribute to the achievement of objective B1 as they would set 
common requirements for labelling and ingredients. This objective is less relevant for option 
4, implying a ban of STP. Option 1 would facilitate market surveillance (objective B2) as it 
implies a lifting of the ban on oral tobacco and thus removes the circumvention potential for 
such products. Also options 3 and 4 would contribute to objective B2 as they would result in a 
ban of all STP (except in Member States of traditional use in option 3). Also option 2 would 
contribute to this objective as it would include a clearer definition of chewing tobacco and 
thus prevent circumvention and facilitate surveillance. Policy consideration C1, regulating 
hazardous products, would be fully fulfilled under policy options 3 and 4 as these options 
allow no new STP on the market This policy consideration (C1) is partly fulfilled by option 2 
as this option prevents oral tobacco to be placed on new markets and limits the development 
of novel STP in the sense that it prevents products with characterising flavours to be 
developed. Options 1, 2 and 3 are well in line with policy considerations C2 and C4 as they 
prohibit STP with characterising flavours and strengthen the labelling provisions, i.e. increase 
the visibility of the information to consumers. Option 3 and in particular 4 would also 
contribute to policy consideration C5 as they would reduce/remove access to STP. Option 2 
would partly fulfil this consideration, but only as regards oral tobacco and STP with 
characterising flavours.           
 
Lifting the ban on oral tobacco in option 1 provides market opportunities and thereby 
advantages for certain economic operators (others are likely to suffer). Options 2, 3 and 4 
would mean that STP producers have to comply with the requirements in terms of labelling 
and ingredients and the growth potential for oral tobacco would remain unexplored but an EU 
solution is preferable to consecutive changes at national level. Option 3 and 4 would also limit 
novel tobacco products from being placed on the market and require some chewing and nasal 
tobacco manufacturers to exit the markets, but the effect on existing chewing and nasal 
tobacco producers would be mitigated under option 3 by exemptions for traditionally used 
STP.   
 
                                                 
305 Swedish National Institute of Public Health (FHI). Public Consultation. Possible revision of the Tobacco 
products directive. Ostersund: FHI; 2010. http://www.fhi.se/Documents/Om-oss/remisser/2010/Remissyttrande-
tobacco-products-directiveVERK-2010-546.pdf (accessed 28 Nov 2012). 
306 Minutes from SANCO's meeting with PMI, 8 March 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20121202_mi_en.pdf (accessed 28 Nov 2012). 
307 Only the objectives/considerations relevant for this policy area are discussed in this section.  
308 See the Courts reasoning in Case C--434/02 Arnold André GmbH & Co. KG v Landrat des Kreises Herford 
[2004] ECR I-11825, p 41. 
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Lifting the ban on oral tobacco (option 1) would have adverse health effects. It could also 
attract new tobacco users who would otherwise not have taken up tobacco consumption. 
Moreover, it would have a negative health impact on smokers who would otherwise have quit 
smoking, but who continue to use both FMC/RYO and STP (dual use) and for smokers taking 
up STP use who would otherwise have quit using tobacco altogether. For individuals 
replacing FMC/RYO with STP completely, the health effects would be positive. Considering 
the uncertainty in relation to substitution, an overall negative outcome under option 1 cannot 
be excluded. Therefore, this option raises doubts in terms of coherence with the 
precautionary principle.  
 
Preferred policy option 2: Maintain the ban on oral tobacco, subject all novel tobacco 
products to a notification obligation and all STP placed on the market to stricter labelling 
and ingredients regulation   
 
The preferred option would provide a common framework for STP in terms of ingredients 
and labelling while keeping the current ban on placing of the market of oral tobacco 
untouched. The proposed ban of placing on the market of STP with characterising flavour 
would address recent market development and discourage young people from taking up STP 
use. Putting health warnings on both sides of the package will increase the visibility and thus 
better inform consumers about the health risks associated with STP use. The preferred option 
is well in line with FCTC guidelines on ingredients (ban on STP with characterising flavours) 
and labelling (warnings on both sides). The preferred option would also contribute to 
increasing the knowledge base as regards novel tobacco products following Member States’ 
notifications of these products.  
 
It is not considered justified to lift the current ban of placing on the market of oral tobacco 
which was introduced already in 1992 and which was justified from an internal market point 
of view since three Member States had already banned or announced bans of the product due 
to its harmful and addictive effects. At that point in time oral tobacco had also started to be 
distributed on the market of certain Member States in such a way as to attract young people. 
Given the introduction of smoke-free environments and the continuous development of oral 
tobacco, although limited to the Swedish market, the risk of uptake in new population groups 
(including young people) remains. The industry has also confirmed that oral tobacco has huge 
market potential, referring to gross revenues to the retail sector in the amount of 3-9 bEUR 
per year, if the ban was lifted (see section 2.2.1). Although industry emphasises that oral 
tobacco is less harmful than FMC, they do not claim that it is harmless.309 Adverse health 
effects were indeed confirmed by several risk assessment bodies, including one of the 
Commission's advisory Committees (SCENIHR).310  
 
Maintaining the ban of placing on the market of oral tobacco is considered to be the only 
effective measure to contain the use of this product and avoid uptake in new population 
groups, among non-smokers and by young people. Reinforcing the health warnings and ban 
oral tobacco with characterising flavours would not be a sufficient measure in this regard. 
Although it could have some effect on discouraging young people from taking up use of oral 
tobacco, the product would still be promoted for use in smoke-free environments and as 
described under option 1, in particular given the significant growth potential referred to by 
manufacturers. The establishment of general product regulation (option 1) could reduce, to a 
                                                 
309 See the minutes from SANCO meeting with ESTOC, Swedish Match and other stakeholders on 19 December 
2011:  http://ec.europa.eu/health/tobacco/docs/ev_20111219_mi_en.pdf (accessed 28 Nov 2012). See also the 
potential ranking of the overall risk of different products by BAT:  
BAT. Harm reduction. London: BAT; 2012. http://www.bat.com/harmreduction (accessed 28 Nov 2012). 
310 SCENIHR 2008 
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certain extent, the hazardous effect of STP, but as illustrated in the assessment section (option 
1), the product remains addictive and has adverse health effects.  The current ban was also 
seen as proportionate by the Court in 2003 due to the harmful effects of oral tobacco, the 
uncertainty of oral tobacco as a substitute for FMC, the addictive and toxic properties of 
nicotine, oral tobacco's risk potential for young people and the novelty of the product.311 This 
reasoning is still valid today. The current ban was moreover deemed non-discriminatory by 
the Court in view of the fact that oral tobacco was new to the markets of the Member States, 
authorising a difference in treatment with regard to other STP.312 This reasoning is also still 
valid today. 
 
The addictive properties and the adverse health effects are also an issue as far as other STP 
are concerned (see option 1), but despite some market increase (see section 2.3.1) these 
product have still very small markets in the EU although a certain diversification in terms of 
flavours used and promotion of these products could be observed in recent years (see section 
2.3.1). Moreover, the cost-intensive production method (partly done by hand) and the very 
limited number of SMEs who do not have the financial strength to enter new markets where 
STP has no traditional use reduce the export potential of other STP (e.g. chewing and nasal 
tobacco) and preserves a small scale manufacturing.313  
 
For these products, it is therefore considered that further development and recruitment of new 
users can be contained without a general EU ban of placing these STP on the market. 
However, the preferred option would also ban STP other than oral tobacco with characterising 
flavour and make the health warnings more visible. These considerations provide another 
reason why maintaining the ban of oral tobacco with its significantly greater market potential 
(see above in this section) is considered compatible with the principle of proportionality. 
 
There are no less stringent alternative measures that would guarantee the same level of health 
protection as those suggested under option 2. Subjecting STP to general product standards 
would not discourage young people from using these products although it could somehow 
reduce the hazardous effects of STP. The option is also a proportionate limitation of STP 
companies' freedom to conduct business (Article 16 of the Charter of Fundamental Rights of 
the European Union) justified in order to protecting public health.    
 
The preferred option would provide an EU added value as it would ensure a harmonised 
approach throughout the EU and create a level playing field for operators involved in STP 
while ensuring a high level of health protection. By definition, only an initiative at EU level is 
capable of ensuring a harmonised approach. Unilateral actions by Member States can 
contribute to a certain extent to the protection of health, but would certainly result in 
divergences and unequal health protection.  
1.1.13. Nicotine containing products (NCP)  
5.2.1.7. PO1: Subject NCP to labelling and ingredients requirement under TPD   
NCP placed on the market are subject to adapted health warnings, ingredients reporting and a 
prohibition to place on the market NCP with characterising flavours (glossary). 
Delegated/implementing power to adapt health warnings and act on products with 
                                                 
311 Case C-434/02 Arnold André GmbH & Co. KG v Landrat des Kreises Herford [2004] ECR I-11825 paras 44-
56. 
312 Idem, paras 68-70. 
313 SANCO discussions with stakeholders involved in STP. 
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characterising flavours, on products with increased toxicity or addictiveness and to regulate 
additives that cause characterising flavours.       
Economic impacts 
Option 1 would contribute to a more homogenous development, but some Member States are 
expected to continue to consider NCP as medicinal products by function, which would 
maintain legal uncertainty and two parallel legal systems.314 Overall, it is therefore expected 
that the functioning of the internal market is not improved in a satisfactory manner. The use 
of NCP for smoking cessation purposes (see section 2.1.3) can be expected to continue to a 
certain extent under option 1. This would result in maintained negative impact on the internal 
market of smoking cessation products authorised under the medicinal products' legislation.  
 
In terms of compliance costs for the NCP industry, option 1 implies a saving compared to 
the baseline scenario. This is mainly due to the reduced one-off costs related to 
familiarisation, redesign of the package/labelling and possible reformulation of the products 
following from an EU-wide measure rather than several consecutive measures at national 
levels. The costs for adding a textual health warning is estimated to around 7,000-9,000 EUR 
per.315 Additional costs for new equipment and disposal of stocks costs are disregarded as 
these costs could be addressed by granting sufficiently transitional periods. Variable costs for 
changes in printing, packaging and production are estimated to be marginal and in any case 
passed on to the subsequent levels of trade. The same reasoning is applicable as far as 
ingredients regulations (ban on NCP with characterising flavours) are concerned. Continuous 
increase in the sale of NCP is expected under this option although at a lower pace due to 
increased information and stricter ingredients regulation.  
 
Option 1 could influence some Governments to adapt taxes on NCP similar to tobacco 
products and thus contribute to increased tax income. Current increase in health care 
risks/costs associated with NCP is expected to slow down due to stricter ingredients 
regulation and increased awareness. Enforcement would remain an issue in light of many 
small companies active in the business and internet sales. Option 1 would allow EU 
consumers to maintain a wide choice, with some limitations due to the ban on products with 
characterising flavours.   
Social impact 
The current increase in employment opportunities in NCP is likely to continue at a pace in 
line with the expected consumption. Option 1 would contribute to more equal protection, but 
targeting of young people cannot be excluded, although the marketing of products with 
characterising flavours would be removed and health warnings would be added. The 
prohibition of advertising for tobacco products pursuant to Directive 2003/33/EC does not 
apply to these products.  
                                                 
314 Following the EU case-law, for the purposes of determining whether a product falls within the definition of a 
medicinal product by function, the national authorities, acting under the supervision of the courts, must decide on 
a case-by- case basis, taking account of all the characteristics of the product, in particular its composition, its 
pharmacological properties to the extent to which they can be established in the present state of scientific 
knowledge, the manner in which it is used, the extent of its distribution, its familiarity to consumers and the risks 
which its use may entail (Case C-319/05, Commission of the European Communities v Federal Republic of 
Germany, ECR [2007] p I-09811, para 55) 
315 Impact Assessment Report from the European Commission on General Food Labelling Issues, 30 January 
2008. As for tobacco products, RAND Europe has estimated an annual cost of 2000-9720 EUR per SKU related 
to administrative burden of labelling (i.e. not only costs related to redesign). As these products are currently not 
subject to labelling requirements it has been estimated more appropriate to apply these food related figures than 
figures available for tobacco products. 






A health warning would provide more accurate information and increase awareness. The 
current increase in the use of NCP is expected to continue, but at a slower pace due to 
improved information and less attractive products.  
The uncertainty in terms of adverse health effects associated with NCP use outlined in the 
problem identification (section 2.2.1) would persist under option 1. In terms of substitution, 
there is no conclusive evidence at this stage that NCP can be effectively used in smoking 
cessation (see section 2.2.1) and, as described in section 2.1.3, manufacturers and distributors 
of these products normally make no such claims because they know it would oblige them to 
ask for authorisation as medicinal products. On the other hand, option 1 would allow people 
to keep up their nicotine dependence also in situations where they cannot smoke and then 
resume smoking when this is allowed.  
If, on the basis of the reporting obligation, data is collected on the content of NCP, this option 
would allow for further content regulation over time based on toxicity and addictiveness 
consideration through delegated/implementing act. Such a measure could remove some of the 
health hazards associated with NCP. 
5.2.1.8. PO2: Establish a new authorisation scheme for NCP 
Only NCP that have been authorised under a new authorisation procedure (risk/benefit 
analysis) set up under TPD are allowed to be placed on the market. Otherwise, placing on the 
market of NCP is prohibited. The authorisation procedure would also cover labelling and 
additives control.  
Economic impacts 
Option 2 would result in two parallel authorisation schemes for NCP: one scheme which 
would apply if the product falls under the medicinal products’ legislation by presentation or 
by function and another one for consumer products. Competition between these two 
categories cannot be excluded. Some of the current legal uncertainty would persist under this 
policy option due to this dual approach which means that similar (or even identical) products 
could be subject to different schemes. Such uncertainty does not favour the functioning of the 
internal market. It raises also the question of equal treatment with existing nicotine 
replacement therapies (NRT), which are subject to medicinal products' authorisations.  
 
In terms of impact on economic stakeholders, option 2 would imply fees linked to the 
authorisation scheme established under this option. The level of the fees would depend on the 
nature of the scheme and the authorisation procedure foreseen, including the criteria used in 
the assessment. The estimations used under the medicinal products’ framework can give an 
indication, but it is likely that the costs would be lower under this policy option as no efficacy 
in terms of smoking cessation would have to be proven.  
 
As far as Governments are concerned, option 2 is expected to result in significant costs in 
terms of establishing and hosting the new authorisation system. The new structure would 
require important human resources to assess the products, ensure follow up and provide 
secretariat and support functions. This would only be partly compensated by the fees paid by 
industry for the actual assessment. The identification of assessment criteria (risk/benefit 
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analysis) is somehow difficult. The pharmaceutical framework provides a safety/efficacy 
assessment where the efficacy is seen in terms of benefit from smoking cessation. As NCPs 
falling under this scheme do not claim to assist in smoking cessation, the efficacy assessment 
is therefore different in particularly as the safety consideration needs to take into account that 
nicotine is a toxic and addictive substance and therefore, per se, not safe. Another open 
question is whether the assessment can be limited to a current smoker using NCP or whether 
also uptake/use among other population groups, including non-smokers and risk for dual use 
should be taken into account. Another approach would be to assess the “attractiveness” in 
order to avoid that, for example, NCP with distinctive flavours are put on the market. Such an 
approach however, would not target the safety or quality of the product as such.   
 
The impact on Governments’ tax revenues is expected to be similar to the impact described 
under option 1. A certain reduction of adverse health effects associated with NCP use is 
expected due to the authorisation requirement, but no impact is foreseen in terms of health 
costs linked to smoking attributable diseases. Consumers would enjoy a higher degree of 
health protection due to the prior authorisation requirement removing the most hazardous 
products from the market. However, nicotine as such is a toxic and addictive substance.  
Social impacts 
In terms of employment, a shift from SMEs to larger companies is expected under option 2, 
mainly as a result of the additional requirements and the fees to be paid for 
assessment/authorisation. However, this is already part of an on-going trend. It is likely that 
the targeting of young people could develop under option 2 as the products would be 
distinguished from pharmaceuticals through the establishment of a parallel authorisation 
scheme.  
Health impacts  
Option 2 would reinforce the character of NCP as “leisure products” rather than a product 
used in smoking cessation. This is inherent in the very nature of establishing a separate 
authorisation scheme. Option 2 is therefore expected to lead to increased consumption among 
young people, and people wishing to experiment with new products or to use alternatives to 
FMC where smoking is not allowed. Products authorised under the scheme suggested under 
option 2 are expected to be less interesting for people wishing to quit. On the other hand, a 
reduced health risk is expected following the requirement for prior authorisation as well as 
better control and knowledge of the NCP put on the market. No impact is foreseen in terms of 
tobacco related diseases as, to the contrary, NCP might develop into an entry gate to smoking 
initiation and dual use might prevent smokers intending to quit from quitting.   
5.2.1.9. PO3: Subject NCP over a certain nicotine threshold to the medicinal 
products' legislation and the remaining NCP to labelling requirements 
NCP with a nicotine level over a certain threshold may only be placed on the market if they 
have been authorised as medicinal products on the basis of their quality, safety and efficacy, 
and with a positive risk/benefit balance under the medicinal products legislation.  NCP with 
nicotine levels below this threshold will be subject to an adapted health warning. The nicotine 
threshold identified under this policy option should be established by considering the nicotine 
content of medicinal products (NRTs) for smoking cessation which have already received a 
market authorisation under the medicinal products' legislation.   
Delegated/implementing power to adapt the health warning and the identified nicotine 
threshold taking into account scientific and technical developments.  
Economic impacts 
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Option 3 would consolidate current developments in Member States and ensure a harmonised 
approach for NCP with nicotine levels above a certain threshold, to be based on nicotine 
content in medicinal products authorised for smoking cessation. This would increase legal 
certainty and respond to Member States' requests for clarification. It is difficult to estimate 
with precision how many of the currently marketed NCP would have a nicotine level above 
the identified threshold and how many of those products would pass a prior authorisation, but 
considering that many consumers are reported to use the products for cessation/limitation 
purpose and presuppose a pharmacological reaction it is believed that the majority of products 
currently on the market would be affected. However, if a product is authorised under the 
medicinal products' framework, this would enable application of the mutual recognition 
procedure (MRP) and thus facilitate sale of the authorised products throughout the internal 
market. The approach also ensures equal treatment with NRT which are authorised smoking 
cessation aids with a positive risk/benefit analysis. Option 3 would also approximate the 
labelling requirements as regards NCP with nicotine levels below the identified threshold.   
Option 3 would imply costs for economic players related to the authorisation scheme under 
the medicinal products' legislation. The costs will vary between Member States (e.g. 10,400 
EUR-47,230 EUR per application in the UK, Netherlands, Germany and Denmark plus 
additional costs for each Member States where the applicant wants to enter thereafter under 
Mutual Recognition Procedure).316 However, this would be no change to the current situation. 
As set out in Annex 2, a significant number of Member States see NCP as medicinal products 
by function. The already on-going development towards bigger companies is expected to 
continue and at a higher speed due to innovation opportunities and a clear legal framework. 
Also, bigger companies are more likely to have resources for obtaining market authorisations. 
In addition, some adaptations in terms of composition and/or design might be needed to 
ensure compatibility with the medicinal products framework.  
 
Products below the identified threshold would be subject to national legislation and could be 
placed on the market without prior authorisation. This would imply less cost for economic 
stakeholders, but on the other hand these “low-nicotine” NCP would not respond to users 
cravings for nicotine and could thus be less interesting from a marketing point of view. The 
potential of NCP in smoking cessation under this policy option (see below under health 
impacts) is expected to reduce, to some extent, indirect costs linked to tobacco consumption.    
 
The impact on Governments is expected to be positive as NCP could develop their potential 
as smoking cessation aid and thus lead to improved health outcomes (less premature 
mortality, health care costs, productivity). Governments' tax revenues are expected to be 
neutral but they could no longer charge excise duties for NCP (for indirect impacts, see 
section 5.7 and Annex 5). The administrative burden is limited due to making use of an 
established authorisation regime with adequate fees. Consumers would have a more limited 
choice, but a higher degree of health protection. Some unauthorised low-nicotine NCP are 
likely to remain on the market, but these are expected to be of less interest for smokers trying 
to quit or smokers using NCP as an alternative where smoking is not allowed. In addition, 
consumers would be informed, through the labelling, that these products contain nicotine and 
can have adverse health effects. In terms of international impacts, it should be recalled that 
many of NCP are imported from third countries (notably China). However, given the 
estimated market value (section 2.1.3) this impact is considered limited overall. The option 
would be in line with the recommendations of the WHO Study Group on Tobacco Product 
                                                 
316 Matrix 2012  
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Regulation that has recommended that these products are regulated as combination drugs and 
medical devices.317  
Social impacts 
In terms of employment, a shift from SMEs to larger companies is expected. However, this is 
already part of an on-going trend. Option 3 would lead to improved equality within and 
between Member States, in particular as it would remove NCPs' appeal for young people. In 
particular NCP with characterising flavours are unlikely to be authorised under the medicinal 
products' legislation. NCP with nicotine contents below the identified nicotine content are not 
limited in terms of flavours.  
Health impacts 
Option 3 is expected to reinforce the character of NCP as smoking cessation rather than 
“leisure” product, in particular as the nicotine threshold would be set based on nicotine levels 
already authorised under the medicinal products' legislation. A significant drop in 
consumption of NCP among young people and people wishing to experiment with new 
products or to use alternatives to FMC where smoking is not allowed is expected. It would 
also provide the consumer with more appropriate information, including through the patient 
leaflet and better controlled marketing activities. Improved information about the adverse 
health effects associated with NCP is expected following the requirement for prior 
authorisation.  
 
Under option 3, NCP would primarily target people wishing to quit smoking. Further research 
on the efficacy of NCP (notably electronic cigarettes) in smoking cessation would be 
encouraged and products put on the market would be safer and more adapted for smoking 
cessation. It is estimated that option 3 would lead to some reduction of tobacco related 
diseases and mortality due to the potential of NCP in smoking cessation under this option. 
Post-authorisation obligations, including pharmacovigilance, would provide further 
protection. It would put NRTs and NCPs on a level playing field.  
5.2.1.10. PO4: Subject all NCP to the medicinal products' legislation  
Only NCP that are authorised as medicinal products on the basis of their quality, safety and 
efficacy, and with a positive risk/benefit balance are allowed to be placed on the market. 
Otherwise, the placing on the market of NCP is prohibited. The authorisation procedure is 
described under option 3.     
Economic impacts 
Option 4 would go one step further than option 3 and provide a fully harmonised approach in 
the sense that all NCP placed on the internal market (regardless of the nicotine content) 
would need a prior authorisation as a medicinal product. However, as it is not certain whether 
all NCP would fall under the medicinal products definition under Directive 2001/83 it is 
possible that some products would be excluded from the market.   
 
                                                 
317 World Health Organization (WHO) Study Group on Tobacco Product  Regulation. Report on the Scientific 
Basis of Tobacco Product Regulation. WHO Technical Report Series, no. 955. Geneva: WHO; 2010. If the 
nicotine containing part of the NCP/the nicotine cartridge/refill bottle would be (was?) considered a medicinal 
product, the device designated to administer the nicotine would most likely be considered a medical device under 
Directive 93/42.    
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The costs related to authorisation and the market developments are expected to be the same as 
under option 3. However, it is possible that some NCP would have to be taken off the market 
as they do not fit under the regulatory framework for medicinal products (no efficacy).  
 
The impact on Governments and the international impact are very close to the impact under 
option 3. The consumer would have a more limited choice than under option 2, but a 
somehow higher degree of protection considering that only authorised NCP (regardless of 
nicotine level) would be put on the market.  
Social impacts 
The social impact is expected to be similar to the impact under option 3.  
Health impacts 
Similarly to option 3, option 4 is expected to reinforce the character of NCP as smoking 
cessation rather than “leisure” product. This is expected to lead to a drop in consumption 
similar to the impact under option 3.   
5.2.1.11.  The views of stakeholders 
The tobacco industry and consumer focused advocacy groups have argued that NCP are 
different from tobacco products and therefore require a separate regulation. The argument of 
consumers’ choice was reiterated. Part of the pharmaceutical industry also supported this 
approach, while another part argued that NCP should be regulated as medicinal products. The 
European Respiratory Society (ERS) is opposed to the use of all (tobacco and) unapproved 
nicotine delivery products, including electronic cigarettes.318 The approach of subjecting NCP 
to the pharmaceutical legislation was also supported by health NGOs expressing concerns 
about the health risks of NCP. Among Member States responding to the public consultation, 
the views were divided. Some presented arguments for regulating NCP as medicinal products 
(which is already the situation in about half of the Member States) and others for the inclusion 
of electronic cigarettes in the TPD. Electronic cigarettes industry trade (ECITA) referred to 
self-regulation and claimed that no further regulation is needed.   
5.2.1.12. Comparing the options and preferred option 
In terms of effectiveness, regulating NCP under the medicinal products' legislation (partly 
policy option 3 helps to remove differential treatment between NCP and NRT (policy 
objective A1) and facilitate a level playing field (policy objective A2) as it would subject all 
economic stakeholders involved in NCP and NRT to the same rules. Regulating NCP under 
the TPD (options 1 and 2) would lead to the creation of different legal systems, associated 
with legal uncertainty. Policy option 1 would contribute to the achievement of objective B1 as 
it would result in harmonised labelling and the same is true to a certain extent for NCP under 
the identified nicotine threshold. Options 2, 3 and 4 would facilitate market surveillance 
(objective B2) as it would set up requirements for prior authorisation. Options 3 and 4 are 
well in line with policy consideration C1 as it would require prior authorisation and thus 
regulate NCP in the sense that only products which have passed a risk benefit balance would 
be allowed on the market. Option 2 would partly contribute to this consideration as also this 
option would require an authorisation scheme although the benefit criteria is less clear under 
this option. Adding health warnings and banning NCPs with characterising flavour (option 1) 
or authorising these products under pharmaceutical legislation (options 3 and 4) would help to 
                                                 
318 European Respiratory Society (ERS). European Respiratory Society statement on E-cigarettes and emerging 
products. Lausanne: ERS; 2012. http://www.ersnet.org/news/item/4494-european-respiratory-society-statement-
on-e-cigarettes-and-emerging-products-.html (accessed 28 Nov 2012). 
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remove NCP that could be attractive to young people (policy consideration C2). Regulating 
NCP under the TPD (policy options 1 and 2) or under the medicinal products' legislation 
(policy options 3 and 4) would also contribute to improved consumer information (policy 
consideration C4) due to labelling and/or the patient leaflet. In any event, for all products 
covered by the TPD, the pharmaceutical legislation is lex specialis. 
 
Regulating NCP under the TPD (policy option 1) is a cost effective solution given that no 
prior authorisation is required and the products could thus make use of the already existing 
tobacco legislation. Requiring authorisation of NCP (policy options 2, 3 and 4) would imply 
additional costs, but these assessment costs would primarily be paid through fees from 
industry. Setting up of a new structure for authorisation under option 2 entails however 
important costs for public administrations, while options 3 and 4 take advantage of already 
existing structures under the pharmaceutical legislation.  
 
Authorising NCP under the medicinal products' legislation (policy options 3 and 4) would be 
coherent with the medicinal products’ framework, but option 4 would fully exclude some 
NCPs from the market as they might not fit under the legal framework.  
 
Preferred policy option 3: Subject NCP over a certain nicotine threshold to the medicinal 
products' legislation and the remaining NCP to labelling requirements.    
 
The preferred option would remove current legislative divergence between Member States 
and the differential treatment between NRTs and NCP, increase legal certainty and 
consolidate the on-going development in Member States based on the function of these 
products. It would encourage research and innovation in smoking cessation with the aim of 
maximising health gains.  
 
It appears appropriate to focus, at this stage, on NCP above a certain nicotine threshold, in 
particular considering these products' similarities with already existing medicinal products for 
smoking cessation. In addition, most consumers use these products for cessation/limitation 
purpose, which presupposes a pharmacological reaction, i.e. a certain level of nicotine.  
 
For NCP below the identified nicotine threshold, a less stringent measure appears more 
proportionate, in particular as there are not sufficient evidence that these products would fit 
under the medicinal products' legislation. The economic burden on industry is also taken into 
consideration in the proportionality assessment concluding that the suggested labelling 
requirement is sufficient for NCP below the identified nicotine threshold.    
  
There are no less strict measures available to obtain the objectives. Subjecting all NCP to 
labelling requirements and ingredients regulation only (option 1) would have a positive 
impact on health, but to a lesser extent than the preferred option. A separate authorisation 
scheme (option 2) could address some safety concerns, but this option would not have the 
same potential in smoking cessation.  
 
In terms of economic costs and burden weighed against the benefits, it is likely that some of 
the current NCP would be removed from the market or would have to change composition or 
design under the preferred option, but this burden is considered appropriate due to the health 
concerns associated with NCP. In any case, the economic impacts on industry under the 
preferred option are lower than the additional burden of a separate authorisation mechanism 
(option 2) or the option of subjecting all NCP to the medicinal products’ regime (option 4).   
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The preferred option provides a clear added value as it contributes to a level playing field for 
operators involved in NCP and NRT. Only an initiative at EU level is capable of preventing 
further diversity and legal uncertainty.   
 
1.1.14. Herbal products for smoking  
5.2.1.13. PO1: Subject all herbal products for smoking to labelling requirements 
under TPD   
Adapted health warnings are required for herbal products for smoking. 
Delegated/implementing power to adapt health warnings. 
Economic impacts 
Option 1 would ensure increased convergence of national rules and removal of some of the 
existing discrepancies on the internal market.  
 
The benefit for economic players (cost savings compared to baseline scenario) would be 
similar to that described above for NCP because taking action at EU level in one go is less 
costly than consecutive changes at national level. In terms of sales, the current increase is 
expected to slow down due to stricter requirements and less demand due to more accurate 
health information. The expected slowdown in sales, would affect Governments' tax income, 
but taking into account the market size the decrease would be moderate if any. In return, the 
Governments would benefit from improved public health as herbal products for smoking are 
associated with some health concerns as indicated in the problem identification (section 
2.2.1). Option 1 would have a positive impact on consumers as it would provide adequate 
protection in terms of health warnings while maintaining a wide choice of products.  
Social impacts 
Current increase in herbal products for smoking (see section 2.1.3) is likely to slow down, 
having a limited negative impact on employment. Option 1 would lead to improved and more 
equal protection of citizens throughout the EU, in particular by reducing some of the products 
potential of attracting/misleading consumers, including young people.  
Health impacts 
The labelling requirements under option 1 would contribute to increased awareness. It would 
also contribute to removing some misleading features, including wording such as natural, no 
additives etc. and better inform consumers of the health risks associated with herbal products 
for smoking e.g. herbal cigarettes and tobacco-free filling to water-pipes (sisha). This is 
expected to lead to reduced consumption which will, over time, result in less health problems 
related to herbal products for smoking.  
5.2.1.14. PO2: Phase out the placing on the market of herbal products for smoking 
Placing on the market of herbal products for smoking is phased out.  
Economic impacts 
Option 2 provides full harmonisation of national rules, but removes the current cross-border 
trade of herbal products for smoking on the internal market. Under the assumption that the 
product could not be regarded as medicinal products, option 2 would result in reduced sale 
and possible closure of businesses involved in herbal products for smoking, mainly affecting 
SMEs involved in this sector. This limits the freedom to conduct business need to be balanced 
against health cosiderations. A reduction of Governments’ tax income as well as health care 
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costs/concerns is expected under option 2, but due to the modest market size, this impact 
would be limited. Consumers would enjoy a higher level of health protection, but less choice.   
Social impacts 
Option 2 would have a negative impact on employment in herbal products for smoking, 
including possible regional impact, but redistribution is expected to take place. Option 2 
would provide full and equal protection of EU consumers.  
Health impacts 
A ban would remove the current appeal of herbal products for smoking and reduce 
significantly the consumption, resulting in reduced health risks from herbal products for 
smoking. No impact on tobacco consumption is foreseen as it has not been demonstrated that 
the two categories are interchangeable. 
5.2.1.15.  The views of stakeholders 
Health NGOs argued for the inclusion of herbal cigarettes into the TPD framework, referring 
to the harmful aspects following the combustion of these products. Most Member States 
which submitted contributions to the public consultation were either in favour of extending 
the scope of the TPD or did not refer to the question in a detailed manner. Other key 
stakeholders have not addressed specifically this area.  
5.2.1.16. Comparing the options and preferred option 
In terms of effectiveness, both regulating herbal products for smoking under the TPD or 
phasing them out (policy options 1 and 2) would create a level playing field and remove 
current national disparities (policy objectives A2 and A3). Option 1 would also partly fulfil 
objective B1 as it would unify the labelling rules, while this objective is not relevant as far as 
a full phasing out (option 2) is concerned. Phasing out herbal products for smoking (policy 
option 2) would provide regulation of products harmful to health and thus be fully in line with 
policy consideration C1, while option 2 (labelling rules) only partly would achieve this 
consideration. The labelling requirements suggested under option 2 would be well in line with 
policy consideration C4 as it would contribute to better information to consumers, while 
phasing out these products (option 2) would reduce the availability of herbal products for 
smoking and thus fulfil policy consideration C5. 
 
Regulating herbal products for smoking under the TPD (policy option 1) would provide a 
cost-effective measure to better inform consumers about the health risks of these products, 
while phasing them out (policy option 2) would have more important consequences for 
economic stakeholders having to exit the market altogether (except export possibilities).  
 
Preferred policy option 1: Subject all herbal products for smoking to labelling requirements 
under TPD   
 
The preferred option would ensure a more homogenous development in the EU and create a 
safety net for consumers. The preferred option would also provide consumers and potential 
consumers with more appropriate information about the adverse health effects of herbal 
products for smoking and thus allow them to make informed choices.   
 
A stricter measure (option 2) would further harmonise Member States’ legislations, and fully 
remove the adverse health effects associated with herbal products for smoking. However, 
considering that the main health concern is the frequent misperception about the health risks 
and that herbal products for smoking entail more limited risks of developing an addiction 
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compared to tobacco products, a full ban (option 2) is not considered proportionate. In 
addition, such a measure would be unnecessarily burdensome for economic stakeholders.   
 
The objective of harmonising the labelling of herbal products for smoking is to ensure a 
harmonised approach throughout the EU and to create a level playing field for operators 
involved in these products while ensuring a high level of health protection. By definition, only 
an initiative at EU level is capable of ensuring a harmonised approach and thus added value. 
Unilateral actions by Member States can contribute to the protection of health, but would 
certainly result in divergences.  
5.3. PACKAGING AND LABELLING 
1.1.15. PO1: Mandatory enlarged picture warnings 
Combined warnings (picture plus text) of 75% displayed on both sides of the packages of 
tobacco products, presented in rotation. TNCO levels on the packages are replaced with 
descriptive information on content, emissions and risks. Display of cessation information (e.g. 
quit-lines, websites) is added to the packages.  
Tobacco products other than FMC and RYO are exempted (current TPD rules apply). 
Delegated/implementing power to remove/extend the exemption for these products if there is 
a change of circumstances and to adapt the health warnings.  
 
Economic impacts 
Increased convergence of national rules on labelling and packaging, including mandatory 
pictorial warnings, would facilitate the functioning of the internal market in terms of cross 
border trade and improve the level playing field for economic stakeholders.  
 
The actual one-off cost for introducing pictorial warnings for economic players 
(manufacturers) changing the labelling on FMC is estimated to range between 14,500 and 
50,000 EUR per SKU and for RYO between 2,500 and 9,000 EUR per SKU (see section 
5.1).319 However, considering the economies of scale referred to in section 5.1, it should 
substantially reduce the burden for manufacturers if changes are done in one go across the EU 
instead of individual adaptation to different national legislations. In particular SMEs could 
benefit from a harmonised approach in one go as they might have less resources to adapt to 
many different legal systems in case they would like to expand their activities to other 
Member States.  
 
In addition, the package producers have reported that they have already made the investments 
necessary to comply with the expected regulation on pictorial health warnings.320 Therefore, 
there would be no additional costs for buying new equipment (e.g. printing equipment). Costs 
for disposal of old stocks are also disregarded as a transitional period would allow 
manufacturers to adapt the production process and retailers to manage their inventory 
accordingly.  
 
In terms of running costs (e.g. use of more expensive ink to produce combined instead of 
text-only warnings), the packaging industry has reported that the on-going costs related to 
                                                 
319 Matrix 2012. ESTA estimations for RYO (fine cut tobacco), Facts and figures for DG SANCO 2011-2012. In 
addition to the one-off cost, FMC industry has reported an increase of 1,3-1,5% in variable costs.  
320 Minutes from SANCO’s meeting with tobacco suppliers on 6 February 2012: 
http://ec.europa.eu/health/tobacco/events/index_en.htm#anchor4 (accessed 28 Nov 2012). 
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pictorial warnings would be "slightly above" the costs for packages with text-only 
warnings.321 It has been estimated that costs could increase by 1.3-1.5% following the 
introduction of EU-wide pictorial warnings.322 Assuming this reported increase can be 
extrapolated across the four biggest tobacco companies, this would imply an annual cost 
increase for them of between 59 mEUR and 68 mEUR. Comparing these estimates to data 
from impact assessments in other jurisdictions (e.g. the UK, the US, Canada and Australia)323 
compliance costs, in particular recurrent costs as presented here, appear to be relatively high. 
Taking into account that the printing is generally outsourced, the costs would not occur in the 
first place with tobacco manufacturers, but rather with the packaging and paper industry. If 
the packaging industry manages to charge higher prices from the tobacco manufacturers as 
has been suggested it is likely that the costs would be passed on by the tobacco industry to the 
subsequent levels of trade.324 In terms of innovation, the option maintains the possibilities of 
the tobacco industry to redesign packages and labels, albeit with limited space.  
 
Under the provisions considered under option 1, manufacturers would be confronted neither 
with commoditisation of the market nor with a prohibition of the use of trademarks on the 
package. The measures proposed would continue to allow brand recognition albeit the space 
of the trademarks would be somewhat limited. However, this is considered to be a 
proportionate limitation of the right of property (trade marks).325  
 
Overall, the option would have a neutral or even positive direct effect on economic players 
(manufacturers) as possible minor increases in variable costs would be counterbalanced by 
savings in familiarisation costs due to implementation in one go. The same applies to the 
packaging industry. The indirect impact in terms of reduced profit following the estimated 
drop in consumption is further described in section 5.7 (and Annex 5).  
 
As all Member States already have cessation services in place, only a limited additional 
burden is expected for Governments as a result of the introduction of references to such 
cessation services (quit-lines or other services) on the packages, e.g. in form of an increase in 
call volume.326 Outsourcing this role to NGOs with an expertise in providing such services 
could be an effective and efficient approach to reduce costs. Other administrative burdens 
                                                 
321 Idem.  This is in line with the estimates given in the context of industry interviews carried out, Matrix 2012. 
322 Matrix 2012  
323 UK Department of Health (UK DoH). The Introduction of Picture Warnings on Tobacco Packs – Final 
Regulatory Impact Assessment. London: UK DoH; 2007. US Dept. of Health and Human Services.   Required 
Warnings for Cigarette Packages and Advertisements. 2011 Federal Register Vol. 76, 22 June 2011/Rules and 
Regulations, pp.36628-36777.   Industrial Economics Incorporated (IEc). Economic evaluation of Health 
Canada’s proposal to amend the tobacco product information regulations: Final report. Cambridge, MA: IEc;  
2009. (Report for Health Canada). Applied Economics. Cost-benefit analysis of proposed new health warnings 
on tobacco products. Canberra: Applied Economics; 2003. (Report prepared for the Commonwealth Department 
of Health and Ageing, Australia) 
324 Industrial Economics Incorporated (IEc). Economic evaluation of Health Canada’s proposal to amend the 
tobacco product information regulations: Final report. Cambridge, MA: IEc;  2009. (Report for Health Canada). 
325 There is no absolute right to use a trademark and the Court has confirmed the validity of Articles 5 (health 
warnings) and 7 (ban on misleading descriptors) of the current TPD which constitutes a limitation to use the 
trademarks. BAT case: C-491/01 The Queen v Secretary of State for Health, ex parte British American Tobacco 
(Investments) Ltd and Imperial Tobacco Ltd.[2001] ECR I-11453,  para 131-132. Although not precedent for the 
Union, , the High Court of Australia ruled, on 15 August 2012 the Government's tobacco plain packaging 
legislation to be constitutionally valid.  
326 Such an increase has been shown in the past. See e.g.: Willemsen MC, Simons C, Zeeman G. Impact of the 
new EU health warnings on the Dutch quit line. Tob Control 2002; 11:381–2. Miller CL, Hill DJ, Quester PG, 
Hiller JE. Impact on the Australian Quitline of new graphic cigarette pack warnings including the Quitline 
number. Tob Control 2009; 18:235-7. Wilson N, Weerasekera D, Hoek J, Li J, Edwards R. Increased smoker 
recognition of a national quitline number following introduction of improved pack warnings: ITC Project New 
Zealand. Nicotine Tob Res 2010;12 Suppl:S72-7. 
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associated with this policy option are rather limited. For indirect impacts (e.g. improved 
public health and reduced tax revenues), see section 5.7 and Annex 5. Furthermore, the 
adoption of uniform rules across Member States could reduce the burden of developing 
individual solutions. The proposed measure would improve consumer protection across the 
EU, including providing assistance to smokers wishing to quit (e.g. quit lines, web sites), 
protecting consumers from misleading information on the health impact of smoking 
(replacement of TNCO levels) and providing appropriate information (strengthened 
labelling). At the same time, it is expected that the measures would affect neither the range of 
products available on the EU-market nor their quality. It can be expected that the tobacco 
industry will try to pass on the additional compliance costs to consumers, but these are 
expected to be very small if any (see above). In terms of international impact, the labelling 
requirements under option 1 would bring the EU more in line with international developments 
and the FCTC commitments.  
Social impacts 
The impact on employment would follow the expected drop in prevalence. This is further 
described in section 5.7 and Annex 5, but in the light of the input/output model, money not 
spent on tobacco is spent on other goods and services. No major impact is expected on 
package manufacturers, as these generate only 10% of their turnover with tobacco industry. 
Positive impact is expected in terms of equality. Pictorial warnings appear to be more 
effective than texts among persons with lower levels of literacy and particularly in young 
people.327 References to cessation services would have a positive impact on vulnerable 
groups.328 
Health impacts 
Overall, it is expected that option 1 would make a substantial contribution to the expected 
decrease in consumption and prevalence over five years (see section 5.7 and Annex 5).  
 
Evidence suggests that the effectiveness of health warnings depends on their size, location 
and design. In general, prominent pictorial warnings placed on the front of the packages are 
seen to be the most effective in increasing perceptions of risk and promoting behavioural 
change.329 Enlarged picture warnings on both sides of the package are expected to result in 
greater noticeability and salience for consumers, stronger beliefs about the health risks of 
smoking, as well as increased motivation to quit smoking.330 There is evidence that the 
                                                 
327 Malouff J, Gabrilowitz D, Schutte N. Readability of health warnings on alcohol and tobacco products. Am J 
Public Health 1992; 82:464.  Créatec+. Effectiveness of Health Warning Messages on Cigarette Packages In 
Informing Less-literate Smokers, Final Report. Montreal: CREATEC+; 2003. (Prepared for Communication 
Canada). Warner KE, Tam J. The impact of tobacco control research on policy: 20 years of progress. Tob 
Control 2012; 21:103-9Hammond D. Health warning messages on tobacco products: a review. Tob Control 
2011; 20:327-3.  Gagné L.  Econometric Evaluation of Tobacco Control Initiatives in Canada, 1999-2009, Final 
Report. Victoria: University of Victoria; 2010. 
328 Wilson N, Weerasekera D, Hoek J, Li J, Edwards R. Increased smoker recognition of a national quitline 
number following introduction of improved pack warnings: ITC Project New Zealand. Nicotine Tob Res 
2010;12 Suppl:S72-7. 
329 As reviewed in Hammond D. Health warning messages on tobacco products: a review. Tob Control 2011; 
20:327-3. Sambrook Research International. A Review of the Science Base to Support the Development of 
Health Warnings for Tobacco Packages.  Newport: Sambrook Research International; 2009. (Report prepared for 
the European Commission). Borland R, Wilson N, Fong GT, Hammond D, Cummings KM, Yong H-H, et al. 
Impact of graphic and text warnings on cigarette packs: findings from four countries over five years. Tob 
Control 2009;18:358–364 
330 Wardle H, Pickup D, Lee L, Hall J, Pickering K, Grieg K, Moodie C, Mackintosh AM. Evaluating the impact 
of picture health warnings on cigarette packets. London: Public Health Research Consortium; 2010. 
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warnings are more visible if placed on the front panel in the upper part of the package.331 
Furthermore, messages and images which elicit strong emotional reactions are considered 
particularly effective.332 Finally, evidence suggests that the impact of health warnings tends to 
decrease over time (wear-out effect) whereas regular rotations and updates of the health 
warnings and messages, already prescribed in the current TPD, are associated with increased 
effectiveness.333   
 
Research comparing pictorial warnings with text-only warnings from several countries (e.g. 
Australia, France, Spain, the UK and US) also demonstrates that pictorial warnings increase 
consumers' awareness of warnings, knowledge and credibility of health risks, depth of 
processing and also cessation behaviours such as forgoing FMC, quit intentions and 
quitting.334 They also contribute to reduced consumption as indicated above.335 Research 
conducted for the Canadian Government also found that larger warnings are more effective at 
eliciting negative reactions, conveying information about the health risks of smoking and 
reducing consumption.336 Consumers living in countries that have introduced graphic tobacco 
health warnings have a greater knowledge on the health effects of smoking337, and may have 
                                                 
331 Moodie C, MacKintosh AM, Hammond D. Adolescents’ response to text-only tobacco health warnings: 
results from the 2008 UK Youth Tobacco Policy Survey. Eur J Public Health 2009: 20; 463-9. 
332 Gallopel-Morvan K, Gabriel P, Le Gall-Ely M, Rieunier S, Urien B. The use of visual warnings in social 
marketing: The case of tobacco. J Bus Res 2011; 64:7-11. Hammond D, Fong GT, McDonald PW, Brown KS, 
Cameron R. Graphic Canadian cigarette warning labels and adverse outcomes: evidence from Canadian smokers. 
American Journal of Public Health 2004; 94(8):1442–5. Crespo A, Barrio A, Cabestrero R, Hernandez O. 
Cognitive processing and assessment of anti-smoking combined warning labels set by the European 
Commission: an empirical study with a Spanish sample. [in Spanish] (Procesamiento cognitivo y valoración de 
las nuevas advertencias combinadas antitabaco propuestas por la Comisión Europea: estudio empírico en una 
muestra española) Clinica y Salud 2007;18(2):163–80Hammond D, Thrasher J, Reid JL, Driezen P, Boudreau C, 
Santillán EA. Perceived effectiveness of pictorial health warnings among Mexican youth and adults: a 
population-level intervention with potential to reduce tobacco-related inequities. Canc Causes Contr 2012; 
23:57-67. Goodall C, Appiah O. Adolescents' perception of Canadian cigarette package warning labels: 
investigating the effects of message framing. Health Communication 2008;23 (2): 117–27. 
333 Source: UK Department of Health (UK DoH). The Introduction of Picture Warnings on Tobacco Packs – 
Final Regulatory Impact Assessment. London: UK DoH; 2007. Gallopel-Morvan K, Gabriel P, Le Gall-Ely M, 
Rieunier S, Urien B. The use of visual warnings in social marketing: The case of tobacco. J Bus Res 2011; 64:7-
11. Strahan EJ, White K, Fong GT, Fabrigar LR, Zanna MP, Cameron R. Enhancing the effectiveness of tobacco 
package warning labels: a social psychological perspective. Tob Control 2002; 11:183-90.  
334 Gallopel-Morvan K, Gabriel P, Le Gall-Ely M, Rieunier S, Urien B. The use of visual warnings in social 
marketing: The case of tobacco. J Bus Res 2011; 64:7-11. Hammond D, Fong GT, Borland R, Cummings KM, 
McNeill A, Driezen P. Text and graphic warnings on cigarette packages: findings from the international tobacco 
control four country study. Am J Prev Med. 2007; 32:202-9.   Rey JM, Lacave B, Viedma MI, Gallopel-Morvan 
K. An image is worth a thousand words: the effects of visual health warnings in the decrease of tobacco 
consumption: a research from the perspective of social marketing [in Spanish]  (Una imagen vale más que mil 
palabras: efectos de las advertencias sanitarias visuales en el descenso del consumo de tabaco: un estudio desde 
la perspectiva del marketing social.) Cuadernos de Gestión 2010; 10:149-65. 
335 Sambrook Research International, "A Review of the Science Base to Support the Development of Health 
Warnings for Tobacco Packages," Report prepared for the European Commission, Directorate General for 
Health and Consumers, 2009: http://ec.europa.eu/health/tobacco/docs/warnings_report_en.pdf 
336 Créatec+. Quantitative Study of Canadian Adult Smokers: Effects of Modified Packaging Through Increasing 
the Size of Warnings on Cigarette Packages. Montreal: Créatec+; 2008. (Report for Health Canada). Environics. 
Consumer Research on the Size of Health Warning Messages – Quantitative Study of Canadian Adult Smokers. 
Toronto: Environics; 2008. (Report for Health Canada). 
337 Thrasher JF, Hammond D, Fong GT, Arillo-Santillan E. Smokers’ reaction to cigarette warnings with graphic 
imagery and with only text: a comparison between Mexico and Canada. E.Salud Publica Mex 2007; 49 suppl 2: 
S233-40. Hammond D, Fong GT, Borland R, Cummings KM, McNeill A, Driezen P. Text and graphic warnings 
on cigarette packages: findings from the international tobacco control four country study. Am J Prev Med. 2007; 
32:202-9.   Hammond D, Fong GT, Borland R, McNeill A, Cummings KM, Hastings G. Effectiveness of 
cigarette warning labels in informing smokers about the risks of smoking: findings from the International 
Tobacco Control (ITC) Four Country Survey. Tobacco Control 2006; 15 (Suppl III):iii19–iii25. Environics. 
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fewer disparities in health knowledge across educational levels.338 In countries with picture 
warnings on one side of the package the products are typically displayed in such a way that 
the side of the text warnings is visible to consumers.  
  
The replacement of TNCO levels with descriptive information on contents/emissions under 
option 1 would help to better address a possible confusion among consumers regarding 
possible effects of the product (see problem identification 2.2.2). The inclusion of concrete 
quitting information is strongly supported by smokers and has been shown to increase the 
use of these services dramatically. 339  
 
1.1.16. PO2: PO1 plus harmonise certain aspects of packets and prohibit 
promotional and misleading elements   
 
Option 1 plus:  
1) The tobacco labelling and packaging and the tobacco product itself shall not include any 
promotional and misleading elements (e.g. misleading colours, symbols, slim FMC),  
2) setting certain requirements for packages (e.g. cuboid shape, minimum number of and 
FMC per package) as well as for the size of the warnings  
 
Member States are allowed to regulate the area not regulated by the TPD or other Union 
legislation, including adopting provisions providing full standardisation of packaging of 
tobacco products (i.e. plain packaging) as far as these provisions are compatible with the 
Treaty. The Commission will report on experiences gained with respect to surfaces not 
governed by the TPD five years after the transposition of the TPD.  
 
For Point 2) Tobacco products other than FMC and RYO are exempted (current TPD rules 
apply). Delegated/implementing power to remove the exemption for these products if there is 
a change in circumstances. 
 
Economic impacts 
Option 2 would further advance the functioning of the internal market following e.g. 
harmonisation of additional elements including the removal of promotional/misleading 
elements where some Member States already have taken actions (2.2.2). The standardisation 
of the size of the health warnings as well as the shape of the package would contribute to 
effective display of the warnings and thus maximise the effect of the TPD.  
 
Option 2 would further reduce compliance costs for tobacco manufacturers and it would 
result in even larger economies of scale, including standardised package size. The 
harmonisation of legislation in one go under option 2 rather than consecutive changes at 
national level would be cost efficient for the industry. The prohibition of promotional and 
                                                                                                                                                        
Consumer Research on the Size of Health Warning Messages – Quantitative Study of Canadian Youth. Toronto: 
Environics; 2008. (Report for Health Canada). 
338 Siahpush M, McNeill A, Hammond D, Fong GT. Socioeconomic and country variations in knowledge of 
health risks of tobacco smoking and toxic constituents of smoke: results from the 2002 International Tobacco 
Control (ITC) Four Country Survey. Tob Control 2006;15 Suppl 3:iii65-70. 
339 Such an increase has been shown in the past. See e.g.: Willemsen MC, Simons C, Zeeman G. Impact of the 
new EU health warnings on the Dutch quit line. Tob Control 2002;11:381–2. Miller CL, Hill DJ, Quester PG, 
Hiller JE. Impact on the Australian Quitline of new graphic cigarette pack warnings including the Quitline 
number. Tob Control 2009; 18:235-7.  Wilson N, Weerasekera D, Hoek J, Li J, Edwards R. Increased smoker 
recognition of a national quitline number following introduction of improved pack warnings: ITC Project New 
Zealand. Nicotine Tob Res 2010;12 Suppl:S72-7. 
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misleading elements, including inserts prepared by several manufacturers for marketing 
reasons340 would lead to some cost savings. For indirect impacts linked to consumption, see 
below references to section 5.7 and Annex 5. According to industry reports, the total ongoing 
administrative burden for producing inserts from reduced factory efficiency (i.e. higher 
production cost per unit of output) and the costs of the insert itself (i.e. paper and printing ink) 
would be likely to be between 42.2 and 75.5 mEUR a year in the EU-27.341 Regulating the 
appearance of FMC should not place a major burden on manufacturers as most FMC currently 
on the market comply with a standard format, but products with a misleading size ("slim") 
would be affected. No impact beyond option 1 is expected on package producers and retailers. 
For tobacco products other than FMC and RYO the rules of the existing TPD could continue 
to apply (e.g. size and location), but with some minor modifications of the health warnings. 
 
The further harmonization of packages and labelling requirements will support and save costs 
for Governments who would not have to invest in developing their own legislation. The 
measures reduce the administrative burden as the measures are self-executing and mutually 
reinforcing (package shape/sized pictures). For the indirect impact on Governments following 
the estimated additional drop in consumption reference is made to section 5.7 and Annex 5. 
The protection of consumers would be reinforced by regulating promotional and misleading 
aspects of the packaging (see glossary). Option 2 would complement those measures foreseen 
under policy area 3 (ingredients), which aim at banning characterising flavours (see glossary), 
as these provide tobacco products with a misleading taste and smell. As in option 1, it is 
expected that the measures would affect neither the range of products available on the EU-
market nor their price and quality. Option 2 provides a further step towards implementing the 
FCTC guidelines. It does not prevent Member States from regulating surfaces not regulated 
by TPD or other legislation and thus implement full standardisation (plain packaging).   
Social impacts 
The impact on employment following the estimated drop in prevalence is further described in 
section 5.7 and Annex 5, including redistribution effects. No additional impact is foreseen for 
package manufacturers. Option 2 is expected to strengthen the effects of option 1 on equality, 
in particular as it would further limit the possibility of developing packages and FMCs 
particularly appealing to young people.  
Health impacts 
The envisaged measures under option 2 are expected to significantly contribute to the 
projected decrease of consumption and prevalence. Reducing the packages' potential to 
mislead consumers would have a positive impact on awareness.  
 
As illustrated in the problem identification (section 2.2.2), many studies indicate that package 
design influences the perception of risks  and has the potential of misleading consumers.  
 
The measures proposed under this option are expected to reduce these problems. A ban on 
promotional/misleading elements would reduce the packages' potential to mislead consumers 
and increase the noticeability of health warnings. Setting certain requirements for package 
appearance and regulate the size of health warnings would reduce the promotional and 
misleading potential of the package, ensure that labelling requirements are not undermined 
                                                 
340 Moodie C, Hastings G. Tobacco packaging as promotion. Tob Contr 2010; 19:168-170. International Union 
Against Tuberculosis and Lung Disease (The Union). Tobacco Packaging and Labelling. 
Technical guide. Edinburgh: The Union; 2009. http://www.tobaccofreeunion.org/files/186.pdf (accessed 28 Nov 
2012). 
341 RAND 2010  
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and that the enlarged picture warnings can be appropriately and fully displayed on the 
package in order to ensure their full effectiveness. A minimum number of FMC in each 
package and a minimum weight of tobacco in RYO packages would ensure that the size of the 
package allows a sufficient space for health warnings.  
 
1.1.17. PO3: PO2 plus full plain packaging  
 
Option 2 plus: standardised colour, font, size and position of brand name and brand variant on 
packages (plain packaging) and a readable health warning on each FMC stick.  
 
Other tobacco products than FMC and RYO will be exempted from the requirements (current 
TPD rules apply). Delegated/implementing power to remove the exemption if there is a 
change in circumstances.    
Economic impacts 
The precise economic effects of plain packaging in real life are difficult to quantify at present 
due to lack of empirical data and experience with plain packaging in Member States or other 
countries. 
 
Option 3 would maximise the effects on the internal market. Product would have a 
homogenous appearance throughout the EU and all discrepancies between national 
legislations would be removed. Again, the direct (compliance) costs for economic 
stakeholders would be further reduced under option 3. The industry claims that the initial 
burden of introducing mandatory plain packaging would be the same as the burden of 
mandatory pictorial warnings, i.e. 32.5-125.4 mEUR.342 However, this does not appear to be 
realistic. It is rather expected that companies would spend far less resources on the 
development of packages, considering that their possibility to develop individual packages are 
excluded under this option. Therefore, it is estimated that this option would result in overall 
cost savings as packages would remain the same and regular changes would become 
obsolete.343 Also, the production of a plain package is expected to be cheaper as e.g. fewer, 
simpler and less expensive colours are used on the package itself.344 Finally, the 
harmonisation of legislation in one go would be cost efficient for the industry. In terms of on-
going costs, the full standardisation package appearance would also lead to economies of 
scale in the production of packages and FMC. Printing a health warning on a cigarette stick 
would result in some on-going costs for the printing process (colours, maintaining 
equipment), but no quantitative figures are available.   
 
On the other hand, it is expected that plain packaging would result in reduced possibilities of 
brand differentiation, affecting in particular high margin/premium brands which could, over 
time, result in price competition and commoditisation of the market. Whilst it would be very 
difficult to establish new premium brands, entry barriers for non-branded products would be 
                                                 
342 According to self-reported data of one major cigarette producer in Europe that provided quantitative estimates 
to RAND Europe (RAND 2010). The company disclosed that the initial administrative burden would be 
approximately 40 to 45 million EUR for the company if considerable time were not allowed for compliance. 
This translates into 18,100–20,400 EUR per SKU (no data available on costs for printing a warning on a 
cigarette stick). 
343 According to information from one tobacco product manufacturer, the cost of a general brand re-design which 
tends to happen about every two to three years is more than 20,000 EUR per SKU (Matrix 2012), which would 
be saved by manufacturers under this option. 
344 Minutes from the meeting with suppliers to the tobacco industry, 6 February 2012. 
http://ec.europa.eu/health/tobacco/docs/ev_20120206_mi_en.pdf (accessed 28 Nov 2012). Information provided 
by ECMA to DG SANCO. 
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lowered.345 Considering the high degree of market concentration observed at present there is 
an increased risk of collusion between producers of premium brands. The industry has argued 
that plain packaging will increase illicit trade. However, no convincing evidence has been 
submitted and the argument appears counter-intuitive taking into account that counterfeiters 
try to benefit from the brand recognition associated with premium brands (currently 
recognisable from their trade marks which is not possible with plain packaging). Anyway, the 
actual and alleged additional risk of illicit trade is addressed in policy area 5 (traceability and 
security features). Regarding FMC papers/sticks, representatives from the fine paper industry 
confirmed that tipping paper is subject to very frequent changes346 and it is therefore not 
expected that this would have any significant negative impact. 
 
As regards other economic stakeholders, package producers could be slightly affected by the 
provisions under this option, as the production of the packages would become cheaper and 
could result in a drop in price per package, and possibly also in profit margins. However, this 
impact would be limited, in particular as package producers supply various sectors.347 
Retailers have claimed that plain packaging would make it more difficult for sales persons to 
identify packages. Therefore, management of stock and identification of products would 
become more cumbersome, increase transaction time and slow down the selling process, 
resulting in complaints from customers and higher business costs, affecting SMEs and small 
family enterprises disproportionally.348 However, this problem is expected to be solved after 
an initial period of familiarisation, while staff is getting used to the new system, and by an 
appropriate reorganisation of the display.  
 
For the indirect impact on economic players and Governments following the estimated 
additional drop in consumption, reference is made to section 5.7 and Annex 5. It is very likely 
that any shift from premium to low cost brands. However, Member States are likely to 
counter this with tax increases given the fact they can, in the context of the mixed structure of 
the EU excise duty system, make use of both the specific and the ad valorem component as 
needed.     
 
Consumer protection would be further reinforced by regulating additional promotional and 
misleading aspects of the packaging and highlighting the health warnings, including also a 
warning on the stick. Consumer choice may be limited in the long run as new premium brands 
would have more difficulties to enter the market and second tier brands might exit the market. 
On the other hand, entry barriers of non-branded products would be lowered. No relevant 
impact on quality and price are expected as potential price drops could be compensated by tax 
increases. Option 3 is fully in line with the FCTC guidelines. Legal proceedings have been 
initiated following Australia’s adoption of a similar measure as of 1 December 2012. While 
the High Court of Australia ruled the Government's tobacco plain packaging legislation to be 
constitutionally valid on 15 August 2012,349 discussions are still on-going in the WTO 
                                                 
345 Glossary of statistical terms – Barriers to entry from: Khemani RS, Shapiro DM (compilers). Glossary of 
Industrial Organisation Economics and Competition Law. Paris: Directorate for Financial, Fiscal and Enterprise 
Affairs, OECD; 1993.  
346 Minutes from the meeting with suppliers to the tobacco industry, 6 February 2012. 
http://ec.europa.eu/health/tobacco/docs/ev_20120206_mi_en.pdf (accessed 28 Nov 2012).   
347 Related figures were not delivered by the industry despite repeated requests. 
348 Information provided by EU retailer association, CEDT, to DG SANCO 
349 High Court of Australia. Judgement Summary: Cases S389/2011 and S409/2011.Canberra: High Court of 
Australia; 2012. http://www.hcourt.gov.au/assets/publications/judgment-summaries/2012/projt-2012-08-15.pdf   
(accessed 29 Nov 2012). 
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following requests for consultations by Ukraine, Honduras and the Dominican Republic.350  
Legal proceedings are also on-going under the Australia-Hong Kong Bilateral Investment 
Treaty.351   
Social impacts 
The impact on employment due to further reduction in consumption is described in section 
5.7, including the input / output model. No major impact on package manufacturers is 
foreseen as they are also serving multiple other industries. Option 3 would, overall, improve 
equality, in particular as it would further limit the possibility of developing packages 
appealing to young people. However, standardising the font and size of brand and product 
name could to a certain degree make products less easily identifiable to people with lower 
levels of literacy.  
 
Health impacts 
Option 3 is expected to strengthen further the effects of option 2. Although, no studies based 
on real life experiences are available at this stage, many recent studies indicate that plain 
packaging not only increases the noticeability and effectiveness of health warnings, but also 
reduces substantially the attractiveness and appeal of tobacco packaging, the product, 
particular brands, the user and smoking (both to smokers and potential smokers) as well as 
false beliefs about the risks associated with different brand variants.352 
 
These effects are expected to be particularly strong in young people and for initiation. 
For example, a recent eye tracking study showed that plain packaging increased the salience 
of health warnings among non-smokers and light (i.e. non-established) smokers.353 These 
results have recently been replicated in adolescents.354 As a consequence, plain packaging 
may help to reduce tobacco consumption and smoking prevalence, in particular by 
discouraging young people from taking up smoking, by reducing tobacco consumption among 
young adult smokers, by keeping the "in-between-category" of occasional smokers from 
                                                 
350 World Trade Organization (WTO). Dispute Settlement: Dispute DS434. Geneva: WTO; 2012. 
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds434_e.htm (accessed 29 Nov 2012). World Trade 
Organization (WTO). Dispute Settlement: Dispute DS435. Geneva: WTO; 2012.  
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds435_e.htm (accessed 29 Nov 2012). World Trade 
Organization (WTO). Dispute Settlement: Dispute DS441. Geneva: WTO; 2012. 
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds441_e.htm (accessed 29 Nov 2012). 
351 Australian Attorney-General's Department. Investor-State Arbitration - Tobacco Plain Packaging. Canberra: 
Attorney-General's Department; 2012. http://www.ag.gov.au/tobaccoplainpackaging (accessed 29 Nov 2012). 
352 See various papers reviewed in: Moodie C, Stead M, Bauld L, McNeill A, Angus K, Hinds K, et al. Plain 
Tobacco Packaging: A Systematic Review. PHRC Report. Stirling: University of Stirling; 2012. Hammond D. 
Tobacco packaging and labelling: A review of evidence. Waterloo: Department of Health studies: University of 
Waterloo; 2007. Bansal-Travers M, O'Connor R, Fix BV, Cummings KM. What do cigarette pack colors 
communicate to smokers in the U.S.? Am J Prev Med 2011: 40:683-9. Hoek J, Wong C, Gendall P, Louviere J, 
Cong K. Effects of dissuasive packaging on young adult smokers. Tob control 2011; 20:183-8. Hoek J, Gendall 
P, Gifford H, Pirikahu G, McCool J, Pene G, et al. Tobacco branding, plain packaging, pictorial warnings, and 
symbolic consumption. Qual Health Res 2012;22(5):630-9. Moodie C, Hastings G, Joossens L. Young adult 
smokers' perceptions of illicit tobacco and the possible impact of plain packaging on purchase behaviour. Eur J 
Public Health 2012; 22(2):251-3. Wakefield M, Germain D, Durkin S, Hammond D, Goldberg M, Borland R. 
Do larger pictorial health warnings diminish the need for plain packaging of cigarettes? Addiction 2012; 
107(6):1159-67. Freeman B, Chapman S, Rimmer M. The case for the plain packaging of tobacco products. 
Addiction. 2008; 103:580-90. McCool J, Webb L, Cameron LD, Hoek J. Graphic warning labels on plain 
cigarette packs: Will they make a difference to adolescents? Social Science & Medicine. 2012; 74:1269-73. 
353 Munafò MR, Roberts N, Bauld L, Leonards U. Plain packaging increases visual attention to health warnings 
on cigarette packs in non-smokers and weekly smokers but not daily smokers. Addiction 2011; 106:1505-10. 
354 Maynard OM, Munafò MR, Leonards U. Visual attention to health warnings on plain tobacco packaging in 
adolescent smokers and non-smokers. Addiction 2012. 
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becoming regular smokers and by encouraging - in particular young and occasional – smokers 
to give up their habit.355   
1.1.18. The views of stakeholders 
The tobacco industry has argued that bigger pictorial health warnings or plain packaging have 
no effect on smoking prevalence, that plain packaging increases illicit trade and that it 
undermines their intellectual property rights (trademarks). On the other hand, at least one of 
the four big FMC manufacturers expressed no major concerns with the introduction of 
mandatory picture warnings, replacement of TNCO-levels display and mandatory printing of 
cessation services, although the importance for keeping appropriate space for trademarks was 
underlined.356 Concerns about increased illicit trade following a plain packaging regime were 
also expressed by suppliers to the tobacco industry (packaging, fine paper, ingredients 
industries), but again they were not able to fully substantiate their arguments. Cigar 
manufacturers have referred to the specificity of cigars as an argument against strengthened 
labelling requirements and highlighted that SMEs would be affected disproportionately by 
stricter regulation/plain packaging. Health NGOs have argued that large mandatory pictorial 
warnings and plain packaging reduce the attractiveness and do not facilitate illicit trade. Most 
of the Member States responding to the public consultation were in favour of enlarged 
mandatory pictorial warnings, while the positions on plain packaging were more diverse.      
1.1.19. Comparing the options and preferred option 
Full plain packaging (policy option 3) would be most effective in terms of removing national 
disparities (policy objective A3), but requiring mandatory pictorial warnings and/or 
harmonising package shape and prohibiting promotional elements (options 1 and 2) would 
also help to achieve this aim, albeit to a lesser extent. Additionally, full plain packaging 
(policy option 3) would help to reduce administrative burdens by fully unifying labelling rules 
(policy objective B1), whereas requiring mandatory pictorial warnings and/or harmonising 
certain aspects of the package shape and prohibiting promotional and misleading elements 
(options 1 and 2) would contribute to a lesser extent to this objective. Harmonising certain 
aspects of the package shape and banning promotional elements or introducing full plain 
packaging (policy options 2 and 3) would remove the misleading potential of packages from 
the market (policy consideration C2). Introducing bigger mandatory pictorial warnings (policy 
options 1-3) would help improve consumer information (policy consideration C4).  
 
The assessment above has illustrated that all options 1-3 would lead to cost savings compared 
to status quo in terms of compliance costs and because action is taken at one go at EU level 
rather than many consecutive changes by Member States. Overall, however, it is expected that 
plain packaging (option 3) would also reduce the possibilities for brand differentiation, in 
particular affecting high margin/premium brands and impact more negatively on 
revenues/profits due to the drop in consumption (see section 5.7 and Annex 5), which is 
expected to be more important than under options 1 and 2.  
 
                                                 
355 Moodie C, Hastings G, Ford A. A brief Review of Plain Packaging Research for Tobacco Products, report 
prepared for the UK Department of Health. Stirling: Centre for Tobacco Control Research; 2009. Germain D, 
Wakefield MA, Durkin SJ. Adolescents’ perceptions of cigarette brand image: Does plain packaging make a 
difference. J Adol Health 2010; 46:385-92. Thrasher JF, Rousu MC, Hammond D, Navarro A, Corrigan J. 
Estimating the impact of pictorial health warnings and “plain” cigarette packaging: Evidence from experimental 
auctions among adult smokers. Health Policy 2011; 102:41– 8. 
356 Minutes from the meeting with FMC manufacturers, 2 December 2011: 
http://ec.europa.eu/health/tobacco/events/index_en.htm#anchor4 (accessed 28 Nov 2012). 
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Preferred policy option 2: Mandatory enlarged picture warnings plus harmonise certain 
aspects of packets and FMC appearance and prohibit promotional and misleading 
elements. 
 
The preferred option addresses the current heterogeneous development in Member States, in 
particular as regards pictorial warnings and cessation information where different regimes 
affect the internal market negatively. The suggested standardisation of the package 
appearance will ensure effective display of the health warnings. The option provides an 
ambitious and balanced approach taking into consideration the concerns of some stakeholders. 
It addresses in particular the concerns of the tobacco industry as it leaves a certain space on 
the package for manufacturers to display their trademark. The limitation of the product scope 
to FMC and RYO in a first stage would also take into consideration the concerns expressed by 
cigar manufacturers (often SME's). This is justified also because cigars (and pipe tobacco) are 
primarily used by adult smokers (see section 2.2.1). The option is based on new evidence 
showing that bigger and pictorial warnings are more effective and current indications of 
TNCO level and other aspects of packaging and labelling are misleading. The exact size of 
the warning (75%) has been suggested after thorough analysis of scientific evidence and 
international experience357 and developments as well as the impact on economic stakeholders.  
 
There is no less stringent measure available to reach the objective of improving the internal 
market while protecting public health. All elements included in option 2 would contribute to 
the objective, but none of them can, on their own, be expected to achieve the objective as 
effectively as the package of measures proposed in the preferred option. It is assumed that the 
measures proposed in the preferred option reinforce each other. Finally, some of the measures 
proposed need to be regulated jointly to avoid circumvention of legislation (e.g. picture 
warnings and package shape). Also, the costs associated with the preferred options are 
considered proportionate compared to the overall benefits. On the other hand, a stricter 
measure (option 3, full plain packaging), is expected to achieve the policy objectives even 
more effectively, but, given the current lack of real life experience,358 pending legal disputes 
regarding the plain packaging and serious concerns expressed by some stakeholders it appears 
most appropriate at this stage to choose option 2, while providing an opportunity to evaluate 
the situation after 5 years with a view to considering further standardisation (plain packaging). 
The option would not prevent Member States to regulate surfaces of the packages not covered 
by TPD or other legislation and thus implement full standardisation (plain packaging) 
provided it is compatible with the Treaty.  
 
As illustrated above, only an EU action can bring some of the current provisions in line with 
international and scientific development as Member States are prevented from taking actions 
on their own (e.g. TNCO levels display). Other aspects of labelling (e.g. pictorial warnings) 
are associated with a lot of diversity and only an EU action can ensure a homogenous 
development facilitating the functioning of the internal market.  
 
                                                 
357 75% on both sides in Canada, 30% and 90% in Australia and New Zealand, 80% of both sides in Uruguay, 
60% and 70% in Mauritius, 30% and 100% in Mexico. 
358 Plain packaging entered into force in Australia as of 1 December 2012. 
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5.4. REPORTING AND REGULATION OF INGREDIENTS359 
1.1.20. PO1: Common reporting format on a voluntary basis. Prohibit toxic, 
addictive and attractive additives in tobacco products. 
 
Member States are free to decide whether they oblige manufacturers to report additives in 
tobacco products. If Member States decide to make the reporting obligatory, the common 
reporting format must be used. Member States shall prohibit additives based on the general 
criteria toxicity, addictiveness and attractiveness.      
 
Economic impacts 
A harmonised reporting format would remove current disparities and facilitate the monitoring 
and analysis of ingredients data across the EU, but a voluntary reporting regime would 
provide an incomplete picture of ingredients used across the EU, which is not beneficial for 
the functioning of the internal market. Regarding ingredients regulation, Member States 
would have to ban additives which increase toxicity, addictiveness and attractiveness. This is 
expected to have a positive impact on the internal market, especially as a result of increased 
convergence as regards additives with toxic and addictive properties. Following the obligation 
to ban toxic and addictive additives, Member States are also expected to re-evaluate their 
current ingredients lists (where such lists exists) and update those according to scientific 
developments. Also this, would remove some of the current divergence. In terms of 
“attractive” additives, the effect is expected to be more limited as this concept is more 
subjective and no further guidance would be given in the legislation. Member States could be 
expected to take the FCTC guidelines for implementing Article 9 and 10 as guidance, but they 
give significant discretion to Parties and are expected to be interpreted in different ways.      
 
The optional and harmonised reporting system would lead to cost savings for economic 
stakeholders, Governments (in particularly those opting for no reporting) and the 
Commission as it would reduce the compliance costs compared to the baseline scenario. Also 
the harmonised ingredients regulation under option 1 is expected to lead to some cost savings 
compared to the baseline scenario due to the increased convergence in terms of additives 
allowed or banned in tobacco products. However, as indicated above, some discrepancies can 
still be expected under option 1, in particular in terms of “attractive” additives where Member 
States are expected to interpret the concept differently. For the indirect impact on economic 
players and Governments following the estimated marginal drop in consumption, reference is 
made to section 5.7 and Annex 5.  
 
Under option 1, consumers would benefit from a somewhat increased protection due to the 
ban on toxic, addictive and attractive additives. The consumer choice is expected to be remain 
stable. Even if some of the tobacco products currently on the market would have to be 
reformulated, it is likely that alternative additives or mixture of additives would be used in 
order to maintain the product or a similar one on the market.  
Social impacts 
The indirect impact on employment is expected to follow the limited drop in consumption. 
As indicated above, it is likely under option 1 that the rather general criteria, and in particular 
on attractiveness could be interpreted differently in Member States. This could have a 
negative impact on equality between Member States, i.e. lead to different level of protection. 
                                                 
359 For definition, see glossary 
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As the criteria suggested under option 1 are related to the additives as such and not the 
tobacco products, it is likely that the producers would find alternative additives (instead of 
those banned because of their attractiveness) to create a similar product. Therefore, it is 
expected under option 1 that attractive tobacco products, including fruit and candy-flavoured 
FMC would continue to be marketed, at least in some Member States. This would particularly 
affect young people who are more vulnerable in relation to these products.  
Health impacts 
Option 1 is expected to remove some of the most hazardous additives from tobacco products. 
However, as explained previously in this impact assessment, tobacco consumption as such is 
linked to a number of health risks which would remain despite the regulation foreseen under 
this policy option. It is also likely that an additives-based approach only in terms of 
attractiveness is less effective than a product-based approach (see option 2), in particular 
considering the risk that alternative additives could be used to produce a similar (distinctive) 
flavour.   
1.1.21. PO2: Mandatory reporting in harmonised format. Prohibit tobacco 
products with characterising flavours and products with increased toxicity 
or addictiveness 
 
Manufacturers are obliged to electronically report ingredients (glossary) of tobacco products 
in accordance with a common format and provide supporting data (e.g. marketing reports). 
Fees charged by Member States for handling the information submitted to them shall not 
exceed the cost attributable to those activities. Placing on the market of new or modified 
tobacco products must not take place before the submission of ingredients data. Reported 
data, excluding confidential information, is published. Delegated/implementing power to 
specify the reporting format.  
Tobacco products with characterising flavours (glossary) are prohibited (this is similar to the 
US model). Test panels assist in the decision making process. Additives associated with 
energy and vitality (e.g. caffeine and taurine) or creating the impression that products have 
health benefits (e.g. vitamins) are prohibited. No flavourings are allowed in filters, papers or 
packages. Tobacco products with increased toxicity or addictiveness shall not be placed on 
the market. Member States shall remove from the market tobacco products that include 
ingredients not complying with REACH. Delegated/implementing power to set limits for 
additives imparting a characterising flavour, toxicity and addictiveness.     
Tobacco products other than FMC, RYO and STP (i.e. cigars, cigarillos and pipes) are 
exempted from the prohibition of products with characterising flavour and the prohibition of 
additives associated with energy and vitality or health benefits. Delegated/implementing 
powers to remove the exemption for these products are foreseen if there is a substantial 
change of circumstances.    
Economic impacts 
Mandatory reporting of additives in combination with a harmonised format would ensure a 
level playing field and facilitate analysing and monitoring of data. Also the ingredients 
regulation suggested under option 2 would further harmonise national legislations, prevent a 
patchwork of national regulations, facilitate cross-border trade and thus improve the 
functioning of the internal market. The approach in terms of attractiveness, addictiveness 
and toxicity would rather focus on the tobacco product itself than the additives used in option 
1. In addition, some easily determined additives, such as vitamins and caffeine would be 
banned throughout the EU. This would result in less discrepancy for Member States. Also, 
implementing/delegated powers are foreseen to ensure a consistent approach. Test panels 
would assist in determining products with characterising flavour, which would further 
     100 
increase convergence. Overall, option 2 would increase further the positive impact on the 
internal market compared to option 1.     
 
The EU guide on harmonised reporting format and the already developed tool for data 
submission (EMTOC) would provide a basis for a mandatory harmonised reporting system. 
The costs for introducing such a system on a mandatory basis would therefore be marginal 
and largely off-set by the savings generated by the use of one single format across the EU. A 
robust electronic system as the one suggested would also address the concern expressed by 
tobacco manufacturers as regards trade secrets as publication for general public could take 
into account legitimate confidentiality requests. If Member States charge a fee for the 
reporting, the economic players have indicated in the context of the public consultation that 
they would be ready to participate to the financing of an electronic reporting system.360 
Available market studies and scientific studies (e.g. on toxicity) would need to be submitted.  
 
In terms of ingredients regulation, the economic actors (the tobacco industry) would benefit 
from cost savings under option 2.361 For products sold across various Member States the 
decision is adopted once across the EU rather than several times consecutively, which reduces 
the compliance costs, including understanding of the new requirements and possible 
reformulation of products. In order to quantify these costs, a question was submitted to four 
major FMC manufacturers to know the average cost per brand of changing the composition of 
cigarettes. The replies provided were incomplete which made it difficult to quantify the extra 
costs for changes of ingredients regulation in a given Member State. One company stated, 
however, that a major product redesign would cost in excess of 1 mEUR per brand. Costs 
included in this figure are development work, specification maintenance, pre-trials, pilot plant 
trials, analytical work, as well as the cost impact on stock holdings and factory efficiency. It is 
estimated, under option 2, that a limited part of the market would be affected by the change 
(including the menthol FMC counting for 4% of the market). Also the ban of flavourings 
added to the filters, paper and packages would affect the (limited) segment of products 
currently including such flavourings. Moreover, the regulation of products with increased 
toxicity or addictiveness is harmonised under this policy option, which could result in limited 
additional costs savings for economic stakeholders. The possibility for the Commission to 
adopt harmonised rules (delegated/implementing acts) should further reduce compliance costs 
compared to option 1. The production costs would also decrease under option 2 as less 
ingredients are expected to be used. Ultimately, option 2 would allow manufacturers to 
produce one product which could be sold across borders in all Member States. The measure 
would primarily affect a specific segment of the market, namely products with characterising 
flavours or additives giving the misleading impression of energy or vitality (such as caffeine 
and taurine) or associated with health benefits (such as vitamins).362   
 
Menthol-flavoured FMC are more common than other FMC with characterising flavours. 
They account for 4% of all FMC sales over the past ten years ranging from 25% in Finland 
                                                 
360 CECCM submission to the public consultation on the possible revision of the Tobacco Products Directive 
2001/37/EC.  
361 Matrix 2012. One company stated, in the context of an interview carried out by Matrix, that a single 
regulation across Europe might be less expensive than Member State level changes with different limits across 
each of the EU Member States, as long as ingredient regulation is proportionate and evidence based. 
362 Certain flavourings are used in relatively high quantities, such as cocoa and liquorice, without necessarily 
resulting in a product with a characterising flavour, whilst other products includes flavourings in lower quantities 
giving the product a characterising flavour (distinguishable taste or aroma). Often, the characterising flavour is 
indicated on the package. Tobacco products overtly marketed as containing additives (e.g. menthol cigarettes) 
command a relatively small market share in EU (SCENIHR 2010) 
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and 0,1% in Greece.363 As indicated under health impacts below, it is estimated that flavours 
have an effect on smoking initiation.364 It is impossible to predict with certainty the response 
of already established smokers of menthol FMC if these products were not allowed. However, 
it appears likely, in particular taking into account addictiveness that a significant part of these 
smokers would switch to traditional FMC without characterising flavours. Sales lost from 
menthol cigarettes would therefore be partially off-set by sales of other FMC or by efforts to 
acquire the products outside the EU or illicitly. However, some current menthol smokers are 
also expected to quit others are expected not to start. The impact on growers is limited to the 
drop in consumption and there is no risk of distortion between growers of different tobacco 
types. The impact on flavouring suppliers is expected to be limited as they normally supply 
multiple actors and multiple flavourings. The indirect impacts on the economic stakeholders 
following the expected drop in consumption are further described in section 5.7 and Annex 5.  
 
Regarding the reporting obligations, the main impact expected for Governments is that 
enforcing and verifying the reporting obligations is facilitated. National authorities would also 
be able to charge a fee for the ingredients reporting. Regarding ingredients reformulation, 
however, there may be some additional administrative burden for Governments and the 
Commission when analysing the market studies submitted by industry or when taking 
decisions on characterising flavours. From an international perspective, option 2 is well in 
line with the FCTC guidelines on ingredients and similar to the US approach. All products 
with characterising flavours (e.g. menthol and clove) are treated the same way to avoid un 
justified differences of treatment.365 The indirect impacts directly linked to 





In terms of employment, the impacts of option 2 are in line with trends outlined above for the 
economic stakeholders, i.e. they would broadly correspond to the foreseen reduction in 
consumption (see section 5.7 and Annex 5). This applies to upstream suppliers (e.g. growers 
and producers of additives), tobacco industry and distributors. Reference is also made to the 
redistribution effect which is based on the input/output model (see Annex 5). The option 
would not affect additives essential for the manufacturing of tobacco products (other than 
those imparting a characterising flavour). It would not discriminate between different tobacco 
varieties. Option 2 would provide improved and more equal protection due to the removal of 
certain appealing products. This is expected to have a particular impact on young people.  
Health impacts 
As described in the problem identification, scientific studies have demonstrated an influence 
of flavourings on smoking initiation.366 Tobacco products may also be designed in such a way 
that they are easier to start smoking with. This may be attained by making it easier to inhale 
the smoke in the lungs and by creating a sweeter, milder or “colder” smoke. By reducing and 
changing the harshness of the smoke, special target groups may be reached.367 In a number of 
                                                 
363 Matrix 2012. Based on Euromonitor (volume ) data for 24 Member States (no data available for Cyprus, 
Malta and Luxembourg) 
364 SCENIHR 2010  
365 See WTO Appellate Body, AB-2012-1, United States – Measures Affecting the Production and Sale of Clove 
Cigarettes (DS406) 
366 SCENIHR 2010  
367 Carpenter C, Wayne GF, Connolly GN. Designing cigarettes for women: new findings from the tobacco 
industry documents. Addiction 2005; 100: 837-51.Carpenter CM, Wayne GF, Pauly JL, Koh HK, Connolly GN. 
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countries, sweet and tasteful tobacco products are the most preferred tobacco products among 
children and adolescents as well as experimenting smokers.368 A study by Hersey et al., using 
data from the National Youth Tobacco Survey in the US, found that menthol FMC use was 
significantly more common among newer, younger smokers.369 A recent study analysing data 
of more than 47,000 US-pupils US found a greater risk of progression to regular smoking and 
nicotine dependence for those who start smoking menthol cigarettes compared to those 
starting with non-menthol cigarettes.370 The US FDA Tobacco Products Scientific Advisory 
Committee has also confirmed, on the basis of the extensive review of all available 
information, that the evidence was sufficient to conclude that it is more likely than not that the 
availability of menthol FMC increases the likelihood of experimentation and regular smoking 
beyond the anticipated prevalence if such FMC were not available.371 Overall, it is expected 
that option 2 would result in lower appeal and increased awareness. Additives that give the 
impression that FMC are less harmful, contain healthy properties or are associated with 
energy and vitality (including fruits, vitamins and caffeine) would no longer be allowed and if 
new attractive products appeared on the market, the Member States and the Commission 
would be able to react, if necessary, through a delegated/implementing act. This would 
contribute to the projected decrease in consumption. The option is likely to reduce smoking 
uptake rather than affecting habits of established smokers although a certain impact is also 
expected for established smokers. Option 2 would be further reinforced by stricter 
requirements in the area of packaging and labelling (see policy area 2), namely by the 
removal of misleading and promotional elements under that policy area. Over time, it will 
result in reduced morbidity/mortality from smoking and a higher level of well-being.  
 
1.1.22. PO3: Mandatory reporting in harmonised format. Prohibit all additives 
not essential for manufacturing (similar to Canada model) 
 
Ingredients reporting as in option 2. In terms of ingredients regulation, all additives in tobacco 
products, except those essential for manufacturing are prohibited. Maximum limits are set for 
sugar and sweeteners. 
Other tobacco products than FMC, RYO and STP are exempted from the ingredients 
regulation. Delegated/implementing power to remove the exemption for these products if 
there is a change of circumstances.   
                                                                                                                                                        
New cigarette brands with flavors that appeal to youth: Tobacco marketing strategies. Health Aff (Millwood) 
2005; 24:1601-10. Cummings KM, Morley CP, Horan JK, Steger C, Leawell NR. Marketing to America’s 
youth: evidence from corporate document. Tob Control 2002; 11:15-7. Wayne G, Connolly G. How cigarette 
design can affect youth initiation into smoking: Camel cigarettes 1983-93. Tob Control 2002; 11(Suppl 1):i32-
39.  
368 Ashare RL, Hawk LW Jr, Cummings KM, O’Connor RJ, Fix BV, Schmidt WC. Smoking expectancies for 
flavored and non-flavored cigarettes among college students. Addict Behav 2007; 32:1252-61. Giovino GA, 
Yang J, Tworek, Cummings KM, O’Connor J, Donohue K, et al. Use of flavored cigarettes among older 
adolescent and adult smokers: US 2004. Presentation at the National Conference on Tobacco or Health. Chicago, 
Illinios; May 6, 2005. Klein SM, Giovino GA, Barker DC, Tworek C, Cummings KM, O’Connor RJ. Use of 
flavored cigarettes among adolescent and adult smokers. United States 2004-2005. Nicotine Tob Res 2008; 10: 
1209-14. 
369 Hersey JC, Ng SW, Nonnemaker JM, Mowery P, Thomas KY, Vilsaint MC, et al. Are Menthol Cigarettes a 
Starter Product for Youth? Nicotine Tob Res 2006; 8:403-13. 
370 Nonnemaker J, Hersey J, Homsi G, Busey A, Allen J, Vallone D. Initiation with menthol cigarettes and youth 
smoking uptake. Addiction 2012 Aug 3. 
371 Tobacco Products Scientific Advisory Committee (TPSAC). Menthol Cigarettes and Public Health: Review 
of the Scientific Evidence and Recommendations.  Rockville, MD: US Food and Drug Administration; 2011.  
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Economic impacts 
As regards ingredients reporting, the impacts would be similar to option 2, although the 
volume of reporting could be reduced following the restriction of ingredients allowed. 
 
Regarding ingredients regulation, option 3 would further improve the functioning of the 
internal market due to the removal of the remaining discretion for Member States. Products 
could then circulate freely across borders without additional health concerns. Compared to the 
previously described options, manufacturers would be faced with significantly higher costs 
associated with reformulation and removal of products from the market. Using the same cost 
estimated as under option 2 means that a major product redesign would cost in excess of 1 
mEUR per brand, but compared to option 2, most brands across the EU are expected to be 
affected by option 3. The costs associated with a change at EU level would however still be 
lower than consecutive changes at national level.372  
 
Option 3 would also impact negatively on product differentiation opportunities for the 
industry and is therefore likely to reduce turnover and profits, see section 5.7 and Annex 5.  
Option 3 would have a particular impact on economic players involved in Burley and Oriental 
tobacco (growers, manufacturers of American blend FMC) compared to Virginia as more 
additives, including sugar, are used in the manufacturing of FMC based on these tobacco 
types. Some additional impacts on flavouring suppliers can be expected compared to option 2, 
although they normally supply multiple sectors.  
 
On balance, the option is not expected to have any additional direct impacts on 
Governments. Compared to option 2, the costs of option 3 associated with ingredients 
regulation are on the one hand lower (less administrative burden), but on the other hand result 
in significantly reduced choice for consumers although they would benefit from a more 
comprehensive protection. In terms of international impacts, option 3 is well in line with the 
FCTC guidelines and similar to the Canadian and Brazilian approaches which have been 
discussed in the framework of the WTO. It could have some impact on EU trade, considering 
that it would affect primarily Burley and Oriental producers (mainly in the EU), while 
Virginia producers (including non-EU) would be less affected.  
Social impacts 
The indirect impact on employment linked to the drop in consumption is described in section 
5.7 and Annex 5. In terms of distributional effects, option 3 is expected to have a greater 
impact on employment related to Burley and Oriental tobacco (American blend FMC) as 
explained above. In this context, it should be recalled that more than 80% (69,000) of the EU 
farmers are involved in these tobacco types. These are often small family businesses 
concentrated in specific regions, including rural areas in Bulgaria, Poland, Greece, Spain and 
Italy. In terms of equality, option 3 would provide similar (or marginally improved) 
protection of young people compared to option 2 as it would remove additional products from 
the market that could be attractive for young people.  
Health impacts 
Option 3 would further reinforce the effect on awareness and prevalence outlined under 
option 2, although only to a limited extent as most of the particularly appealing products are 
already banned under option 2. The indirect impacts are further developed in section 5.7 and 
Annex 5.  
                                                 
372 This is certainly true if one Member State opts for a full ban on additives (Canadian/Brazilian model). 
     104 
1.1.23. The views of stakeholders 
All stakeholders have expressed support for mandatory reporting on ingredients in a 
common format.373 The tobacco industry has referred to commercially sensitive data and the 
importance of keeping this data confidential. In addition, FMC manufacturers have indicated 
that they agree to participate to the financing of a reporting system with regard to running 
costs.374  
 
In relation to ingredients regulation, the tobacco industry as well as the flavouring industry 
have emphasised that there is no scientific basis to regulate attractiveness arguing it would be 
a "subjective concept". Growers have expressed particular concern that a ban on all additives 
would discriminate against certain types of tobacco (Burley and Oriental) and have very 
negative impact on employment. Cigar manufacturers have argued against further 
requirements on ingredients, in particular stressing that cigars are mainly used by adult users 
and not by young people taking up smoking. The four big FMC manufacturers indicated, 
however, that prohibiting certain characterising fruit and candy-like flavours for products 
such as pina colada and strawberry can be further explored375. Growers indicated that a ban on 
dominant flavour could be acceptable.375 Health NGOs have expressed support for an 
approach addressing the attractiveness of tobacco products. A majority of the Member States 
that responded to the public consultation supported some kind of ingredients regulation 
(Annex 1).  
1.1.24. Comparing the options and preferred option 
In terms of effectiveness, prohibiting products with characterising flavours (policy option 2) 
or (even more so) prohibiting all additives not essential for manufacturing (policy option 3) 
would remove national disparities and unify national rules (policy objectives A3 and B1). 
Option 1 would partly contribute to the achievement of these objectives. The mandatory and 
electronic reporting system under options 2 and 3 would also be well in line with objective B2 
as it would facilitate enforcement and verification by Governments as regards reporting 
obligations. All options 1-3 would contribute to policy consideration C1 as they would 
regulate the most hazardous products on the market. Options 2 and 3 would fulfil 
consideration C2 as they would remove products which are particularly attractive, including 
to young people.  
 
Prohibiting products with characterising flavours (policy option 2) appears to be a 
manageable and efficient measure to regulate tobacco products appealing and attractive to 
young people, therefore taking into account the concept of “attractiveness”. The measure 
would affect a limited number of products, while prohibiting all additives not essential for 
manufacturing (policy option 3) would affect most of the products on the market and thus 
have more significant economic impact. A ban of all products with characterising flavours, 
rather than just a limited number of identified flavours would ensure coherence and equal 
treatment and avoid unjustified differences of treatment (e.g. menthol vs clove).    
 
Preferred policy option 2: Mandatory reporting in harmonised format. Prohibit tobacco 
products with characterising flavours and products with increased toxicity or addictiveness. 
 
                                                 
373 Based on the existing system, EMTOC.  
374The European Association for Cigarette Manufacturers (CECCM) considers the introduction of fees for 
operating costs acceptable in its contribution to the public consultation on a possible revision of the Tobacco 
Products Directive 
375 Minutes from the meetings are available at : http://ec.europa.eu/health/tobacco/events/index_en.htm#anchor4 
(accessed 28 Nov 2012). 
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A harmonised reporting format and mandatory reporting will create a level playing field and 
facilitate collection, analysing and monitoring of data. It will also reduce the administrative 
burden of the industry, Member States and the Commission and provide a more robust system 
to handle sensitive data. All stakeholders support this approach and the European Association 
for Cigarette Manufacturers (CECCM) considers the introduction of fees for operating costs 
acceptable (see above). 
 
The preferred option also addresses the heterogeneous development in Member States in 
relation to ingredients regulation and takes into account international developments (FCTC). 
It allows industry to adapt the production lines in one go whilst allowing industry some 
margin to differentiate products. It focuses on products particularly attractive to young people 
and is estimated to reduce smoking initiation. It addresses recent market developments, 
including the new technology of inserting additives (e.g. menthol) in the filters of the 
cigarettes, and allows for further guidance and developments through implementing/delegated 
acts. A general ban on characterising flavours (instead of regulating individual additives) 
makes it more difficult to circumvent the ban by developing alternative chemical 
combinations with the similar properties (taste/aroma). The option provides a balanced 
approach, taking into consideration the concern of some stakeholders, in particular regarding 
demand for certain tobacco types (Burley and Oriental) and EU growers have indicated that 
they could accept the suggested approach.376   
The preferred option would contribute to the achievement of the policy objective, i.e. improve 
the functioning of the internal market through further alignment of Member States’ 
regulations. In terms of health, it would in particular target smoking initiation among young 
people. A stricter approach (option 3) would go beyond the focus on young people and affect 
a substantial number of products which could be seen as less proportionate to the expected 
additional impact on smoking initiation. A less stringent measure (option 1) would not 
improve the functioning of the internal market. Also, when balancing the benefits with the 
costs for the economic operators, option 2 appears to be a proportionate solution given the 
number of products affected compared to option 3.   
Only an initiative at EU level is capable of removing the current and expected diversity in 
terms of regulation and provide a standardised format for reporting of additives.  
 
5.5. CROSS-BORDER DISTANCE SALES OF TOBACCO 
1.1.25. PO1: Notification and age verification system 
Retailers of tobacco products intending to engage in cross-border distance sales shall notify 
their cross-border activities to the Member States where the company has its seat and where it 
intends to sell. Member States may require the retailer to appoint a natural person, who 
ensures compliance with the TPD of products delivered to customers in Member States 
concerned. Mandatory age verification mechanism is foreseen.    
Economic impacts 
Option 1 would provide more equal market conditions for internet retailers operating on the 
EU market. The requirement to notify internet retail under option 1 is expected to 
ensure/improve compliance with the law (including TPD) and is expected to reduce the 
amount of illegal sales of tobacco products in favour of legal business (traditional retailers 
                                                 
376 Minutes from SANCO's meeting with tobacco growers, September 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20110914_mi_en.pdf (accessed 28 Nov 2012).  
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and legal internet retailers) operating in compliance with the TPD (e.g. labelling and 
ingredients regulation). This would maximise the effect of TPD and have positive impact on 
the internal market.  
 
The notification requirement and the age control mechanism are expected to impose some 
compliance costs on tobacco internet retailers. The cost of notification is expected to be 
minor as the actual requirement will be limited to sending an e-mail/letter to the competent 
authorities of the host Member State as well as Member States of destination. This must be 
seen in the context of the specificities of tobacco products responsible for almost 700,000 
deaths in the EU each year. The designation of a natural person to ensure compliance with the 
TPD is optional for Member States and it is expected that the retailer can make use of 
resources already required by other legal frameworks (tax legislation). The age control 
verification is also expected to result in minor costs.  Option 1 is expected to result in a 
reduced number of internet retailers as many of the current retailers would close their business 
rather than notify their (illegal) activity.377 This reduction would partially reduce 
consumption, partially lead to a return of consumption to the legal supply chain. Overall, the 
impact on economic stakeholders is expected to be positive following the estimated shift from 
illegal to legal sale, despite the somehow reduced consumption.  
 
The shift towards legal sale would also have the unintended but welcome side effect of 
increased tax revenues for Governments and would facilitate criminal investigations, as 
internet sales by non-notified businesses would be automatically illegal. On the other hand, 
option 1 would imply additional, but limited costs for national authorities in terms of setting 
up the notification system. It is expected that 0.5 full time equivalent (FTE) would be more 
than adequate whilst law enforcement would be simplified compensating largely for the 
additional costs. Consumers would continue to have access to several sales channels, 
including cross-border distance sale and have access to products not available on their 
domestic markets. They could verify before purchase whether the internet seller is a legal 
entity competent to engage in such activity. The protection against illicit supply and 
protection of young people would be improved and more consumers would obtain products 
complying with the TPD, including with warnings in their own language. Consumer prices 
are expected to increase as a result of the shift from illegal to legal supply. Option 1 provides 
a step towards, but is not fully in line with the FCTC guidelines recommending a full ban.  
 
Social impacts 
As most of the consumers currently purchasing from illegal internet sources are expected to 
divert to other legal distribution channels, option 1 is likely to have a positive overall impact 
on employment in the legal supply chain. Option 1 would lead to improved protection of 
young people as internet retailers would be obliged to control the age of the purchaser.  
Health impacts 
Option 1 is expected to further reduce availability and access to tobacco, in particular for 
under-aged people. The option would improve awareness as the safeguards of the TPD would 
be better respected and would contribute, to some extent, to a drop in 
consumption/prevalence, particularly in the illicit segment of the market. Most of the 
consumers currently using the internet as a source for tobacco products are expected to turn to 
alternative, legal sources, but some are also expected not to start, quit or reduce their 
consumption. It would also limit young people's access to promotional aspects often visible 
                                                 
377 Some retailers are also expected to continue illegal, non-notified activities. 
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on the internet and could discourage uptake of tobacco use, in particular among young people. 
Overall this is beneficial for public health.   
1.1.26. PO2: Prohibit cross border distance sales of tobacco products 
Cross-border distance sales of tobacco products are prohibited in the EU.  
Economic impacts 
A ban on cross-border distance sales of tobacco would remove current divergences on the 
internal market and ensure that certain provisions concerning protection of the internal market 
(e.g. labelling and ingredients rules set out in the TPD) are fully respected/not 
circumvented.378 The measure would also facilitate enforcement.379 The current disadvantage 
of traditional retailers having to compete with lower prices applied by (mainly) illegal internet 
retailers would be removed. This would have the positive impact on the internal market. 
However, option 2 would also remove legal cross-border distance sale. 
 
Option 2 could imply a one-off compliance cost of lost stocks and of equipment used for the 
tobacco internet retail activity, although these costs would be very limited considering the 
transposition period. The products can also still be sold domestically and there is no 
legitimate expectation for illicit activities to continue. Option 2 would interfere with the 
freedom to conduct business which would need to be balanced against the principle of health 
protection.380 The shift towards sales in the legal supply chain is also expected, as an 
unintended side effect, to improve Governments’ ability to collect taxes resulting in 
increased tax revenues. Indirect impacts directly linked to consumption are further described 
in Section 5.7 and Annex 5. Option 2 would limit the number of sales channels for 
consumers, but provide a higher level of protection as it would reduce the availability of 
illicit tobacco products not necessarily complying with the TPD. The measure is fully in line 
with the FCTC guidelines, but needs to be justified under WTO rules. 
Social impacts 
Option 2 would further reinforce the positive impact on legal employment in tobacco 
outlined under option 1. It would also remove the current negative impact on young people 
and apply in an equal manner to all EU citizens. 
Health impacts 
Many of the current internet sites include promotional aspects and the products are unlikely to 
comply with required labelling or content rules. This has a negative impact on availability and 
awareness. Option 2 is expected to further reduce access, both to under-aged people who 
might be tempted to purchase on the internet due to less strict age controls and cheaper prices 
and adults who wish to avoid paying the applicable taxes. This would lead to a drop in 
consumption exceeding the one described in option 1.  
1.1.27. The views of stakeholders 
The FMC manufacturers expressed support for distance selling of tobacco products to adults 
provided that such sale is regulated and proper tax payments are ensured (see Annex 1). 
Retailers have indicated that internet sale of tobacco is associated with problems in relation to 
                                                 
378 Compare the reasoning in Case C-491/01, The Queen v Secretary of State for Health, ex parte British 
American Tobacco (Investments) Ltd and Imperial Tobacco Ltd, ECR [2002], p I-11453, para 81-91. 
379 Whilst it is true that distance purchases can also take place from countries outside the EU, remaining customs 
control offer better chances of detection.  
380 Article 16 v. Article 35 of the Charter of Fundamental Rights of the European Union  
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under age control and collection of taxes. They argue that stricter measures, if any, should be 
introduced at national levels. Health NGOs have asked for a ban of internet sales of tobacco 
as a logic extension of the advertising ban.    
1.1.28. Comparing the options and preferred option  
In terms of effectiveness, both a notification system combined with age verification (option 1) 
and prohibiting cross-border distance sale (option 2) would facilitate the creation of a level 
playing field (policy objective A2). Both options would also facilitate market surveillance 
(policy objective B2). Moreover, both options (and even more so, option 2) would contribute 
to reduced access for young people (policy consideration C5) and minimum level of health 
protection (policy consideration C6).  
 
In terms of costs, the establishment of a notification system under option 1 would imply 
additional, however limited, costs for national authorities whilst facilitating law enforcement. 
Prohibiting cross-border internet sales (policy option 2) would fully remove one sales channel 
and thereby limit market opportunities. It would deprive consumers of the possibility to buy 
tobacco products not available in the Member States of location. Both options are also 
expected to lead to reduced illicit trade and thereby benefit economic players involved in the 
legal supply chain.  
 
Preferred policy option 1: Notification and age verification system 
 
The preferred option will facilitate legal activity without removing any sales channel, while 
allowing consumers legitimate access to tobacco products not available on their domestic 
market. The option reinforces the effect of the TPD by preventing purchasing of products not 
complying with the Directive, including health warnings in the right language and ingredients 
regulation. An unintended side-effect is that the preferred option also will reduce the 
availability of cheaper products not respecting national price policies, address underage 
purchasing and allows Governments to better collect applicable taxes.  
The preferred option complies with the principle of proportionality. It contributes to the 
achievement of the internal market objective by ensuring TPD safeguards and facilitating 
trade in products complying with TPD. The additional burden for retailers involved in cross-
border distance sale of tobacco products is considered justified taking into consideration the 
specific characteristics of tobacco products (responsible for almost 700,000 death in the EU 
each year) not comparable with any other product on the internal market. The preferred option 
will also contribute to a drop in consumption/prevalence. Given that option 1 will contribute 
to better compliance with TPD, a full prohibition of cross-border distance sale (option 2) 
would go beyond what is necessary to obtain the objective. There is no less strict measure 
available to attain the objective. The costs associated with the preferred option both for 
economic operators and Governments are considered limited (if any) compared to the benefits 
following from reduced consumption, reduced illicit trade in tobacco and facilitated 
enforcement.  
Cross-border distance sales can only be addressed effectively at EU level as the sales, by 
definition take place between Member States. Therefore, an EU action in these areas is of 
added value. 
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5.6. TRACEABILITY AND SECURITY FEATURES 
1.1.29. PO1: EU tracking and tracing system  
 
An EU tracking and tracing system at packet level for tobacco products throughout the supply 
chain (excluding retail) is introduced. Tobacco manufacturers shall conclude contracts with 
independent third parties that provide data storage capacities for such system ensuring full 
transparency and accessibility by Member States at all times. Tobacco products other than 
FMC and RYO are granted a transitional period of five years.  
Delegated/implementing power to adopt technical specification to ensure compatibility 
between the systems used. 
Economic impacts 
Ensuring full traceability and a strong control of the supply chain by a tracking and tracing 
system will contribute to the functioning of the internal market by reducing the volume of 
illicit supply, which is undermining the safeguards of the TPD. The system would create a 
level playing field for all operators on the internal market and remove the current situation 
where only the four biggest tobacco companies are bound by obligations as regards tracking 
and tracing via the Agreements with the EU and the Member States (see section 2.2.5). 
Currently, there is no harmonisation of national legislations on tracking and tracing in the EU 
although, in practice, there is increasing convergence in terms of technical standards used by 
tobacco manufacturers.381 Option 1 would thus ensure a harmonised approach in Member 
States.  
 
Tracking and tracing systems are generally seen as an effective means to address the risk of 
diversion of genuine products into the illicit market and such systems have already been 
developed and used in recent years. Based on industry data an effective tracking and tracing 
system reduces illicit contraband by 30% in five years. The main part of these additional 
revenues will go to the legal supply chain (FMC/RYO manufacturers and distribution chain), 
but some smokers are also expected to stop smoking/not to start smoking.  
 
Due to the existing Agreements between the four largest tobacco manufacturers and the EU 
and participating Member States (see section 2.2.5), the largest tobacco manufacturers are 
already implementing some of the requirements foreseen under option 1 and additional costs 
(e.g. associated with the outsourcing of the data storage are considered proportionate when 
compared with the existing contractual obligations (tracking and tracing at packet level). It 
should also be noted, that the Agreements will start expiring as of 2016 (unless they are 
extended). The proposed measure will be more burdensome for smaller operators who will 
possibly have to build up a tracking and tracing system from scratch. However, there are 
possibilities to benefit from existing experience382 and in any case it will be easier if such a 
system is introduced at EU level rather than in 27 Member States individually. Operators 
involved in tobacco products other than FMC and RYO products (e.g. cigars and pipe 
tobacco) will benefit from longer transitional periods.   
 
It is not easy to fully estimate the costs associated with the introduction of a tracking and 
tracing system. However, the following cost estimates, which were provided in the context of 
                                                 
381 Divergence might still exist regarding the package level and the level of trade.  
382 For example, PMI declared its readiness to grant royalty free licenses to third parties that want to use PMI's 
tracking and tracing software. Presupposing that the PMI system is compatible with the international obligations 
this would reduce the costs for introducing such a system substantially.  
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the international negotiations for an Illicit Trade Protocol (based on information from PMI) 383 
are a good indication:  
 
For the currently used carton level tracking and tracing, the industry's indications are that the 
actual one-off costs include machines for printing the label for master cases (5,000–20,000 
EUR per machine) and for cartons (10,000–35,000 EUR) as well as for carton coding system 
(10,000-35,000 EUR) and carton tracking system (30,000-50,000 EUR). To this should be 
added hardware (10,000-30,000 EUR), IT infrastructure for the retention of tracking and 
tracing data (10,000-150,000 EUR) and hosting and maintenance of data (50,000-150,000 
EUR). All costs for the equipment etc. would be covered by the manufacturers (including 
equipment used in the distribution chain). The only additional costs at distributor level are 
handling costs, but it is believed that the system would be highly automated.  
 
Taking into account the significant cross-border trade, only an EU system can be effectively 
enforced. On the positive side, it also needs to be noted that the expected decrease of illicit 
trade would have the effect of increasing the sales in the legal supply chain. The total illicit 
market at retail level (excluding taxes) is estimated to amount to 3 billion EUR, of which 30% 
are attributed to contraband products. Based on industry data an effective tracking and tracing 
system reduces illicit contraband by 30% in five years. Part of these additional revenues will 
go to the FMC/RYO manufacturers (other parts to the distribution chain, and some smokers 
are also expected to stop smoking/not to start smoking). 
 
For Governments, option 1 would have positive impacts in that it strengthens the legal 
supply chain and ensures that consumers benefit from the safeguards of the TPD. A tracking 
and tracing system which gives the authorities access to the data storage of the independent 
third party, will help the authorities (including the Commission) to monitor systematically the 
movement of tobacco products from the place of their manufacture, through the distribution 
chain to the intended market of retail sale ("tracking”). It will also enable the authorities, at 
the time of an audit or seizure of a product, to recreate the route taken by the product from the 
place of its manufacture, through the distribution chain to the point at which the product was 
diverted into illegal trade channels ("tracing"). On the other hand, some administrative costs 
are expected from the monitoring of the system. The measure would thus facilitate market 
surveillance. An unintended but welcome side effect would be that the measure would 
increase Governments' tax revenues by decreasing tax evasion. For consumers, option 1 
would mean a higher level of protection. It would also mean that the availability of cheap 
illicit FMC and RYO that do not comply with the TPD is reduced. Option 1 improves 
compliance with the FCTC.  
Social impacts 
The shift from illegal to legal trade would result in increased employment opportunities in 
the legal tobacco sector despite the predicted overall prevalence drop (which would 
essentially come from the illicit segment). There would also be increased employment 
opportunities in the setting up and operating tracking and tracing systems (including data 
storage). In terms of equality, the measure would contribute to removing illicit tobacco 
products' potential to target young and deprived people.384 
Health impacts  
                                                 
383 FCTC/COP/4/INF.DOC./1 of 15 September 2010. 
384 On the question of price elasticity of demand cf. International Agency for Research on Cancer (IARC). IARC 
Handbooks of Cancer Prevention: Tobacco Control. Volume 14. Effectiveness of Tax and Price Policies for 
Tobacco Control. Lyon, France: IARC; 2011.  
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The proposed measure would ensure that the intended increase in awareness is not 
circumvented by illegal products which do not comply with the relevant requirements 
(such as labelling and ingredients regulation). Part of the demand previously met by illicit 
products would shift to the legal supply chain, whereas another part is expected not to be 
substituted, i.e. would result in reduced consumption, which would in turn lead to reduced 
health risks and increased well-being in the long term. For the indirect impacts, see section 
5.7 and Annex 5 which apply, however, primarily to the legal supply chain (as the illegal part 
of the supply chain has no legitimate expectations).   
1.1.30. PO2: Tracking and tracing system, complemented by security features  
 
Option 1 plus: security features against counterfeiting and against illicit/cheap whites 
(glossary) on all tobacco products (e.g. holograms). Tobacco products other than FMC and 
RYO are granted a transitional period for five years. Delegated/implementing power to adopt 
technical specifications for the security features.  
The subsequent assessment only covers the additional elements beyond option 1.  
Economic impacts 
Adding special security features to limit sales of counterfeits and illicit whites (glossary) at 
EU level would help limiting sales of these products and further facilitate the functioning of 
the internal market of legal tobacco products. It avoids disparities and differences as regards 
security features and prevents further heterogeneous development in coming years following 
national measures to address illicit trade. It would also improve compliance of tobacco 
products with the safeguards of the TPD. Adding a security feature would imply additional 
costs for the industry to comply with the requirements. These costs depend largely on the 
technology chosen and might reach 0.005 EUR per package, for example for a hologram.385 
According to Euromonitor, 608 billion sticks of FMC were sold in the EU in 2010. This 
corresponds to approximately 30.4 billion packages of FMC (assuming a package size of 20 
sticks per package). The costs for applying holograms on all cigarette packages would thus 
amount to approximately 150 mEUR386. It is assumed that these costs would be passed on to 
subsequent distribution level and ultimately to the consumer.  
 
On the other hand, the industry would benefit from reduced illicit trade. In addition to the 
reduction of illicit trade (contraband) estimated under option 1, it is assumed that counterfeit 
and illicit white products would be reduced by 10% under option 2. Again, the larger part of 
these additional revenues is expected to go to the legal supply chain (FMC/RYO 
manufacturers, distribution chain), but some smokers are also expected to stop smoking/not to 
start smoking. In addition, the economic operators would benefit from a harmonised approach 
as they do not have to adapt to different regimes in different Member States. The calculations 
of the indirect impacts linked to a change of consumption patterns are set out in Section 5.7 
and Annex 5. 
 
Governments would benefit from a common system for security features. Whilst only seen as 
an unintended side effect for the purpose of the TPD revision, option 2 would also contribute 
to the collection of taxes. As the costs for the security features will be borne by industry, no 
                                                 
385 This is based on costs for a self-adhesive frangible (tamper evident) polyester hologram closure seal to be 
machine-applied at the packing or filling station, which is considered one of the more sophisticated security 
measures. (indication by the International Hologram Association) 
386 The calculation presupposes that the actual application of the security features on the package is included in 
the price. 
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additional costs beyond option 1 are foreseen. Increased tax income and facilitated market 
surveillance as well as effective implementation of the FCTC are further benefits for 
Governments. Moreover the security feature would assist consumers in determining whether 
the product is authentic and ensure a higher level of protection against products not 
complying with the TPD.   
Social impacts 
The positive impacts on employment outlined in option 1 would apply and be reinforced 
under this option. In addition, some employment would also be created in the production and 
application of security features. The option would also further strengthen equality due to the 
reduction of counterfeit and illicit white products (or at least by slowing down their growth). 
Availability of cheap (illegal) products would be reduced, which are through their lower price 
particularly appealing to young or deprived persons. 
Health impacts 
Security features will increase the awareness of the problems around illicit tobacco products 
and thus indirectly lead to increased awareness of the risks associated with tobacco 
consumption in general. Option 2 would further reinforce the positive health impacts outlined 
in option 1 and is expected to contribute to a significant reduction in consumption.  
1.1.31. The views of stakeholders 
 
Policy area 5 was introduced in reaction to concerns expressed by the industry (in particular 
FMC and RYO manufacturers, upstream suppliers and downstream distributors) in the 
context of the public and targeted stakeholder consultations. They argued that illicit trade 
already accounts for a large part of the market and is expected to increase. They pointed in 
particular to the risks associated with some of the policy options on plain packaging and 
display ban at PoS (which was subsequently disregarded in this impact assessment, see 
section 4.1) (nota bene: the evidence submitted by the economic stakeholders to support this 
argument is not considered compelling/convincing). No concrete proposals on how to 
effectively address illicit trade were made, but tracking and tracing is believed to provide the 
appropriate response and is already standard practice for the big four tobacco manufacturers. 
Providers of security systems (e.g. holograms) said that such a measure would reduce 
counterfeit to a certain degree (up to 30%) but would not eliminate it all together (nota bene: 
for the purpose of this impact assessment reduction of 10% was assumed). Member States are 
generally supportive, in particular in view of their tax revenues. Health NGOs contested that 
other planned TPD measures, e.g. on packaging would increase illicit trade, but nevertheless 
expressed support for additional measures to fight illicit trade.  
5.6.1.1. Comparing the options and preferred option 
In terms of effectiveness, an EU tracking and tracing system complemented by security 
features (policy option 2) would contribute the most to facilitating a level playing field (policy 
objective A2), although a tracking and tracing system on its own (policy option 1) would also 
go into this direction. Both options would contribute to better market surveillance (policy 
objective B2). A tracking and tracing system complemented by security features (policy 
option 2) would assist consumers in verifying the authenticity and ensure a minimum level of 
health protection (policy considerations C3 and C6). Both options would contribute to 
reducing accessibility to young people (policy consideration C5).  
 
An EU tracking and tracing system without security features (policy option 1) would provide 
a less costly solution to set up, in particular as a large part of the market already has a tracking 
and tracing system in place, at least at carton level. However, it would not specifically address 
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the issue of counterfeiting which is important in terms of ensuring a high level of health 
protection in line with the TPD. The costs associated with these two measures are expected to 
be outweighed by the significant benefits in terms of reduced illicit trade, resulting in 
increased sales for economic stakeholders (for more details, see Annex 5).   
 
Preferred policy option 2: Tracking and tracing system, complemented by security features 
 
The preferred option maximises the effect of the TPD and ensures that consumers throughout 
the EU benefit from a minimum level of protection when purchasing tobacco products (e.g. 
health warnings and ingredients regulation). The option creates a level playing field between 
different operators (currently only the biggest four tobacco manufacturers are bound to 
develop and use tracking and tracing systems) and would be beneficial for them (unless they 
are themselves involved in illicit trade). The option ensures compliance with Article 15 FCTC 
and ensures a common EU approach. It also facilitates market surveillance and empowers 
consumers in verifying the authenticity of tobacco products. The option addresses concerns of 
some stakeholders claiming that revision of the TPD would result in increased illicit trade 
(however without substantiation). The option also foresees a longer transitional period for 
manufacturers of tobacco products other than FMC and RYO (e.g. STP, cigars and pipe 
tobacco). This will allow small business to adapt and learn from bigger companies.  
There is no less restrictive measure available, because only if the market is effectively 
protected against illegal supply can the measures foreseen in the TPD achieve their objective. 
The two elements included in the preferred option are mutually reinforcing and address two 
separate aspects of illicit trade. A tracking and tracing system addresses contraband products 
non-complying with the TPD, while the security features deal with counterfeit and illicit 
whites.  
The costs associated with these two measures are expected to be outweighed by the benefits in 
terms of reduced illicit trade which partially benefit the legal supply chain and leads to 
reduced consumption. 
By definition, only an initiative at EU level is capable of ensuring a harmonised approach. 
Unilateral actions by Member States can contribute to the protection of health, but result in 
many legal and factual divergences and reduced effectiveness taking into account the 
significant cross-border nature of the market. The preferred option would provide an EU 
added value and an EU wide measure also facilitates enforcement in Member States. The 
preferred option is a necessary addition to all other measures in this proposed TPD, as only 
strong measures can provide for a protection of the legal market with all the necessary 
safeguards for consumers, manufacturers and retailers.  
 
In designing the legislation, due attention will be paid to the freedom to conduct business and 
to the protection of personal data in line with existing legal requirements.  
 
5.7. INDIRECT EFFECTS / HEALTH IMPACTS 
As explained the various policy options are expected to impact the economic stakeholders and 
Governments not only in a direct manner (e.g. costs/benefits associated with the 
implementation of the measure), but also in an indirect manner. Over time the proposed 
measures are expected to impact on peoples' awareness on the risks associated with tobacco 
products, which in turn will lead to a change in behaviour. Less young people will start 
smoking and some adults will successfully quit smoking. This is expected to lead to a 
reduction of smoking consumption/prevalence. 
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When comparing with international experiences, it is assumed for the purpose of this impact 
assessment that the combination of the preferred policy options will lead to a reduction of 
consumption of around 2 % (1.7-2.6% see figure 14 below) within a five year period after 
transposition beyond the baseline for FMCs and RYO. This corresponds to a reduction of 2.4 
million smokers in the EU. It has to be stressed that this figure is a best effort estimation.  
 
The assumption of 2% is mainly based on experiences and estimations from other 
jurisdictions. All policy areas are expected to make a contribution to the overall consumption 
drop, albeit not to the same degree. The main contributions are expected from the policy areas 
on packaging and ingredients which are mutually reinforcing.  
 
Several independent studies have assessed and attempted to quantify the impacts of 
packaging and labelling measures. Practically all reached the conclusion that such measures 
impact on the awareness of consumers, which over time changes also smoking behaviour but 
there was some divergence as to the exact level. The prevalence of adult smoking in Canada 
has declined approximately 6% since the implementation of large pictorial warnings in 2001, 
which is at least partially attributable to the picture warnings.387 Another study prepared for 
Health Canada assessing a set of policy measures on labelling similar to the ones proposed in 
option 1 under packaging and labelling estimated a rather small reduction of 0.3 percent to 0.8 
percent in the number of smokers within ten years.388 Assuming uniform quit rates across 
smokers with different consumption levels this corresponds to a comparable drop in 
consumption of about 0.3-0.8% resulting from those quitting.389 It should be emphasized that 
at the time of the Canadian assessment picture-based warnings were already in use which 
could limit the additional impact to be expected. A cost-benefit analysis prepared for the 
Australian Government estimated that introducing pictorial warnings covering 50% of the 
front and back of the packets would result in a 1.3% decline in smoking prevalence rate per 
annum (12.3% decrease in 10 years) and a 3% decrease in tobacco consumption per capita per 
annum (26.3% decrease in 10 years).390 The UK Department of Health’s impact assessment 
(2007) estimated that the introduction of pictorial warnings would result in a 0.5% decrease in 
smoking prevalence in the long term compared to 0.05 percent decrease in consumption if the 
status quo (text warnings only) were maintained.391 Finally, a more recent US impact 
assessment estimated the reduction in smoking prevalence as a result of introducing nine 
pictorial warnings, occupying 50% of both display areas, including a mandatory reference to a 
toll-free quitline.392 The reduction in the US smoking population in 2013 was estimated at 
213,000 persons (corresponding to a prevalence reduction of 0.45%), with small subsequent 
effects.  
 
                                                 
387 Health Canada. Canadian Tobacco Use  Monitoring Survey (CTUMS). Ottowa: Health Canada; 2008. 
www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/ctums-esutc_2008-eng.php (accessed 06 Nov 2012) 
as referenced in Hammond D. Health warning messages on tobacco products: a review. Tob Control 2011; 
20:327-3. 
388 Industrial Economics Incorporated (IEc). Economic evaluation of Health Canada’s proposal to amend the 
tobacco product information regulations: Final report. Cambridge, MA: IEc;  2009. (Report for Health Canada). 
389 As a result of the measures proposed, an additional reduction in consumption levels can also be expected for 
those who keep smoking 
390 Applied Economics. Cost-benefit analysis of proposed new health warnings on tobacco products. Canberra: 
Applied Economics; 2003. (Report prepared for the Commonwealth Department of Health and Ageing, 
Australia) 
391 UK Department of Health (UK DoH). The Introduction of Picture Warnings on Tobacco Packs – Final 
Regulatory Impact Assessment. London: UK DoH; 2007. 
392 US Dept. of Health and Human Services. Required Warnings for Cigarette Packages and Advertisements. 
2011 Federal Register Vol. 76, 22 June 2011/Rules and Regulations, pp.36628-36777.  
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In its opinion from 2010, SCENIHR concluded that the use of fruit and candy flavours seems 
to favour smoking initiation in young people and that some additives decrease the harshness 
and increase the smoothness of the smoke.393 The US FDA Tobacco Products Scientific 
Advisory Committee confirmed, on the basis of the extensive review of all available 
information, that the evidence was sufficient to conclude that it is more likely than not that the 
availability of menthol FMC increases the likelihood of experimentation and regular smoking 
beyond the anticipated prevalence if such FMC were not available.394  
 
The contribution to the reduced smoking prevalence from policy area “STP and extension of 
the product scope” is primarily expected to result from the possibility that e-cigarettes can 
develop a potential as a smoking cessation aid under the preferred option.  
 
Also the measures in the policy areas dealing with cross-border distance sales395 and 
traceability & security features are expected to contribute to a drop in consumption, in 
particular in the illicit segment of the market. Part of this demand will return to the legal 
supply chain, which is however more expensive and therefore it is expected to encourage 
some consumers not to start smoking/stop smoking or smoke less, in particular in parts of 
society with lower revenues such as young people. Also, consumers are better informed by 
the health risks of tobacco products fully compatible with the TPD.  
Figure 14 provides a tentative break-down of the contributions of individual policy areas. 
More information is provided in Annex 5. While 2% is estimated reasonable, it needs to be 
underlined that even a lower drop in consumption remains beneficial from a macro-economic 
and Governmental/societal perspective (see section 6.2.4 and Annex 5). It needs also to be 
stressed that conclusive empirical data is lacking for some of the measures, including NCP 
(where no electronic cigarettes have been authorised, at this stage, under the medicinal 








Figure 14: Tentative contributions of individual policy areas to the projected decrease of 
 cigarette/RYO consumption 





Packaging & Labelling 1-1.5 
Ingredients 0.5-0.8 
                                                 
393 SCENIHR 2010. 
394 Tobacco Products Scientific Advisory Committee (TPSAC). Menthol Cigarettes and Public Health: Review 
of the Scientific Evidence and Recommendations.  Rockville, MD: US Food and Drug Administration; 2011. 
395 In an experimental Californian study from 2004 96.7% of participating minors were successful in finding and 
ordering tobacco on the internet. Jensen JA, Hickman NJ 3rd, Landrine H, Klonoff EA. Availability of tobacco 
to youth via the Internet. JAMA 2004; 291(15):1837. 
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TOTAL   1.7-2.6% 
Cross-border distance sales + Illicit 
trade 
Additional decrease of consumption, 
however not in the legal supply chain. 
(Decreases in illicit consumption could 
mitigate the decrease in the legal chain). 
 
In addition to the predicted drop in smoking prevalence, the preferred options are also likely 
to result in reduced uptake of STP and herbal products for smoking. In particularly, it is 
expected that STP use will remain limited to specific population groups already using these 
products and that recruitment of new users will become more difficult. However, it is difficult 
to quantify this effect, also in the light of increased use of smoke-free environments.   
1.1.32. Economic Stakeholders 
For the tobacco industry (the manufacturers of FMC and RYO) a reduction of consumption 
in the range of 2% within five years would mean that their revenues would decrease by 376 
mEUR per annum. This figure is a “worst case scenario” for the industry, as it does not take 
into account the effects of the policy options developed in policy areas 4 and 5, which have 
the effect that certain sales in the illicit supply channel return to the legal supply chain. In 
terms of employment, the reduction of consumption is also expected to reduce the work force 
of the tobacco industry. Based on the input output model explained in Annex 5 the reduction 
is expected to amount to 1500 employees. On the other hand it should be noted that money 
not spent on tobacco products will be spent on other goods and services. In this respect the 
“input-output model” used for the purpose of the impact assessment indicates net gains in 
employment of around 2,200.396 Industries that are most likely to benefit are food/beverage, 
textiles manufacture and the service sector. 
 
 
Annex 5 also presents what a reduction of tobacco consumption would mean for the 
upstream suppliers (e.g. growers, ingredients suppliers, paper industry) and downstream 
distributors (wholesale, retail). Overall the impacts associated with the reduction in 
consumption do not seem to be of a significant nature, as the economic stakeholders typically 
sell other products (e.g. package industry makes only around 10% of its turnover with the 
tobacco industry) or generate a significant part of their turnover with export sales outside the 
EU which would not be affected. Even the impact on specialised retailers does not seem to be 
significant as – according to the EU association of the retailers (CEDT) – these specialised 
shops nowadays generate about half of their turnover with non-tobacco products. The impact 
on the revenues for tobacco growers would mean an annual reduction in income of 158 EUR 
per farmer, which would however, not affect all farmers alike. Rather it is expected in line 
with previous trends (discontinuation of direct subsidies) that certain farmers will discontinue 
their activities irrespective of the TPD revision.   
1.1.33. Governments/society  
The main socioeconomic impact for Governments/society – associated with a reduction of 
tobacco consumption - is the improvement of public health. Non-smokers live longer and 
benefit from more healthy life years. It has been estimated that smokers who die as a result 
of their tobacco consumption pass away 14 years earlier than people who never-smoked (see 
Annex 5, 5.2.3.1.1). A reduction of consumption of 2% corresponds to 2,4 million smokers 
                                                 
396 Yurekli A, de Beyer J (eds). Understand and Evaluate the Impact of Tobacco Control Policies on 
Employment. Washington, DC: World Bank; 1999. 
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stopping the behaviour and 16.8 million life-years (not quality adjusted) gained.397 The gain 
of (healthy) lifeyears is a value in its own right and of greatest importance for the persons 
concerned as well as their families. On the basis of the impact guidelines it is possible to 
monetise the gain in public health.398 In this light, a reduction of the tobacco consumption by 
2 % would correspond to a benefit for society of 10.3 bEUR annually. 
 
In addition, a reduction of tobacco consumption will reduce health care expenditure by 506 
mEUR annually. Also society would benefit from a reduction of productivity losses (less 
absenteeism and premature retirements) in the region of 165 mEUR annually (see Annex 5). 
As explained these are conservative estimates as other studies report about significantly larger 
cost savings for health care and gains in productivity.  
 
Another impact for Governments would be that they are confronted with a risk of reduced tax 
revenues by 1.6 bEUR annually because of reduced consumption. It is important to note from 
a macro-economic perspective the reduction of taxes is not a cost, but only a question of 
allocations within society (State/companies).  It also needs to be taken into account that the 
reduction of taxes is an unlikely "worst case scenario". The figures do not yet take into 
consideration the positive effects of the policy options developed in policy areas 4 and 5 
which would increase Governments' tax revenues. Additionally, a reduction of tobacco 
consumption does not necessarily lead to lower tax incomes as tax rates can be increased (like 
in the past). As a matter of fact despite decrease of tobacco consumption since 2000 tax 
revenues for Member States increased very significantly in the same period. In addition, 
money not spent on tobacco would be spent on other sectors also benefitting the Governments 
in terms of taxes.  
 
In summary it can thus be concluded that the impact of reduced tobacco consumption would 
lead to overall benefits of 9.4 bEUR per annum. The calculation is based on present values 
and thus in principle expressed in current prices.  
 
Social discounting399 allows comparison of benefits and costs that occur at different times 
based on the rate at which society is willing to make such trade-offs. This is also relevant in 
the case of tobacco control as some of the expected benefits will only develop over time 
whilst certain impacts (e.g. on tax revenues) would materialise earlier. Different scenarios for 
social discounting have been developed in Annex 5 (5.2.3.4). Under the most likely scenario 
(i.e. when decrease in tax revenues and health care/absenteeism savings materialise in the 
period of 5 years, while on average the benefits from reduced premature mortality accrue only 
in 25 years), the annual net benefit of a reduction in tobacco consumption by 2 % would be 4 
bEUR. 
 
Figure 15 provides a breakdown of the overall net costs and benefits (including discounted 
values).  
Figure 15: Overall net costs and benefits (mEUR) 
Different percentage reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
                                                 
397 Population over 15 is covered by EB - according to Eurostat this is 431 million adult citizens. 28% percent of 
them, thus 120.8 million are smokers. 2% of those correspond to 2.426 million smokers. Assuming than 7 years 
are gained per smoker (14 years /2 prematurely dying), this result in 16.8 million lifeyears (not quality adjusted). 
398 European Commission. Impact Assessment guidelines. Brussels: European Commission; 2009.  
http://ec.europa.eu/governance/impact/commission_guidelines/docs/iag_2009_en.pdf (accessed 28 Nov 2012). 
399 Social discounting renders benefits and costs that occur in different time periods comparable by expressing 
their values in present terms based on the rate at which society is willing to make such trade-offs. 
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Decrease in excise tax revenues400 794 1588 2382 3176 3970
Decrease in health care expenditures  253 506 759 1012 1265
Decrease of productivity loss  83 165 248 331 413
     - due to early retirement / deaths 61 122 183 244 305
     - due to absenteeism 22 43 65 87 108
Decrease in premature mortality costs  5,167 10,334 15,501 20,669 25,836
Overall net benefit 4,709 9,417 14,126 18,836 23,544
Discounted values 2,016 4,032 6,048 8,064 10,080
 
The preferred options would have a significant positive impact on public health. For 
example, the current targeting of young people with specifically developed products like 
candy-flavoured FMC and attractive packages would be removed, young people's access to 
tobacco would be further restricted and improved health warnings would improve all citizens’ 
possibilities to make informed decisions. In addition, due to the foreseen reduction in illicit 
trade smokers would benefit more from the protective rules set up by TPD (e.g. health 
warnings and ingredients control).  
6. OVERALL CONCLUSION OF THE IMPACT ASSESSMENT 
6.1. COMPARING THE OPTIONS AND THE PREFERRED OPTIONS 
Following the conclusions in the previous sections, the table below gives an overview of the 
policy options as well as justifications for choosing the preferred options (which are marked 







2 3 4 
 
Justification 
1a. STP Lift the ban on 
oral tobacco and 









products to  
notification 
obligation 






ban on oral 
tobacco, 
restrict the 
sale of other 
STP to areas 
of traditional 
use only and 
subject all 






Ban all STP 
with the 
exception of 
oral tobacco in 
Sweden. Subject 




regulation.   
-achievement of policy 
objectives/considerations: B1, C2, 
C4 and partly A1, A2 and C1. 
-harmonised labelling and 
ingredients regulation for all STP.  
-facilitated level playing field. 
-proportionate  to prevent the 
introduction / expansion of new 
addictive, harmful products in the 
internal market  
-health concerns with all STP  
-no evidence that STP leads to 
smoking cessation, risk of entry 
gate and dual use 
-risk for market development 
(ingredients and smoke-free 
environments)  
-Trade-off/ impact on SME justified 
due to health risks associated with 
product development, marketing 
and expansion to new user groups. 
Option 3 and 4 would have more 
positive impact on health, but 
option 2 was considered more 
proportionate after a cost/benefit 
balance.   
                                                 
400 Disregarding measures taken against illicit trade and possibility to increase tax levels. 
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Subject all NCP 
to  the medicinal 
products' 
legislation 
-achievement of policy 
objectives/considerations: A1, A2, 
B2, C1, C2, C4 
-clear and well established legal 
framework for risk/benefit analysis 
facilitating the free circulation of 
duly authorised products, in 
conformity with their nature 
-possibility of mutual recognition 
within the internal market.  
-same treatment of NCP and NRT.  
-harmonised approach, 
consolidating trend in MS 
-minimum safety standard 
-potential in smoking cessation 
-Trade-off: additional burden for 
application justified by the setting 
up of a harmonised safety net with 















Subject all herbal products for 
smoking to labelling 
requirements under TPD 
Phase out marketing of herbal 
products for smoking 
-achievement of policy 
objectives/considerations: A2, A3, 
C4 and partly B1, C1  
-facilitates the free circulation of 
products 
-remove current misperception on 
health 
Trade-off: Removes misperceptions 















Option 1 plus 
harmonise certain 






Option 2 plus full 
plain packaging   
-achievement of policy 
objectives/considerations A3, B1, 
C2, C4 
-removes disparities on internal 
market and facilitates free 
circulation 
-improves awareness and removes 
misleading elements 
-in line with FCTC commitments 
-proportionate: focus on smoking 
initiation, products attractive for 
young people 
-takes into account economic 
stakeholders’ concerns (e.g. no 
plain packaging/interference with 
trademarks) 
-allows awaiting international and 
scientific developments 
-allows Member States to adopt 
plain packaging  to comply with 
FCTC guidelines as far as it is 
compatible with the Treaty 
-Trade-off: Option 3 more effective 
from health point of view, but  






format on a voluntary 
basis. Prohibit toxic, 
addictiveness and 











in harmonised format. 
Prohibit all additives 
not essential for 
manufacturing.   
-achievement of policy 
objectives/considerations: A3, B1, 
B2, C1, C2 
-removes disparities on the internal 
market and facilitates free 
circulation 
-reduces administrative burden 
(reporting) 
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and addictiveness. -in line with FCTC 
obligations/commitments 
-proportionate: focus on smoking 
initiation, products attractive for 
young 
-takes into account stakeholders 
concerns, including growers (no 
discrimination of Burley/Oriental) 
-Trade-off: Focus on smoking 
initiation while minimising costs 
for economic stakeholders. Option 
3 would have been more effective 













Notification and age verification 
system  
Prohibit cross-border distance sale 
of tobacco products 
-achievement of policy 
objectives/considerations: A2, B2, 
C5, C6 
-ensures that safeguards of the TPD 
are respected 
-facilitates legal activities (retail) 
-limited economic impact on legal 
activity 
-Trade-off: Option 2 would have 
been more effective from a health 








EU tracking and tracing system Tracking and tracing system, 
complemented by security 
features  
-achievement of policy 
objectives/considerations: A2, B2, 
C3, C5, C6 
-ensures that safeguards of the TPD 
are respected 
-level playing field (small-big 
industry) 
-costs compensated by savings 
following shift from illegal to legal 
trade 
-addresses economic stakeholders’ 
concerns regarding illicit trade 
Trade-off: Costs for industry are 
outweighed by benefits from 
reduced illicit trade. 
 
 
In terms of effectiveness, the combined preferred options contribute to the overall objective 
of the revision of the TPD to guarantee a proper functioning of the internal market while 
ensuring a high level of public health. As illustrated below, the preferred options are also well 
in line with the objectives and considerations identified in section 3.  
 
As far as the main objective (internal market) is concerned, the options: 
• facilitate the free movement of goods in the internal market by removing existing or 
expected discrepancies between national legislations and/or,  
• adapt the level of harmonisation in the current TPD to a new level warranted by 
scientific development or international obligations/commitments and /or, 
• ensure that the safeguards of the TPD are not undermined by illicit products or by 
cross-border sales not respecting these safeguards. 
 
As far as health considerations are concerned, the envisaged revision focuses on discouraging 
young people from taking up tobacco consumption and allowing adult consumers to take 
informed decisions. The revision also allows smokers to benefit from the protective measures 
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set by the TPD. In instances where new products aim at exploiting smoke-free policies, this is 
also tackled.  
 
The combined preferred options would allow/facilitate Member States/EU to fulfil their 
commitments/obligations in the context of FCTC. In many policy areas (herbal products for 
smoking, packaging & labelling, ingredients, and cross-border distance sales) a stricter 
option than the one identified as preferred option would have been more beneficial for health. 
However, the overall assessment of all applicable assessment criteria, including impact on 
economic stakeholders, has led to the conclusion that a less strict measure was more 
appropriate (see table above).  
 
There are also important synergies between individual options increasing the overall 
effectiveness of the “preferred options package”. For example, prohibiting tobacco products 
with characterising flavours is reinforced by the removal of misleading and promotional 
elements on the labelling and the obligation to notify cross-border distance sale will reinforce 
the reduction of illicit trade expected from the measure on traceability and security features.  
 
The combined preferred options are cost-efficient in the sense that they are expected to result 
in overall socio economic benefits for society. For economic stakeholders the preferred 
options are foreseen to lead to reduced direct (compliance) costs which, however, can be 
outweighed by lost revenues due to a decrease in consumption. The overall impacts of the 
preferred options are further described in the next section, 6.2.  
 
The identified options constitute a coherent approach consistent with international 
commitments and fundamental rights and values as well as the overall aim of the EU to 
promote well-being of its people (Article 3 TEU). The combined options contribute to the 
Europe 2020 strategy in the sense that keeping people healthy longer will have positive 
impact on productivity and competitiveness.  
 
A proper stakeholder consultation has been carried out throughout the impact assessment 
process (section 1.3) and the comments from various stakeholders have been considered 
carefully. The next section (section 6.2) describes further the overall impact on key 
stakeholders.  
 
6.2. OVERALL IMPACTS OF THE PREFERRED OPTIONS  
1.1.34. Internal market 
As explained, it is expected that the combined preferred options would improve the 
functioning of the internal market by removing current disparities in national legislation, 
ensure homogenous development and facilitate the creation of a level playing field among 
economic actors. In contrast to the baseline scenario, the preferred options would also 
contribute to a consistent approach in the implementation of international commitments 
(FCTC).  
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1.1.35. Economic stakeholders 
6.2.1.1. FMC and RYO manufacturers 
The impacts on FMC and RYO manufacturers consists of the direct impact from complying 
with the preferred options (direct effects) and indirect impacts following an expected decrease 
in consumption.  
 
The direct impact on FMC and RYO manufacturers is expected, to be positive compared 
to the baseline scenario. The benefits stem in particular from reduced one-off costs 
associated with familiarisation (all product related areas) and redesign/reformulation 
(labelling and ingredients) as well as acquisition of new equipment (tracking and tracing). 
With respect to the variable costs it is assumed that no noteworthy additional costs are 
expected. To the contrary in certain areas such as traceability and security features, cost 
savings are expected. In any event additional costs are likely to be passed on to consumers 
taking into account the significant market power of the tobacco manufacturers.401 Higher 
revenues are also expected for FMC/RYO manufacturers as a result of the measures against 
illicit trade. While a precise quantification is not possible, the table below describes the 




Preferred option Baseline scenario 
 One-off costs  -Economic stakeholders only have to get familiar 
with one legal system, implemented within a 
limited time frame.  
 
-Economic stakeholders have to undertake one 
redesign/reformulation only adapted to the 
markets of all Member States.   
 
-Some economy of scale is/can be achieved when 
acquiring of new equipment due to harmonisation. 
 
-Disposal of old stocks. This cost can normally be 
disregarded taking into account transposition and 
transitional periods. 
 
Packaging and labelling:  
FMC: 14,500-50,000 EUR per SKU 
RYO: 2,500-9,000 EUR per SKU    
 
Ingredients:  
Product redesign: 1mEUR per brand 
 
Tracking and tracing: 
Indicative costs for carton level tracking and 
tracing:  
Printing machine master case: 5,000-20,000 EUR 
per machine 
Printing machine carton: 10,000-35,000 EUR per 
machine 
Carton coding system: 10,000-35,000 EUR 
Carton tracking system: 30,000-50,000 EUR 
Hardware: 10,000-30,000 EUR 
IT infrastructure: 10,000-150,000 EUR 
Hosting and maintenance: 50,000-150,000 EUR 
-Economic stakeholders need to monitor 27 
different legal systems and get familiar with 
all unilateral changes adopted by Member 
States.  This can also include seeking legal 
advice.  
 
-Economic stakeholders need to adapt to 
subsequent unilateral changes adopted by 
Member States. This also includes testing 
and legal/marketing/scientific advice. 
Stakeholders also have to adapt production 
lines to comply with different national 
legislations. 
 
-Economic stakeholders might have to buy 
new equipment to comply with national 
measures.  
-Disposal of old stocks. This cost can 
normally be disregarded provided sufficient 
transitional periods are granted. 
 
The cost estimates provided for the 
preferred option would be higher under the 
baseline scenario due to multiple and 
consecutive adaptations to national systems 
under the baseline scenario.    
                                                 
401 In the latest Eurobarometer 2012 consumers stated that they are ready to accept price increases to fight 
against illicit trade.  
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Variable/on-going 
costs 
Proportionate to the volume of products affected, 
which means that costs can be slightly higher or 
lower than in the baseline scenario. However, it is 
likely that these on-going costs would be passed 
on to subsequent level of trade. 
 
Packaging and labelling402:  
59-68 mEU per year for combined warnings 
 
Ingredients:  
Depends on ingredients used after reformulation. 
 
Security Feature: 
e.g.Hologram: 150 mEUR per year 
Economic stakeholders might have to 
change the types and quantities of material 
to be used in the manufacturing process. 
This could be either a cost (e.g. more 
expensive ink) or a saving (e.g. less 
ingredients to be used) and is proportionate 
to the volume of sale. 
 
On the other hand, the indirect impacts following from an expected decrease in 
consumption will over time lead to a loss of revenue for the FMC and RYO manufacturers 
of 376 mEUR ("worst case scenario" as the benefits from reduced illicit trade are not 
considered in this figure). This negative impact on FMC and RYO manufacturer might 
outweigh the benefits from the cost savings referred to above. However, money not spent on 
tobacco is expected to be spent on other sectors which would then benefit. 
6.2.1.2. Upstream suppliers 
Growers would only be affected indirectly by the reduction of smoking and the annual 
reduction in the farmers’ income has been estimated to amount to 158 EUR per farmer. 
However, as explained under section 5.7.1, it is expected in line with previous trends 
(discontinuation of direct subsidies) that certain farmers will discontinue their activities 
irrespective of the TPD revision.  The preferred options would not discriminate between 
growers of different tobacco types (Oriental, Burley, Virginia).    
 
Similarly to the FMC and RYO manufacturers, the packaging and labelling industry is 
expected to benefit from the “one go” solution at EU level compared to multiple adaptations 
under the baseline scenario. The industry reported to have carried out the main investments 
already. On the other hand, a negative impact on revenues of around 18.2 mEUR is estimated 
following the reduced tobacco consumption. This represents 0.2% of the total sector turnover 
taking into account that the packaging and labelling industry only generates 10% of its 
turnover with the tobacco industry. A similar reasoning applies to producers of additives 
and flavours. 
6.2.1.3. Downstream sectors and other industries 
Wholesalers are primarily affected indirectly by the reduction in tobacco consumption 
resulting in reduced revenues of around 465 mEUR403 and by compliance with the tracking 
and tracing system (no cost estimate available). This needs to be counterbalanced, however, 
with the increased revenues stemming from reduced illicit trade benefitting wholesalers. The 
introduction of EU tracking and tracing systems will call for some technical adjustments in 
warehouses, but the costs for the equipment should normally be limited as they should be 
borne by the tobacco industry, which is under the obligation to introduce the tracking and 
tracing system. The introduction of a common EU wide system is beneficial for the 
wholesalers, as one system takes less space and is easier to handle for its staff.  
 
                                                 
402 As pointed out in sections 5.3.1, the cost increases reported by industry seem exaggerated. 
403 Obviously, the wholesalers would have reduced purchasing costs in the region of 376 mEUR. 
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Retailers are in a similar situation as wholesalers regarding the indirect impacts. The 
measures on tracking and tracing and security features are not expected to lead to additional 
costs for retailers as retailers are not part of the tracking and tracing system. As even 
specialised tobacco retailers generate only up to 50% of their revenues from tobacco products 
(dependence of other retailers on tobacco products, e.g. supermarkets, is even lower), the 
impact is not expected to be disproportionate.  
 
A variety of other industries are expected to benefit from certain of the preferred policy 
options, e.g. companies developing tracking and tracing systems or security features.   
6.2.1.4. Small and medium sized enterprises (SMEs) 
The particular situation of micro-enterprises and SMEs has been taken into account when 
identifying the preferred option. The preferred policy options are primarily targeting FMC, 
RYO and STP. Pipe tobacco and cigars which are often manufactured by SMEs are not 
affected, in the first stage, in most policy areas. As referred to above, the impact on growers is 
limited. The impact on retailers is also expected to be limited as referred to above, in 
particular since the policy area/option of restricting display of tobacco at point of sale was 
discarded (see section 4.1). Products other than FMC and RYO which will be included in the 
tracking, tracing and security regime will be granted an additional transitional period which 
will benefit primarily SMEs. 
1.1.36. Employment 
In terms of employment it is estimated that jobs lost in tobacco will be off-set by jobs gained 
in other sectors (input/output model), as money not spent on tobacco is spent on other 
goods/services. This will be a gradual process as tobacco consumption is expected to decrease 
over time (2% in five years). The input/output model suggests that a 2% reduction of tobacco 
consumption would lead to a net gain in employment of 2,235 employees in the EU taking 
into account that tobacco is not a labour intensive industry whilst a number of the sectors 
benefitting from the redistribution are (e.g. hospitality sector). Possible regional employment 
impacts, as well as the specific situations of SMEs and micro-enterprises, have been carefully 
considered when formulating the preferred options. Obviously it cannot be excluded that 
some tobacco manufacturers will use the TPD revision as a welcome excuse to further 
automate production/concentration and would therefore lead to factory closure. On the other 
hand, keeping people healthy and active for longer has a positive impact on the productivity 
and competitiveness in general and is an integral part of Europe 2020 strategy. In the light of 
an ageing population in the EU it also appears important to assist young people staying 
healthy.   
1.1.37. Governments/Society 
The main benefit for Governments is the improvement of health which is a value in its own 
right. The preferred options are expected to result in a 2% drop in consumption within a five 
year period, corresponding to 2.4 million smokers. The expected socio-economic benefits 
(reduction of health care costs, productivity losses and monetised life years saved) represents 
an annual amount to the EU of 9.4 bEUR (see section 5.7) even if one deducts reduced tax 
revenues. A somewhat lower figure would be achieved if discounting is applied. 
The preferred options are also associated with a number of administrative costs for national 
authorities. With respect to the measures envisaged in the scope section (STP, NCP and 
herbal products for smoking), a limited additional burden is expected when assessing NCP 
under the medicinal products' framework, however in a well-established legal framework and 
against fees. For labelling, no major impact is expected for Governments, possibly with one 
exception, namely that additional resources might be needed for cessation services. Regarding 
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ingredients reporting, costs savings associated with the improved reporting system and 
additional revenues in terms of fees from the industry are expected. Regarding ingredients 
regulation some investment might be needed to develop further – in conjunction with the 
Commission – the concept of attractiveness. Regarding cross-border distance sales the 
notification system would lead to very limited additional costs, but will also facilitate law 
enforcement. Also regarding traceability and security features, the main direct impact is on 
law enforcement, but overall it is assumed that law enforcement is facilitated/simplified by 
the proposed measures, i.e. the costs for Governments should be reduced. 
 
7. MONITORING AND EVALUATION 
The successful implementation of the revised TPD will depend on several factors: 
Transposition of the Directive 
Member States need to transpose the revised TPD correctly and in time. The European 
Commission should assist Member States in this exercise through meetings where Member 
States report about transposition progress and can discuss problems and seek clarifications. 
Member States should also be encouraged to communicate their draft transposition measures 
to the Commission.  
 
An implementation plan will be developed to ensure effective implementation of the 
Directive.  
Indicators  
A key indicator for achievement of the objectives outlined in this impact assessment is the 
implementation by Member States, infringement cases launched and the number of 
complaints. 
 
In addition, the following indicators will be monitored on a regular basis 
- the smoking consumption and prevalence in the EU, including smoking uptake in young 
people 
- the awareness of the harmful effects of tobacco 
- the number of novel tobacco, nicotine and niche products as reported by Member States 
- the frequency of use of quit lines/cessation services 
- the number of electronic cigarettes authorised as medicinal products 
- the consumption of herbal products for smoking 
- the number of seizures of illegal tobacco products reported by Member States 
- the level of additives used in marketed products and their variations between Member States 
- the number of cross-border distance sale notifications. 
Consultation and reporting  
A network of Member States will provide a regular platform to discuss issues related to the 
implementation of the Directive.  
 
The Commission should report to the European Parliament and the Council about the 
implementation of the revised TPD five years after transposition. The report should address 
the impact of the new rules in respect of the internal market, public health and international 
developments. In particular, the Commission should report on international, legal and 
scientific developments in terms of labelling and packaging as well as on novel tobacco 
products and, if appropriate, provide suggestions for further EU action in this area.  
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A.1 OUTCOME OF CONSULTATIONS AND STAKEHOLDERS' OPINIONS 
 
This annex summarises the comments and opinions expressed by stakeholders in the context 
of the revision of the Tobacco Products Directive. The first part of the annex refers to 
comments and opinions expressed by stakeholders in targeted discussions throughout the 
process. The second part contains a summary of the public consultation organised between 
September and December 2010.  The third part of the annex presents a more detailed picture 
of citizens' attitudes towards tobacco control measures, as published in the latest 
Eurobarometer survey on "Attitudes of Europeans towards Tobacco."1 
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A.1.1. SUMMARY OF STAKEHOLDERS' POSITIONS IN THE CONTEXT OF TARGETED 
STAKEHOLDER CONSULTATIONS ON THE REVISION OF THE TOBACCO PRODUCTS 
DIRECTIVE 
A.1.1.1. Health NGOs 
General 
• Concerns were expressed regarding some of the data and estimates presented by the 
external contractor RAND Europe in its study assessing the impacts of revising the 
Tobacco Products Directive. Health NGOs claimed that the health impacts and health 
costs of various policy options were underestimated and that industry costs were 
overestimated. The assumption made by the contractor that smoking prevalence would 
decline without further intervention was questioned. It was also expressed that tobacco 
companies are already reducing employment through efficiency savings. The 
"transferable" nature of tobacco tax revenue and employment should also have been 
recognised. Money not spent on tobacco would be spent on something else.   
Smokeless tobacco products (STP), Nicotine Containing Products (NCP) and herbal 
products for smoking  
• Health NGOs expressed support for keeping or even extending the current ban on oral 
tobacco and argued that oral tobacco cannot be seen as a rational substitute to 
cigarettes.  
• Health NGOs expressed concerns that many of the NCP, in particular electronic 
cigarettes, are not subject to any specific safety rules and argued that they should be 
regulated similarly to pharmaceuticals. 
• Health NGOs were in favour of including herbal products for smoking in the scope of 
the TPD. 
• The European Respiratory Society (ERS) is opposed to the use of all (tobacco and) 
unapproved nicotine delivery products, including electronic cigarettes.1 
Labelling 
• It was concluded that plain packaging and pictorial warnings reduce the attractiveness 
of tobacco.  
• It was argued that plain packaging would not increase illicit trade.  
• It was suggested that the costs for plain packaging estimated by the external evaluator 
(RAND Europe) were overestimated.  
• The importance of a quit-line number placed on the cigarette packages was 
emphasised.  
• It was mentioned that there is a difference in the extent of knowledge between 
Member States regarding the harmful effects of tobacco consumption and that 
information should be equally provided within the EU. 
• Health NGOs expressed support for mandatory pictorial health warnings of 80% on 
both sides of the packs.  
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Ingredients 
• Additives in cigarettes often transform tobacco smoke into an even more complex 
chemical mixture and thereby increase the carcinogenic and harmful effects of 
tobacco.  
• Too little is mentioned on how additives increase the attractiveness of tobacco 
products, in particular among young people. 
• Support was expressed for banning flavours and sweeteners which increase the 
palatability and make tobacco uptake more attractive among young people.    
Access to tobacco 
• It was pointed out that Internet-sales lead indirectly to advertising on the Internet. 
• It was concluded that the discussions regarding Internet sales raise questions of 
identification and enforcement as well as proportionality.  
• It was concluded that different rules apply among the Member States in this area. 
• Health NGOs argued that stricter regulations on tobacco vending machines, promotion 
and display of tobacco at point of sale and cross-border distance sale of tobacco were 
effective means for reducing tobacco consumption among young people. They 
emphasised, however, the importance of not losing what has already been achieved at 
national levels.    
A.1.1.2. Tobacco industry 
General 
• The study assessing the impact of revising the Tobacco Products Directive prepared 
by the external contractor RAND Europe was heavily criticised. The respondents 
claimed that the study does not sufficiently analyse the impacts on the functioning of 
the internal market, EU competence, subsidiarity, proportionality and legal basis. They 
also stressed that other vital elements such as illicit trade, intellectual property rights 
and competition aspects were missing. The effects on SMEs and growers should have 
been analysed further and the study does not provide enough scientific data. 
Respondents in this group also argued that the methodology of the study was weak, 
and the analysis poor. 
Oral tobacco 
• It was argued by some of the stakeholders in this group that the health statistics 
showing that Swedish men consume fewer cigarettes (even though they have the 
highest consumption of oral tobacco) and have a lower incidence of lung cancer 
compared to the overall EU population supports lifting the ban on oral tobacco. 
• Oral tobacco was presented as a substitute to cigarettes which could help smokers quit 
and it was argued that Swedish oral tobacco is less harmful than other smokeless 
tobacco products currently allowed on the EU market.   
• The current ban on oral tobacco was seen as discriminatory compared to other STP.  
• Some stakeholders within this group also referred to the negative economic 
consequences of the current ban on oral tobacco as well as the current unequal 
treatment of similar products. They also referred to the unfavourable position of the 
Aland Island.  
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Labelling 
• It was suggested, by respondents in this group, that the introduction of plain packaging 
would increase the amount of counterfeit goods. It would also reduce the possibilities 
to protect IP-rights and make it harder for consumers to make informed purchases. 
• It was stressed that there is no evidence that plain packaging would reduce the 
smoking prevalence.  




• Support was expressed for mandatory reporting on ingredients in a common format 
and the tobacco industry referred to commercially sensitive data and the importance of 
keeping this confidential.  
• It was argued that there is no scientific basis to regulate attractiveness of cigarettes as 
this was considered inherently subjective.  
Access to tobacco 
• In particular wholesalers and tobacco vending machine operators questioned the legal 
competence of the EU for regulating or banning tobacco vending machines. The same 
stakeholders also argued that an ID age verification system provided a good protection 
from underage purchasing.   
• Stakeholders from the tobacco industry also claimed that there is no evidence to 
justify a ban on tobacco display at point of sale.  
Cigars and pipe tobacco 
• Cigar manufacturers argued that cigars are mainly used by adult users and not by 
young people taking up smoking.  
• It was explained that most of the economic stakeholders involved in this business are 
SMEs.   
• Cigar manufacturers argued against stricter rules on labelling, ingredients and on 
display at points of sale.  
• Pipe tobacco manufacturers also stressed the need for a different treatment compared 
to cigarettes due to different production methods and consumer profiles. It was 
emphasised that pipes are not used by young people.  
A.1.1.3. Retailers 
• Tobacco retailers argued against a tobacco display ban at points of sale and stressed 
that such a ban would be very burdensome for retailers and have no effect on smoking 
prevalence. In particular it was indicated that many SMEs would be affected by such a 
regulation and that is would increase illicit trade.  
• Tobacco retailers also argued against plain packaging.  
• Concerning the issue of internet-sale, CEDT (European retailer association) has 
recognised that this activity should be regulated at the national level by each Member 
State, considering the negative impact on the sale network and its possibility of public 
health control.2 CEDT has also underlined that internet-sale would increase the risks 
for public health, since it is easier to bring non-genuine products onto the market 
                                                 
2 Correspondence of 12 March 2012. 
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while tobacco retailers ensure both a control on minors purchase and the actual 
collection and precise transfer of state revenues. 
A.1.1.4. Tobacco growers 
• The main concern of tobacco growers expressed throughout the revision process was 
in relation to ingredients, where they argued against a full ban. It was said that sugar 
and some other flavours are necessary for the manufacturing of certain varieties of 
tobacco (e.g. Burley and Oriental tobacco). 
• The tobacco growers also emphasised that a ban on ingredients would have important 
negative impacts on employment, in particular as a vast majority of growers have 
tobacco growing as their principal source of income and many live in poor and rural 
areas.   
A.1.1.5. Tobacco suppliers  
• The tobacco cartons manufacturers, fine paper industry and cellulose acetate industry 
expressed some concerns in relation to plain packaging and the risk for increased illicit 
trade.  
• The flavouring industry emphasised the need for basing the revision on science based 
criteria, rather than subjective concepts such as attractiveness.  
A.1.1.6. Electronic cigarettes Industry Trade (ECITA)3  
• ECITA argued that electronic cigarettes are neither pharmaceuticals nor tobacco 
products and that these products do not require further regulation. A self-regulation 
document has been established by ECITA to regulate electronic cigarettes.  
• ECITA stated that although they view existing regulations as sufficient, they are not 
always properly enforced. ECITA urged the European Commission to encourage 
stricter enforcement in Member States. 
A.1.1.7. Pharmaceutical industry 
General 
• It was stressed that it is very hard to assess the impact of switching from tobacco to 
nicotine products.  
• Production can drop quite a lot before there is an effect on employment. There are 
other factors which affect employment. 
Scope 
• Smoking addiction should be seen as a disease which should be treated with medicine 
(for example nicotine products).  
• It was suggested, by some respondents within this group, that non-tobacco nicotine 
products should be put more firmly into the medicinal area and consequently fall into 
the scope of pharmaceutical regulation.  
• Other respondents argued that all nicotine containing products, which are not 
otherwise regulated by EU food or pharmaceutical legislation, should be included in 
the scope of the EU Tobacco Products Directive. 
                                                 
3 Representing vendors of electronic cigarettes in the UK 
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Labelling  
• Health warnings are a good way to decrease smoking prevalence. 
• The regulatory procedures are very different for pharmaceuticals, this means it might 
be hard to compare. Control of packages is more rigorous in the pharmaceutical area.  
A.1.1.8. Tobacco vending machine manufacturers4 
• Stricter national regulations on tobacco vending machines (TVM) have affected 
different companies in different ways. Some companies were negatively affected by 
national TVM bans and their sales dropped, while others had anticipated the 
development and benefitted from new areas of activities, e.g. “ban-compliant” 
dispensers of tobacco.   
A.1.2. SUMMARY ON THE OUTCOME OF THE PUBLIC CONSULTATION ON A POSSIBLE 
REVISION ON THE TOBACCO PRODUCTS DIRECTIVE 
A.1.2.1. General 
The public consultation generated over 85 000 contributions. Citizen contributions accounted 
for 96% of the survey response. While it is encouraging to see such a large number of 
responses, it should be noted that this volume appears to be a result, to a large extent, of 
several citizen mobilisation campaigns that took place in some Member States. For example, a 
campaign was organised by a group representing over 75% of Italian Tobacconists. This 
action was followed by submissions of personal signatures by over 30,000 tobacconists across 
Italy.5  
 
The actions and efforts of these campaigns seem to have affected the overall results of the 
public consultation. This is illustrated by the significant number of pre-programmed 
“duplicate” responses which counted for 57% of all citizens’ responses.6 
 
The full report, including arguments used by respondents can be found on:  
http://ec.europa.eu/health/tobacco/docs/consultation_report_en.pdf 
A.1.2.2. Government representatives 
Scope 
A significant majority of Member States who submitted contributions to the public 
consultation were either in favour of extending the scope of the Directive or did not refer to 
the question in a detailed manner. Two EFTA States were also in favour of extending the 
scope of the Directive. A small number of respondents were in favour of either maintaining 
the status quo or extending the directive to all tobacco products, but not to tobacco-free 
nicotine products, ENDS (Electronic Nicotine Delivery Systems), or herbal cigarettes. 
 
                                                 
4 Interviews with four main manufacturers of tobacco vending machines in Europe carried out by the external 
contractor, Matrix insight. See Matrix Report 2012.   
5 European Voice, 10 February, 2011 
6 A response considered “duplicate” in the public consultation was a response fulfilling the following criteria: 1. 
At least six duplicate responses containing the same text. 2. Text box containing more than three words. 3. Text 
box not containing text directly copied from the consultation document.    
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As regards the future regulation of 'electronic cigarettes’ in tobacco legislation, Member 
States responding to the consultation seemed to be divided, with some presenting arguments 
for regulating the product as a pharmaceutical or medical device, and others arguing for the 
inclusion of electronic cigarettes in the Tobacco Products Directive. 
 
Reactions from MEPs, National Parliamentarians, and local/regional authority respondents 
were mixed.  
Smokeless tobacco 
The majority of Member States were in favour of banning all types of smokeless tobacco 
products, which was also the position of the two EFTA countries responding to the 
consultation. A very small number Member States proposed that the EU considers lifting the 
ban on snus. One Member State expressed a particularly strong interest in this. The main 
arguments for this solution came from the concerns about the harmful health effects of STP, 
STP as a gateway to FMC consumption and dual use. It was also argued that all STP need to 
be banned while these products still have relatively limited market shares as the supply of 
novel forms of STP is likely to increase.   
 
Very few MEPs provided a response to this question, and of those who did, the majority was 
in favour of keeping the existing ban on oral tobacco products. Most responses from National 
Parliamentarians, and local/regional authorities favoured lifting the current ban on snus 
products, while a small group of respondents were interested in extending the current ban to 
all smokeless tobacco products.  
Consumer information 
Almost half of the respondents among Member States supported the introduction of plain 
packaging alongside the other suggested recommended changes including mandatory pictorial 
warnings, but several indicated that plain packaging should be more carefully analysed. A 
small number of Member States were in favour of maintaining the existing regulations, noting 
a strong reservation against plain packaging. 
 
Overall, almost all Member States were in support of removing the tar, nicotine and carbon 
monoxide levels.  
 
MEPs, National Parliamentarians, and local/regional authority representatives responding to 
the consultation were split over this issue.  
Reporting on ingredients 
Member States were in favour of establishing a common compulsory reporting format for 
communicating ingredients information. A majority of them referred to the Electronic Model 
Tobacco Control (EMTOC), an application already used for this purpose in some Member 
States, as the basis on which such a system should be established. There were also proposals 
encouraging the Commission to consider a reporting system where tobacco industry would 
report directly to the Commission in order to enable the further development of European 
legislation in this field.  
 
Almost all responses from MEPs, National Parliamentarians and local/regional authorities 
were in favour of establishing a common compulsory reporting format.  
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Regulation of ingredients 
As a whole, a majority of Member States supported some sort of ingredients regulation, 
though when asked to select a specific policy option, Member States were less likely to 
provide a response. Some supported a positive common list of ingredients, while others 
supported the use of a negative common list of ingredients. Two EFTA countries supported 
the use of a negative common list of ingredients, insofar as it is not an exhaustive list.  
 
A few Member States expressed concerns about the EU’s ability to quantify the term 
‘attractiveness’. Others were against any change to the status quo. 
 
Most responses from MEPs, National Parliamentarians, and local/regional authority 
representatives were not in favour of introducing EU-level ingredients regulation.  
Access to tobacco 
Almost all Member States supported some form of increased tobacco control across the range 
of options, though the specific breakdown of options was quite varied. Most Member States 
supported a ban on internet sales or a ban on vending machines. About one fourth of Member 
States, and the two EFTA States were in favour of a wide ban in all three cases. Finally, a 
small number of Member States were in support of leaving these areas to Member State 
competence.  
 
Very few responses from MEPs, National Parliamentarians, and local/regional authority 
representatives were in favour of an outright ban on all three options i.e. internet sales, 
vending machines and retail displays.  
A.1.2.3. Non-governmental organisations 
Scope 
Public health organisations universally supported regulating tobacco and nicotine products. 
They also argued for the inclusion of herbal cigarettes into this framework.  
 
Smokeless tobacco 
Public health organisations emphatically maintained the ‘high priority’ status of the current 
ban on snus within the EU. It was also argued by some NGOs that other forms of smokeless 
tobacco products should be regulated but not necessarily banned, because many are only 
popular within specific ethnic groups.  
 
Smokers' rights groups pushed for lifting the ban on snus.  
Consumer information 
Public health organisations supported increasing the size of pictorial warnings to 80% of the 
pack, to regularly rotate warning messages to maintain the ‘freshness’ of each statement, and 
to include information on the packaging about a 'quit line' to help stop smoking.  
 
Additionally, public health organisations opted for plain packaging. 
 
Smokers' rights groups, argued against plain packaging and pictorial warnings.   
Reporting on ingredients 
For many stakeholder organisations, the solution was clear cut: the current situation which 
allows for different formats and reporting mechanisms is unsatisfactory. They argued that 
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tobacco companies should be required to use a standardised reporting format and pay a 
registration fee to cover the costs of administering the data collection.  
 
Smokers' rights groups argued that information on ingredients is already appropriately 
mandated by the Directive on an annual basis.  
Regulation on ingredients 
In general, public health organisations were in favour of establishing common ingredients 
lists. As an example they often referred to the Guidelines on Article 9 and 10 of the WHO 
FCTC, adopted by consensus at the Fourth Conference of the Parties in Uruguay on the 20th 
November 2010. 
 
While respondents were split over what type of list should be included, they almost 
universally supported that the main purpose of such a list should be to regulate flavours and 
ingredients that mainly enhance attractiveness, encourage youth initiation and discourage 
cessation. 
Access to tobacco 
Public health organisations were universally in favour of banning sales of tobacco via the 
internet, tobacco vending machines and display of tobacco at point of sales.   
 
Smokers' rights group were against changes in this area.  
A.1.2.4. Industry and tobacco growers  
Scope  
The tobacco industry representatives argued almost universally that a fundamental difference 
exists between products which use tobacco to deliver nicotine and those that do not. They 
claim that the Directive is aimed at regulating tobacco products, and no further regulation is 
needed for other products.  
 
The Pharmaceutical industry favoured regulation of nicotine products, some of them in the 
context of the pharmaceutical legislation and others by including them in the scope of the 
Tobacco Products Directive.   
Smokeless tobacco 
The great majority of respondents from the tobacco industry and EU tobacco growers were in 
favour of lifting the ban on smokeless tobacco (snus) across the EU.  
Consumer information 
According to tobacco industry representatives and EU tobacco growers, packaging and 
labelling does not affect or help predict the rates of youth uptake, and thus without a direct 
link, the basis for change is inaccurate.  
 
Representatives from the cigar industry cited additional challenges with the changes 
proposed, as many of these changes would impose an excessive financial burden on a 
relatively small industry.  
 
The pharmaceutical industry argued in favour of improving consumer information about 
smoking, especially smoking cessation services. They cited evidence suggesting that 
advertising quit lines and cessation services on tobacco packaging results in increased usage 
of these services in the short- and medium-term. Representatives also argued for mandatory 
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pictorial warnings and expressed support for the replacement of the tar, nicotine and carbon 
monoxide information on packaging. 
Reporting on ingredients 
The tobacco industry representatives and the flavouring industry seemed to be in favour of 
synthesising reporting standards.  
 
Other stakeholders, such as smokeless tobacco manufacturers, retailers and growers 
questioned the validity of this issue, as several organisations stated they were completely 
unaware of difficulties within the compliance processes.  
 
Several organisations raised concerns that common reporting standards could release 
information about trade secrets.  
 
The pharmaceutical sector advocated a common compulsory reporting format.   
Regulation of ingredients 
Across the tobacco industry, a significant amount of representatives did not support the 
establishment of a common list of ingredients. EU tobacco growers were particularly 
concerned that a general ban on ingredients would put EU blends at a disadvantage and have a 
devastating effect on employment. Burley organisations were particularly concerned over a 
possible ban on sugars. The flavouring industry and retailers also raised concerns about 
establishing a positive or negative ingredients list.  
 
On the contrary, the pharmaceutical industry pushed for regulation of ingredients through a 
positive common list of tobacco ingredients.  
Access to tobacco 
The tobacco industry, retailers and growers were against regulating or restricting tobacco 
vending machines, tobacco display at point of sales and internet sale of tobacco. Smokeless 
tobacco manufacturers raised particular concerns over restricting internet sales of tobacco.  
 
The pharmaceutical industry pushed for a ban on all three distribution channels.  
A.1.2.5. Citizens 
Scope 
A significant majority of respondents were against extending the scope of the Directive.  
Smokeless tobacco 
A vast majority, but not all, of respondents were in favour of lifting the ban on snus.  
Consumer information 
Most respondents were largely in favour of maintaining the status quo.   
Reporting on ingredients 
Respondents were generally in favour of establishing a common compulsory reporting format.  
Regulation of ingredients 
A significant majority of respondents disagreed with the regulation of ingredients at the EU 
level.  
Access to tobacco 
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A significant majority of respondents opposed limiting access to tobacco products and opted 
rather for more effective controls, such as age verification, in these channels of tobacco 
products. 




The Eurobarometer survey was carried out in all 27 Member States of the European Union in 
early 2012. 7 Face-to-face interviews were conducted with 26,751 respondents aged 15 and 
older. Citizens' were asked a number of questions related to tobacco consumption, including 
their support for various policy options considered in the revision of the Tobacco Products 
Directive. These figures were also compared to citizens' attitudes towards tobacco control 




EU citizens, including smokers, were largely and increasingly in favour of tobacco control 
measures. As shown in the figure below, the absolute majority of EU citizens were in favour 
of the policy options polled. 
 
Figure 1: European citizens' attitudes towards tobacco control policy measures9 
 
 
Source: Special Eurobarometer 385, May 2012 
 
                                                 
7 Special Eurobarometer 385, May 2012. 
8 Special Eurobarometer 332, May 2010.  
9 Eurobarometer 385, May 2012. 
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Three out of four citizens supported putting pictorial health warnings on all tobacco product 
packages (76% favourable). Over six in ten supported banning advertising at points of sale 
(64%) and almost six in ten supported keeping tobacco products out of sight in shops (58%). 
Roughly the same number believed that flavours that make tobacco products more attractive 
should be banned (63%). Slightly more than half of respondents were in favour of increasing 
taxes on tobacco products (53%), which made this the least popular policy option amongst 
citizens. In comparison to 2009, support for all policy measures, except increasing taxation, 
went up. 
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A.2.1. THE TOBACCO MARKET  
This annex provides an overview of the EU tobacco market including the main product 
categories. It sets out the value and volume of sales as well as manufacturing methods and 
consumption patterns. 
 
The second part of this annex describes in detail the production process and main tobacco 
production-related economic activities in Europe including farming, product manufacturing, 
distribution and sales. 
A.2.1.1. Tobacco products 
The total value of the EU Tobacco Market at retail level including taxes was 136.5 bEUR 
in 2010. The market consists of the five main tobacco products categories:1 
 
1. Factory manufactured cigarettes 
(FMC); 
2. Roll-your own tobacco (RYO) 
3. Pipe tobacco; 
4. Cigars and cigarillos 
5. Smokeless tobacco products (STP): 
oral, chewing and nasal tobacco.  
 
 
Figure 1: Comparison of relative market value of 
tobacco products in 2010 
 
Source: Euromonitor, and industry estimates 
 
The figure shows that FMC are by far the largest part of the market (almost 90%), followed 
by RYO (almost 7%). Nicotine containing products such as e-cigarettes are not part of the 
market tobacco markets. It is expected that in coming years a number of new tobacco 
products might be launched, which are allegedly less harmful.    
 
The sales trends from 2000 to 2010 for the five main product categories are set out in the table 
1. It can be observed that although volume has decreased in the ten year period between 2000 
and 2010 by 19%, there has been an increase in the revenues (including taxes) by 37%. This 




                                                 
1 This categorisation is in line with the Commission's merger practice. It is important to underline that the notion 
of a market in this impact assessment is not based on competition law terminology. Value includes excise tax 
and VAT. Merger cases: M4424, M4581, M5086. 
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Table 1: Market trends 2000-2010  
Value 2000 Value 2010 Change Vol. 2000 Vol. 2010 Change 
Category  




Cigarettes 90.7 121.3 +33.8 793.7 bs 608.8 bs  -23.3 
Roll-your-own 4.2 9.3 +123 53.1 tt 75.5 tt 42.2 
Pipe tobacco 0.576 0.48 -17 6.33 tt 4.03 tt -36 
Cigars/cigarillos2 4.62 4.65 +0.6 7.81 bs 9.92 bs 27 
Smokeless tobacco 3 0.48 0.83 +73 5.3 5.9 10 
Total4 100.6 136.6 +36    
 Source: Matrix,5 based on Euromonitor data 
A.2.1.1.1. Factory Manufactured Cigarettes 
For the year 2010, was the value of the market for FMCs, by far the most significant sector of 
the tobacco market in the EU, 121.3 billion EUR.6 As illustrated in figure 1, FMCs represent 
almost 90% of the market value and the last ten years have seen an increase of 34% in the 
overall market value of FMCs despite a decline of 23% in volume sales over the same period.  
Taxes accounted for most of the turnover, net value of the cigarette market at retail level was 
calculated at 28.3 bEUR (23% of the total retail value) as shown below. Government taxes on 
tobacco products serve two aims; they act as a source of revenue for governments and 
increasingly as a public health measure against smoking, as by definition they render tobacco 
products more expensive and thus less affordable. 
 
It is estimated that the margin of retailers and wholesalers accounts for approximately 40% of 
this amount, which means that the ex-factory revenues of the cigarette manufacturers 
amounted to 17 bEUR. These amounts do not capture illicit sales of cigarettes which 
according to Euromonitor represent more than 8% of the market. 
 
 Table 2: FMC revenue breakdown 
Pre-tax value 28.345 billion EUR 
Excise-tax 72.519 billion EUR 
VAT 20.400 billion EUR 
 Total 121.264 billion EUR 
  Source: Euromonitor, DG TAXUD, Matrix 2012 
 
Cigarettes containing the American blend, based on the combination of Virginia, Burley and 
Oriental tobacco varieties, continue to have the biggest share of the market compared to 
                                                 
2 This covers also the so-called "eco-cigarillos" exempted from the definitions for cigars and cigarillos through 
Directive 2010/12/EC on the structure and rates of excise duty applied on manufactured tobacco. 
3 The Euromonitor data on STP covers only a small number of countries: Sweden, Denmark, Slovenia and 
Germany. Sweden accounts for the most significant share of the STP market.  
4 Total does not include cigars and cigarillos taking into account that average tobacco content of cigars and 
cigarillos vary and nowadays more cigarillos are sold. For FMC is was assumed that each FMC contains 1 gr of 
tobacco. 
5 Economic analysis of the EU market of tobacco, nicotine and related products. Further referred to as Matrix 
report, 2012. 
6 Euromonitor data processed by Matrix, and industry estimates. 
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Virginia and other blends. In 2010, American blend cigarettes accounted for 462.6 billion 
sticks (76% of the market), Virginia for 72 billion sticks (12%, in particular in the UK, 
Ireland, Cyprus and Malta), and other blends for 71.6 billion sticks (12%). 
 
Despite the general decline in FMC sales, sales of slim cigarettes, particularly popular among 
female and younger smokers, grew, according to the Euromonitor data, by 50% from 23,855 
million sticks in 2000 to 35,673 million sticks in 2010. A small increase has also been 
observed in the segment of menthol cigarettes (+2.4%), a product which is particularly 
suitable for smoking initiation.7 In addition a range of cigarettes with fruit, candy and alcohol 
flavours have been recently introduced to the market as well as some unusual ones such as 
black tea, cassis, lemongrass and natural rose oil.8 Flavourings are often used to enhance the 
taste and reduce the harshness of tobacco smoke and thus to make the product more attractive 
and palatable to consumers. 
A.2.1.1.2. Roll Your Own 
RYO cigarettes are usually made of fine cut tobacco, the oldest form of smoking tobacco. The 
RYO market in the EU was reported to be worth 9.3 billion EUR (incl. taxes) in 2010.9  Part 
of these sales can be attributed to the segment of MYO ("make your own" using a specialised 
equipment), which has grown and contributed significantly to the expansion of the market in 
recent years, most likely as a result of higher FMC prices and more favourable tax regimes for 
fine-cut tobacco. The net value of the RYO market was estimated at 3.0 bEUR in retail prices 
(33% of the total revenue) as shown in Table 3. 
 
  Table 3: RYO revenue breakdown 
Pre-tax value 3.019 billion EUR 
Excise-tax 4.734 billion EUR 
VAT 1.534 billion EUR 
 Total 9.287 billion EUR € 
 Source: Euromonitor, DG TAXUD, Matrix 
  
In the context of the Commission's merger control practice10 the conclusion was reached that 
FMC and RYO are not part of the same “product market”. At the same time, tobacco 
manufacturers acknowledged there could be a degree of switching between FMC and RYO 
tobacco in view of differing excise treatment and consumer preferences. This discussion is of 
limited relevance for the purpose of this impact assessment. 
 
Between 2000 and 2010, the size of the RYO market in the EU grew by 42.2% and 
Euromonitor estimates that this market segment will continue to grow up to the year 2015.11  
The Member States in which RYO has a significant share of tobacco sales are Germany, 
Belgium/Luxembourg, the Netherlands, France, Spain, the UK and Poland.  
 
                                                 
7 Addictiveness and Attractiveness of Tobacco Additives, SCENIHR Opinion of 12 November 2010. 
8 Euromonitor. Trend Watch – Flavoured cigarettes controversy rages on, 23 April 2008. 
9 Euromonitor data processed by Matrix and industry estimates 
10 M.4424  / Gallaher; M.4581 Imperial Tobacco  / Altadis;  M.5086 BAT/ Skandinavisk Tobakskompagni 
11 Matrix report, 2012. 
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A.2.1.1.3. Pipe Tobacco 
Compared to other tobacco products, the segment for pipe tobacco is quite small, reported to 
be worth 0.48 bnEUR in the EU in 2010 at retail level including taxes.12 The primary markets 
are Germany, France, Denmark and the United Kingdom.13 Pipe tobacco is considered to be a 
niche product, generally sold in small quantities by specialist shops. According to European 
Smoking Tobacco Association (ESTA), the typical pipe tobacco consumer is male, 80% over 
the age of 60 years. The industry association recognises that its market is decreasing, as the 
current consumer is getting older and younger consumers are not choosing pipe tobacco.13 
Most varieties of pipe tobacco are flavoured and these flavours are added to pipe tobacco at 
higher quantities than is the case for other tobacco products.14 The cut and flavour 
differentiate pipe tobacco from RYO. The legal definition of pipe tobacco has been recently 
amended to avoid substitution between pipe tobacco and fine-cut tobacco15. 
A.2.1.1.4. Cigars and Cigarillos 
Cigars are rolls of tobacco with an outer wrapper of natural tobacco or of reconstituted 
tobacco. They are produced and sold in a significant variety of models, sizes, brands, types of 
packaging and prices. Cigarillos are in principle following the same definition (outer 
wrapper), but they can contain a filter and until recently the outer wrapper normally consisting 
of tobacco could made of other material (so called eco-cigarillos). In 2010, according to 
Euromonitor, 1.98 billion cigars and 7.94 billion cigarillos were sold across the EU. The 
largest market for cigars during the ten year period was the United Kingdom, where 20% of 
all cigar purchases in the EU took place.16 The cigarillos market is largely made up of sales 
from three countries: 47% of the cigarillos market in 2010 consisted of German sales, whilst 
French and Spanish sales made up 16% and 14% of total sales, respectively. 
 
Producers of cigars argue that their product, similarly to the pipe tobacco, is not targeted at 
younger consumers. Absolute cigar sales decreased over by 1.2 billion units (a 38% fall) 
between 2000 and 2010. Approximately 15-20% of their products contain added flavourings, 
of which 80% are coffee, vanilla and caramel-like flavours.17 Estimates from European Cigar 
Manufacturing Association suggest that the demand for cigars and cigarillos (in line with their 
definition in the taxation legislation) in the EU between 2002 and 2010 experienced a more 
modest decrease i.e. a fall from 6,712 million units in 2002 to 6,252 million units in 2010.18   
 
This statement seems not in line with the information provided by Euromonitor (see figure 2). 
However the difference can be explained by the reclassification of so-called eco-cigarillos as 
cigarettes in the amended EU tax legislation.19 These products are presented as 
cigars/cigarillos in order to benefit from the reduced tax rate, despite being similar in 
function, taste, filter and presentation to a cigarette.20 However, these products are classified 
                                                 
12 Euromonitor, and industry estimates  
13 ESTA European Smoking Tobacco Industry: Facts and Figures for DG Sanco (ESTA 2011-2012) 
14 ECMA Data: Annex III: Estimated Size of the EU Cigar Market 2002 and 2010 
15 Council Directive 2011/64/EU 
16 Matrix report, 2012. 
17 ECMA Data: Annex III: Estimated Size of the EU Cigar Market 2002 and 2010 
18 Meeting with Industry Stakeholders and DG SANCO, 19th December 2012  
19http://europa.eu/rapid/pressReleasesAction.do?reference=IP/08/1149&format=HTML&aged=0&language=EN
&guiLanguage=en 
20  See for example: http://www.tabak-brucker.de/themes/kategorie/index.php?kategorieid=591 
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as cigarettes (exceptions apply for Germany and Hungary until 2014). In 2007, cigarillos 
consumption peaked in Germany at 6.2 billion sticks, the bulk of which consisted of eco-
cigarillos.  
 






























Source: Euromonitor. EU25 exlcude sales in Spain and Germany which are shown  separately 
 
 
Despite the amendment of the EU definition the sales of filter cigarillos soared in a number of 
countries in 2010. These products are sold in packs of twenty units similar to those of 
cigarettes. Unlike traditional cigarettes, the paper wrapping of a stick is not white but brown, 
and its flavour is more intense. Given this formula, consumers have turned to these products 
as substitutes for the classic cigarettes. In Spain a price of a pack of "minicigarritos" 
marketed under the brands Coburn, Braniff, Rex, Friends or Salsa starts from 1.20 EUR, 2.75 
EUR less than a pack of cigarettes. Their sales grew by more than 300% in the first eight 
months of 2010.21 Introduction of economy Partner cigarillos by Philip Morris in Latvia and 
Lituania in early 2010 caused cigarillo sales to skyrocket from 4 million sticks to more 
than 100 million sticks in both countries within one year period, as many smokers switched 
from cigarettes to twice cheaper Partner cigarillos.22 
 
Since the cigar/cigarillos market ranges from hand-made premium cigars to machine-made 
mass market products and the so-called little cigars or cigarillos, overall market trends needs 
to be analysed also in value terms. The overall market value of cigars and cigarillos sold 
across the EU in 2010 was €4.65 billion, with cigars constituting 64% of the total market 
value (€2.98 billion) and cigarillos 36% of the total market value (€1.67 billion). In 2000, the 
value of the total market was €4.62 billion, i.e. market value increased by 0.6% over the ten 
years. The relatively constant market value over the time period is to be attributed to the fact 





that cigars are, on average, more expensive than cigarillos and their reduction in sales has 
offset the increase in value from more cigarillos being sold.  
A.2.1.1.5. Smokeless Tobacco Products 
Smokeless Tobacco Products (STP) can be defined in a broad sense as non-combustible 
tobacco products, including chewing tobacco, nasal tobacco and oral tobacco (snus, snuff et 
alia).23 Marketing of oral tobacco is banned in the EU according to the current Directive, 
except for Sweden having an exemption in its Accession Treaty24. In general, Eurobarometer 
statistics indicate that daily use of tobacco products other than FMC and RYO is low, at just 
1% per category.25 The market for nasal and oral tobacco is small, comprising just 0.6% of 
the EU tobacco products market. 
 
Sweden is the largest market for STP market, consisting mainly of oral tobacco (snus). Other 
significant markets are Denmark (chewing and nasal tobacco consumption), Slovenia 
(chewing tobacco) and Germany (chewing and nasal tobacco) and the UK (use of chewing 
tobacco is largely restricted to members of the Indian, Pakistani and especially Bangladeshi 
communities). The sales of chewing tobacco increased by 255% between 2000 and 2010 in 
Denmark (from 4 tonnes to 14.2 tonnes) and sales are expected to increase further by 4 tonnes 
up to the year 2015.26 For Slovenia and Germany a decline was observed, but German sales of 
nasal tobacco grew again in recent years, possibly in reaction to the smokefree environment 
policy. 
 
A.2.1.2. Tobacco manufacturing 
EU FMC manufacturing is increasingly concentrated and dominated by four large 
multinational companies. In 2010, British American Tobacco (BAT), Imperial Tobacco (IT), 
Japan Tobacco (JT), and Phillip Morris International (PM) – collectively often referred as Big 
Four - together shared 91.41% of the European Union cigarettes market, up from 59.4% in 
2000. This increasing consolidation is attributed to both organic growth and acquisitions.26 
The only other companies with a market share above 0.5% are Bulgartabac Holding Group 
and Karelia Tobacco Co Inc. 
 
Case study 1 
In 1990's, the German company Reemtsma acquired and upgraded a number of production facilities in 
Central Europe which had benefited from considerable tax benefits from the national governments. In 
2002 Reemtsma was acquired by Imperial Tobacco. Shortly after EU enlargement in 2004, Imperial 
Tobacco closed the facilities in Hungary, Slovenia and Slovakia in order to remove over capacities. 





                                                 
23 Commission Staff Working Document accompanying the proposal for a Directive of the European Parliament 
and of the Council on the approximation of the laws, regulations and administrative provisions of the Member 
States concerning the manufacture, presentation and sale of Tobacco Products. 
24 Treaty concerning the accession of Norway, Austria, Finland and Sweden to the European Union, 24th June 1994 
25 Attitudes of Europeans towards Tobacco, Special Eurobarometer 385,  May 2012. 
http://ec.europa.eu/health/tobacco/docs/eurobaro_attitudes_towards_tobacco_2012_en.pdf 
26 Matrix report, 2012 
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Figure 3: EU24 market (size, in million sticks) share of 'Big Four' (in per cent), 2000-2010 
 
 
Source: Euromonitor. No data on Cyprus, Luxembourg or Malta. Refers to the global brand owner. 
 
 
Case study 2 
Japan Tobacco International (JTI), the world’s third-biggest tobacco manufacturer, planned to close 
down its cigarette factory in Hainburg in Austria and to move the operations to two plants in Central 
Europe: in Gostkow Stary near Lodz and in Bucharest, romania.insider.com reported. The relocation is 
expected to take place by the end of the year.27 The Hainburg factory with 320 employees had the 
capacity to make 10 billion cigarettes a year and produced brands such as Benson&Hedges or 
Memphis. Japan Tobacco built the Gostkow plant in 2009 at a cost of $100m (€70m), creating more 
than 400 jobs. The company said at the time that its initial annual capacity of 5.5 billion cigarettes 
would rise to more than 20 billion in 2011. The factory is located near an existing tobacco factory 
which JTI acquired from Gallaher of the UK as a result of a merger that propelled it to number three 
cigarette maker in the world. 
 
 
The RYO market consists of a larger number of companies, and, at the moment, is considered 
less concentrated than the FMC market. Nevertheless, "Big Four" account also for 
approximately 70% of the RYO market.  
 
In contrast, cigars, pipe tobacco, nasal and chewing tobacco are mainly produced by 
SME’s.28 For cigars and cigarillos in particular, only two companies have a market share of 
more than 10% and the market share of Big Four is just above 20%.29 Contrary to common 
assumptions, about 90% of the EU cigar market is in the hands of EU producers. The 
production is said to be labour intensive and cigar manufacturing industry employs 
approximately 5,000 people.30 In the case of Pipe Tobacco, there are more than 750 different 
brands available on the EU market; the majority of these are manufactured in Germany or 
Denmark by small and medium enterprises.31 Swedish Match is the market leader in snus, but 
                                                 
27 http://www.romania-insider.com/jti-to-move-cigarette-production-from-austria-to-romania-poland/23187/# 
28  European Cigar Manufacturers Association, ECMA and European Smoking Tobacco Association, EST 
contributions to DG SANCO 
29 Matrix Report, 2012 
30 Meeting with Industry Stakeholders and DG SANCO, 19th December 2011  
31 ESTA European Smoking Tobacco Industry: Facts and Figures for DG Sanco (ESTA 2011-2012) 
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it is also engaged in the production of US mass-market cigars and chewing tobacco.32 The 
market leader for chewing tobacco in Denmark and Sweden is House of Oliver Twist, with a 
market share of 82.4%.33 
 
There were 48,500 people employed in tobacco manufacturing in the European Union in 
2009.34 Tobacco manufacturing is highly concentrated in geographical terms. Three Member 
States (United Kingdom, the Netherlands and Germany) account for more than 50% of total 
EU production. 
 
A.2.1.3. Tobacco growing 
As far as raw tobacco is concerned, the EU accounts for approximately 280,000 tonnes 
(4.1%) of world production.35 Inside the EU, approximately 118,190 hectares are devoted to 
tobacco growing, according to 2009 estimates, which represents a decrease of 38% from the 
year 2000.36 Tobacco production in the EU can be subdivided in four main variety groups; 
Virginia, Burley, Dark (Dark air-cured and Fire-cured) and Oriental. Virginia varieties 
represent about 46% of the EU production, Burley 21% and the others together about 33%. 
The EU counts about 86,000 tobacco farmers.37 Bulgarian farmers represent 50% of them, 
followed by Poland and Greece (both 17%). The tobacco production is often limited to small 
regions carried out by family businesses. The average area (1.6 ha per farmer) differs 
considerably according to the varieties grown, with Burley and Oriental varieties requiring 
more labour force than Virginia varieties.38 As a consequence, 81% of EU tobacco farmers 
are involved in Burley or Oriental growing, while 15% grow Virginia varieties. According to 
tobacco producers, certain ingredients, including sugar, are indispensable for the use of 
certain tobacco varieties (Burley and Oriental). This is because these varieties lose their sugar 
content during the drying process whereas other varieties, such as Virginia, keep it.  
 
In addition, there are around 100 first processors of tobacco in the EU. The first processors 
collect the raw tobacco cured by the farmers and make a first process before selling it to the 
industry producing cigarettes, cigars or manufactured tobacco. 44% of the first processors are 
located in Bulgaria and 22% in Italy. Second processors subsequently purchase, process, 
blend pack, store and ship tobacco to meet each specifications of manufacturers of cigarettes 
and other consumer  tobacco products. Two U.S. based leaf tobacco merchants - Alliance One 
Int. and Universal Corporation - with substantially similar global market shares,  control most 
of the EU market, e.g. Alliance One delivered in 2011 54% of its tobacco sales to customers 
in Europe (approx. 800 million EUR)39. Recently, the Commission fined the company's 
subsidiaries in Spain, Italy and Greece for operating cartels and but the outcome of the 
appeals process is still ongoing. 
                                                 
32 http://www.swedishmatch.com/en/Our-company/Financial-fact-sheet/ (Financial Fact Sheet for Swedish 
Match , 2010 figures) 
33 Matrix Final Draft Report 
34 Eurostat Statistics 2008/2009 
35 Member States statistics communicated to DG AGRI 
36 http://www.who.int/tobacco/en/atlas41.pdf 
37 Member States statistics communicated to DG AGRI. In addition to the farmers, a number of people 
(including seasonal workers) are employed on the farms. Copa-Cogeca (European farmers and agri-cooperatives) 
has estimated this figure to 400 000. 
38 Nomisma report 
39 AOI 2011 Annual Report, http://phx.corporate-ir.net//phoenix.zhtml?c=96341&p=irol-reportsannual, accessed 
on 29 February 2012 
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A.2.1.4. Tobacco distribution levels 
In terms of distribution, there were 2784 enterprises and 45,900 employees, involved in 
tobacco wholesale in the EU in 2009. In a number of MS's are the wholesale activities, 
formerly part of national tobacco monopolies, operated by the large tobacco manufacturers. 
However in other MS's the wholesalers are often involved in distribution of various product 
categories and therefore only part of their revenue would be impacted.   
 
The tobacco retailers’ market is quite varied across the EU. For instance, the tobacconists in 
France need a license, whilst the Belgian newsagents, supermarkets and corner shops do not. 
 
Figure 4: The place of purchase of tobacco products in the EU 
 
 
Source: Eurobarometer 2012 
 
According to the European Retail Association, in the EU-27 there are almost a million points 
of sale for tobacco products (988,480 points of sale recorded, excluding vending machines.)40 
For the Member States where such information has been made available, 229,012 of these 
outlets are recorded as being either kiosks, tobacconists or convenience stores. According to 
European Confederation of Tobacco Retailers (CEDT) estimation that there are 
approximately 1.45 employees per point of sale, 332,067 people are said to be employed in 
the specialised retail of tobacco, although such figures seem to be overstated, particularly in 
relation to larger retail outlets.41 Considering the whole added value42 generated by cigarettes 
and RYO in the retail sector 7.825 bnEUR (in average 25% margin applied) and the average 
salary in the sector provided by Eurostat (12,879 EUR), the total number of people involved 
in the sales of tobacco products should not exceed 600,000 FTE's43. 
 
                                                 
40 Tobacco Retailers Figures, CEDT, sent in January 2012 
41 According to figures provided by Federazione Italiana Tabaccai 
42 This is a hypothetical assumption as besides the labour  the whole range of other cost occurs in the retail 
sector: rent, energy, transportation, furniture, cost of financial transactions etc.  
43 Full Time Equivalent 
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A.2.1.5. Upstream/downstream activities 
A number of other upstream- and downstream activities are associated with the tobacco 
manufacturing process and might be impacted by the proposal considered in this impact 
assessment. This includes suppliers of flavourings, papers, filters and packaging as well as 
producers of a number of accessory products such as tobacco vending machines and pipes.   
 
The European Carton Makers Association (ECMA) represent 500 carton producers which 
account, by volume, for 90% of the European carton market (corresponding to approximately 
8.1 bnEUR in turnover). Only 10% of their total turnover (approximately 800 mEUR) is 
derived from tobacco products and only 6% of employees of companies represented by 
ECMA work in cigarette carton manufacturing in the EU.44  
 
In the case of filters, a prominent manufacturer of filters estimates that 37.5% of their total 
turnover of 200.7m GBP, (i.e. circa. 75m GBP) came from the EU market.45 New and more 
innovative variants of filters are being developed by filter manufacturers, which could 
potentially make the associated tobacco products more attractive to consumers.46 
 
A.2.1.6. Trade  
As far as trade is concerned, EU imported about 600,000 tonnes of raw tobacco and exported 
about 170,000 tonnes in 2010.47 This corresponds to a value of 3,164,087,504 EUR for 
exports and 2,366,294,046 EUR for imports of manufactured tobacco.48 There is also 
substantial intra EU trade with about 268,000 tonnes of raw tobacco being subject to such 
internal trade between Member States in 2010. The overall value of tobacco products traded 
within the EU in 2010 was 9.5 bnEUR.49 Figure 5 illustrates the main trade intra-EU flows in 
the production of American blend cigarettes. 
Figure 5: Trade flows between tobacco-growing, tobacco-producing and tobacco-consuming countries 











Romania, Hungary, Greece, 
Lithuania, Netherlands, 
Portugal, Czech Republic, 
Italy




EU 26 (all countries but the 
United Kingdom)
 
Sources: Industry respondents, Euromonitor, FAOSTAT, DG AGRI 
 
                                                 
44 Minute of Meeting of Industry Representatives and DG SANCO, Feb.6th 2012 
45 www.filtrona.com 
46 http://www.filtronafilters.com/poverview.htm 
47 EUROSTAT This figure includes normal trade and inward processing, i.e. tobacco imported and processed in 
the EU for export to third countries. 
48 Eurostat Statistics, 2010 
49 Eurostat (Procom), 2008 
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A.2.2. TOBACCO AND SOCIETY 
A.2.2.1. Consumers 
While the number of smokers in the EU has been decreasing in the past decades, 28 % of all 
EU citizens and 29% of young people 15-24 years still smoke.50 The prevalence levels differs 
widely between Member States with a range in the proportion of smokers between 13% and 
40%. The prevalence levels of smoking also vary between different socio-economic groups 
differs greatly within the Member States.  
 
It may be useful, for illustrative purposes, to look at the demographic trends as they present 
themselves on the level of the individual Member States. For example, 2011 estimates by the 
Bundesministerium für Gesundheit in Germany that 22% of women smoke and this 
estimation rises to 38% for young women. Smoking prevalence amongst women with lower 
levels of education and amongst single mothers in Germany is said to be 'remarkably high.'51 
Statistics for certain EU countries suggest that in the last fifteen years, there has been a trend 
towards increasing numbers of young people starting to smoke, although overall statistics 
suggest that there are less people smoking now than in the 1980s or 1990s. Tobacco 
consumption among young people in Slovenia increased from 16% in 1993-96 to 26% in 
1997-2001.52 Statistics in Hungary from 2003 show that 38.2% of Hungarian adult males and 
almost one quarter of Hungarian adult females are smokers and that in spite of more men than 
women smoking there, school-age girls are far more likely to initiate smoking cigarettes than 
boys (27.9% for girls as opposed to 15% for boys.)53 In Slovakia, where the rate of smoking 
in the adult population in 2003 was 30.1% for men and 17% for women, an increase in 
occasional smoking amongst women during the 1990s has been attributed to a change in 
societal attitudes towards women smoking.54 
 
On average EU smokers are smoking 14.4 cigarettes a day. The retail price of cigarette 
packages differs widely between Member States, with a range between 1.48 EUR and 8.45 
EUR within the EU.  
 
A.2.2.2. Illicit Trade 
The issue of illicit trade in tobacco products has been recognized as fundamental by 
regulators, enforcement administrations and by tobacco industry. In the EU, the main problem 
area is the illicit trade in manufactured cigarettes. This illicit trade has to be clearly 
distinguished from legal non-domestic consumption, for example cross-border shopping in 
another EU country in legal amounts in order to avoid higher taxation.  
 
In the context of the Tobacco Products Directive, the main problem is that illicit products 
undermine the existing EU wide regulations as regards, for example, health warnings and 
maximum yields for tar, nicotine and carbon monoxide, ingredients regulations. Similarly 
they undermine measures at national level like the prevention of underage smoking.   
 
                                                 







As explained in the IA report (section 2.2. problem identification) one needs to distinguish 
between genuine products which are diverted into the illegal supply chain (mostly for sale 
in high tax/price Member States - contraband55) – and falsified products, which are 
counterfeits of genuine products, made for the illegal supply chain56. 'Illicit/cheap whites" – 
often referred to as a third and rapidly growing area of concern – are in principle genuine 
products, but do not respect the regulatory safeguards of the Tobacco Products Directive nor 
pay the appropriate taxes and have insofar common features with both contraband and 
counterfeit.   
 
According to the information collected by OLAF (the Commission's antifraud office), the 
total loss in tax revenues amount to € 10 billion57 annually, which corresponds to a market 
value in the legal supply chain (retail level excluding taxes) of € 3 billion. Overall, 50% of 
these lost sales are attributed to contraband and 50% to counterfeits, with variations in the 
Member States.   
 
In all categories, the main threat comes from large-scale smuggling (estimated by 
Euromonitor of being 70 % of all illicit trade), by highly organised criminal actors. Besides 
large-scale smuggling there is also “bootlegging”, the trafficking of relatively small quantities 
of contraband by making journeys across the border with small amounts of cigarettes. 
Another way of illicit supply is the use of internet sites to sell and ship tobacco products by 
post worldwide to evade taxation. There are also instances of illicit manufacturing of (mostly) 
cigarettes, without the crossing of a border, therefore not "smuggled" (for example on a site 
not licensed or registered for manufacturing or an undeclared (over) production on a legal 
site). 
As regards the volume, it lies in the nature of illicit trade that precise figures are difficult to 
obtain. Although some data are available, generally speaking, transparent, publicly available 
data on illicit trade are very limited. According to Euromonitor, illicit trade in cigarettes in the 
EU amounts to 8.25 % of total trade, with a significant variation across EU countries58.  
 
The “STAR project” 59, a study carried out by KPMG for PMI International in the context of 
the legally binding agreement between the company and the EU, comes to the following 
result: In 2010, 9.9 % of total cigarette consumption could be regarded as contraband or 
counterfeit. Similarly, from a study done at global level, the estimate for high income 
countries (in which category the EU falls) is, that 9.8 % of the cigarette market is illicit60.  
 
According to OLAF, in 2010, Member States reported seizures of around 4.6 billion 
cigarettes. If these seized cigarettes had penetrated the EU markets, it is estimated that the 
losses to the EU and Member States' budgets in 2010 would have been approximately 1 
billion euros. According to OLAF figures, illicit trade represents annual revenue losses of 10 
billion euros for the EU and its Member States61.  
                                                 
55 For the purpose of this impact assessment the notion of "contraband" is used to describe all situations in which 
a genuine product is diverted into the illicit supply chain, i.e. also if the product is produced in the country of 
destination, but no appropriate taxes are paid. 
56 Falsified (counterfeit) cigarettes also circulate without appropriate taxes having been paid 
57 http://ec.europa.eu/anti_fraud/media-corner/press-releases/press-releases/2011/20110315_01_en.htm 
58 See MATRIX report 2012 
59 http://www.pmi.com/eng/tobacco_regulation/illicit_trade/documents/Project_Star_2010_Results.pdf 
60 Joossens L,Merriman D, Ross H,Raw M. How eliminating the global illicit cigarette trade would increase tax 
revenue and save lives. Paris; International Union Against Tuberculosis and Lung Disease; 2009 
61 http://europa.eu/rapid/pressReleasesAction.do?reference=IP/10/1179 
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A.2.3.  MAIN STEPS IN THE MANUFACTURING PROCESS OF CIGARETTES  
A.2.3.1. Growing and harvesting  
Tobacco is initially grown in outdoor frames called seedbeds. In warm regions, the frames are 
covered with mulch or a cotton top sheet; in cooler regions, glass or plastic shields are 
installed to protect the plants. After 8-10 weeks, when the seedlings are almost 10 inches (25 
cm) tall, they are transplanted to the fields. Although transplanting machines are available, the 
vast majority of the world's tobacco plants are still planted manually. As the plants grow, the 
heads are broken off by hand so the leaves will grow fuller, a process called topping. The 
plants stay in the field 90-120 days before they are harvested.  
Tobacco plants are harvested in three times between July and September and in many regions 
this is done manually. The plants are harvested by one of two methods, priming or stalk-
cutting. In the priming method, the leaves are gathered and brought to a curing bam as they 
ripen. In the stalk-cutting method, the entire plant is cut and the plants are allowed to wilt in 
the field before being taken to the curing barn.  
Growers are often organized into farmer cooperatives or other producer groups.  
A.2.3.2. Curing the leaf  
Curing is the process of drying freshly harvested tobacco with partially or fully controlled 
temperature and moisture schedules. It is done by the growers. Different curing processes are 
used for different tobacco varieties as illustrated in the table below:  
EU variety 
groups Features for curing 
Main varieties in 
the EU Final destination 
I 
Flue-cured: tobacco dried in 
ovens with controlled air 
circulation, temperature and 
humidity 
Virginia, Bright Non blend and American Blend cigarettes 
II 
Light air-cured: tobacco dried 
in the air under cover, not left 
to ferment 
Burley, Mariland American Blend cigarettes 
III 
Dark air-cured: tobacco dried 
in the air under cover, 
fermented before being 
marketed 
Paraguay,Havana, 
Badischer, Beneventano Dark cigarettes and cigars 
IV Fire-cured: tobacco dried by fire Kentucky, Salento 
Cigars and Toscany (strong 
cigars) 
V Sun-cured: tobacco dried in the sun "oriental tobacco" Xanti-Yakà, Erzegovina 
Aromatic for American Blend 
cigarettes 
VI Sun-cured: Basmas varieties Basmas 
VII Sun-cured; Katerini varieties Katerini 
VIII Kaba-Koulak (classic) and similar Sun-cured Kaba-Koulak, Elassona 




Virginia tobacco leaves contain a higher carbohydrate (e.g. sugars) level and lower nitrogen 
level than Burley leaves. The natural drying of the Burley leaves at relatively low 
temperatures allows plant respiration which continues to consume sugars during the process, 
leaving negligible sucrose and (reducing) reduced sugars in the cured leaf. Burley leaves 
contain higher levels of nitrogen than Virginia leaves. The smoke of Virginia or flue-cured 
leaves is more aromatic and less alkaline than that of Burley tobacco, with a slight acidic taste 
resulting from the high levels of natural sugars. Burley tobacco produces a more alkaline 
smoke than flue-cured tobacco and therefore imparts a bitter aroma and taste to cigarettes. 
Oriental leaves tend to have a low nitrogen content and moderate levels of carbohydrates, but 
fewer proteins, than the other varieties.62 Burley and Oriental varieties require much more 
labour force and/or investments for curing than Virginia varieties.63 
 
A.2.3.3. First processing  
Raw tobacco leaves are sorted into grades based on size, color, and quality. Grading is 
performed by first processors. The first processing step includes the following activities: 
• Leaves are sorted by quality to form homogenous lots which are then delivered to 
manufacturers. 
• The leaves are beaten in order to separate the leafy material from the stalks; this is 
done for some varieties only. 
• The tobacco is re-dried to stabilize it and thus enable long-term storage.  
• The tobacco is re-sorted to form homogenous lots.  
• The tobacco is aged and fermented to assist long terms storage.  
• Tobacco strips are prepared ready for industrial use; this is done for some varieties only.  
• Packaging for delivery to manufacturers.  
A.2.3.4. Preparation of basic blends and making of cigarettes 
This is performed by second processors and cigarette manufacturers.  
Blending is the selection and thorough mixing of the tobacco-based components plus any 
associated casings, humectants and flavouring required for a particular product or brand. The 
tobacco based components may include the leaf lamina, cut and rolled stem, reconstituted 
sheet and expanded tobacco. The tobaccos stored in bales are broken up, cut into specific 
dimensions, and combined with other blend components such as casing and top dressing, and 
the moisture content is adjusted. 
The final shredded tobacco is dispersed over a continuous roll of cigarette paper. A machine 
rolls the shredded tobacco into the paper and cuts it to the desired length. A device then grabs 
each cigarette and fastens a filter in one end. Modern cigarette machines can produce 25-30 
cigarettes a second.  
                                                 
62 Addictiveness and Attractiveness of Tobacco Additives, SCENIHR Opinion of 12 November 2010 
63 Factsheet on the Production of Raw Tobacco in the EU: European Commission DG AGRI, Directorate C.3. : 
Wine, alcohol, tobacco, seeds and hops. 
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The process for the manufacture of cigarettes incorporates the use of 'Fine Paper Products', 
such as cigarette paper, plug wrap paper and tipping paper.64  
A.2.3.5. Adding of humectants, flavors and flavourings 
There are no fixed rules as to where humectants, flavourings and other additives are added to 
the processed tobacco but generally the more volatile additives are added as late as possible in 
the production process in order to prevent losses.  
Tobacco blends that contain flavourings are usually held in a bin to allow for equilibration 
across the blend before it is passed to the making machine as the final blend. Top flavourings 
are generally applied to the total tobacco blend as one of the last steps in processing. They are 
usually carried in an alcohol base. They are used to improve quality of smoke and to impart a 
pleasant pack aroma and side-stream aroma. Flavourings are used to enhance the taste of 
tobacco smoke, to make the product more desirable to consumers.65 Menthol may be added at 
any of the following stages; spraying onto the final blend, through addition to the filter via a 
thread, or by application to the cigarette paper or the foil used to wrap the cigarettes. Due to 
the high level of volatility of menthol, different manufacturers have over the years developed 
a variety of methods for producing mentholated products that are as consistent as possible in 
terms of their finished product menthol levels. 66 
Casing refers to the sauce composed of a variety of ingredients such as humectants, sugars, 
cocoa, liquorice and fruit extracts.67 Additives such as cocoa may be used as a means of 
dilating the airways, which allows the smoker to inhale the smoke deeper into their lungs, 
which leads to a more intense exposure to nicotine and to tar.65 The basic material of casing 
for reducing harshness is sugar. A commercial solution of tannin also sweetens and softens 
the smoke of tobacco. The best known example of an additive that changes markedly and 
even masks the taste of tobacco is the use of cloves. Addition of menthol is another example, 
but in this case the tobacco taste is still discernible. Burley leaf has the ability to absorb up to 
25% of its weight of added material. 68 
Casings are usually applied to tobacco strips or leaf early in the primary processing scheme to 
tone down or mute the strength or harshness of tobacco smoke, enhance  the processing 
potential of tobacco and add deep flavour notes to the smoke. Casings are traditionally added 
to US blended styles of product that contain significant proportions of Burley type tobacco 
blends. These casings are added to the Burley tobacco line through the means of the casing 
cylinder or Cased Leaf Dryer. 
Ammonia technology has been used mainly in American blend products containing cased 
Burley tobacco. Ammonium salts could be added at the Cased Leaf Dryer (CLD) stage or 
with the manufactured reconstituted tobaccos. 
In cigarettes, flavours may be added to tobacco, cigarette paper, or the filter, in a plastic pellet 
placed in the filter or the foil wrapper, in an attempt to enhance the tobacco flavour, mask 
                                                 
64 Factsheet 'Fine Paper Industry': Meeting with DG SANCO, Feb 6th 2012 (Benkert, B. and Brinker, A.) 
65 MATRIX report, 2012 
66 Response submitted to the SCENIHR Committee “call for information” by British American 
Tobacco; 2010.  Accessed 22 June 2010 from: 
http://ec.europa.eu/health/scientific_committees/consultations/calls/scenihr_call_info_08_en.htm 
67 Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997;50:307-64. 
68 Akehurst BC. Tobacco. 2nd ed. London: Longman; 1981. 
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unpleasant odour, and deliver a pleasant cigarette-pack aroma. Internal industry documents 
reveal additional flavour technologies such as flavour microencapsulation in the paper, carbon 
beads, and polymer-based flavour fibres inserted into the filter, flavoured tipping etc. (WHO 
2007b). 
 
A.2.3.6. Packaging  
Packaging contributes to the overall costs of producing and marketing cigarettes and is the 
final stage of cigarette manufacture. The completed cigarettes are normally packed 20 to a 
package. The packs are mechanically sealed in cellophane and hand-placed in cartons. The 
size of cigarette packages, in terms of the quantity of cigarettes contained therein, is regulated 
by some of the Member States. Current TPD bans misleading terms such as ‘light’, ‘mild’, or 
‘low tar’ and requires that all tobacco products sold in the EU display two text warnings: the 
first compulsory warning is either "tobacco kills" or "tobacco can seriously harm you and 
others around you". The second warning is selected from a list of 14 warnings (text and a 
corresponding picture) developed by the European Commission.   
Cigarette carton manufacturing follows a very specific process, which produces the cartons in 
'flat form', which are then sent to the cigarette manufacturers for assembly to be completed. 
According to information from one major manufacturer, pre-printed flat packages are 
purchased from suppliers generally at a price around 0.02 EUR, however costs differ 
significantly between different types of packages and between packages used in different 
countries. 
The proposed mandatory use of pictorial health warnings on cigarette packages would involve 
the use of three standard process colours; cyan, magenta and yellow plus black. Overall, the 
labelling of branded cigarette cartons involves the use of complex process colours (so called 
'spot colours'.) There are also metallic finishes and structural varnishes which can be used in 
the manufacturing of cigarette cartons. Compared to the colours needed to produce a graphic 
health warning, it is claimed by industry representatives that ten to twelve colours are used in 
the production of typical hinged lid or soft packet packaging. According to the ECMA, 
specifications for particular colours have very tight 'control tolerances.' The process of foil 
stamping and embossing takes place after the carton has been manufactured.69 
 
A.2.4. THE MARKET FOR RELATED NON-TOBACCO PRODUCTS 
 In addition to the traditional tobacco market, recent years have seen a diversification of 
nicotine containing- and other novel and niche products which can be associated with tobacco 
use.   
A.2.4.1. Electronic cigarettes and other nicotine containing products for consumer use 
Electronic cigarettes appear to be the most commonly available nicotine containing 
consumer/leisure product in the EU. The EU electronic cigarette market is growing rapidly 
and it is difficult to estimate the total value. The electronic cigarette supplier, Red Kiwi, 
estimates that the current value of the German market is around 100 mEUR and that the total 
value of the EU27 e-cigarette market (including devices and refills) is between 400 and 500 
                                                 
69 Document from European Carton Makers Association; Production Explained  
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mEUR.70 The Electronic Cigarette Industry Trade Association (ECITA) estimates that they 
represent 60-70% of the volumes sold on the UK market and reports that the market is 
growing 20-30% monthly.71 ECCA UK estimates that in 2012 there will be 750,000 electronic 
cigarette users (see the figure below).72 Red Kiwi estimates the figure for Germany to be 1.2 
million for the year 2011.70  
 
Figure 5: Estimation of the use of electronic cigarettes in the UK  
 
Graph adapted from http://www.eccauk.org/index.php/uk-sitrep.html 
 
For non-electronic cigarettes, the brand "Similar" has reported sales of one million packs per 
annum in 2010.72 Other nicotine containing consumer products (such as nicotine drinks and 
sweets) appear, at this stage, to be less common in the EU, but it cannot be excluded that a 
further market development will take place in coming years.  
 
Many of the nicotine containing consumer products are manufactured in third countries (most 
electronic cigarettes are produced in the Shenzhen region of China) and the EU market is 
characterised by a large number of distributors rather than manufacturers.72 Many of these are 
SMEs, but there is a growing interest from bigger companies to enter into this business. For 
example, British American Tobacco has recently launched its own subsidiarity company 
“Nicoventures” for the purpose of developing non-tobacco nicotine products, with similar 
moves from Philip Morris International.73 Electronic cigarettes are most often bought in bulk 
from the manufacturers and sold, via the internet or in physical shops, re-branded in the EU. 





                                                 
70 Matrix insight. 2012. (Interview with Red Kiwi, 16 December 2011)  
71 DG SANCO meeting with ECITA, 20 June 2012: 
http://ec.europa.eu/health/tobacco/docs/ev_20120703_mi_en.pdf 






A.2.4.2. Herbal products for smoking 
The overall size of the market of herbal cigarettes has grown in recent years, from around 
40,603,000 units in 2000 to 49,953,000 in 2010.74 These products are available from 
numerous internet sites and health food stores (e.g. Holland and Barrett in the UK). The 
products are marketed in a range of different flavours, including vanilla and ginseng and are 
often suggested as a help for quitting smoking.   
                                                 
74 Matrix report, 2012 
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A.3 REGULATORY FRAMEWORK & DEVELOPMENTS IN MEMBER STATES 
AND AT INTERNATIONAL LEVEL 
Part I of this Annex provides an overview of the regulatory situation at EU, national and 
international level in the five policy areas considered within this impact assessment. Part II 
presents an overview of the Tobacco Products Directive in relation to the WHO Framework 
Convention on Tobacco Control obligations and commitments. Part III is based on information 
collected from the national authorities in the context of the Regulatory Committee established 
under the Tobacco Products Directive (TPD). It describes in more details the legislation in place 
in each Member State.1  
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A.3.1. PART I: OVERVIEW OF THE REGULATORY SITUATION AT EU, NATIONAL AND 
INTERNATIONAL LEVEL 
A.3.1.1. Regulation of STP and possible extension of the scope 
A.3.1.1.1. EU Legislation 
a)  Smokeless Tobacco Products (STP) 
The Tobacco Products Directive (hereinafter the TPD) covers tobacco products "for the purpose 
of smoking, sniffing, sucking or chewing, inasmuch as they are, even partly, made of tobacco" 
(Article 1). Article 8 currently bans one type of smokeless tobacco products (oral tobacco) while 
others (chewing and nasal tobacco) are freely marketed in the EEA. In their Accession Treaty, 
Sweden and Norway were granted a permanent derogation from the prohibition to market oral 
tobacco.1 According to Article 5(4) of the Tobacco Products Directive where it is allowed, i.e. in 
Sweden and Norway, oral tobacco shall carry the following warning: "This tobacco product can 
damage your health and is addictive." 
b) Nicotine Containing Products (NCP) and herbal products for smoking 
The Commission Orientation note of 22 May 2008 provides some guidance as to which EU 
legislation applies to electronic cigarettes under the current situation.2 
 
Non-tobacco products, such as NCP and herbal products for smoking , fall outside the TPD.  
 
Whether these products fall under Directive 2001/83/EC of the European Parliament and of the 
Council of 6 November 2001 on the Community code relating to medicinal products for human 
use3 depends on whether they can be characterised as human medicine by presentation or 
function. National authorities, acting on a case-by-case basis, decide whether a product falls 
within the definition of a medicinal product by function. As illustrated below, there is at this 
stage no convergent view among Member States whether an electronic cigarette should be 
considered a medicinal product by function or not.   
 
The delivery system (i.e. without the nicotine) of an electronic cigarette may possibly also be 
qualified as a medical device according to Council the Directive 93/42/EEC if it is intended to 
administer a medicinal product concerning medical devices.4 However, this would imply first that 
the nicotine cartridge is considered to be a medicinal product under Directive 2001/83/EC. Article 
1 (2a) of Directive 93/42/EEC requires that, in order for a product to be qualified as a medical 
device, it is to have a medical purpose.Products made of nicotine that are ingested are covered by 
the Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 
2002 laying down the general principles and requirements of food law, establishing the European 
                                                 
1 OJ L 1, 1. January 1995  (see article 151 and Annex XV thereof) 
2 http://ec.europa.eu/health/archive/ph_determinants/life_style/tobacco/documents/orientation_0508_en.pdf 
3  OJ L 311, 28.11.2001, p. 67–128  
4 Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, OJ L 169, 12.7.1993, p. 1–43 
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Food Safety Authority and laying down procedures in matters of food safety5, unless they are 
regarded as human medicines under Directive 2001/83/EC. The Novel Food Regulation (258/97)6 
applies to placing on the market of food which has not, by 14 May 1997, been used for human 
consumption to a significant degree within the EU.  
Finally, Directive 2001/95/EC of the European Parliament and of the Council of 3 December 
2001 on general product safety applies in so far there are no specific provisions with the same 
objective in other EU law.7 The Directive enables a withdrawal from the market if the regulator 
can show that it is dangerous for the health and safety of consumers.  
A.3.1.1.2. The situation in the Member States 
a) Smokeless Tobacco Products (STP) 
In addition to the EU-wide ban on oral tobacco, five Member States, (Latvia, Lithuania, Ireland, 
Greece and Poland) have banned the marketing of chewing tobacco and two Member States 
(Latvia and Lithuania) ban nasal tobacco.  
b) Nicotine containing products (NCP)  
There is no uniform legislation in place in Member States concerning NCP. As indicated above, 
the national authorities decide on a case-by case basis whether a product falls within the 
definition of medicinal product by function. It is therefore difficult to indicate with certainty how 
the legal landscape looks. However, 14 Member States have reported that they would regard at 
least some electronic cigarettes as medicinal products by function.8 Two Member States ban 
(Lithuania and Greece) electronic cigarettes under their tobacco legislation and two Member 
States (Malta and Poland) regulate the products (including ban on advertising). Nine Member 
States have no specific rules in place for electronic cigarettes.9  
c) Herbal products for smoking 
With regard to herbal products for smoking, the situation in Member States is also fragmented 
and ranges from banning these products (Lithuania and Greece) to no specific regulation.10 Other 
Member States have various provisions in place, including ingredients regulation (Belgium), 
labelling requirements (Latvia), advertising restrictions (Malta and Finland), smoke-free 
environment protections (Denmark, Latvia, Malta, Slovakia, and the United Kingdom) or general 
tobacco provisions (Italy). Austria has reported that  it considers herbal products for smoking as a 
medicinal product by function if it contains a pharmacologically active substance and/or by 
                                                 
5 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the 
general principles and requirements of food law, establishing the European Food Safety Authority and laying down 
procedures in matters of food safety, OJ L 31, 1.2.2002, p. 1–24 
6 OJ L 43, 14.2.1997, p. 1–6 
7 Directive 2001/95/EC of the European Parliament and of the Council of 3 December 2001 on general product safety, OJ L 
11, 15.1.2002, p. 4–17. For further orientation on electronic cigarettes and EU legislation, see orientation note of 22 May 
2008: http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/orientation_0508_en.pdf 
8 AT, BE, DE (the nicotine containing liquids in the electronic cigarettes) , DK, EE, FI (along with advertising ban under 
the Tobacco Act), FR (depending on the nicotine level as described in the table in part 2), HU, LU (if they contain 
nicotine without containing tobacco extract, and/or if presented as cessation treatment), NL, PT, RO, SE and SK 
9 BG, CY, CZ, ES, IE, LV, IT, SI and UK (considering whether all NCPs should be considered medicinal by 
function) 
10 BG, CY, ES, FR, HU, IE, LU, NL, PL, PT, RO and SI 
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presentation if the product is promoted for smoking cessation or treatment of nicotine addiction. 
Some Member States have also reported that they are taxing these products in the same way as 
tobacco products.11     
A.3.1.1.3. The situation at international level 
The WHO Framework Convention on Tobacco Control (FCTC) covers all tobacco products and 
contains no specific rules on STP.  As regards electronic cigarettes, it can be noted that the WHO 
Study Group on Tobacco Product Regulation has recommended that these products are regulated 
as combination drugs and medical devices.12 
A.3.1.2. Packaging and labelling 
A.3.1.2.1. EU Legislation 
Article 5 of the TPD currently stipulates that all tobacco products must carry one general text 
warning covering not less than 30% of the most visible side of the package and – except for 
tobacco for oral use and other smokeless tobacco products -  one additional text warning covering 
not less than 40% of the other most visible side.13 Packages of manufactured cigarettes should 
also display the results of tar, nicotine and carbon monoxide (TNCO) yield measurements. In 
addition, Article 5 empowers the Commission to take rules on the use of pictorial warnings that 
Member States must comply with if they decide to require additional warining in that form. If 
they are required, the pictorial warnings shall, together with the additional text warning, cover 
40% of the other most visible side of the package.14 Moreover, Article 7 of the Directive bans the 
use of misleading descriptors such as light and mild.  
 
Section 1(f) of Council Recommendation 2003/54/EC recommends prohibiting the sale of single 
cigarettes and packs of less than nineteen. 
A.3.1.2.2. The situation in the Member States 
Combined health warnings (picture plus text) on cigarette packs are in place in eight Member 
States15 (Belgium (2007), Romania (2008), United Kingdom (2008), Latvia (2010), France 
(2011), Malta (2011), Spain (2011), Denmark (2/2012)). Two Member States have passed 
legislation introducing pictorial health warnings from 2013 (Hungary, Ireland) and one is 
planning to pass similar legislations (Poland).  
 
The implementation of their use varies significantly between these Member States. Some of them 
use pictorial warnings on cigarette packages only and others on all smoked tobacco packages16. 
Thirteen Member States have complemented the packages with references to cessation services, 
                                                 
11 CZ, DE, EE, LV and SE 
12 WHO Study Group on Tobacco Product Regulation, Report on the Scientific Basis of the Tobacco Product 
Regulation: Third Report of a WHO Study Group, WHO 2009. 
http://www.who.int/tobacco/global_interaction/tobreg/publications/tsr_955/en/index.html 
13 These figures are increased to 32% & 45% in MS with 2 offic- languages and 35% & 50% in MS with 3 offic- languages.  
14 This figure is increased to 45% in MSs with two official languages and 50% in MS with three official languages. 
15 Starting date of mandatory use in paranthesis 
16 As of June 2012, France, Malta, Latvia (from June 1, 2010), Spain and the UK use pictorial warnings on smoked 
tobacco products other than cigarettes. Denmark, Ireland and Hungary will start using them in 2012/2013 and Poland 
is planning to pass legislation which would require their use on all smoked tobacco products. 
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four of them on a mandatory basis (Belgium, France, the Netherlands and Slovenia)17. All 
Member States offer support via cessation services to smokers. 
 
The choice of actual use of pictures also varies from one Member State to another. While 
Belgium and Hungary are using the whole library of 42 warnings (Belgium: divided into three 
sets which alternate every year, Hungary: the manufacturer can choose between them, respecting 
the rules on rotation), the remaining eight Member States have chosen 14 images that they deem 
most effective for their population.  
 
While no Member State has yet fully standardised tobacco packaging there is at least one 
Member State, France, where promotional elements on the package are already banned as part of 
the advertising ban.18  
 
In addition, the possibility of introducing standardised (plain) tobacco packaging is currently 
discussed in a number of Member States as well as Norway. In April 2012, the UK launched a 
public consultation on standardised packaging of tobacco products running until August 202.19 A 
Belgian MP tabled a proposal for plain tobacco packaging in May 201120 and the Belgian 
Minister of Health has stated (in the health committee) of the parliament that she will push for the 
adoption of plain packaging.21 In July 2011, France’s minister of health asked MP Bur to propose 
a policy recommendation on tobacco. These were published in March 201222 and the fifth 
recommendation was to develop plain packaging. More recently reports in the French media have 
also confirmed that the French government intends to present a tobacco control plan that includes 
plain packaging.23 Finland and Norway are also exploring the possibility of introducing plain 
packaging. As these discussions are at an early stage, the exact nature of potential national 
actions, including which features would be standardised, remains uncertain.  
 
Member States have different rules in place as regards the minimum number of cigarettes per 
package, which affects the size of the package. Fourteen Member States (Austria, Czech 
Republic, Estonia, Finland, France, Greece, Ireland, Luxembourg, Lithuania, Poland, Portugal, 
Denmark, Romania and Spain) specify a minimum pack size of twenty cigarettes. In four 
Member States (Hungary, Germany, the Netherlands and Sweden), the minimum pack size is 
nineteen cigarettes. Italy specifies that cigarettes must be sold in either packets of ten or twenty. 
In the UK the minimum pack size is 10 cigarettes. Slovenia expressly bans the sale of single 
cigarettes or the sale of other tobacco products separately from their original packaging and 
Lithuania bans the sale of single cigarettes, cigarillos and long cigarettes. Latvia bans the sale of 
single tobacco products and herbal smoking products, with the exception of cigars and cigarillos. 
Hungary has also fixed a maximum number of fifty cigarettes.  
                                                 
17 Quitlines are included in some warnings in Austria, Denmark, Germany, Hungary, Ireland, Latvia, Poland, 
Sweden, and the United Kingdom. 
18 http://www.inpes.sante.fr/itc/pdf/ITC_rapport_FR.pdf 
19Article L3511-3 of the French public health code 
20 http://www.lesoir.be/actualite/sciences/2011-05-02/des-paquets-de-tabac-sans-logo-837626.php 
21 http://www.lachambre.be/doc/CCRI/pdf/53/ic096.pdf Report of the health commission of 19th January 2011, p 29-31 





A.3.1.2.3. The situation at international level 
Article 11 of the FCTC stipulates that warnings should be 50% or more, but no less than 30%, of 
the principal display areas. The guidelines for implementing Article 11 suggest that the 
effectiveness of health warnings increases with their size and recommend Parties to consider the 
use of pictorial health warnings on both principal display areas. Article 11 of the FCTC gives the 
states three years, running from the time that the convention enters into force for them, in which 
to adapt and implement effective packaging and labelling measures. 
 
The guidelines for implementing Article 11, (tobacco packaging and labelling) and Article 13, 
(advertising) recommend to consider the introduction of "plain" (standardised, generic) 
packaging.  
 
The FCTC guidelines on ingredients (Article 9 and 10) regulation also recommend to ban 
ingredients that have colouring properties. For cigarettes, Australia is the first jurisdiction in the 
world to introduce plain packaging, including standardised appearance of individual cigarettes.24 
The legislation entered into force as of 1 December 2012.  
 
Moreover, the FCTC guidelines on labelling (Article 11) recommend Parties to consider 
introducing other innovative measures regarding location of the warnings, including, but not 
limited to, requiring health warnings and messages to be printed on the filter overwrap portion of 
cigarettes and/or on other related materials such as filters and papers.  
 
Article 16(3) of the FCTC states that 'each party to the convention shall endeavour to prohibit the 
sale of cigarettes individually or in small packets, which increase the affordability of such 
products to minors'.   
A.3.1.3. Ingredients 
A.3.1.3.1. EU Legislation 
a) Reporting 
Article 6 of the TPD requires that manufacturers communicate all tobacco ingredients 
information, together with available toxicological data, to the Member States. Member States 
communicate this information to the Commission.  
b) Regulation of ingredients 
TPD does not regulate how and by whom the ingredients shall be assessed and invites, in Article 
12, the Commission to submit a proposal providing for a common list of ingredients. Such a 





                                                 
24 Tobacco Plain Packaging Act 2011 
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A.3.1.3.2. The situation in Member States 
a) Reporting 
Despite the development of EU guidelines25 on an electronic model for reporting of ingredients 
data (EMTOC), different reporting formats (e.g. paper, CDs, electronic) are still used for the 
submissions of tobacco product information. The use of the electronic model for data submission 
(EMTOC) is legally binding in Austria and Romania and six other Member States (Belgium, 
Denmark, Germany, Malta, Netherlands and Poland) use the model on a voluntary basis. 
Additional Member States are planning to start using the model in the years to come.  
b) Regulation of ingredients 
Fourteen Member States regulate ingredients in their national law, while 13 Member States have 
no specific rules in place in addition to the TNCO-levels required in the TPD.26 Poland bans the 
use of ingredients, which enhance the addictive properties of tobacco.27 Most of the current 
regulations are based on toxicology considerations and many lists have found inspiration from 
food legislation. Four Member States (Belgium, France, Romania, and the UK28) have introduced 
positive lists indicating ingredients which are allowed to be used in tobacco products. Lithuania 
has introduced a negative list which restricts specific additives (e.g. vanilla root and clove) from 
being included in tobacco products and the Czech Republic, Germany, Hungary, Bulgaria29 and 
Slovakia have a combination of positive and negative lists. The positive lists of Germany, the 
Czech Republic and Hungary are very detailed and include several hundreds of ingredients. 
Finland and Spain also have lists of permitted substances but these are very broad and cannot be 
interpreted as a positive list. In 2009, France adopted a legislation focusing more on the 
attractiveness of certain tobacco products. The French law allows setting up maximum levels for 
ingredients that impart a sweet or fruity/acid taste to cigarettes (article D3511-16 of the French 
public health code). In Sweden, there is no positive or negative list but it is possible to regulate 
ingredients on an ad-hoc basis. Member States are also taking different legal approaches as 
regards additives integrated in the filter of cigarettes.  For example, Germany does not allow 
cigarettes with flavoured capsules embedded in the filter to be placed on the market. A national 
court recently confirmed this approach.30 Also in Belgium 3 ingredients ('E418 gomme gellane, 
E133  « bleu brillant FCF », Medium Chain Triglycerides (MCT)) needed to include the 
“menthol capsules” in cigarettes were recently banned. 
A.3.1.3.3. The situation at international level 
The Conference of the Parties to the WHO FCTC has adopted partial guidelines for 
implementation of Articles 9 and 10 of the FCTC (regulation of content and tobacco products 
disclosure). The guidelines focus mainly on how to reduce the attractiveness of tobacco products 
in order to reduce the prevalence of tobacco use and dependence among new and confirmed 
users. More specifically, the guidelines recommend Parties to regulate, by prohibiting or 
                                                 
25 http://ec.europa.eu/health/ph_determinants/life_style/Tobacco/Documents/practical_guidance_en.pdf 
26 No information received from one Member State 
27 Art. 7a of the Health Protection Act against the Consequences of Tobacco Use 
28 The United Kingdom has maintained a voluntary agreement between the Department of Health and the manufacturers 




restricting, ingredients that may be used to increase palatability in tobacco products and that have 
colouring properties.31 The guidelines also recommend Parties to prohibit ingredients in tobacco 
products that may create the impression that they have a health benefit or that are associated with 
energy and vitality, such as stimulant compounds.  
A.3.1.4. Sales arrangements 
A.3.1.4.1. EU Legislation 
Distribution channels and sales arrangements are not regulated in the current TPD. Council 
Recommendation 2003/54/EC recommends that Member States remove tobacco from self-service 
displays in retail outlets, to restrict access to TVM and to restrict tobacco distance sale for general 
retail such as sales via the internet.32  
 
It is also recommended to require vendors of tobacco products to establish that tobacco 
purchasers have reached the age for purchase of tobacco products required in national law, where 
such an age limit exists.  
 
As regards distance sales, Article 36 of Council Directive 2008/118/EC of 16 December 200833 
concerning the general arrangements for excise duty, stipulates that tobacco products already 
released for consumption in one Member State, which are purchased by a consumer in another 
Member State and which are dispatched or transported to another Member State directly or 
indirectly by the vendor or on his behalf shall be subject to excise duty in the Member State of 
destination.   
 
While Directive 2000/31/EC of the European Parliament and of the Council of 8 June 2000 on 
certain legal aspects of information society services, in particular electronic commerce, in the 
internal market (Directive on electronic commerce) aims at facilitating electronic commerce, it 
allows, in Article 3, derogations necessary for the protection of public health.34  
A.3.1.4.2. The situation in Member States 
All EU Member States have age limits in place as regards purchasing of tobacco. The legal 
buying age is 18 years in 22 Member States and 16 years in the remaining five. 35   
a) Tobacco vending machines (TVM) 
Thirteen Member States have banned sale of tobacco from TVM completely36 and one Member 
State (Finland) that currently has restrictions in place has announced that it will introduce a full 
ban as of 2015.  
 
In the remaining thirteen Member States there are different types of restrictions in place to limit 
underage consumers’ uncontrolled access to tobacco products. Restrictions range from ID control 
                                                 
31 http://www.who.int/fctc/protocol/guidelines/adopted/guidel_2011/en/index.html 
32 http://eur-lex.europa.eu/LexUriServ/site/en/oj/2003/l_022/l_02220030125en00310034.pdf 
33 OJ L 9, 14.1.2009, p. 12–30 
34 OJ L 178, 17.7.2000, p. 1–16 
35 AT, BE, IT, LU and NL all stipulate that the legal age to purchase tobacco products is 16. 
36 Full ban is in place in Bulgaria, Cyprus, Estonia, France, Greece, Hungary, Lithuania, Latvia,  Poland, Romania, 
Slovakia, Slovenia, and the United Kingdom (as of 1 October 2011, in England only, rest of the UK to follow). 
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systems to other technical requirements or supervision of the TVM. Germany, Austria and Italy 
have ID-control systems in place, while other Member States have other restrictions such as locks 
(Belgium) or electronic or other kind of system (Portugal). More generally worded restrictions 
are in place in some Member States, where it is simply stated that the TVM needs to be 
supervised (Finland, Malta, the Netherlands37 and Spain), that the age limits must be respected 
(Czech  Republic and Luxembourg) or that sale by TVM must be regulated in the same way as 
sale of tobacco from a shop (Sweden).  
 
Some Member States also regulate where the TVM can be installed. Ireland and Denmark permit 
the use of vending machines only in licensed premises or retail stores. Portugal bans the use of 
vending machines in certain environments. In cases where tobacco vending machines do not have 
an age verification system, Germany limits the installation of tobacco vending machines to places 
that children and adolescents cannot access. However, in practice, most TVM in Germany have 
an age verification system. 
 
b) Tobacco promotion and display at point of sale (PoS) 
Currently, three Member States (Finland, Ireland and the UK38) and two EEA countries (Iceland 
and Norway) have introduced laws to prohibit the visible display of tobacco products at the PoS. 
Fourteen Member States (Austria, Denmark, France, Greece, Hungary, Latvia, Lithuania, 
Luxembourg, Malta, the Netherlands, Poland, Portugal, Sweden, and Spain) allowing PoS display 
have put in place restrictions or bans on promotion at point of sale. Approximately one third of 
Member States have no regulations in place for Point of Sale display.39 
c) Cross-border distance sale of tobacco 
Internet sale of tobacco is not allowed in nine Member States.40 Among those Member States, 
some (including France and Lithuania) have introduced outright ban on this type of sale. Others 
(including Austria, Bulgaria, Hungary, Latvia and Spain) only grant licences or permission to sell 
tobacco through other sales channels.  
 
Several other Member States have different restrictions in place as far as internet sale of tobacco 
is concerned. The restrictions range from licensing of the internet retailer (Cyprus, Denmark, 
Greece and Finland), to age limits (Czech Republic and Sweden) and advertising bans (Germany, 
Malta, Portugal and the UK). 
A.3.1.4.3. The situation at international level 
Article 16 (1d) of the FCTC includes measures to ensure that TVM are not accessible to minors 
in the list of measures that Parties can adopt in order to comply with their obligation to adopt and 
implement effective measures to prohibit the sale of tobacco products to persons under the age 
limit.    
 
                                                 
37 Vending machines must be placed in a spot where they can be supervised to make sure age restrictions are 
respected. Outdoor vending machines are not allowed. 
38 The UK has introduced legislation banning point of sale display in England for large shops from April 2012 and 
small shops from April 2015 (the rest of the UK to follow). 
39 BE, BG, CY, CZ, EE, DE, IT, RO, SI and SK.  
40 AT, BG, ES, FR, HU, IT, LT, LV and SK.  
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The guidelines for the implementation of Article 13 of the FCTC call on the Parties to ban 
display and visibility of tobacco products at point of sale since they constitute a  method of 
advertising and promotion.41 The same guidelines also recommend Parties ban TVMs. 
 
The guidelines for implementing Article 13 of the Convention also recommend Parties to ban 
internet sale of tobacco. 
A.3.1.5. Traceability and Security Features 
A.3.1.5.1. EU Legislation 
Only some elements of the current EU regulatory framework address traceability and security of 
tobacco products.  
  
Article 5(9) of the TPD stipulates that to ensure product identification and traceability, the 
tobacco product shall be marked in any appropriate manner, by batch numbering or equivalent, 
on the unit packet enabling the place and time of manufacture to be determined. Technical 
measures to apply these provisions should be adopted by comitology, but no such decision has 
been taken at this stage.   
 
Article 39 of Directive 2008/118/EC states that Member States may require excise goods to carry 
tax markings or national identification marks used for fiscal purposes. 
A.3.1.5.2. The situation in Member States 
Thirteen Member States42 have indicated they have transposed the requirement enshrined in Art 5 
(9) of Directive 2001/37/EC more or less literally. However, they did not provide any 
information on the concrete implementation. From other responses it can be concluded that such 
marking is de facto done by the tobacco industry (voluntarily or as part of their obligations under 
the legally binding agreements) (Cyprus, Denmark and Germany), or that further guidance or 
decisions by the Commission are awaited to implement the provision (Sweden).   
 
A.3.1.5.3. The situation at international level 
The FCTC defines illicit trade in Article 1: 
 
For the purpose of this Convention 'illicit trade' means any practice or conduct prohibited by law 
and which relates to production, shipment, receipt, possession, distribution, sale or purchase 
including any practice or conduct facilitating such activity. 
 
Article 15 FCTC establishes that the elimination of illicit trade in tobacco products is an essential 
component of tobacco control and outlines the measures that are to be implemented to combat 
illicit trade in tobacco products. Article 15 FCTC contains various provisions and obligations as 
regards illicit trade in tobacco products. According to paragraph 2, unit packets have to be 
marked in order to determine the origin and the point of diversion and to monitor, document and 
control the movement of tobacco products and their legal status. The development of a tracking 
                                                 
41 http://www.who.int/fctc/protocol/guidelines/adopted/guidel_2011/en/index.html 
42 AT, BG, FR, CZ, HU, LV, LT, LU, ES, PT, SI, SE and the UK 
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and tracing system forms part of Article 15 (2). Article 15 (4) (b) includes the requirement for 
Parties to "enact or strengthen legislation, with appropriate penalties and remedies, against illicit 
trade in tobacco products, including counterfeit and contraband cigarettes."    
 
In 2008, it was decided to start negotiations for a Protocol (a stand alone international Treaty) 
based on Article 15 FCTC to eliminate the illicit trade in tobacco products. These negotiations 
have resulted in the adoption of the Protocol in November 2012. The Protocol will make a major 
contribution in the global fight against illicit trade in tobacco products.  
 
The core provisions of the protocol relate to the control of the supply chain for tobacco products 
through notably licensing (or equivalent approval), due diligence, record keeping, control of duty 
free sales, of internet sales and of free zones and a tracking and tracing regime.  
Apart from legislation, it should be noted that the EU Commission and the Member States have 
also engaged with legitimate traders in order to address the illicit trade issue. Starting from 
litigations, the European Union and the participating Member States have signed four legally 
binding and enforceable multi-year Cooperation Agreements with the four largest tobacco 
manufacturers43. These Agreements ensure that the manufacturers carry out certain procedures to 
prevent the diversion of their products into illicit trade channels. These agreements with the 
tobacco manufacturers have led to positive results, notably in reducing the illicit trade in genuine 
products, for which case seizure payments have to be paid by the respective manufacturer. In case 
of counterfeit products, the consequences under the agreements are less severe. The agreements 
do not address the issue of “illicit white” cigarettes destined for the EU market.    
 
Generally speaking it should be noted, that these agreements are at different stages of 
implementation, that they solely cover cigarettes and fine cut tobacco for smoking and that only 
the four largest tobacco manufacturers are covered.  
                                                 
43  Philip Morris International (July 2004), Japan Tobacco International (December 2007), British American Tobacco 
(July 2010) and Imperial Tobacco Limited (September 2010) 
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A.3.2. PART II: THE TOBACCO PRODUCTS DIRECTIVE IN RELATION TO THE FCTC OBLIGATIONS AND COMMITMENTS  
 
 
Policy Area TPD FCTC and Illicit trade protocol (legally 
binding) 
Guidelines or other relevant WHO docs Preferred options in revised TPD 






Article 2(1) tobacco 
products  
 
STP fall inside the scope 
of FCTC.  
 
NCP and herbal products 
fall outside the scope of 








STP fall inside the scope of FCTC.  
 
NCP and herbal products fall outside the 
scope of the FCTC, but some provisions 
could be relevant, for example Article 
5(2b) requiring Parties to adopt and 
implement…effective measures…for 
preventing and reducing …nicotine 
addiction…", Art 13(2) no indirect 
promotion of a tobacco product,  Art 16(1) 
prohibit the manufacture and sale of any 
objects in the form of tobacco products 





WHO Technical Report, 1988 
-Recommends that countries with no established 
smokeless tobacco habit should consider a ban 
on the manufacture, importation, sale and 
promotion of smokeless tobacco products before 
they are introduced to market or become 
established habit.1 
WHO Study Group on Tobacco Product 
Regulation (TobReg) 2009 
 
-STP: Recommendations on limits for 
carcinogenic components for carcinogenic 
components: Tobacco specific N-nitrosamines 
(TSNA) and polycyclic aromatic hydrocarbons 
(PAH).2  
 
-Electronic cigarettes: Recommendation to 
regulate as combination drug and medical 
devices and not as tobacco products.  
 
-Report by the Convention Secretariat to 
Conference of the Parties (CoP)  to the FCTCand  
CoP5: no conclusive guidance on how to regulate 
the products. 
STP (option 3): Maintain the ban on oral tobacco, subject 
all novel tobacco products to a notification obligation and 
all STP placed on the market to stricter labelling and 
ingredients regulation plus a clearer definition of chewing 
tobacco. 
-Stricter than current TPD. 
-In line with WHO Technical Report 1988  
-In line with general principle in FCTC Article 4 (4) adopt 
measures to reduce consumption of all tobacco products.  
 
NCP (option 3): Subject NCP over a certain nicotine 
threshold to the medicinal products' legislation and the 
remaining NCP to labelling requirements 
-Outside current TPD 
-In line with WHO TobReg recommendation.  
-In line with FCTC Article 5(2) to prevent and reduce nicotine 
addiction, and Article 14 to ensure that the effectiveness of 
tobacco cessation treatments is scientifically proven. 
Herbal products for smoking (option 1): Health warning 
-Outside both TPD and FCTC.  
Packaging and 
labelling  
TPD Article 5  
 
All tobacco products must 
carry one general text 
FCTC Article 11 
 
Large, clear, visible and legible health 
warnings should be 50% or more of the 
The FCTC guidelines Article 11  
 
-Parties should consider using health warnings 
covering more than 50% of the display areas.  
Option 2: 75% combined warnings on both sides, 
cessation information, no promotional or misleading 
elements, Member States allowed to regulate surface not 
regulated by TPD or other legislation if compatible with 
                                                 
1 The scientific basis of tobacco product regulation. Second report of a WHO Study Group. Geneva, World Health Organization, 2008 (WHO Technical Report Series, No. 951). Available 
from:  http://www.who.int/tobacco/publications/prod_regulation/tsr_951/en/index.html 
2 However, the report does not recommend STP to be put on the market. 
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Policy Area TPD FCTC and Illicit trade protocol (legally 
binding) 
Guidelines or other relevant WHO docs Preferred options in revised TPD 
(IA Report, chapter 4) 
warning covering not less 
than 30% of the most 
visible side of the package 
and one additional text 
warning covering not less 
than 40% of the other 




should display the results 
of tar, nicotine and carbon 
monoxide (TNCO) yield 
measurements.  
 
The Commission has the 
power to take rules on the 
use of pictorial warnings 
that Member States have 
to comply with if they 
decide to introduce 
combined warnings 
(picture plus text).  
 
The pictorial warnings 
should, together with the 
additional text warning, 
cover 40% of the other 
most visible side of the 
package.3  
 
TPD Article 7 
Text, names, trade marks 
and figurative and other 
signs suggesting that a 
tobacco product is less 
harmful than others should 
principal display areas but no less than 
30%. They may be in the form of or 
include pictures or pictograms. 
 
-information on relevant constituents and 
emissions of tobacco products as defined 
by national authorities. 
 
-packaging and labelling should not 
promote a tobacco product by any 
means that are false, misleading, 
deceptive or likely to create an erroneous 
impression about its characteristics, 
health effects, hazards or emissions, 
including any term, descriptor, trademark, 
figurative or any other sign that directly or 
indirectly creates the false impression that 
a particular tobacco product is less 
harmful than other tobacco products. 
These may include terms such as “low 
tar”, “light”, “ultra-light”, or “mild”.  
 
FCTC Article 16(3)  
Each party shall endeavour to prohibit the 
sale of cigarettes individually or in small 
packets, which increase the affordability 
of such products to minors'.   
 
 
-Parties should consider pictorial health 
warnings on both principal display areas.  
 
-Health warnings and messages should in 
addition to harmful effects address different 
issues such as advice on cessation.  
 
-Parties should prohibit the display of figures for 
emission yields such as TNCO.   
 
-Parties should consider adopting measures to 
restrict or prohibit the use of logos, colours, brand 
images or promotional information on packaging 
other than brand names and product names 
displayed in a standard colour and font style 
(plain packaging). This may increase the 
noticeability and effectiveness of health warnings 
and messages, prevent the package from 
detracting attention from them, and address 
industry package design techniques that may 
suggest that some products are less harmful than 
others. 
 
The FCTC guidelines Article 13  
Packaging and product design are important 
elements of advertising and promotion. Parties 
should consider adopting plain packaging 
requirements to eliminate the effects of 
advertising or promotion on packaging. 
Packaging, individual cigarettes or other tobacco 
products should carry no advertising or 
promotion, including design features that make 
products attractive. 
 
FCTC guidelines Article 9 and 10 –Parties 
should prohibit or restrict ingredients that have 
colouring properties in tobacco products.  
the Treaty: 
-Stricter than current TPD 
-In line with FCTC Article 11. 
-Less strict than FCTC guidelines for Article 11 and 13 in 
terms of plain packaging, but Member States are allowed to 
implement fully the guidelines as not all the elements of the 
packaging are regulated by the Directive. Other aspects of 
guidelines are respected (cessation, warning size, both sides 
of pack, no TNCO display, no promotional elements)  
                                                                                                                                                                                                                                                             
3 This figure is increased to 45% in MSs with two official languages and 50% in MS with three official languages. 
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Policy Area TPD FCTC and Illicit trade protocol (legally 
binding) 
Guidelines or other relevant WHO docs Preferred options in revised TPD 
(IA Report, chapter 4) 
not be used.  
Ingredients TPD Article 6  
Manufacturers are 
required to communicate 
all tobacco ingredients 
information, together with 
available toxicological 
data, to the Member 
States. Member States 
communicate this 
information to the 
Commission. 
 
TPD Article 12 
The Commission is invited 
to submit a proposal 
providing for a common 
list of ingredients. (Such a 
proposal has not yet been 
submitted.) 
FCTC Article 9 
Guidelines shall be proposed for the 
regulation of ingredients. Parties shall 
adopt and implement effective measures 
for such regulation.  
 
FCTC Article 10 
Each Party shall adopt and implement 
effective measures to disclose to 
governmental authorities information 
about content and emissions.  
Each Party shall adopt effective measures 
for public disclosure of information on  
toxic constituents and emissions. 
FCTC guidelines Article 9 and 10 
 
-Parties should regulate, by prohibiting or 
restricting, ingredients that may be used to 
increase palatability in tobacco products and 
that have colouring properties. 
 
-Parties should prohibit ingredients in tobacco 
products that may create the impression that they 
have a health benefit or that are associated 
with energy and vitality, such as stimulant 
compounds. 
 
-Parties should consider making information 
about the toxic constituents and emissions 
disclosed to governments publicly available.   
 
Option 2: Ban products with characterising flavours, 
common reporting and information publicly available. 
-Stricter than current TPD.  
-In line with FCTC Article 9 and 10 










that Member States 
restrict tobacco distance 
sale for general retail such 
as sales via the internet.   
 
FCTC Article 16 (1d) 
 
Parties shall adopt measures to prohibit 
the sale of tobacco to under-aged 
persons. The future Protocol on illicit 
trade foresees in Article 11 (1) that 
Parties shall require that all legal and 
natural persons engaged in any 
transaction with regard to tobacco 
products through Internet-, 
telecommunication- or any other evolving 
technology-based modes of sale comply 
with all relevant obligations, including 
licensing.  Article 11 (2) provides that 
Parties shall consider banning retail sales 
of tobacco products through Internet, 
telecommunication or any other evolving 
technology.  
FCTC guidelines Article 13FCTC  
 
-Internet sales of tobacco should be banned as 





Cross-border distance sale (option 1): Notification of 
retailers: 
-Outside current TPD. 
-In line with Illicit Trade Protocol.  
-Less strict than FCTC guidelines for Article 13. 
- 
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Policy Area TPD FCTC and Illicit trade protocol (legally 
binding) 
Guidelines or other relevant WHO docs Preferred options in revised TPD 




TPD Article 5(9) 
 
Tobacco products shall be 
marked in any appropriate 
manner, by batch 
numbering or equivalent, 
on the unit packet 
enabling the place and 
time of the manufacture to 
be determined. 
 
Technical measures shall 
be adopted by 
"comitology". (This has not 
been done). 
FCTC Article 1 
 
For the purpose of this Convention 'illicit 
trade' means any practice or conduct 
prohibited by law and which relates to 
production, shipment, receipt, possession, 
distribution, sale or purchase including 
any practice or conduct facilitating such 
activity. 
 
FCTC Article 15  
 
The elimination of illicit trade in tobacco 
products is an essential component of 
tobacco control.  Article 15 FCTC contains 
various provisions and obligations as 
regards illicit trade in tobacco products. 
According to paragraph 2, unit packets 
have to be marked in order to determine 
the origin and the point of diversion and 
to monitor, document and control the 
movement of tobacco products and 
their legal status. The development of a 
tracking and tracing system forms part of 
Article 15 (2). Article 15 (4) (b) includes 
the requirement for Parties to "enact or 
strengthen legislation, with appropriate 
penalties and remedies, against illicit 
trade in tobacco products, including 
counterfeit and contraband cigarettes."  
 
Protocol on illicit trade  
 
The provisions relevant for the TPD 
revision relate to a tracking and tracing 
regime. (Part III of the Protocol on Supply 
Chain Control) 
 
 Preferred option 2: Tracking and tracing system plus 
security feature 
-Stricter than current TPD. 
-Compatible with FCTC Article 15 and Illicit Trade Protocol.  
 








A.3.3. PART III: LEGISLATION IN MEMBER STATES 
A.3.3.1. Regulation of STP and possible extension of the scope 
MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 




Allowed, only snus forbidden (see § 2 Abs. 1 
lit. 2 Tabakgesetz)  
Regarded as medicinal products by function if the product contains 
nicotine or other pharmacologically active substances and/or by 
presentation if the product is promoted for smoking cessation or 
treatment of nicotine addiction (see § 1 Arzneimittelgesetz). In this 
case the apparatus is also regulated as a medical device (see § 5(1) 
Medizinproduktegesetz). 
Regarded as medicinal products by function if the product contains a 
pharmacologically active substance and/or by presentation if the 
product is promoted for smoking cessation or treatment of nicotine 
addiction (see § 1 Arzneimittelgesetz). If an apparatus is used, it will 
be regarded as a medical device if it is intended to be used with a 
medicinal product (see § 5(1) Medizinproduktegesetz). 
Belgium 
 
 With nicotine regarded as pharmaceuticals by function and/or 
presentation.  
- Considered as tobacco products if it contains tobacco extract  
- considered as pharmaceuticals by function if it contains nicotine without 
containing tobacco extract. 
- considered to be pharmaceutical by presentation if, even without nicotine, 
there are claims that it helps to quit smoking 
Royal decree of 13 August 1993 regulating tobacco products refers 
to   “product that replace tobacco” (art. 1, 5°). Herbal cigarettes are 
considered to be part of this category. Subject to the same positive 
ingredients list as tobacco products. No authorisation needed. 
http://www.health.belgium.be/internet2Prd/groups/public/@public/@
dg1/@mentalcare/documents/ie2law/15760531_fr.pdf 
Bulgaria The chewing and nasal tobacco products are 
not banned and they are available at the 
market in Bulgaria. Only the oral tobacco 
products are banned for selling in accordance 
with the Tobacco Product Directives (TPD) 
2001/37/EU and the Law for Tobacco and 
Tobacco Products. 
Not regulated as a pharmaceutical or medicine device by legislation. 
The regulation is only under the Consumer Protection Act. 
The position of MoH is that the scope of the TPD have to be widened 
and could be called Directive for Tobacco and Tobacco Imitative 
products (whith an external or internal imitative chacteristics of tobacco 
products by shape, contents, name etc.). According to (3) and (4) 
paragraphs of the Preamble of TPD 2001/37/EU we have to protect the 
individual and public health by the TPD. The future Directive have to 
forbid each novel tobacco or tobacco imitative product and should list 
the old and already aproved tobacco products. The main arguments 
are: 1) that tobacco industry will become as more creative as more the 
public invented instruments will press industry and restrict its industry 
Not regulated. There is not an information to be sold in Bulgaria. 
They fall under the text which is written for the electronic cigarettes 
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MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 
Herbal products (herbal cigarettes and other non-tobacco and non-nicotine 
products) 
activities; 2) there is not a safty level of consumption of tobacco or 
tobacco imitative products; 3) we have to put combined health warning 





Chewing tobacco non-banned by Dir 2001/37 
is permited to be marketed in Cyprus. 
Although such product are only popular 
among ethnic groups. 
Regarded as medicinal products by presentation provided they are sold 
as a product to quit smoking. In the market there are also nicotine 
containing products which are not regarded as medicinal products but 
rather “nicotine consumer or leisure products. Such products are not 
regulated. 




These kinds of products are not banned and 
they are available on the market in CZ (only 
tobacco for oral use is banned). 
 
 
Electronic cigarettes are not regulated explicitly as regards status of 
product : If presented as a product for tobacco cessation treatment -
considered as pharmaceuticals in combination with medical device 
(however,no registrated electronic cigarette in this regard so far). If this 
function not presented - general product safety law applies.  
 
There is a definition in Act no. 379/2005 Coll. on measures for protection against the 
harmful effects of tobacco products, alcohol and other addictive substances and on the 
amendment of related laws, as subsequently amended. According to this act sale of 
electronic cigarettes to minors (less than 18 yers old) is prohibited. (since July 2010).  
Herbal products are not regulated as regards status of the product 
etc. However, they are taxed as other tobacco products (Act No. 
353/2003 Coll., on Excise Duties, as subsequently amended) 
Denmark 
 





With nicotine regulated as pharmaceuticals due to the pharmacological 
function of the nicotine.  
Not regulated by Law on Tobacco Products but herbal cigarettes are 
like tobacco cigarettes covered by Law on smoke-free environment.  
 
https://www.retsinformation.dk/Forms/R0710.aspx?id=11388 
Estonia  Electronic cigarettes are regarded as pharmaceuticals if with nicotine.  Herbal cigarettes are not classified as pharmaceuticals. They are 
taxed like other tobacco products. 
Finland Chewing and nasal tobacco are regulated as 
the other tobacco products by Tobacco Act. 
Treated as pharmaceutical products but with problems. Nicotine 
cartridges are classified as medicinal products by function.  
 
Possible ban coming on all nicotine products other than medicine and 
pesticides. 
 
The Finnish Medicines Agency (Fimea) is the national competent 
authority for regulating pharmaceuticals.  
Fimea considers nicotine cartridges as medicine. Furthermore, it has 
been equated with a prescription drug (Fimea’s statement given to the 
Customs laboratory on 27 September 2010). The plastic device or 
transformer or the nicotine-free cartridge are not considered medicine. 
Not regulated in Tobacco Act. However, advertising of tobacco 
imitations is banned. 
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MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 
Herbal products (herbal cigarettes and other non-tobacco and non-nicotine 
products) 
The product cannot be sold in Finland without license.  
Fimea has specified its opinion for the classification on 23 November 
2010. It still classifies the nicotine cartridge and nicotine solutions as a 
medicine irrespective of the concentration. However if the amount of 
the nicotine exceeds 0,42 grams in the whole product or 10 mg in one 
portion (cartridge) it must be considered as a prescription drug. If the 
nicotine content is lower than this, prescription is not needed. 
There has been at least one case in Vantaa district court (16.2.2011), 
where a man was freed from medicine offence charges because the 
court thought that the portions were small and therefore did not need a 
prescription. Tobacco Act bans advertising of tobacco, tobacco 




The manufacturing, the sale and the 
distribution of tobacco products for oral use 
are forbidden with the exception of those 
which are intended to be smoked or chewed. 
 
Nasal tobacco products are authorized 
If presented as cessation treatment, whatever the nicotine dosage, the 
product is regarded as a medicinal product.  
If not presented as cessation treatment, regarded as a medicinal 
product by function if the quantity of nicotine within the vial is equal or 
above 10 mg nicotine or if the refill solution has a nicotine 
concentratioon equal or above 20 mg/ml.  
If not medicinal products according to the description above, the 
General Product Safety Directive applies.  
French consumer code provides rules of security.  
Some plants are regulated upon pharmaceutical monopoly and as 
such are medicinal products by presentation.  
Herbal cigarettes presented as tobacco cessation treatment are also 
medicinal products.  
Other herbal products are considered as products of general 
consumption and must answer to the general rules of security 




 Nicotine containing liquids in electronic cigarettes have been qualified 
as medicinal products (a few special products). Therefore, a marketing 
authorization according to the German Medicinal Products Act is 
required prior to any marketing of these products. No marketing 
authorizations for electronic cigarettes have been granted yet. Without 
this authorization a marketing would be unlawful. The execution of the 
German Medicinal Products Act falls within the competencies of the 
German Federal States. Accordingly, if the Federal States authorities 
notice an unlawful sale or offering of electronic cigarettes (containing 
nicotine) they ought to prohibit it. 
There are currently court proceedings pending regarding the 
classification of electronic cigarettes as medicinal products. 
Taxed as tobacco products. Exception: products containing no 
tobacco and used exclusively for medical purposes under German 




Common Minister Decision 266/2001, art.8. 
According this decision chewing tobacco is 
Prohibited under the new tobacco legislation unless approval by the 
Ministry of Health.   
Prohibited under law 3730/23.12.08, art.2, par.1&2 unless a) they 
have received approval by the Ministry of Health that they present a reduced 
health risk compared to conventional tobacco products, or, b) they have 
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MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 
Herbal products (herbal cigarettes and other non-tobacco and non-nicotine 
products) 
banned  
Law 3730/23.12.08, art. 2, par. 1 & 2. 
Art. 2 Regulations for tobacco products 
1. From the date of publication of this law, it is forbidden: 
………………………….. 
c) The manufacture, promotion, trading and sale of objects that have the 
external shape of tobacco products, as well as the electronic cigarette, with 
the reservation of paragraph 2 of this Article. 
2.  “From the date of publication of this law, it is forbidden, without previous 
approval by the MoH: … 
 i) any accompanying indication on the packaging of tobacco products or any 
other form of communication, according to which the use of tobacco products 
presents a reduced health risk and 
 ii) the circulation of products that are intended for the cessation of smoking. 
The conditions for the granting of such an approval, as well as the relevant 
procedure, will be determined by a Common Decision by the Minister of Health 
and the Minister of Development.” 
 
received approval by the National Medicines Organization that they can be 
used as a tool for smoking cessation 
 
Law 3730/23.12.08, art. 2, par. 2. Art. 2 Regulations for tobacco 
products 
1. From the date of publication of this law, it is forbidden: 
………………………….. 
c) The manufacture, promotion, trading and sale of objects that have the 
external shape of tobacco products, as well as the electronic cigarette, 
with the reservation of paragraph 2 of this Article. 
2.  “From the date of publication of this law, it is forbidden, without 
previous approval by the MoH:  
i) any accompanying indication on the packaging of tobacco products or any 
other form of communication, according to which the use of tobacco 
products presents a reduced health risk and … 
 ii) the circulation of products that are intended for the cessation of smoking. 
The conditions for the granting of such an approval, as well as the relevant 
procedure, will be determined by a Common Decision by the Minister of 




Additives regulated in Annex 2 and 4 to 
Decree 102/2005 (X. 31.) FVM which applies 
to tobacco products in general, involves 
chewing tobacco as well (the reference will 
change with the adoption of the new tobacco 
products decree, but content remains the 
same) 
 
Not regulated explicitly, but regarded as medicinal products by 
function.  
Interested parties (prospective manufacturers, distributors, their legal 
representatives, consumer protection organs) receive the following 
information: nicotine is contained as an active pharmacological 
ingredient in the European Pharmacopoeia. It has pharmacological 
action undoubtely. Some authorized pharmaceutical products contain 
1,5 mg nicotine per unit and the pharmacological efficacy has been 
recognized by the competent authority. Consequently, nicotine 
containing electronic cigarettes are considered as medicinal products 
by function. 
 
Not regulated explicitly,  they are considered as consumer products 
as long as they do not fall under the definition of pharmaceutical 
products by function. 
 
Interested parties have been asked to provide the national 
competent authority with the exact composition to decide whether 
pharmacological action plays a role in the claimed use. If not, it 
would not be a medicinal product. Some of these questions 
remained unanswered. Some products contained medicinal herbs, 
the prospective applicant could not exclude pharmaceutical action.  
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MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 




The Tobacco (Health Promotion and 
Protection) Act, 1988 prohibits the  
importation, manufacture, sale, disposal, offer 
for sale or other disposal, or advertisement of 
oral smokeless tobacco (defined as product or 
substance, made wholly or partly from 
tobacco, which is intended for use, unlit, by 
being placed in the mouth and kept there for a 
period, or by being placed in the mouth and 
sucked or chewed). 
Not regulated. Electronic cigarettes currently on the Irish market are 
not presented as medicinal products for smoking cessation or as 
medical devices with therapeutic purpose.  
If presented as medicine, containing medicinal claims etc. the product 
would be regulated as medicinal product. However, Ireland has had 
difficulties in classifying nicotine as a medicinal product (i.e. by 
function) because there are other products on the market containing 
nicotine which produce pharmaceutical effect but which are clearly not 
medicines, eg tobacco products.In addition, nicotine has other uses, 
such as pesticide.  
Not regulated. 
Italy  Electronic cigarettes are at not regarded as medicinal products in Italy.  
Decreto legislativo 14 marzo 2003, 65 regulates the labelling of 
dangerous substances. A decree forbidding the sale of electronic 
cigarettes to persons aged less than 16 years has been issued.  
The herbal cigarettes are under the same legislation as tobacco 
products except if they are registered as medicinal products.  
Latvia 
 
All chewing and nasal tobacco products are 
banned.  
 
Law On Restrictions Regarding Sale, 
Advertising and Use of Tobacco Products 
Section 5. Restrictions on the Manufacture, 
Sale and Release for Free Circulation of 
Tobacco Products and Herbal Smoking 
Products 
It is prohibited: 
1) to sell snuff and chewing tobacco;  
7) to sell tobacco products for oral use. 
 
Electronic cigarettes and nicogel - Not specially regulated. 
 
Electronic cigarettes follow the rules as for all consumers’ products 
(Directive 2001/95/EC of the European Parliament and of the Council of 3 December 
2001 on general product safety). 
Electronic cigarettes follow the Unfair Commercial Practice Prohibition 
Law. The purpose of this Law is to ensure the protection of the rights 
and economic interests of the consumers by prohibiting the performers 
of commercial practices from utilizing unfair business-to-consumer 
commercial practices. (Consumer Rights Protection Centre has made 
some administrative decisions about misleading advertising, for 
instance, electronic cigarettes were advertised as healthier and 
cheaper products than conventional cigarettes.) 
Electronic cigarettes are sold in shops and on Internet. 
Nicogel is sold on Internet or using distance selling possibility (through 
catalogues), for example, 
http://www.hansapost.lv/pl/nicogel_sma_aizvietotjs/220303017 
Electronic cigarettes are mostly sold as alternative to traditional 
(conventional) cigarettes. 
Nicogel is sold as smoking replacement. Latvia does not consider 
these products as pharmaceuticals. When electronic cigarettes 
appeared on the market, there was an interest from merchants to sell 
them as cessation product. 
Herbal cigarettes fall under the Law On Restrictions Regarding Sale, 
Advertising and Use of Tobacco Products (amended from 4 March 
2010).  
Herbal smoking products are defined as plants or plant ingredients 
(for example, industrially produced herbal cigarettes, industrially 
produced mixtures of plants for rolling up), which are intended for 
smoking and do not contain tobacco.  
Each packaging unit of herbal smoking products to be sold in Latvia 
shall display the following: 
1) an indication in the official language of the tar and carbon monoxide yields in 
milligrams per cigarette; and 
2) an attached excise duty stamp. 
It is prohibited to place on the packaging of herbal smoking products 
texts, names, trade marks or other signs indicating that the particular 
product is less harmful than tobacco products. Herbal cigarettes 
have requirements for smoke-free environments. It is prohibited to 
sell them to persons who are under 18 years of age. 
Herbal cigarettes are taxed as tobacco products (law On Excise Duties). 
No regulations on ingredient rules in place, no need to submit to the 
Health Inspectorate of Latvia a list of all ingredients. 
Latvia does not consider herbal cigarettes as pharmaceuticals. 
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MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 




Marketing of all forms of tobacco intended for 
oral use and snuff is prohibited by the Law on 
Tobacco Control. 
No specific legislation, but all imitation products are banned by the Law 
on Tobacco Control.  
The ban also covers non-nicotine products: 
Law on Tobacco Control: 
Article 18. Other Prohibitions related to Tobacco Products 
1. It shall be prohibited in the Republic of Lithuania:  
8) to manufacture and/or sell toys, food products and other goods 
whose design imitates tobacco products or packaging 
No specific legislation, but all imitation products are banned by the 
Law on Tobacco Control.  
The ban also covers non-nicotine products, including Herbal 
cigarettes. 
Law on Tobacco Control: 
Article 18. Other Prohibitions related to Tobacco Products 
1. It shall be prohibited in the Republic of Lithuania:  
8) to manufacture and/or sell toys, food products and other goods 
whose design imitates tobacco products or packaging 
Luxembourg  - Considered as tobacco products if they contain tobacco extracts. 
- Considered as pharmaceuticals by function and/or presentation, if 
they contain nicotine without containing tobacco extract, and/or if 
presented as cessation treatment. 
- Electronic cigarettes not yet regulated specifically (probably they will 
be considered as pharmaceuticals if they contain nicotine and are used 
in smoking cessation treatment) 
Not regulated.  
Malta 
 
 With nicotine,  regulated under tobacco act – requirements for labelling, 
no advertising, no cessation claims and smoke-free environments 
requirements apply 
Any product labelled as tobacco or intended to substitute a tobacco 
product is legally considered as a tobacco product and therefore 
legislation on advertisements and smoking-free environments apply. 




We have implemented the definition of 
tobacco products as mentioned in the current 
directive. Any other products which do not fall 
under the scope of the Directive are not 
specifically regulated. 
Considered pharmaceutical by function or presentation if it contains 
nicotine.  
Herbal cigarettes without tobacco are not regulated.  
Poland 
 
All smokless tobacco, with exception of nasal 
tobacco powder are banned (Art. 7 of the 
Health Protection Act against the 
Consequences of Tobacco Use of 9 
November 1995) 
Electronic cigarettes are not regarded as medicinal products.  




Portugal Chewing tobacco non-banned by Dir 2001/37 
is permited to be marketed. Although such 
product are not very popular among the 
Portuguese population. 
According to a Informative Provision by the portuguese National 
Autority on Medicines and Health Products (INFARMED) electronic 
cigarettes containing nicotine should be regarded as medicinal 
products by presentation and/or function. 
Not regulated 
Romania  Regarded as medicinal products by function.  Not regulated 
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MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 
Herbal products (herbal cigarettes and other non-tobacco and non-nicotine 
products) 
Slovakia  Regarded as medicinal products by function.  
Act no. 377/2004 in protecting of non-smokers – total ban on selling 
and smoking electronic cigarettes in public places such as schools, bus 
stations, hospitals and cinemas. Smoke-free environments. 
Act no. 377/2004 in protecting of non-smokers Restriction on sale 
and smoke-free environments (applies to all products where the 
method is smoking). 
Slovenia 
 
 If presented as cessation treatment, regulated  as pharmaceuticals; if 
not covered by the General Product Safety Directive. 
 
If containing even a small amount of tobacco regulated under 
Restriction of the use of tobacco products act, otherwise not 
regulated.  Available but not popular 
Spain 
 
Not banned but there are no products 
marketed. Regulated under same legislation 
that tobacco products as smokless tobacco 
products. 
No specific regulation. Electronic cigarettes have not been considered 
medicinal products,unless the intented use falls under the definition of 
medicinal product. The products have been considered recreational 
consumer products without therapeutic indications.  
Protection of consumers' interests Directive (1) and General Product 
Safety Directive applies (2) 
No specific regulation,unless the intented use falls under the 
definition of medicinal product. Protection of consumers' interests 




The Swedish National Institute of Public 
Health is the regulatory agency regarding the 
parts in the Tobacco Act (1993:581) 
concerning Dir. 2001/37/EG. 
 
Chewing, sucking (snus) and sniffing (nasal) 
tobacco are regulated, as any other tobacco 
product, by the Tobacco Act (1993:581), 
according to the definition in article 2 of Dir. 
2001/37/EC.  
 
The Swedish Food Agency regulates 
additional requirements as stipulated by the 
food regulations in e.g. LIVSFS 2012:6 for 
chewing and sucking tobacco (i.e. snus), but 
not sniffing (nasal) tobacco, regarding e.g. 
permitted food additives, flavours, new 
ingredients, labelling, hygiene, hazard 
analysis and critical control points, traceability, 
contaminants, and materials and products in 
contact with chewing and sucking (i.e. snus) 
tobacco.  
 
The production of chewing and sucking 
tobacco (i.e. snus) has further to comply with 
Products containing purely nicotine are not regulated by the Tobacco 
Act (1993:581) but are generally classified as medical products since 
nicotine has a well-known pharmacological effect on the body 
according to section 1 point 2 of the Medicinal Products Act 
(1992:859).  
 
The Medical Products Agency regulates and classifies nicotine 
containing products, which do not contain tobacco. The Medical 
Products Agency classifies the ampoules/filters of “electronic 
cigarettes”, but not the “cigarette” itself. The classification applies 
irrespective of the intended use, as stated by the seller. The products 





Herbal products are not regulated according to the Tobacco Act 
(1993:581) but may be taxed as tobacco product according to 
section 1 e of the Act (1994:1563) on Excise Duties on Tobacco. For 
example herbal cigarettes (if not solely used for medical purposes), 
but not herbal non-tobacco “snus”, are taxed as tobacco products. 
Taxes are regulated and collected by the Swedish Tax Agency.   
 
Herbal non-tobacco “snus” for sucking, but not herbal cigarettes for 
smoking, are regulated according to the Food Act (2006:804), the 
Food Decree (2006:813) and other food regulations. 
 
The general issue of how electronic cigarettes e.g. without nicotine 
should be interpreted and regulated is currently being investigated 
by the Government, regarding for example market surveillance 
responsibility for ensuring safety and other compliance issues. 
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MS Chewing and nasal tobacco (i.e. non-
combustible products not banned by Dir 2001/37) 
Nicotine containing products (electronic cigarettes and poss. other 
products) 
Herbal products (herbal cigarettes and other non-tobacco and non-nicotine 
products) 
food regulations section 3 point 2 of the Food 
Act (2006:804) and the local authority may 
exercise control and can issue e.g. injunctions 





 Not regulated at present (other than by General Product Safety 
Directive).  Consideration is being given to regulation of all nicotine 
containing products as medicinal products by function.  
Products not regulated but smokefree legislation prohibits smoking 
of anything in enclosed work and public places (including specified 
vehicles) 
Iceland  Regarded as medicinal products both by presentation and function.  Under tobacco act 
 
Norway Labelling requirements are the same as 
regulation of oral tobacco products .In other 
areas chewing and nasal tobacco is regulated 
as other tobacco products under the Tobacco 
Control Act (i.e advertising ban, reporting 
requirements, display ban etc). The 
Norwegian Directorate of Health is the 
supervisory authority. 
New products with tobacco or nicotine are prohibited 
Regulations no. 1044 of 13 October 1989 concerning the prohibition 
against new tobacco and nicotine products 
Section 2. Prohibition  
It is prohibited to produce, bring to Norway, sell or hand over to others new 
types of tobacco and nicotine-containing products. The same applies to 
tobacco and nicotine-containing products which are intended to be used in 
other ways than those normally practised in Norway.  
Section 3. Definitions  
In these regulations, the term ”new types” of tobacco and nicotine-containing 
products means all products containing tobacco or nicotine, with the exception 
of the products which, by tradition, are or have been sold in Norway (cigarettes, 
cigars, cigarillos, smoking tobacco, chewing tobacco and snuff).  
 
In these regulations, the expression ”intended to be used in other 
ways” means intake of tobacco and nicotine-containing products to the 
human body in ways other than the form of smoking, taking snuff and 
chewing used today. 
 
Electronic cigarettes and waterpipe/shisha tobacco are banned under 
this regulation.  
 
There is a limited derogation for private import of electronic cigarettes 
under medicinal products legislation. 
If herbal products contain nicotine and/or tobacco, they are covered 
by Regulations no. 1044 of 13 October 1989 concerning the 
prohibition against new tobacco and nicotine products.  
 
If they do not, herbal products are not directly covered by the 
Tobacco Control Act as they do not contain tobacco. However, 
herbal cigarettes and herbal snus may, in some cases, be covered 
by the display ban (section 5) as the display ban also covers 
“imitations of tobacco products”. They may also be covered by the 
ban on indirect advertising.  
 
Turkey    
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required size of 
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starting date of 










which products and 
specify, including 
starting date of 
actual use) 
Pictures used 
(how many? rotation, 
please specify) 
Are cessation services* 
included in warnings? 
(please specify) 
 
[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
Austria  
 
No legislation yet. No No -None Yes, included in one of the 
periodically changing warnings 
– not included in every 
warning. 
[The "Rauchertelefon", a 
cooperation project of the 
Austrian Social Security 
Insurance, the Austrian 
Provinces and the Austrian 
Federal Health Ministry, runs a 
cessation service including 
quitline, website and fax- and 
email-service.] 
Error! Bookmark not defined. 
Minimum 20 cigarettes in a 
pack.  The marketing of single 
cigarettes or unpacked 
cigarettes is also forbidden. 
Art. 5.9 of Dir 2001/37/EC 




pictures already in 
place 
Yes (from April 
2007) 
No 42 pictures divided 
into three sets 
alternating each 
year 
Yes (mandatory on all packs 





Belgian MP tabled a proposal 
for plain tobacco packaging in 
May 2011and the Belgian 
Minister of Health has stated 
(in the health commission of 
the parliament) that she will 
push for the adoption of plain 
packaging.5 
 
                                                 
4 see § 7 Abs. 1 Tabakgesetz 
5 http://www.lachambre.be/kvvcr/showpage.cfm?section=/flwb&language=fr&rightmenu=right&cfm=flwbn.cfm?lang=F&legislat=53&dossierID=1424 
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required size of 
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starting date of 










which products and 
specify, including 
starting date of 
actual use) 
Pictures used 
(how many? rotation, 
please specify) 
Are cessation services* 
included in warnings? 
(please specify) 
 
[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 




Work on the 
introduction of pictorial 
health warnings is 
ongoing. 
 
Since the end of 2011, 
as a result of dialog 
between two deputy 
ministers and experts – 
from MoH and Ministry 
of Economics, Energy 
and Tourism (MEET), a 
working group has been 
set up to amend and 
supplement the old 
Ordinance for labeling 
and packaging of the 
tobacco products. 
 
The  draft for  the 
amendment of the 
Ordinance for 
requirements for 
labeling, marking and 
external appearance of 
tobacco products is 
developed and it is in a 
procedure to be 
presented to the 
political cabinet of the 
The size of the 
pictures  is 50%. 
It’s difficult to 
predict the 
starting date of 




ordinance is not 
yet adopted and 
there will be a 
transitional 
period after the 
adoption. 
The size is 50%. 
It’s difficult to 
predict the 
starting date of 




ordinance is not 
yet adopted and 
there will be a 
transitional 
period after the 
adoption 
Generally all the 
42 pictures are 
used but they are 
divided on three 
groups and if they 
will be adopted,  
they will be rotated 
every 8 months. 
The period when 
two groups may 
meet each other is 
4 months. 
 
If adopted, one of the 
combined health warnings will 
contain reference to a National 
tobacco smoking telephone 
quit line 0700 10 323. In 
addition, on all the packages 
will be printed the National 
tobacco smoking telephone 
quit line 0700 10 323 and the 
web page www.aznepusha.bg 
of the National Tobacco 




lists of free-of- charge and 
paying cessation services. 
Free of charge services have 
been run by the MoH since 
2005 in the regional Health 
Inspections of the 28 
administrative districts in 
Bulgaria. 
The costs of the services 
(private, in hospitals etc.) 
where the clients pay depend 
If the warnings are changed, 
we will require that each packet 
of cigarettes has written: “The 
Ministry of Health warns that in 
1 cigarette there is .... 
(information on tar, nicotine 
and CO yields). 
The internal labelling of the 
packages would also be 
banned. 
 
Article 5.9 of Directive 
2001/37/EC has been 
transposed by: 
 
1) the Law of Tobacco and 
Tobacco Products, art. 30, 
paragraphs 2, points 7 & 8: 
Art. 30 (2) The selling of 
tobacco products shall be 
prohibited: 
(...) 7. (amend. SG 110/96) 
without pointed out on the 
packing obligatory elements for 
informing of the consumers in 
Bulgarian language and the 
coding of the tobacco products 
of the Bulgarian and the foreign 
producer; 8 (new – SG 110/96) 
without stuck excise band; 
 
2). the Ordinance for  
requirements for labeling, 
marking and external 
appearance of tobacco 
products and on defining 
standards for evaluation of the 
compliance with the yield of 
harmful ingredients in 
cigarettes, art. 8, paragraph 1: 
Article 8  
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starting date of 










which products and 
specify, including 
starting date of 
actual use) 
Pictures used 
(how many? rotation, 
please specify) 
Are cessation services* 
included in warnings? 
(please specify) 
 
[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
MoH for approval.  
 
The approved draft will 
be presented at the 
Council of Ministers for 
adoption. After the 
adoption of the 
Ordinance the 
combined health 
warnings on the  
packages of tobacco 
products will be used 
after a transitional 




See the  draft for 
amendments in the Law 
for Tobacco and 
Tobacco products in a 




on the methods of the services 




1. The unit packet of the 
tobacco product shall be 
marked in any appropriate 
manner (by batch numbering or 
equivalent) to ensure the 
identification of the place and 
time of manufacture of the 
product and its traceability. 
Cyprus 
 
No No No No No Warnings according to 
Directive 2001/37/EC. No plans 
of plain package. 
Use of coding by tobacco 
industries. Such coding is 
available to the competent 
authority on demand 
Czech No legislation No No  No. Minimum of 20 cigarettes per Article 5 (9) of the Directive 
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required size of 
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(please specify, e.g. 
starting date of 










which products and 
specify, including 
starting date of 
actual use) 
Pictures used 
(how many? rotation, 
please specify) 
Are cessation services* 
included in warnings? 
(please specify) 
 
[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
Republic 
 
[Quit line is run by Czech 
Coalition against Tobacco 
since 2005, e.g.websites of the 
Society for tobacco 
dependence treatment 
(Společnost pro léčbu závislosti 
na tabáku)  where to find  
among others addresses of 




pack. 2001/37/EC is transposed into 
art. 7 (5) of the Decree No 
344/2003 Coll., on 

















Yes- the helpline appears on 
one of the 14 rotating health 
warnings for cigarette 
packages. However, no 
mandatory display of quitline 
details on cigarette packaging 
or packaging for other tobacco 
products.  
Cigarette packages with less 
than 20 cigarettes are 
prohibited. 
Currently no regulation 
regarding tracking and tracing. 
According to agreements between 
Denmark and leading producers of 
tobacco such regulations will be 
adopted if production of relevant 
products should occur in Denmark. 
Estonia     It is not mandatory for a quitline 
number to be displayed on 
packaging or labelling.  
Minimum 20 cigarettes in a 
pack. 
 
                                                 
6 The czech wording of the decree in this regard is: „U tabákových výrobků se na obalech určených spotřebiteli uvede vhodným způsobem číslo šarže nebo rovnocenný údaj, který umožní určit místo a dobu 
výroby tak, aby byla umožněna jasná identifikace a sledovatelnost tabákového výrobku“. 
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specify, including 
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*All MS have cessation services in 
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Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
Finland Plans but no concrete 
date yet 
No No No It is not mandatory for quitline 
numbers to appear on 
packaging or labelling. 
However, there is web address, 
through which quitline number 
can be found. 
Is exploring the possibility to 
introduce plain packaging. 
Cigarettes may only be sold in 
packets with a minimum of 20 
cigarettes. 7 
Tobacco Act requires that 
manufacturers or importers of 
tobacco products must label 
the unit packets and there must 
be information necessary to 




Legislation adopted the 
15th of April of 2010. 
Yes (from 20 
April 2011) 
Yes (from 20 
April 2012) 
14 pictures 
selected on the 
basis of focus 
group testing 
Yes, the quitline is indicated on 
each warning. This is 
mandatory for cigarette 
packages but not for packages 
of other tobacco products. 
[Quitline “Tabac info service“ 
run by Inpes (Institut national 
de prevention et education 
pour la santé) : 
Phoneline ( 0.15 €/min, from 8 
am-20 pm, 6 days/7)  
+  website : http://www.tabac-
info-service.fr] 
Promotional elements on the 
packaging have been regarded 
as part of the advertising ban 
and thus not permissible.  
 
In France, a legislative 
proposal on plain packaging 
was presented to the National 
Assembly in December 2010 
but failed in the Assembly.8 A 
new proposal was been 
submitted in February 2012.9 
The list of ingredients (tobacco 
%, paper %, flavour, texture 
and conserving agents %) are 
also indicated on the 
packaging.  
The following shall be indicated 
in an apparent manner on each 
unit of packaging of 
manufactured tobacco for 
detailed trade.  
The lot number or an 
equivalent permitting the 
identification of the place and 
date of manufacturing.  
                                                 
7 Section 7.1; Tobacco Act. 
8 http://www.assemblee-nationale.fr/13/propositions/pion3005.asp 
9 Yves Bur. Propositions pour une nouvelle politique de lutte contre le tabac. Rapport au Ministre du Travail, de l'Emploi et de la Sante. Paris: 2012. 






include info (e.g. name, date)  




required size of 
the warning  
(please specify, e.g. 
starting date of 










which products and 
specify, including 
starting date of 
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services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
Minimum 20 cigarettes in a 
pack. If more than 20 must be 
divisible by 5.  Fine cut tobacco 
for smoking: at least 30g by 
pack. 
Germany     Yes the quitline is one of the 
rotating health warnings. 
[The federal center of health 
promotion is running a quitline 
and an internet-based 
cessation programm for adults 
www.rauchfrei-info.de/ and a 
special one for young people 
www.rauch-frei.info. There are 
also cessation services on the 
local level which can be found 
under www.anbieter-
raucherberatung.de] 
Minimum 19 cigarettes in a 
packet. Minimum 30 gram fine-
cut tobacco in a packet. 
There is a ban on selling single 
cigarettes. 
Concerning  Tracking and 
Tracing reference to  Article 7 
of the draft protocol to eliminate 
illicit trade in tobacco products 
(FCTC/COP/4/5) and the 
agreements between the  EU, 
the member states and  Philip 
Morris, British-American 
Tobacco, Imperial Tobacco and 




No No No No  Law: forbids packs with less 
than 20 cigarettes. 10 
 
Hungary The newly amended Act 
XLII of 1999 on the 
Yes, from 1st 
January 2013. 11 
   Yes, cigar, 
cigarillo, pipe 
42 pictures of the 
Commission 
Yes 
Two of the warnings (6 
Not yet The following should be 
marked in this regard on the 
                                                 
10. There is a ban on selling single or unwrapped cigarettes There are no plans for standardised packaging. The Greek Government is against standardised packaging as this lead towards a “Commoditisation” 
of tobacco products to an increase in counterfeit and will violate international treaties (such as the TRIP’s agreement, Paris Convention for the protection of Industrial Property). 
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on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
 Protection of Non-
smokers and Certain 
Regulations on the 
Consumption and 
Distribution of Tobacco 
Products introduces 
pictorial health 
warnings, referring to a 
future Government 
Decree establishing the 
detailed rules of their 
application and 
containing the pictorials 
themselves. The 
referred Government 
Decree is in course of 
preparation.  
tobacco, and 










them, but should 
respect the rules 
on rotation regular 
appearance on 
every main side 
should be 
guaranteed   
pictorials) contain  information 
on cessation, giving the phone 
number and website address of 
the quitline. 
[A quitline has been run by the 
National Health Promotion 
Institute since 2005.] 
 
 
For cigarettes; packages 
containing minimum 19 
cigarettes and maximum 50 
cigarettes. 
For cigars and cigarillos, they 
may be sold by the piece or in 
packs of minimum 5 pieces. 
packaging of  tobacco 
products: 
Date of production (year, 
month, day) and the place of 
production or a batch 
numbering or coded 
identification enabling the place 
and time of manufacture to be 
determined. 
Ireland Legislation adopted 16 
December 2011. 12 
 
Yes Yes 14 pics selected on 
the basis of focus 
group testing 
Quitline included in 1 pictorial 
warning. 
[Operated by the Health 
Service Executive (HSE) 
throughout the country.] 
Minimum 20 cigarettes in a 
pack.  
 
Italy Evaluation after the 
revision of the Tobacco 
   It is not mandatory to display 
quitlines on packaging or 
Cigarettes may only be sold in 
packs of 10 or 20 pieces.  
The Italian law, to fight against 
smuggling provides that 
                                                                                                                                                                                                                                                             
11 Cigarette products that do not meet the new requirements of the Modifying Act shall a) from the first day of the 8th month following the entry into force of the detailed legislation on pictorials, not be 
manufactured and they shall not be put into free circulation and b) from the first day of the twelfth month after the same date they shall not be put into circu lation or handed over to end consumers. 
12 The regulations shall apply to all tobacco packages placed on the market on or after 1 Feb 2013. To allow for the “wash through” of older stock or slow moving stock,  tobacco packages placed on the market 
before 1 Feb 2013 have an additional year on the market i.e. 1st February 2014. 
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which products and 
specify, including 
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actual use) 
Pictures used 
(how many? rotation, 
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Are cessation services* 
included in warnings? 
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[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 




[According to a survey 
conducted by National Institute 
of Health (ISS) December 
2011, there are 396 Anti-
smoking Centres in Italy, of 
which 303 are affiliated with the 
Italian national health service 
and 93 with the Italian anti-
cancer league (LILT). 
The ISS provides 
consultancies, support, and 
information on problems 
related to smoking through the 




affiliated with the national 
observatory on smoking, 
alcohol, and drugs of the 
national Institute of Health. 
The LILT operates the toll-free 
number 800 998877 
(http://www.legatumori.it/sos_lil
t.php?area=995)  a Quit-Line 
service provided by 
Fine cut tobacco for the rolling 
of cigarettes cannot be sold in 
less than 10g. packages. 
 “No plans on standardized or 
plain packaging because of 
possible negative effects on 
the contrast of smuggling and 
counterfeiting. On this theme 
we consider more effective the 
possibility to introduce 
limitations on the use of 
wording and graphical 
elements on packages that can 
be increase tobacco products 
consumption” 
cigarettes manufacturers shall 
adopt a system of identification 
on pack to identify the date, 
place and machinery of 
production and the first buyer. 
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which products and 
specify, including 
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actual use) 
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(how many? rotation, 
please specify) 
Are cessation services* 
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[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
professional physicians and 
psychologists affiliated with the 
LILT, and which aims to help 
smokers who are unable to 
physically attend one of the 
quit-smoking support 





pictures already in 
place 
Law On Restrictions 
Regarding Sale, 
Advertising and Use of 
Tobacco Products 
Section 6. Design of the 
Packaging of Tobacco 
Products 
 
Cabinet Regulation No. 
868 (Adopted 21 
October 2008) 
Regarding Addition of 
Colour Photographs or 
Illustrations to Tobacco 
Packaging Units 
Yes (from 1 
June 2010) 
Yes (from 1 
June 2010) 
14 pictures (same 
as those in the UK) 
Quitline included in 1 pictorial 
warning 
 
No plans or legislation 
concerning plain packaging yet. 
Discussions were only in the 
Ministry of Health. Taking into 
account that pictorial warning 
appeared in Latvia only in June 
2010, the Ministry of Health 
supports bigger pictorial 
warning on both sides of the 
package as the next step in 
order to reduce the 
consumption of tobacco 
products. 13 
The sale of single tobacco 
products and herbal smoking 
products, with the exception of 
cigars and cigarillos, is banned. 
Article 5.9 of Directive 
2001/37/EC is implemented in 
the Law On Restrictions 
Regarding Sale, Advertising 
and Use of Tobacco Products 
stating that - In order to ensure 
tobacco product identification 
and traceability, the tobacco 
products shall be marked with 
a batch number or equivalent 
marking on each packaging 
unit, so that the place and time 
of manufacture may be 
determined.14 
                                                 
13Health sector NGOs support the plain packaging, but representatives from tobacco industry and Latvian Traders Association do not support the idea of implementation of the plain packaging. 
14In reality it is a number printed using deep print machine. The number is located on the bottom of vertically oriented package. 
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which products and 
specify, including 
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Pictures used 
(how many? rotation, 
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[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
Lithuania 
 
No concrete plans yet    It is not mandatory to display a 
quitline on packaging or 
labelling. 
In March 2010, a Draft Law 
Amending the Law on Tobacco 
Control was considered in the 
Seimas of the Republic of 
Lithuania 15 However, this 
proposal was not approved by 
the Seimas since provisions 
like this appear to be 
contradictory to the 
Constitution of the Republic of 
Lithuania. 
It is prohibited to sell cigarettes 
in packs of less than 20. 
Lithuania bans the sale of 
single cigarettes, cigarillos and 
long cigarettes 
Provisions of Article 5.9 of 
Directive 2001/37/EC  have 
been transposed to Article 8 of 
the Law on Tobacco Control 16 
 
Luxembourg  No (but 16 health 
warnings) 
No pictures. 
Size of health 
warnings 
regulated. 
No.  Not included in health 
warnings. 
[Programme de sevrage du 
Ministère de la Santé, 
fonctionnant avec un réseau de 
Sale limited to packs of 
minimum 20 pieces.  
Yes (RGD du 10 septembre 
2003: Article 4, paragraphe (7): 
“Afin d’assurer l’identification et 
la  traçabilité des produits, le 
numéro du lot ou un équivalent 
est indiqué sur l’unité de 
                                                 
15 the Draft Law proposed to establish that tobacco products for sale in the Republic of Lithuania must be packed in a standard white packaging and all the information must appear on the packaging in a single 
fount , except the information relating to the harm caused by smoking. 
16 „Article 8. Labelling Requirements of Tobacco Products Intended for Marketing in Republic of Lithuania 
To ensure product identification and traceability, the tobacco product shall be marked by batch numbering or equivalent on the unit packet (packaging) enabling the place and time of manufacture to be 
determined. Where the batch number or equivalent are encoded, which makes it impossible to determine the place and/or time of manufacture of tobacco products, the undertakings manufacturing, importing 
or bringing in tobacco products to Lithuania must provide controlling institutions with a code key for subsequent decryption.“ 
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which products and 
specify, including 
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(how many? rotation, 
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[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
médecins offrant des  
consultations en tabacologie : 
cure de 8 mois, 1ière et 
dernière consultation gratuites, 
produits de substitution 
nicotinique remboursés à 
concurrence 100€. Tabac-Stop 
: ligne téléphonique, 
d’information, d’aide et de 
soutien de la Fondation 
Cancer. Projet e-Coach : 
Website d’aide au sevrage par 
internet, organisé par la CE.] 
conditionnement sous toute 
forme appropriée permettant 
d‘identifier le lieu et le moment 
de la fabrication”.) 
 (Directive 2001/37/EC) 
Malta 
 
Legislation has been 
adopted; this is the Use 
of Colour Photographs 
or Other Illustrations as 
Health Warnings on 
Tobacco Packages 
Regulations, 
Yes (from 27 
April 2011) 
Yes (from 27 
October 2011) 
14 warnings No   
Netherlands  
 
No plans.    It is mandatory to display a 
quitline on packaging. 





The project of the 
regulation introducing 
the pictorials is waiting 
for the signature. 
According to the project 
The sizes of the 
warnings reflect 
Art. 5.5 of 
Directive 
The pictorial 
warnings will be 





from the library 
approved by the 
Only one warning contains the 
tel. number of quit line of the 
Cancer Institute in Warsaw. 
[Different units on central, 
Minimum 20 cigarettes per 
pack;  
Plain packaging is not planned 
at present. 
On tobacco product packet 
there are placed: name and 
address of manufacturer, date 
of produce and/or serial 
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(how many? rotation, 
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[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
pictorials will appear on 
the packages 1 March 
2013 
 
2001/37/EC EC according to 
Commission 
Decision on 5 
Sept. 2003 and 12 
Apr. 2006. 
regional and rural level exist. 
Therapeutic units are led by the 
public and non-public 




Not adopted Not adopted Not adopted Not adopted It is not mandatory to display a 
quitline on packaging or 
labelling. 
[The National Health Service 
offers a few Smoking cessation 
consultations at hospitals – 
specialty in Respiratory 
diseases services.  
In December 2007 the General 
Directorate of Health approved 
a National Programme to 
normalize the smoking 
cessation services offered by 
the Portuguese NHS. 
The new Tobacco Act (Lei 
37/2007 of 14th August – article 
31.º - established the obligation 
of creating specially 
consultations dedicated to the 
intensive support of smokers, 
in all primary care health 
canters and some hospitals. 
Minimum 20 cigarettes in a 
pack.  
Provisions of Article 5.9 of 
Directive 2001/37/EC  have 
been literally transposed to 
Article 11, nº 11 of the Law on 
Tobacco Control  
Lei 37/2007 of 14th August. 
All the tobacco products sold in 
Portugal must have an official 
fiscal stamp, annually approved 
by law by the Ministry of 
Finance. There is also an 
obligation for the electronic 
reporting of importers and 
manufacturers use of these 
stamps in each fiscal year. This 
process is under the control of 
the national Authority for 
Customs and Excise Duties. 
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on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
Nowadays there are available 
about 200 of these 
consultations throughout the 
country. Additionally Family 
Physicians (GPs) can help 
smokers using brief 
interventions in the context of 
family practice.] 
Romania  Legislation adopted, 
pictures already in 
place 
Yes (from 1 July 
2008) 
Yes (from 1 July 
2009) 
14 warnings 
selected on the 
basis of public 
consultation 
No Minimum 20 cigarettes in a 
pack. 
 
Slovakia     It is not mandatory to display a 





Plans but no concrete 
date yet 
   Yes (mandatory on all cigarette 
packs since 5. August 2007)  
Not mandatory on packaging 
for other tobacco products. 
Under Restriction of the use of 
tobacco products Act it shall be 
prohibited to sell single 
cigarettes and other tobacco 
products outside the 
manufacturer’s original 
packaging 
The batch numbering or 
equivalent must be indicated 
on the packaging of a tobacco 
product to allow the place and 





Legislation adopted on 
14 May 2010. 
Yes (from 26 
May) 2011 
Yes (from 26 
May 2012) 
14 warnings No Under the Spanish legislation, 
2 other labelling requirements 
are mandatory: 
1) “Las autoridades sanitarias 
The article 5.9 has been 
literally transposed. Under the 
regulation of the market control 
the products must be identified 
by specific documents along 
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specify, including 
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(how many? rotation, 
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[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
advierten:”, placed in both 
sides over the main warnings 
with specific requirements 
2)“PROHIBIDA LA VENTA A 
MENORES DE 18 AÑOS”, 
13% on one side with specific 
requirements. 
Plain packaging is under 
consultation. 
Minimum pack size of 20 cig.  
the distribution chain. An 
annual report should be 
submitted by manufacturers, 
importers, distributors and retail 
shops to the competent 
authorities, including 
identification of the products 
and quantity of each one. 
Sweden 
 
Sweden does not 
require the additional 
warnings in the form of 
colour photographs or 
other illustrations, as 
described in article 5.3 
of Dir. 2001/37/EG.  
 
No No No The quit-line’s name and 
telephone number is included 
in accordance with Dir. 
2001/37/EC in one of the 
additional health warnings 
(Annex I – health warning 





This is regulated by the 
Swedish National Institute of 
Public Health regulation; FHIFS 
2002:4 
Sök hjälp för att sluta röka:  
fråga din läkare, på apotek eller 
Legal requirement does exist in 
section 12 b of the Tobacco Act 
(1993:581) with regards to 
pack size i.e. at least 19 
cigarettes in each pack and 
cigarettes are not allowed to be 
sold loose.  
 
Other tobacco products than 
cigarettes are not regulated 
with regard to pack size. 
 
Legal requirements exists with 
regards to pack shape 
according to article 5.7 of Dir. 
2001/37/EG and the Swedish 
National Institute of Public 
Health regulation FHIFS 2001:2   
 
The possibility to require all 
tobacco products to be 
provided with information to 
secure the identification of the 
place and time of production is 
adopted in section 9.3 of the 
Tobacco Act.  
 
Nevertheless, the 
implementation of article 5.9 in 
Dir.2001/37/EG awaits further 
regulation from the Regulatory 
Committee and the European 
Commission.  
 
However, tracking and tracing, 
with regards to sucking and 
chewing tobacco, is regulated 
according to LIVSFS 2012:6. 
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number of cigarettes per pack, plans 
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Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 




LINJEN” on 020- 84 00 00 and 
www.slutarokalinjen.org is a 
national, cost free helpline, 
which started initially as a 
voluntary project in 1998. From 
2002 onwards the quit-line 
receives a 5 million SEK 
governmental grant (subsidy) 
for the activity. The quit-line is 
run by the County Council of 
Stockholm and receive yearly 
about 10 000 calls, mainly from 
smokers and users of sucking 
tobacco (i.e. snus).] 
 
The Swedish National Institute of 
Public Health is regulatory agency 
regarding pack size and shape.  
 
Legal requirements exist with 
regards to marketing in section 14 
of the Tobacco Act.The law only 
gives a few exceptions to the 
general ban on advertising.  
 
According to practice, it is not 
possible to have advertising on the 
package, in an onsert, insert etc. 
 
The Swedish Consumer agency is 
regulatory agency regarding 
marketing etc. 
 
Sweden does, nevertheless,  take 
a negative view of the concept of 
“plain packaging” due to the  
interest of trademark protection; of 
property protection pursuant to the 
European Convention on Human 
Rights; of observance of other 
international obligations such as 
those of the TRIPS agreement; of 
combating traffic on counterfeit 






pictures already in 
place. Regulations 
made on 23 August 
Yes, came into 
force on 1 
October 2008. 
Yes, came into 
force on 1 
October 2008 
14 warnings 
selected on the 
basis of public 
Not all of them but one warning 
does include quitline number 
In the Tobacco Control Plan for 
England (March 2011), the 
Government undertook to 
consult  on options to reduce 
The Schedule to the Tobacco 
Products Regulations 2001 
requires manufacturers to be 
able to provide information on 
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[Further details on cessation 
services.] 
 
*All MS have cessation services in 
some form (e.g. website, quitline). 
Other packaging or labelling 
requirements (including minimum 
number of cigarettes per pack, plans 
on standardised/ plain packaging, pack 




Tracking and tracing and/or 
authenticity marks (including 
implementation of Article 5.9 
of Dir 2001/37/EC) 
2007.   consultation the promotional impact of 
tobacco packaging, including 
plain packaging. The 
consultation. was publshed on 
16 April 2012.17 Minimum pack 
size of 10 cigarettes. 
seized products, incl the date & 
place of manufacture, destination, 
customer and invoice details. 
Packets manufactured in UK bear 
batch codes which enable place & 
time of manufacture to be 
established. 
Norway Legislation adopted 
Regulations no. 141 of 
6 February 2003 on the 
contents and labelling 
of tobacco products 
Yes (from June 
2011) 
Text warning 
covers 30 % of 
front 
Pictorial warning 




14 warnings Yes. It is mandatory for all 
tobacco products. 
[National quitline since 1996 
and website since 2010. Run 
by the Norwegian Directorate 
of Health. Personell:4.5] 
Norway is exploring the 
possibility to introduce plain 
packaging.18 
Packets manufactured in 
Norway bear batch codes 
which enable place & time of 
manufacture to be established, 
see Regulations no. 141 of 6 
February 2003 on the contents 
and labelling of tobacco 
products, section 16. 
 
                                                 
17 http://consultations.dh.gov.uk/tobacco/standardised-packaging-of-tobacco-products/consult_view 
18 Report through the Regulatory Committee in June 2011 









Use of EMTOC Regulation of ingredients (Positive and/or negative lists or other type of regulation? are 




Yes Electronic Yes, mandatory 
since 2010 
No 
To protect consumers from preventable damage caused to their health If necessary, the Federal Minister 









both Yes, on voluntary 
basis 
Positive list. The list is valid for all ingredients used for the product including the filter or other parts. 
Arrêté royal du 13 août 1990 relatif à la fabrication et à la mise dans le commerce de produits à base de 




Also in Belgium 3 ingredients ('E418 gomme gellane, E133  « bleu brillant FCF », Medium Chain 
Triglycerides (MCT)) needed to include the “menthol capsules” in cigarettes were recently banned. 
Basically, it was proposed not to accept them because of the increase of the attractiveness of the product. 
The intern debate was more on the capsule. But the public debate was also on the fact that one of the 
three product could change the colour of the smoke (that could increase attractiveness). 
Bulgaria No Both We plan to use 
EMTOC obligatory 
by project of Law 
for amendment and 
supplementing the 
Law for Tobacco 
and Tobacco 
Products which is 
in the Parliament 
now. We are 




The legislation regulates the kind of ingredients, their toxicity and the addictiveness by the Law for 
Tobacco and Tobacco Products. At this time we use informally both a positive and a negative list for 
ingredients. There is an opportunity to find a consensus to be preferred the positive list. The main 
argument is: the scientists has enough knowledge and experience to know which components/ingredients 
are obligatory for one tobacco product, including the filter, the liquid for printing on the tobacco products 
and so on. That’s enough to elaborate a positive list. 
It will be one time effort. If we will choose a negative list then we have to have a working group which 
uninterruptedly has to change it because of the creativeness of the tobacco industry. 
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Use of EMTOC Regulation of ingredients (Positive and/or negative lists or other type of regulation? are 







Nevertheless there is some 
recommended structure of it.  It was 
proposed a 3 list format for reporting 
ingredient information. This 3 list 
format comprises: List 1 – Composite 
list of ingredients added to tobacco, 
List 2 – Composite list of non-tobacco 
ingredients and List 3 – Brand lists of 
ingredients added to tobacco in each 
brand. 
Both Not planned Positive and negative list 




17 pages positive list, 1,5 page negative list 
 
The usage of ingredients and flavours being put in the filter and other paraphernalia of tobacco products 
is regulated in CZ. The positive list of ingredients in the annex of the Decree No 344/2003 Coll., on 
requirements on tobacco products, is divided into sections. One section contains ingredients which are 
allowed when manufacturing tobacco products directly for the filters and also other sections concern other 
parts of tobacco products (not only the tobacco mixture). 
Cyprus 
 
Yes Common reporting formats 
according to the practical Guide of 
Reporting on Tobacco Product 
Ingredients of 31/5/2007 SANCO C6 
TPE/ub D(2007) 360206 
Both No No positive or negative list flavours are also not regulated 
Denmark 
 
No, but EMTOC recommended as of 
2012. 
Both Start voluntary use 
of EMTOC as of 
Jan 2012  
No 
Estonia Voluntary Both No, but discussions 
ongoing 
No 
Finland No Both No, but follow the 
process 





Decree on Measures to Reduce Tobacco Smoking 225/1977 
CHAPTER 2 Composition 
Section 2 
 
The following may be used in tobacco products and in their manufacture: 
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Use of EMTOC Regulation of ingredients (Positive and/or negative lists or other type of regulation? are 
ingredients in filter and other paraphernalia regulated Is the tobacco leaf regulated and if yes, 
how?) 
1) tobacco; 
2) tobacco substitutes originating from other plants not dangerous or harmful to health; 
3) sugars, honey and cocoa; 
4) tobacco leaves for wrapping, ground tobacco and paper or man-made films manufactured from other 
plant fibres; and 





Yes (ministerial order (arrêté) of the 




Electronic Not yet, but intend 
to make it 
compulsory 
Positive list of ingredients classified by categories ministerial order (Arrêté) of the 12th of September 1995 
 
Code de la Santé Publique : Article L3511-2 Modifié par LOI n°2009-879 du 21 juillet 2009 - art. 98 (V) 
 
The sale, the distribution or the offer for free of flavoured cigarettes  which content in ingredients giving a 
sweet or acidulated flavour exceeds thresholds fixed by decree are forbidden 
 
 
Article D3511-16 Créé par Décret n°2009-1764 du 30 décembre 2009 - art. 1 
The maximal content of ingredients giving a flavour sweet or acidulated to flavoured cigarettes, mentioned 
at article L. 3511-2, is defined as follow :  
1° Vanilline : 0, 05 % of tobacco mass ;  
2° Ethylvanilline : 0, 05 % of tobacco mass ;  













2010. 30% uses 
EMTOC, others 
use free  electronic 
data submission 
via national 
network or mail 
Positive and negative list 
 






Over 10 pages positive list and 1 page negative list 
Ingredients in filter and other paraphernelia like paper are regulated. 
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Use of EMTOC Regulation of ingredients (Positive and/or negative lists or other type of regulation? are 




Voluntary Both No No 
Hungary No Both Plan to start using Positive and negative list of additives for tobacco products, including filters and other paraphernalia.  
Tobacco leaf is not part of the definition of “ingredient”. 
Ireland No Both No No 




Law On Restrictions Regarding Sale, 
Advertising and Use of Tobacco 
Products 










Republic Of Lithuania Law On 
Tobacco Control 
Article 9. Reports of Tobacco Product 
Manufacturers and/or Importers on the 
Ingredients of Tobacco Products 
Manufactured for Marketing in the 




Both No, but intend to 
start using  
Negative list of ingredients.  
Republic Of Lithuania Law On Tobacco Control 
Article 4. General Ingredient and Quality Requirements for Tobacco Products 
4. The Government of the Republic of Lithuania or an institution authorised by it, acting in conformity with 
research-based evidence, shall have the right to prohibit the use of ingredients which have the effect of 
increasing the addictive properties of tobacco products.  
 
Order of the Minister of Health Care of the Republic of Lithuania On the Approval of the Lithuanian 
Hygiene Norm HN38:2009 “Maximum amounts of noxious substances permitted in tobacco products”, 11 
September 2009, no. V-736 lists maximum levels of substances in tobacco products and substances 
prohibited for use during the manufacturing tobacco products or mixtures with tobacco.(23 restricted and 
27 prohibited substances listed) 
 
The following additives are forbidden: Agaric Acid, Birch Tar Oil, Tansy Herb, Yellow Melilot, Juniper 
Tar Oil, Camphor, Camphor Oil, Camphorwood, Bitter Almond Oil, Woody Nightshade Stems, Areca Nut 
Palm, Coumarin, Vanilla plant, Sweet Woodruff, Cloves, Soap Bark, Quassia Wood, Rue Herb, Indian 
Tobacco, Safrole, Oil of Sassafras, Sassafras Leaves, Sassafras Wood, Sassafras Root Bark, Polypody 
Rootstock, Pennyroyal herb, Tonka Beans and Thujone. 
 
Luxembourg No but reporting is compulsory (Article 
4 de la loi du 11 août 2006; Article 5 
du RGD du 16 septembre 2003) 
Not specified.  No Depending on implementing regulation. 
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Use of EMTOC Regulation of ingredients (Positive and/or negative lists or other type of regulation? are 




No, but recommended Both Start voluntary use 












Poland No. There is some recommended 
structure of report: list of ingredients by 
brands which needs name of the 
substance, the aim of use, quantity 












Only ingredients which may increase the addictive properties of tobacco products are prohibited. (Art. 7a 
of the Health Protection Act against the Consequences of Tobacco Use) 
Portugal 
 
No, but its use is promoted. Almost 
100% of tobacco companies or 
importers use the harmonised  
formats. 
Both No No 
Romania Yes, since 2009 No No, but start using 
in 2012 
(compulsory) 
Positive list – a list with the ingredients allowed for all tobacco products, classified by categories 
 
Slovakia No Both No, but plan to 
start using it 
Positive and negative list 
By Regulation of Ministry of Agriculture of the Slovak Republic and Ministry of Health of the Slovak 
Republic on 21th of October 2004 no. 2606/2004 on tobacco products. 
 
Almost 50 pages listed ingredients 
Slovenia Not obligatory, recommended Both No No 
Spain 
 
Obligatory Both, but very 
few use it by 
paper. 
No Spanish Food Code, where some general indications on ingredients that are or are not permitted in 
tobacco products are given.  
Spanish Food Code, Chapter XXV Section 8 
Ingredients: 
3.25.79. Manipulaciones. 
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Use of EMTOC Regulation of ingredients (Positive and/or negative lists or other type of regulation? are 
ingredients in filter and other paraphernalia regulated Is the tobacco leaf regulated and if yes, 
how?) 
En la elaboración de tabaco, cigarros y cigarrillos se permite utilizar o adicionar: 
a) Agua, amoníaco, ácido acético, láctico, cítrico y tartárico. 
b) Azúcar de caña, de higos, de arce o invertida, glucosa, melaza, miel, regaliz, sustancias aromáticas 
autorizadas y agua de rosas. 
c) Mentol, vainillina, cumarina, cacao, goma, cloruro sódico, nitratos, carbonatos, cloruros alcalinos y 
hasta 1 por 100 de cal en forma de agua de cal. 
d) Jugos concentrados de frutas y extractos o partes de haba Tonka («Dipterix odorata», Willd), meliloto 
(«Mellilotus officinalis», Ders.), asperilla («Asperula odorata», L.), vainilla de carolina («Liatrix 
odoratissima», Mich.) y otras especies que contengan cumarina. 
f) Glicerina, etilenglicol o propilenglicol. 
g) Los edulcorantes artificiales y productos conservadores autorizados para estas elaboraciones en las 
listas positivas complementarias de los Capítulos XXXI y XXXIII de este Código. 
h) En la elaboración de cigarros y cigarrillos, el empleo de adhesivos a base de agua con caseína, 
almidón, dextrina, goma tragacanto o arábiga y otros productos inofensivos. 
Papers 
3.25.80. Papeles para cigarrillos. 
Reunirán fundamentalmente las siguientes condiciones: 
a) Serán elaborados con fibra de lino, cáñamo, cereales, algodón, «cargas» autorizadas, y los 
edulcorantes artificiales incluidos en las listas positivas de este Código. 
b) Estarán exentos de sustancias nocivas. 
c) No producirán en la combustión olor o gusto desagradable. 
d) Contendrán solamente indicios de acidez, cloruros y nitratos. 
Filters: 
3.25.81. Filtros. 
Los filtros para cigarros y cigarrillos, así como aquellos para utilizarse en pipas y boquillas, estarán 
formados por una base inerte filtrante, impregnada o no por sustancias absorbentes fijas. 
C:\Documents and Settings\ampelan\Local Settings\Temporary Internet Files\OLK7E7\Codigo alimentario 
español- Documento BOE-A-1967-16485 última actualización.mht 
Sweden 
 
Not mandatory but recommended 
using EU’s practical guide. 
Both. No. Article 3.1 Dir. 2001/37/EC (i.e. TNCO levels for cigarette smoke) is implemented by section 18 of the 
Tobacco Act (1993:581), 2 § 2 of the Tobacco Regulation (2001:312) and further regulated by section 6 of 
the Swedish National Institute of Public Health regulation; FHIFS 2001:2.  
For tobacco products, other than chewing and sucking tobacco (i.e. snus), there is no positive or negative 
lists in place but  according to section 17-18 and 20 of the Tobacco Act (1993:581) and section 2 of the 
Tobacco Decree (2001:312) it is possible to regulate tobacco ingredients on an ad hoc basis, in justified 
cases.  
The tobacco leaf is not regulated as a tobacco ingredient according to Dir. 2001/37/EG. However 
according to the food regulations it may be seen as part of the tracking and tracing process of the new 
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Use of EMTOC Regulation of ingredients (Positive and/or negative lists or other type of regulation? are 
ingredients in filter and other paraphernalia regulated Is the tobacco leaf regulated and if yes, 
how?) 
regulation LIVSFS 2012:6 regarding chewing and sucking (i.e. snus) tobacco (see above). 
United Kingdom Not mandatory but recommended. Both Not mandatory but 
we are currently 
considering starting 
to use it in the UK 
through a voluntary 
arrangement. 
Have a positive list based on a voluntary agreement between the Department of Health and 
manufacturers and importers on permitted additives to tobacco products which includes a comprehensive 
list of ingredients allowed with maximum quantities. The agreement mentions that other compounds not 
included in the list, but approved by another MS are allowed. 
http://www.dh.gov.uk/ab/scoth/dh_095371#_4 
25 pages of listed substances 
Norway Voluntary Both No, but intend to 
make it obligatory 
No regulation of ingredients, but the Regulations no. 141 of 6 February 2003 on the contents and labelling 
of tobacco products mandate the Directorate of Health to ban addictive enhancing ingredients. This has 
not been done. The tobacco leaf is not regulated. 
A.3.3.4. Sales arrangements 
 
Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
Austria (18/07/12) 16 Restriction  
 
Minors (< 16) are not allowed to buy tobacco from vending machines 
and there is an electronic age control by bank card or mobile phone. 
 
No advertising allowed (general ban on advertising and sponsoring, 
Art. 11 Tobacco Act) with the exception of a TVM that is part of the 
outer face or the interior of the tobacconist´s shop as advertising is 
allowed on these surfaces. 
Ban. 
 
Only licensed merchants are allowed 





¾ presentation of tobacco products meant for sale 
including prices at points of sale; 
¾ distribution of single pieces of newly introduced 
trademarks free of charge for a period of 6 months 
in the interior of points of sale to grown up smokers; 
¾ further advertising allowed at the exterior and 
interior of points of sale if health warning covers 
10% of surface. 
Not allowed: 
¾ promotion of cigarettes without filter; 
¾ promotion that leads to false impression that 
smoking is not unhealthy; 
¾ promotion concerning minors; 
¾ promotion towards smokers aged under 30, 
                                                 
19 see § 11 Abs. 4 and 5 Tabakgesetz together with § 39 Abs. 1 Tabakmonopolgesetz 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
athletes, prominents including their comments on 
smoking; 
¾ comics; 
¾ distribution of promotional items to minors or 
intended for minors;  
¾ discounts, distribution free of charge (exception: 
see above) and direct mail. 
Belgium (18/07/12) 
 




-vending machines can only be installed where tobacco products are 
sold traditionally. 
-vending machines have to be locked 
-the responsibility to unlock the vending machines for the persons 
over 16 is the seller selling tobacco traditionally.  
 
Advertising banned except for the display of trademarks in tobacco 
shops and newsagents. 
None Display of the trademark permitted at point of sale 
 




Bulgaria 18 Ban 
 
Art. 30. (1) (amend. SG 110/96; amend. SG 57/04; amend. - SG 
70/06; suppl. - SG 110/08, in force from 01.01.2009; amend. – SG 
12/09, in force from 13.02.2009; amend. – SG 95/09, in force from 
01.12.2009) The tobacco products shall be sold by traders, who have 
permission for selling tobacco products, issued under the conditions 
and by order of the Law on the Excise and Tax Warehouses. 
(2) The selling of tobacco products shall be prohibited: 
(…) 
11. (new – SG 110/01, in force from January 1, 2002; amend., SG 
70/04; suppl. - SG 70/06) from automatic machines for sale of 





Internet sale is not mentioned as a 
permitted way of selling in the Law for 
the Tobacco and Tobacco Products 
and Law on excises and tax 
warehouses and Trade law putting 
together a retail system for tobacco 
products.   
 
But this fact open the doors: which is 
not banned it is allowed. That’s why 
we have a project of Law for 
amendment and supplementing the 
Law for Tobacco and Tobacco 
Products which is in the Parliament 
now and we are expecting to be 
adopted. By this amendments and 
supplementation we forbid the selling 
Permitted. 
 
The MEET is absolutely against such kind of 
amendment of law. That’s why we need so much such 
kind of ban in the new TPD. 
 
There is a Canadian research – 60% from smokers by 
cigarettes when they see them at point of sale inspite of 
that they have cigarettes in their pocket. 
 
The scientific results of Ireland are very positive and 
inspiring after ban at point of sale. 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
of tobacco products by the services of 







Article 9 of the Law providing for the taking of measures to restrict 
smoking states that: 
A person who- 
(a)    Has under his control or in his possession any automatic 
vending machine for sale of tobacco, or allows the installation of such 
a machine or its use in any of the premises under his control or 
possession, or 
(b)   Uses or puts in operation any tobacco vending machine, or 
(c)    Imports or manufactures for local use any automatic vending 
machine for the sale of tobacco, 
Shall be guilty of an offence and shall be liable on conviction to a fine 
not exceeding one thousand pounds (1,700 euros) or imprisonment 
not exceeding six months or both imprisonment and fine and the court 
adjudicating the case may order the confiscation of the vending 
machine in connection with which the offence was committed.  
 
 
No specific restriction, but the sale of 
tobacco products requires a license 
granted by the public authorities. 








TVM must display a clearly visible text in Czech that states that the 
sale of tobacco products to persons less than 18 years of age is 
prohibited. If there is an advertisement on the TVM it must be 
accompanied by the health warning "Ministry of Health warns: 
Smoking causes cancer." 
 
Act no. 379/2005 Coll. on measures for protection against the harmful 
Restriction 
 
Act no. 379/2005 Coll. on measures 
for protection against the harmful 
effects of tobacco products, alcohol 
and other addictive substances and on 
the amendment of related laws 
stipulates it in Division 1 – Section 4 : 
(§ 4) 
No restriction 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
effects of tobacco products, alcohol and other addictive substances 
and on the amendment of related laws stipulates it in Division 1 – 
Section 4 : 
(§ 4) 
The sale of tobacco products, tobacco accessories and electronic cigarettes 
in vending machines, where the sale to persons less than 18 years of age 
cannot be precluded, is prohibited. Act No. 379/2005 Coll., as subsequently 













…. The mail-order sale and all other forms 
of sale of the products listed in the first 
sentence, during which it is not possible to 
verify the buyer’s age, are prohibited.  
Act No. 379/2005 Coll., as subsequently 

















Denmark 18 Restriction at point of sales: In special automatic dispensers which 





Advertising, besides that on the cigarette package, is prohibited. 
Businesses from other EU-member 
states which carry out distance selling 
to Danish consumers are liable to pay 
excise duties and VAT in DK. The 
businesses have an obligation to apply 
for a license with the Danish customs 
and excise authorities. Also sellers 
have an obligation to produce a 
guarantee before shipping the goods. 
https://www.retsinformation.dk/Forms/
R0710.aspx?id=13234  
Ban on all Tobacco Product Advertisements and 
sponsoring.  
The ban does not cover neutral display at point of sale 




Estonia 18 Ban 
Tobacco Act Passed 4 May 2005 (RT2 I 2005, 29, 210), entered into 
force on 5 June 2005: 
§ 22. Prohibitions upon retail trade in tobacco products 
(2) Retail trade in tobacco products is prohibited… 
2) from automatic vending machines; 
… 
None None 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 





18 Restriction. Advertising on TVM is banned. 
Ban of TVM to be introduced from  2015. 
 
The wording currently in force:  
Tobacco Act 693/1976  
Section 11 (14.6.2002/498) 
Tobacco products and smoking accessories may be sold from 
automatic vending machines only where such sales are under 
supervision. An automatic vending machine shall be placed so that its 
use can be monitored continuously. 
The placing and supervision of the use of an automatic vending 
machine is the responsibility of the owner, proprietor or responsible 
manager of the premises where the vending machine is placed or by 
an employee designated to perform this task. 
New wording : 
Tobacco Act 693/1976  
Section 10 a (Tobacco Act 20.8.2010/698) 
 It is forbidden to sell tobacco products from automatic vending 
machines. 
 
No specific restriction, but 
-  sale of tobacco products requires a 
retail license   
-  it must be possible for the seller to 
supervise the purchase situations 
-  advertising ban covers also Internet 
sale 
-  tobacco products must be labeled by 
warnings and some information   
 
Banned from 2012 onwards 
 
Act amending the Tobacco Act Section 8a of the 
Tobacco Act (693/1976), as it appears in Act 698/2010: 
 
"Display of tobacco products and their trademarks in 
retail sale facilities for tobacco, tobacco products, 
tobacco substitutes, tobacco imitations and smoking 
materials is forbidden.  
Paragraph 1 shall not apply to points of sale that have a 
separate entrance and mainly sell tobacco products and 
smoking materials where the tobacco products sold, or 
their trademarks, are not visible outside the point of 
sale. 
Paragraph 1 shall not apply to the sale of tobacco 
products on board vessels engaged in international 
maritime traffic.  
Retailers of tobacco products may present a purchaser 
of tobacco products, upon request, with the printed 
collection of pictures showing the packaging of tobacco 
products available for retail sale at the point of sale. 
Retailers may also supply the purchaser, upon request, 
with a printed catalogue of tobacco products and their 
prices. The content and outward appearance of the 
collection of pictures and the catalogue shall be 
regulated in greater detail by Decree of the Ministry of 
Social Affairs and Health.  
Paragraph 4 concerning the collection of pictures and 
catalogue of tobacco products shall also apply to 
tobacco, tobacco substitutes, tobacco imitations and 
smoking material."  
 
France  (13/06/12) 
 
18 Ban 
Code de la Santé Publique : Article L3511-2 Modifié par LOI n°2009-
879 du 21 juillet 2009 - art. 98 (V) 
… 





Code général des impôts 
According to Public Health Code, Article L3511-3 : 
Propaganda or advertising, direct or indirect, in favour of 
tobacco, tobacco products or the ingredients, as defined 
in the second paragraph of the L. 3511-1 article, as well 
as any free distribution or sale of a tobacco product at a 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
 Article 568 ter 
 
The remote sale of tobacco products is 
forbidden in metropolitan France and 
in French overseas departments. 
 
price lower than that mentioned in the article 572 of the 
general taxes code are forbidden.  
These measures do not apply to the signs of tobacco 
retail outlets, nor to the posters situated inside these 
establishments, not visible from the outside. These 
signs or posters must respect the characteristics defined 




18  Restriction (ID verification card) 
 
The selling machine has to be installed at a location not accessible for 




The selling machine has to be furnished with mechanical devices or 
has to be permanently guarded to ensure that Children and 
Adolescents cannot take tobacco products out of them. 
 




There are no advertising restrictions at the federal level. Several 
tobacco firms have, however, voluntarily removed advertising from 




Restrictions apply to internet sales 
VTabakG §21a (3&4)” It is forbidden to 
do advertising for tobacco products in 
the press…” “(3) equally applies to 
advertising for tobacco products in 






The long distance sale of tobacco 
products from other member states to 
consumers in Germany is according to 
provisions of the tobacco tax law 
strictly regulated. 
The long distance sale of tobacco from 
the German fiscal territory has to be 
notified to the competent main 
customs office. 
 
Tobacco tax law, Art. 22 (1) / (2) and Art. 




National legislation permits tobacco display and 
promotion at the point of sale. 
Greece 
 
18 Ban No specific restriction, but the sale of 
tobacco products requires a license 
Restrictions (Law 3730/23.12.08, art. 2 par1 & Law 
3868/03.08.10, art.17 par. 3): 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
 
Law 3730/23.12.08, art. 2, par. 2. 
Art. 2 
………………… 
3. One year after the publication of the law, the sale of tobacco 
products through vending machines and the sale of single cigarettes 
or in packs with less than 20 cigarettes will be forbidden. 
 
granted by the public authorities.  
 
Advertising/promotion is only allowed inside points of 
sale of tobacco products. Product placement is 
prohibited at the front windows of shops with the 






According to para (6) of Section 6 of  Act XLII of 1999 on the 
Protection of Non-Smokers and Certain Regulations on the 
Consumption and Distribution of Tobacco Products, tobacco products 
shall not be sold by vending machines 
Ban  
 
Annex 3. of Government Decree 
210/2009. (IX. 29.) on the conditions of 
pursuing commercial activities enlists 
tobacco products as a product that can 
only be sold in shops.   
 
Tobacco display is permitted. 
 
Restriction applies to point of sale promotion: 
According to point c) of para (4) of Art. 19 of Act XLVIII 
of 2008 on the Basic Requirements and Certain 
Restrictions of Commercial Advertising Activities, the 
prohibition on the advertisement of tobacco products 
shall not apply to an advertisement installed inside a 
store, in a section designated solely for the sale of 
tobacco products in accordance with specific other 
legislation on the marketing of tobacco products, that 
contains only the name and price of tobacco product, 
provided that it does not exceed size A/5 (148x210 mm) 
for any tobacco product brand name, or twenty per cent 
of the entire surface of the entrance of the store section 
designated for tobacco products only through which 
tobacco products may be accessed, or maximum size 
A/1 (594x841 mm) in any store. Therefore the display 






Section 43 (3) of the Public Health (Tobacco) Act as amended, states that “It 
shall be lawful for tobacco products to be sold by retail, in accordance with 
regulations made by the Minister, by means of a vending machine on 
licensed premises or the premises of a registered club by such persons, or by 
persons belonging to such classes of persons, as are specified in the 
regulations (being persons who are registered under section 37 in respect of 
the licensed premises concerned or the premises of the registered club 
None Ban 
 
Section 33 of the Public Health (Tobacco) Act as amended 
prohibits the advertisement of tobacco products in premises in 
which the business of selling tobacco products by retail is 
carried on in whole or in part. 
A display or other publication of a trademark, emblem, 
marketing image or logo, by reference to which the product is 
marketed or sold is included in "advertisement".  
 52  
Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
concerned).” 
 
The Public Health (Tobacco) (Self Service Vending Machines) Regulations 
2009 outline the procedures for selling tobacco products by means of a 
vending machine. 
 
Self-service vending machines must be free of all tobacco related advertising. 
Selection decals/buttons for self-service vending machines must not display 
tobacco product trademarks, emblems, marketing images or logos. 
The registration number(s) issued by the National Office of Tobacco Control, 
must be affixed to the self-service vending machine(s) following registration. 
 
 
Italy (18/07/12) 16 Restriction 
 
All vending machines should be equipped with electronic devices to 
control the age of the purchaser. 
 
Advertising is forbidden but cigarette packs may be displayed on the 
TVM. The packages displayed have health warnings. 
 
 
Ban  National legislation permits tobacco display at the point 





Law On Restrictions Regarding Sale, Advertising and Use of Tobacco 
Products 
 
Section 7. Procedures for Trade in Tobacco Products and Herbal 
Smoking Products 
 
It is prohibited to sell tobacco products:  
5) Utilising vending machines. 
Ban  
 
No specific restriction, but the sale of 
tobacco products requires a license 
granted by the State Revenue Service 
(taxation legislation). The Licensing 
Commission (under the State Revenue 
Service), issuing the licence, indicates 
the address of the sales premises. 
This address of the sales premises is 
always only a physical address (where 
a person can go and buy products), 
but not a virtual or electronic address. 
Restriction 
 
Tobacco advertising is banned. Law On Restrictions 
Regarding Sale, Advertising and Use of Tobacco 
Products states that tobacco products advertisement is 
information disseminated in any form, including 
commercial notices (for example, printed matter, 
posters, adhesive labels, advertising images on walls, 
radio and television broadcasts, clips, cinema films and 
videos), the purpose of which is the direct or indirect 
promotion of the purchase and consumption of tobacco 
products.  
 
Displays (without any promotional cigarettes’ brand 







Law On Tobacco Control 
Display of tobacco products at point of sale is allowed. 
Advertising of tobacco products at points of sale, except 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
Law On Tobacco Control 
Article 15. Restrictions on the Marketing of Tobacco Products and 
Tobacco Sales Outlets 
It shall be prohibited to sell tobacco products in the Republic of 
Lithuania in the following manner: 
1) through automatic vending machines; 
http://www3.lrs.lt/pls/inter3/dokpaieska.showdoc_l?p_id=389583 
Article 15. Restrictions on the 
Marketing of Tobacco Products and 
Tobacco Sales Outlets 
It shall be prohibited to sell tobacco 
products in the Republic of Lithuania in 
the following manner: 
2) through communication tools; 
http://www3.lrs.lt/pls/inter3/dokpaieska.
showdoc_l?p_id=389583 
an information specified in paragraph 3 of Article 17 of 
the Law on Tobacco Control is prohibited, i.e. only the 
following information may be presented on showcases used to 
display tobacco products at tobacco sales outlets: 
1) the name of the manufacturer, marketing undertaking and 
address of the headquarters 
2) the brand names of the tobacco products sold; 
3) the words “We trade in“ ”We sell”; 
4) the tar, nicotine and carbon monoxide yields of cigarettes; 
5) the indication of prices of tobacco products. 
It shall be permitted to present the information outlined in 
paragraph 3 of this Article only along with the displayed 
tobacco products. It may not be displayed in folders, flyers, or 
other means of advertising, intended for the consumers to take 
with them; additionally, it shall be prohibited in  tobacco 
product sales outlets to display imitations and pictures of 
tobacco products or packaging thereof.  
Information (warnings) must also be displayed regarding the 
harmful effect of the use of tobacco products to health and 
concerning the prohibiting of the sale of tobacco products to 
persons under 18 years of age. 
No other visual or graphic information concerning tobacco 
products not specified in the Law of Tobacco Controll may be 
displayed in tobacco product sales outlets. 
 It is prohibited also:  
1) to apply fixed discounts for owners of disseminated 
coupons, which have been  printed in the mass media or by 
other means, or to consider these coupons as an alternate  
means of payment; 
2) to supply (disseminate) tobacco products and (or) new 
samples thereof, free;  
3) to grant the buyer an immediate  right or over a certain  
term of time following the conclusion of a buy-sell contract, to 
receive gifts or  a supplement to the tobacco products; 
4) to influence buyers through persistently offering  tobacco  
products by indicating supposed price reductions on price lists, 
price labels, indoor  store windows and other means and 
measures contrary to good morals and public order; 
5) to sell tobacco products included in an assortment with 
other goods; 
6) to supply tobacco products as prizes in lotteries, contests, 
sports competitions, game prizes or along with them; 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
7) organise games or competitions and lotteries, which 
would promote acquisition and (or) consumption of tobacco 
products; 
8) to manufacture and (or) sell toys, food products and other 
goods, whose design imitates tobacco products or packs; 
9) to sell other (non tobacco) products, marked with tobacco 
goods trademarks and etc. 
 
Luxemburg 16 Restriction 
 
Article 9 de la Loi du 11 août 2006 relative à la lutte anti-tabac, article 
9(2) : 
“Tout exploitant d’appareils automatiques de distribution délivrant du 
tabac et des produits du tabac est tenu de prendre des mesures 
empêchant les mineurs âgés de moins de seize ans accomplis d’avoir 
accès auxdits appareils.» 
 
(Régulation: Utilisation de jetons ; Apposition d’un autocollant portant 
l’interdiction de la vente aux mineurs de moins de 16 ans; L’exploitant 
peut refuser l’octroi du jeton aux personnes refusant de prouver l’âge 
requis; Pas d’appareils automatiques sur les voies publiques; Pas de 
design spécifique, ni d’avertissements sanitaires spécifiques, hormis 
ceux figurant sur les unités de conditionnement) 
 
 
No regulation Display limited to the name and the price of the tobacco 
product as well as the logo of the brand.  
 
(Article 3 paragraphe 4 de la loi du 11 Août 2006 : « 
Toute publicité en faveur du tabac et de ses produits est 
interdit, sauf dans les surfaces réservées à la vente des 
produits du tabac, et/ou à proximité immédiate des 
étalages exposant des produits du tabac à la vente. La 
publicité autorisée ne peut être effectuée alors qu’au 
moyen d’affiches et de panneaux-réclames, 
mentionnant le nom de la marque, le logo et le prix du 
produit de tabac. Elle ne peut s’adresser aux mineurs, ni 
utiliser des arguments axés sur la santé, ni faire croire 
qu’un produit particulier est moins nocif qu’un autre, ni 





TVM need to be supervised at all times. 
 
TVMs are only allowed to sell cigarettes and tobacco products. 
 
Decoys should include the health warning.   
Restriction regulated through the 
Advertising and Promotion of Tobacco 
Products Regulations, 2010 
(LN344/10) available on 
http://www.doi.gov.mt/EN/legalnotices/
2010/07/LN%20344.pdf  






Besulit van 26 januari 2004 houdende uitvoering van artikel 9, vierde 
lid, van de Tabakswet (Besulit tabaksautomaten) 
 
Vending machines have to be placed in a spot where personnel of the 
None Restricted  
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
location where they are situated in can supervise them to make sure 
age restrictions are respected. Outdoor vending machines are not 
allowed.  
 
Tobacco advertisement is regulated by the national Tobacco Act. 
Tobacco advertising is prohibited in general except for a few small 
exceptions. One of our exceptions is that an image of the brand can 
be shown on de push buttons of the machine, as long as the image is 
not larger than the original package itself. Large advertisement 
posters on the machine are not allowed. On this part of the machine 
only non-tobacco advertisement is allowed. 
Poland 
 
18 Banned since 1996 None Tobacco promotion and advertising is banned. 






According the new Tobacco Law (Law 37/2007 of  14 th of August) it 
is forbidden to sell tobacco (trough vending machines or direct 
vending) in public administration services; health services; schools, 
kindergartens, holiday camps, or other educative or leisure places for 
persons under 18 years old; ageing homes; canteens, in public or 
private enterprises or institutions, for exclusive use of its employees. 
 
Vending machines should have an electronic system or other kind of 
system in order to prevent the access of minors (under 18 years old). 
 
These machines should be placed inside the establishments, under 
the visual control of the vendor, and they cannot be placed in 
corridors, stairs or other spaces out of shops in commercial malls. 
 
Advertising on TVM is prohibited. 
Advertising is prohibited. Advertising is prohibited, including advertising in the 
points of sale; display of tobacco products on the points 
of sale is allowed.  
 
Romania 18 Ban 
 
None allowed 
Slovakia 18 Ban 
By § 6 art. 5 law no. 377/2004 on protecting of non-smokers in 





Slovenia 18 Ban Restriction Allowed. 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
 
Spain (18/07/12) 18 Restriction 
 
Art 3.1 & 4.b of the Ley 28/2005 amended by Ley 42/2010 and Real 
Decreto-Ley 14/2011 
Vending machines can only be placed inside stationery, bars, 
restaurants and convenience shops of petrol stations, under the direct 
surveillance of the owners or their employees and under registration 
procedure, inspection and control carried out by the Comisionado 
para el Mercado de Tabacos.  
The machines must include a technical device to block the access to 
minors.  
 
All types of advertising are forbidden under the Spanish regulation 
included on the vending machines. (Article 9.1 of the Ley 28/2005, 
amended by the Ley 42/2010). 
 
Health warnings about the risk of smoking in Spanish and co-official 
language of the autonomic region should be displayed on a visible 





Art.3.1 of the Ley 28/2005 
The sale of tobacco products is only 
allowed in tobacco shops or vending 
machines placed in specific places and 
having a state authorisation. Any other 
sort of selling is forbidden.  
 
 
Art. 3.6 of Ley 28/2005 
It is forbidden the sale and the supply 
of tobacco product for any other 
method other than direct personal 
sale. In particular, the sale and the 
supply of tobacco products by means 
of mail-order selling or similar 
procedures is forbiddden.  
 
 
Art. 10.Tres of the Real Decreto 1199/1999 
Only indoor. Views from outside is forbidden. 
Sweden (16/07/12) 
 
18 Restrictions apply.  
 
The sale has to comply with the same rules as if made in a shop.  
12 § of the Tobacco Act (1993:581) stipulates that 
 “The sale of tobacco products has to be made in such a way that 
makes it possible to control the ‘recipients’ age. This includes sales 
by vending machines, postal order and by similar ways”. 
 
The Swedish National Institute of Public Health is regulatory agency 
regarding sales. 
 
The same rules apply as for point of sale display – marketing in 
general is banned and the display cannot be invasive, outreaching or 
encourage anyone to use tobacco. 
Restrictions apply.  
 
The sale has to comply with the same 
rules as if made in a shop.  
12 § of the Tobacco Act (1993:581) 
stipulates that “The sale of tobacco 
products has to be made in such a 
way that makes it possible to control 
the recipients’ age.  
 
This includes sales in vending 
machines, postal order and similar 
ways”. 
 
The Swedish National Institute of 
Public Health is regulatory agency 
Marketing etc. are as a general rule banned.  
 
The display at point of sale is, however, according to 14 
§ second part 3 of the Tobacco Act (1993:581) allowed, 
but cannot be invasive, outreaching or encourage 
anyone to use tobacco.  
 
This is regulated by the Swedish Consumer Agency 
regulation KOVFS 2009:7. 
 
The Swedish Consumer Agency is regulatory agency for 
marketing etc. 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 







18 Prohibition of the sale of tobacco from vending machines 
 
England  - the sale of tobacco products directly from an automatic 
vending machine was prohibited from 1 October 2011 
 
The legislation is set out in:-Children and Young Persons (Protection 
from Tobacco Act 1991 section 3A (as inserted by Health Act 2009 
section 22). 
Statutory Instrument 2010 No. 864 
The Protection from Tobacco (Sales from Vending Machines) 
(England) Regulations 2010 
The above legislation can be found at:- 
http://www.legislation.gov.uk 
 
Wales – prohibited sales of tobacco products from vending machines 
on 1 February 2012.  See The Protection from Tobacco (Sales from 




Northern Ireland – prohibted sales of tobacco products from vending 
machines on 1 March 2012.  See The Protection from Tobacco (Sales 




Scotland – commencement of legislation prohibiting tobacco sales 
from vending machines has been delayed pending the outcome of 
legal challenges brought by Sinclair Collis and Imperial Tobacco.   
See the Tobacco and Primary Medical Services (Scotland) Act 2010 
section 9 (http://www.legislation.gov.uk/asp/2010/3/contents) 
Restriction based on transposition of 
Advertising Directive 
Displays of tobacco products prohibited in England 
starting from 6 April 2012 
(with other parts of UK to follow) 
The legislation is set out in:- 
(a) Sections 6(A1),7A, 7B and 7C of the Tobacco 
Advertising and Promotion Act, as inserted by sections 
20 and 21 Health Act 2009 
(b) The Tobacco Advertising and Promotion  
(Display)(England) Regulations 2010 (S.I.2010/445) 
(c) The Tobacco Advertising and Promotion (Display of 
Prices)(England) Regulations 2010 (S.I.2010/863) 
(d) The Tobacco Advertising and Promotion (Specialist 
Tobacconists) Regulations 2010 (S.I.2010/446) 
(e) The Tobacco Advertising and Promotion (Display and 
Specialist Tobacconists) (England) (Amendment) 
Regulations 2011 (S.I.2011/1256).   
(f) The Tobacco Advertising and Promotion (Display and 
Specialist Tobacconists)(England)(Amendment) 
Regulations 2012 (S.I.2012/677). 
 
The above legislation can be found at:- 
http://www.legislation.gov.uk 
Permanent open displays of tobacco products to the 
public in England will end on 6 April 2012 in large shops 
and on 6 April 2015 in all other businesses.  Displays 
will be limited to 1.5 square metres when actively 
carrying out specified activities such as serving 
customers and restocking and must last only as long as 
necessary to complete the activity. This will help reduce 
take up by young people and support adult quitters. 
 
Norway 18 Ban 
 
Act No. 14 of 9 March 1973 relating to Prevention of the Harmful 
None Ban 
 
Act No. 14 of 9 March 1973 relating to Prevention of the 
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Member States  Age 
restriction 
Vending machines 
(Ban or restriction. If restriction specify type, i.e. age control 
such as identification control, remote control, ID coins, 
supervision or other + other types of restrictions such as rules 
on location of the machines and advertising rules) 
Cross border distance sale, 
including Internet  
(Ban or restriction. Specify how it is 
regulated, i.e. through licensing, 
advertising, taxation)  
Tobacco promotion and display at point of sale (Ban 
or restriction. If restriction specify type, i.e. 
advertising ban, limited display and other) 
Effects of Tobacco (the Tobacco Control Act) 
Section 8. Prohibition against the sale of tobacco products from self-
service vending machines 
The sale of tobacco products from self-service vending machines is 
prohibited. This prohibition does not encompass systems where 
customers get tobacco products from vending machines using a 
prepaid vending machine card.  
Cards for use in vending machines may not be labelled with 
trademarks or company logos or other identifying marks for tobacco 
products. Vending machine cards may be labelled only with a neutral 
indication of the trademark name of the relevant tobacco product.  
Vending machines may not be labelled with trademarks or company 
logos or other identifying marks for tobacco products. They may only 
have a neutral written indication that the device is a vending machine 
for tobacco products.  
The Ministry may lay down further rules to implement and supplement 
these provisions. 
Harmful Effects of Tobacco (the Tobacco Control Act) 
Section 5. Prohibition against the visible display of 
tobacco products and smoking accessories 
The visual display of tobacco products and smoking 
accessories at points of sale is prohibited. The same 
applies to imitations of such products and cards for use 
in vending machines that allow customers to obtain 
tobacco products or smoking accessories from vending 
machines.  
The prohibition in the first paragraph does not apply to 
tobacconist shops.  
At points of sale neutral information may be given 
regarding prices and the tobacco products sold there. 
The same also applies to smoking accessories.  
The Ministry may issue regulations regarding 
implementation and supplementation of these provisions 
and may allow exemption from them.  
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Functioning of the internal market 
 
 
-Facilitate cross border trade by removing national discrepancies for 
product specific measures 
-Create/maintain a level playing field for economic stakeholders 
(including SMEs), in particular for imported and domestic products 
-Allow the adaptation of the level of harmonisation in light of market, 
scientific and international developments. 
-Remove unjustified differential treatment of products 
Impact on economic players (farmers, 
manufacturers, wholesalers, retailers, 
others) 
 
     -Cost/benefits for the industry concerned when envisaged measure is 
implemented (one off/fixed costs, running/variable costs, comparison with 
status quo) 
    -Cost/benefits for the upstream suppliers/downstream distributors 
    -Redistribution effects (input/output model)1  
    -Indirect impacts associated with expected change in consumption 
      -Innovation and research 




-Costs/benefits for the public authorities when envisaged measure is 
implemented: administrative burden 
-Indirect impacts associated with the expected change in consumption 
(macroeconomic environment):  public health (as monetised in line 
with IA guidelines), health care costs, productivity/absenteeism, taxes 
(even though no macroeconomic impact) 
-Illicit trade 
Impact on consumers -Consumer choice, price, quality 
-Consumer protection 





-International agreements (WTO, including TRIPs and TBT) 
-WHO Framework Convention on Tobacco Control (FCTC) 
                                                 
1 Whilst money not spent on tobacco will be spent on other goods and services, the "redistribution effects" based 
on the input/output model will not be used in the comparison tables, as it would mean not show the expected 







Employment and labour markets -Employment, including upstream/downstream and specific regions 
-Redistribution effects (input/output model) 
- Impact on SMEs 









Awareness and appeal 
 
 














A.4.2. COMPARING THE OPTIONS 
In order to evaluate the relative effectiveness and efficiency of the options identified in the 
impact assessment, consideration has to be given to their positive and negative impacts and 
how well each option will meet the objective identified in section 3.  
 
Policy option 0, status quo, has been taken as a baseline and therefore the potential positive 
and negative impacts associated with the other options will be measured against the status 
quo.  
 
To help comparisons between options the impacts have been rated: +++: fully achieves the 
objectives; ++: mostly achieves the objectives; +: partly achieves the objectives 0: no impact 
on the achievement of the objectives; -: partly impedes the achievement of objectives; - -: 
mostly impedes the achievement of objectives; ---: fully impedes the achievement of the 
objective.  
 
Two important explanations are warranted: (1) For the purpose of the scoring exercise, the 
impacts on economic players and on employment have been limited to the tobacco sector, 
although it is expected that money not spent on tobacco will be spent on other products and 
services and will benefit the economy and employment in these other sectors. This is 
described in more details in Annex 5, which suggests that – from a macro-economic 
  3
perspective – measures impacting strongly on the tobacco industry are positive for the 
economy as a whole.  
 
(2) When comparing the status quo (national discrepancies) with a situation in which industry 
has to adapt its production lines to one EU standard (e.g. on labelling and content/ingredients) 
it is generally accepted that cost savings are achieved for the "one off costs" (familiarisation 
etc.). Also economies of scale are possible if industry has to comply with one EU standard. 
For the running/variable costs the impact will also depend on the envisaged measure. 
However, these (positive) direct impacts could be outweighed by "indirect impacts" linked to 
the decrease in tobacco consumption (for details see Annex 5), which explains in the table 
below why the impact on the tobacco industry could be negative.  
A.4.2.1. STP and extension of the product scope 
A.4.2.1.1. Smokeless tobacco products (STP) 
A.4.2.1.1.1. Comparison table 
 
A.4.2.1.1.2. Reference 


















Option 2:   














products to a 
notification 
obligation and 
all STP placed 





Option 4:  
Maintain the 
ban on oral 
tobacco and 
subject all 










Internal market 0 + + + + + + + + + 
Economic  players 0 + + + - - - - - - 
Governmental 0 0 0 0 0 0 






International 0 0 + 0 + 0 





Equality 0 - - - + + + + + 
Awareness/Appeal 0 - - - 
+ + 
+ + + + 
Prevalence 0 - - - 
+ 















A.4.2.1.2. Nicotine containing products (NCP) 










Specific criteria Option 0: No 
Change 
Option 1:  
Subject all NCP 




Option 2:  
Establish a new 
authorisation 
scheme for 
NCP    
Option 3:   
Subject NCP 
over a certain 
nicotine 








Option 4:    
Subject all 




Internal market 0 + + ++ +  
Economic  players 0 - -  - - -  
Governmental 0 + -  + + 






International 0 0 0 0 0 





Equality 0 + - ++ + + 
Awareness/Appeal 0 + - + + 








Waste, water, soil 0 0 0 0 0 
  5
A.4.2.1.3. Herbal products for smoking 
A.4.2.1.3.1. Comparison table 
A.4.2.1.3.2. Reference 






Specific criteria Option 0: No Change 
Option 1:   Subject all 
herbal products for 
smoking to labelling 
requirements under 
TPD 
Option 2:  Phase out 
marketing of herbal 
products for smoking 
Internal market 0 + - 
Economic  players 0 -  - - 
Governmental 0 0  0 






International 0 0 0 





Equality 0 ++ +++ 
Awareness/Appeal 0 ++ n.a. 








Waste, water, soil 0 0 0 
  6
A.4.2.2.  Packaging and labelling 










Specific criteria Option 0: No 
Change 




Option 2:  Option 
1 plus harmonise 
certain aspects of 






Option 3:  Option 
2 plus full plain 
packaging   
Internal market 0 +  ++ ++ 
Economic  players 0 -  - - - 
Governmental 0 0 +  + 






International 0 + + + + 





Equality 0 +  +++ ++ 
Awareness/Appeal 0 + ++ +++ 








Waste, water, soil 0 0 0 0 
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A.4.2.3. Reporting and regulation of ingredients 


































all additives not 
essential for 
manufacturing.   
Internal market 0 -- ++ +++ 
Economic  players 0 + 0 --- 
Governmental 0 + + + 






International 0 0 0 -- 





Equality 0 0 + + 
Awareness/Appeal 0 - + + 








Waste, water, soil 0 0 0 0 
  8
A.4.2.4. Cross-border distance sales of tobacco 










Specific criteria Option 0: No change 
Option 1: Minimum 
harmonisation 
requiring notification 
and age verification 
system 
Option 2:  Prohibit 
cross border distance 
sale of tobacco 
products 
Internal market 0 ++ +  
Economic  players 0 + + +  
Governmental 0 + + + 






International 0 + + + 





Equality 0 +  + 
Awareness/Appeal 0 + + + 








Waste, water, soil 0 0 0 
  9
A.4.2.5. Traceability and security features 










Specific criteria Option 0: No change Option 1: EU tracking 
and tracing system 
Option 2: Tracking 
and tracing system, 
complemented by 
security features 
Internal market 0 + + +++ 
Economic  players 0 + + ++ 
Governmental 0 +++ +++ 






International 0 +++ +++ 





Equality 0 + + + 
Awareness/Appeal 0 ++ +++ 








Waste, water, soil 0 0 0 






Brussels, 19.12.2012  
SWD(2012) 452 final 
Part 6 
  
COMMISSION STAFF WORKING DOCUMENT 
IMPACT ASSESSMENT 
Accompanying the document 
Proposal for a 
 
DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL 
 
on the approximation of the laws, regulations and administrative provisions of the 




(Text with EEA relevance) 
 
{COM(2012) 788 final} 
{SWD(2012) 453 final}  
  
A.5 SOCIO-ECONOMIC IMPACT OF THE OPTIONS  
 
A.5.1. Introduction .............................................................................................................. 1 
 
A.5.2. Socio-economic impact associated with a reduction of tobacco consumption.... 1 
 
A.5.2.1. Methodological approach ............................................................................................ 1 
A.5.2.2. Impact on the revenues and profits of the economic stakeholders .............................. 4 
A.5.2.3. Impact on society and Government budgets.............................................................. 14 
A.5.2.4. Impact of the reduction in consumption on employment .......................................... 31 
 1 
A.5.1. INTRODUCTION 
This Annex outlines the expected socio-economic impacts of the policy options on economic 
stakeholders active in the tobacco supply chain as well as on Governments and society at 
large. It analyses how a reduction of tobacco consumption will impact on the stakeholders 
(e.g. loss of revenues). This is referred to as the indirect impact of the envisaged measures. 
The main part of this Annex consists of four sections. 
 
Section 1 outlines the methodological approach taken for the analysis. Section 2 describes the 
expected impact on the revenues and profits of the economic stakeholders. The analysis 
focuses on the tobacco industry, its upstream suppliers and its downstream distributors. The 
section also describes how a negative impact on these stakeholders will be compensated by a 
positive impact on other sectors, taking into account that money not spent on tobacco is spent 
on other economic activities.  
 
Section 3 deals with the impact on Governments and society at large. It explains the positive 
impacts of reduced tobacco consumption on public health, on costs for medical treatment and 
smoking related absenteeism. These positive impacts are also contrasted with the anticipated 
negative impact on tax revenues associated with a decline of tobacco consumption, even 
though the tax reductions are not really a cost to society, but rather a transfer of resources 
within the society. 
 
Section 4 analyses the impact of reduced tobacco consumption on employment in the tobacco 
industry, its upstream suppliers and downstream distributors, as well as in other economic 
sectors (redistribution effect). A particular focus will be placed on the input/output model 
which outlines how money not spent on tobacco would be spent on other economic activities. 
This section also addresses regional issues. 
A.5.2. SOCIO-ECONOMIC IMPACT ASSOCIATED WITH A REDUCTION OF TOBACCO 
CONSUMPTION  
A.5.2.1. Methodological approach 
The main objective of the analysis in this annex is to quantify socio-economic impacts linked 
to a drop in cigarette/RYO prevalence and consumption, as a result of the implementation of 
the proposed preferred policy options.  For this, our analysis was based on the assumption that 
the combination of the envisaged policy options would lead to a drop of tobacco 
consumption of 2% for cigarettes and RYO1 beyond the baseline in 5 years. In absolute 
figures, such a drop in tobacco consumption corresponds to 2.4 million Europeans that 
would either not start smoking or successfully manage to quit smoking.  
 
The expected impacts are analysed for the fifth year after transposition of the envisaged 
directive, i.e. at a time when the measures are expected to develop their major impact in terms 
of decreased consumption. This should not be understood to mean that there are no impacts 
on consumption before or after “year five”. On the contrary, the drop in tobacco 
consumption is expected to develop gradually, starting already in year one and continuing 
                                                            
1 The focus on cigarettes and RYO is due to the fact that the preferred policy options focus on these segments 
and concrete measures are proposed for them whilst for other tobacco products (pipe and cigars) the preferred 
options foresee delegated powers. For smokeless tobacco and herbal products intended for smoking, the 
reference is made to the analysis on policy area 1 (scope). 
 2 
beyond year five. This is for example due to the fact that some provisions (e.g. new 
mandatory picture warnings) are expected to initially affect actual and potential smokers 
awareness before leading to a change in smoking behaviour, while other provisions (e.g. the 
ban of characterizing flavours) may have a more direct/immediate effect on smoking 
behaviour. Overall, the measures are expected in particular to affect the uptake of smoking in 
young people leading to a continuous reduction in smoking consumption in the long run. This 
effect develops and reinforces itself over time2. 
 
Some benefits of reduced tobacco consumption on public health will also only develop 
over time. While improvement for certain tobacco related acute diseases (e.g. respiratory 
illnesses) are expected to be seen within short time period, the effect on some other diseases 
(e.g. cancer) may take several decades to fully materialise. A scientific study from 1997 
suggests that maximum health benefits from tobacco control policies are observed five years 
after a tobacco control measure is introduced3. In this light, "year five after transposition" was 
selected as a good proxy for the analysis of the effects. The long term benefits (e.g. reduced 
cancer rates) are anticipated to allow for a fair comparison. Social discounting is used where 
appropriate. 
 
As indicated the preferred policy measures are – in combination - expected to lead to a 
decrease of consumption of 2% compared to the baseline4. This assumption is in line with 
expectation and experiences of other tobacco control agencies which have observed similar 
drops for comparable policy measures. According to these, the main contributions are 
expected from the policy areas on packaging and labelling and ingredients. Whilst the details 
how each policy area contributes to the decrease of consumption are set out in the 
introductory part of section 5.7 of the IA report, the following table contains an overview:   
Table 2.1: Contributions of individual policy areas to the projected decrease of cigarette/RYO consumption 





Packaging & Labelling 1-1.5 
Ingredients 0.5-0.8 
TOTAL   1.7-2.6% 
Cross-border distance sales + Illicit 
trade 
Additional decrease of consumption, however 
not in the legal supply chain. (Decreases in 
illicit consumption is expected to partially 
mitigate the decrease in the legal chain). 
  
                                                            
2 In this respect it is considered that more than 80% of smokers start smoking when they are under age 
(teenagers) and that nicotine contained in tobacco has addictive properties, which makes smoking cessation a 
challenge. It is also considered that people, who do not start smoking under age, are less likely to start smoking 
at a later stage and that children of smokers are significantly more likely to start smoking 
-  Anne Charlton, Youth and Cigarette Smoking, http://www.globalink.org/en/youth.shtml, accessed on 11 March 2012 
-  Meg Riordan,  Campaign for Tobacco-Free Kids; www.tobaccofreekids.org/research/factsheets/pdf/0127.pdf,     
accessed on 11 March 2012 
- U.S. Department of Health and Human Services, Preventing tobacco use among young people;  
   http://profiles.nlm.nih.gov/ps/access/NNBCLQ.ocr, accessed on 11 March 2012 
3 Jan J. Barendregt, M.A., Luc Bonneux, M.D., and Paul J. van der Maas, Ph.D. N Engl J Med 1997; 337:1052-1057 
4 For description of the base line see section 2.3 of the main report.  
 3 
The figures in the above table should be interpreted with caution. Firstly, the proposed 
measures are mutually reinforcing. For example, improved health warnings and an improved 
ingredients policy both have the public health objective of making it less attractive for young 
people to start smoking5. The combination of these measures is expected to have a better 
effect than the sum of each individual measure. Secondly, from an ex post perspective it is 
sometimes not straight forward to fully disentangle the impact of the different measures. 
Typically tobacco regulators introduce a variety of measures at the same time. This is due 
to the fact that there is not one single policy measure that could make the introduction of all 
other tobacco control measures redundant. Tobacco control policy measures include among 
others price/tax policies, smokefree environments, information campaigns, advertising 
bans/limitations, health warnings. The task to say with precision which measure contributed 
to the success and to which degree is further complicated by the fact that certain measures 
require time to take full effect (see above). Lastly,  the success of many of the policy 
measures implemented in other jurisdictions needs to be judged against the backdrop of 
existing measures, national/cultural differences and the economic situation of the country 
concerned. The same applies to the situation in the different Member States.  
 
In the light of the arguments above, it seems preferable to work on the basis of the assumption 
that the combination of the envisaged measures will lead to a drop of consumption of 2% 
in 5 years' time. 
 
For the sake of clarity and transparency, annex 5 provides not only the calculations for a 2% 
reduction, but also calculations based on higher and lower impact scenarios. This is done 
to show that more stringent measures could have even bigger impact (e.g. plain packaging, 
full ban of additives, full ban of displays, which could lead to a reduction of consumption of 
up to 5%), but also to show - if the current expectations prove not to be correct - that even 
smaller decreases in tobacco consumption are beneficial and therefore make sense from an 
impact assessment point of view. This simplified sensitivity analysis did not suggest any 
significant variation of qualitative outcomes within the broad range of the assumed 
consumption drop.  
In order to bring our range into perspective, a comparison can be made with various global 
targets. For example, the WHO envisages a 40% relative reduction in prevalence of current 
tobacco smoking by the year 2025, taking 2010 as a base year. In comparison to these figures, 
the projected consumption drop is not overly ambitious, even if tobacco product regulation is 
just one tool of many and other tobacco control measures may also contribute to decreasing 
smoking prevalence. 
One last important caveat should be remembered, collecting data and presenting it in a 
coherent form was a challenge when preparing the IA report. Whilst all possible efforts 
were made to gather the most comprehensive data, some challenges remain. For example, 
some stakeholders either did not provide the requested information or did not provide the 
information in a usable format. Furthermore, information received from economic 
stakeholders could not always be reconciled with publicly available data (e.g. Eurostat). The 
data sets received from industry were also not always fully consistent when comparing data of 
different market participants (here every effort was made to reconcile the data to the extent 
possible). In order to ensure overall quality, some key data was verified with associated 
                                                            
5 Although the main objective of the revised directive is the improvement of the internal market, when it comes 
to the assessment of the effects of the proposed options, the drop of consumption needs to be assessed in line 
with the objective of a high level of public health.  
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services (e.g. tax revenues) and/or industry (e.g. turnover generated with tobacco products and 
the allocation of shares across stakeholders along the value chain). Finally, information on the 
illicit part of the market was difficult to establish in a robust form taking into account the 
nature of these activities.  
 
As explained above, this annex addresses the expectation of how reduced tobacco 
consumption impacts on various stakeholders. It does not address other (for example direct) 
impacts associated with a change of regulation (e.g. costs/benefits associated with 
implementing the new regulatory requirements on labelling). These are described in the 
respective sections of section 5.5 of the IA report.  
A.5.2.2. Impact on the revenues and profits of the economic stakeholders 
This section describes the impact that a decrease in tobacco consumption is expected to have 
on the revenues and profits of the tobacco industry, its upstream suppliers and its 
downstream distributors. It concentrates on factory manufactured cigarettes (FMC) and 
roll your own tobacco (RYO), as the different policy options focus on these categories of 
tobacco products6.  
 
The analysis focuses on the legal part of the supply chain. This is not to mean that policy 
options cannot have an impact on the illicit supply sector. However for the purpose of this 
impact assessment, the impact of the illicit part of the sector is only relevant to the extent that 
the illicit market takes away additional revenues from the legal supply chain or that revenues 
previously attributed to the illicit trade return to the legal supply chain. Moreover, the illicit 
sector does not deserve any protection in its own right. To the contrary, law enforcement 
needs to ensure that the illicit part of the market is reduced to the extent possible. 
 
With respect to illicit trade, it is also worth noting that none of the preferred options are 
expected to lead to a (noteworthy) increase in illicit trade beyond the baseline and will 
therefore not shift additional revenues from the legal to the illicit supply chain. On the other 
hand, the preferred options in policy areas 4 (cross border  (including distributors) 5 (tracking 
& tracing, security features) are expected to lead to a decrease in illicit trade, which will 
subsequently lead to part of these revenues returning to the legal supply chain. These effects 
have, however, not been analyzed in this section in order to ensure full transparency of the 
impact of the preferred policy options on consumption and to provide a conservative estimate 
of these impacts7. In this respect the analysis below thus amounts to a “worst 
case/conservative scenario” for economic stakeholders. 
 
The analysis is also a "conservative scenario" for economic stakeholders for another reason, 
when applying the input/output model presented in detail in section 5.2.4 for the impact on 
employment, it appears that money not spent on tobacco will be spent on other goods and 
services. This will not necessarily benefit the tobacco industry, but will benefit certain parts of 
the distribution chain (retailers in particular) or upstream suppliers. Accordingly, the effects 
presented below are maximum negative impacts for the tobacco industry, but not for the 
economy as a whole (including distributors).  
 
                                                            
6  For pipe tobacco and cigars/cigarillos only delegated powers are foreseen, in particular if they develop into a 
smoking initiation products. 
7  See however section 5.6 of the main report. 
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The main factors taken into account in the analysis were (1) revenues generated by the 
economic stakeholders as well as the added values of the individual sectors in the overall 
supply chain, (2) the profit margins of the individual sectors and (3) the dependence of 
different sectors/stakeholders on the revenues generated with tobacco products.  
Shares of the stakeholders in the value chain 
As explained in Annex 2, in 2010 the EU-27 market for FMC and RYO was worth 130.6 
bEUR at retail level including VAT and excise duties8. Thus, a 1% reduction in tobacco 
consumption would mean that a 1.3 bEUR decrease in spending on tobacco. However, in 
order to establish the impact on economic stakeholders the part of turnover associated with 
taxes (VAT and excise duties) must be removed9. Accordingly the total market at retail level 
accounted for 31.36 bEUR. Of this, 90.4% (i.e. 28.34 billion EUR) are generated from the 
sales of FMCs, and 9.6% (or 3.02 billion EUR) from RYO. The value generated from other 
tobacco products10 are not further considered in this assessment, in particular because the 
envisaged policy measures are proposed to be currently suspended for these products.  
 
If one assumes a 1% reduction in tobacco consumption, the company revenues from FMC and 
RYO at retail level would lead to a reduction of 313.6 mEUR, this would double with a 2% 
reduction and so on. The breakdown for the two product categories considered is 283 mEUR 
for FMCs and 30 mEUR for RYO if a 1% reduction is observed. Table 2.2 below summarises 
the revenue loss that all the companies within the tobacco supply chain face when overall 
tobacco consumption decreases by 1, 2, 3, 4 or 5%.  
 
Table 2.2: Reduction of sales (mEUR) 
Reduction of consumption translated into reduction of 
tobacco sales at retail level 
 
1% 2% 3% 4% 5% 
Reduced spending on tobacco 1306 2612 3918 5224 6530 
  - Tax revenue lost  992.4 1984.8 2977.2 3969.6 4962 
  - Company revenue loss11 313.6 627.2 940.8 1254.4 1568 
Source: own calculations 
 
The concept of value added 
In figure 2.1 below we present the production/supply chain for cigarettes in a simplified 
form. It sets out the main categories of suppliers, the activities of the tobacco companies and 
the distribution chain.   
                                                            
8 Matrix report 2012, Euromonitor figure - consist of overall EU market value of FMC (121,3 bEUR) and RYO 
(9.3 bEUR); see also Annex 2 
9 Euromonitor, DG TAXUD, Matrix report 2012; see also Table 2 in Annex 2 
10 Cigars and cigarillos, pipe tobacco; for EU market shares of these products see Table 1 in Annex 2 
11 Overall tobacco suply chain losses  
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Table 2.4: Revenues (sales to tobacco industry or of tobacco products) and profits (in billion EUR)  
Upstream suppliers Downstream Distribution 
Leaf production 
  Farmers Processors 




industry Wholesale Retail 
Revenue  
(bEUR) 
0.68 2.56 0.61 0.61 1.38 0.91 18.82 23.25 31.36 
Profit 
margin 
8.0% 8.0% 6.8% 6.8% 6.8% 6.8% 14.4% 1.5% 1.5% 
Profit 
(bEUR) 
0.04 0.22 0.04 0.04 0.09 0.06 2.71 0.35 0.47 
Source: own calculation for turnover, S&P Index 500 Stocks margins by sectors 
 
The subsequent sections explain what a drop of consumption in the region of 2% would mean 
for the different stakeholders along the tobacco supply chain. The analysis starts with the 
tobacco industry, then turns to upstream suppliers and concludes with downstream 
distributors. 
A.5.2.2.1. Impact on tobacco manufacturing industry  
From Table 2.4 we can derive that the tobacco manufacturing industry generated a 
turnover of 18.8 billion EUR in year 2010 with the sale of FMCs and RYO at an ex-factory 
level excluding taxes12.  
Table 2.5 shows the impact on revenues and profits as a result of a declining consumption of 
FMCs and RYO. The projected decrease of 2% in consumption is expected to lead to total 
revenue losses for tobacco manufacturers of approximately 376 mEUR, which represents a 
reduction of profits in the region of 54 mEUR. The profit margins are based on industry 
averages13.  
                                                            
12 Excise duty and VAT 
13 S&P Index 500 Stocks margins by sectors; 3Q/2011; http://mobile.bloomberg.com/news/2011-10-
28/summary-of-third-quarter-margins-for-s-p-500-stocks-by-sectors (accessed on 14/3/2012) – subsequently 
compared with the reported margins of the industry in their publicly available P/L accounts  
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Table 2.5 Reduction in revenues and profits for tobacco industry  
Reduction in tobacco consumption Tobacco manufacture 
1% 2% 3% 4% 5% 
Revenue loss in sector (mEUR) 188 376 564 753 941 
Profit loss in sector (mEUR) 27.1 54.2 81.3 108.4 135.5 
Source: own calculation 
 
As indicated previously, the presented reduction in revenues and profits is a "conservative 
estimate" for the industry. For example, that certain sales of the illicit supply chain are 
expected to return to the legal supply chain as a result of the measures proposed under policy 
areas 4 (cross border internet sales) and 5 (dealing with measures against illicit trade) has not 
been considered.14 
 
When comparing the expected reduction in revenues and profits with the actual turnover 
and profits of the industry for the year 2010 (Table 2.5) as reported by the big four tobacco 
companies in their P/L accounts (accounting for 80-90% of the EU market), it can be 
concluded that the impact in relative terms would not be major and the measures are therefore 
not disproportionate. 
 
Table 2.6: Revenues and profits reported by the industry in 201015  
Data for the “big four” representing almost 90% of the 
total EU market 
 PMI* BAT JTI* IT* 
Revenues in the EU (in mEUR) - 4,460 - - 
Profits reported for EU (in mEUR) - 1,331 - - 
Revenues worldwide (in mEUR) 13,476 17,964 7,857 6,578
Profits worldwide (in mEUR) 5,586 5,212 2,463 2,192
  Source: Company financial reports 2010; Companies internet websites16 
  
Furthermore, it is important to underline that the relationship between FMC/RYO sales and 
profits of the tobacco companies is not perfectly correlated17. A decrease in cigarette does not 
necessarily lead to a reduction in relative, or even absolute, profits. It seems that companies,  
on the basis of their substantial market power, have been able to maintain profits at high 
levels in recent years despite a decline in sales. 
                                                            
14 Further details in section 5.5 of the main report. 
15 Financial reports of "big four" tobacco companies; companies internet websites; data converted in EUR with 
ECB exchange rate as of 16/02/2012; data for EU 
16 Data on revenues and profits derived from sales within the EU were not available (neither made public nor 
provided by companies on request) 
17 Over last 10 years, Germany and France had a larger sales volume reduction than average, whilst Italy and the 
UK saw a smaller sales volume reduction than average. The French rise in tobacco profits coincided with a 
(larger than the EU average) -34% fall in the volume of cigarettes sold in France, and could be explained by both 
a resistance to the squeezing of profit margins despite rising taxes and strong growth in the volume of RYO 
tobacco (+36%) and cigarillos (+10%) sales; Matrix report 2012 
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A.5.2.2.2. Impact on tobacco growers and other upstream suppliers 
A reduction of tobacco consumption is also likely to impact the upstream suppliers to the 
tobacco industry, as the tobacco industry will reduce its purchases from upstream suppliers in 
the light of declining sales. For the purpose of this impact assessment, these effects were 
estimated and are presented below. It is assumed that a 2% reduction in consumption will lead 
to a linear reduction in purchases of the tobacco industry (FMC/RYO) from upstream 
suppliers. 
Tobacco growers and processors 
In 2010, EU based tobacco growers produced 294,000 tonnes of raw tobacco and 
generated revenues of 682 mEUR18 in sales to the tobacco industry. This includes sales for 
products other than FMCs and RYO, without adjusting for product exemptions (leading to an 
overestimation of the overall reduction considering all tobacco products). 
Table 2.7 shows the revenue and profit losses in the tobacco growing and processing sector as 
a result of a declining consumption of FMCs and RYO. The projected decrease of 2% 
consumption would lead to total revenue losses for tobacco farmers in the EU of 
approximately 13.6 mEUR, representing an overall sector net profit loss of approximately  
1.1 mEUR. This assumes, conservatively, that all sales of raw tobacco were made to EU 
tobacco manufacturers, which cannot be compensated through other sales.  
Table 2.7: Reduction in revenues and profits for tobacco growers and processors  
Reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Tobacco growers      
Revenue loss in sector (mEUR) 6.8 13.6 20.4 27.2 34 
Profit loss in sector (mEUR) 0.54 1.09 1.63 2.18 2.72 
Tobaco processors      
Revenue loss in sector (mEUR) 25.6 51.2 76.8 102.4 128 
Profit loss in sector (mEUR) 2.05 4.10 6.14 8.19 10.24 
Source: own calculation 
 
Whilst it is reasonable to assume that a significant number of growers are able to, and actually 
do, generate at least some additional revenues with other products, it was not deemed 
appropriate to consider these revenues in this impact assessment. In order to maintain a 
“conservative scenario”, it was assumed that no additional revenues were generated by 
growers. If the overall reduction in profits is distributed over all 86,133 farmers19 in the EU, 
the annual reduction in an individual farmers’ turnover amounts to 158 EUR per year.20 
This appears to be an acceptable burden. In particular, it does not appear that certain types of 
farmers (Burley or Oriental growers) would be affected in particular manner. Obviously it is 
unlikely that each farmer will produce 2% less tobacco. Taking into account past experience, 
                                                            
18 DG AGRI data 
19 Sources: Member States' communications (Commission Regulation (EC) No 2095/2005) ; DGAGRI. 
20 As the EU tobacco consumption is composed by 1/3 of EU production and 2/3 of EU imports, we have also 
performed a sensitivity analysis assuming that the reduction of 2 - 3%, will affect only the EU production or will 
affect only the imports into EU. Taking in account these extreme scenarios, the theoretical loss of income for the 
EU tobacco growers should lie between 0 - 711 EUR/grower. 
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it is more likely that certain farmers will discontinue their activities whilst other will continue 
at previous levels. 
 
In this respect it should also be noted that in the past in the EU, the market for growers has 
decreased faster than the market for FMCs (with sales of RYO even growing).21 There is thus 
no linear correlation between the reduction in smoking consumption and EU farming 
output. If this negative trend for growers continues, it is important to distinguish between the 
baseline scenario (which would predict a negative trend for farmers irrespective of the 
measures foreseen) and the relatively moderate effects that can be associated with the reduced 
consumption of FMCs and RYO following the revised TPD.  
 
Finally, table 2.8 below shows that the European market for growers and processors has 
developed differently from the world market. The EU market has seen a decline of 31% 
from 2000 to 2009 in volume terms, whilst the world market has grown by 7%. It is therefore 
fair to assume that the underlying cause for the negative trend for European growers is at least 
partly of a structural nature, including decoupling of subsidies from production in 2004.22 
 
Table 2.8: EU production and trade of unmanufactured tobacco (000, tonnes) 
Trade in unmanucatured tobacco (2010) 
import Export 
  
2000 2009 change 
(000 t) (mEUR) (000 t) (mEUR) 
EU 27 439 304 -31% 597 2170 167 686 
World Total 6676 7122 7%     
Source: Matrix / Euromonitor; Faostat, Eurostat 
 
In 2010, there were 88 first processors23 of tobacco in the EU. These were located close to 
tobacco growing regions, with the majority located in Bulgaria and Italy. Two U.S. based leaf 
tobacco merchants24 with similar market shares control the major part of the EU market of 
second processors.25 In 2011, Alliance One delivered 54% of its tobacco sales to customers 
in Europe (approx. 800 mEUR).26 
Table 2.6 above shows the revenue and profit losses in the tobacco processing sector as a 
result of a declining consumption of FMCs and RYO. The projected decrease of 2% 
consumption would lead to total revenue losses for tobacco processors in the EU of 
approximately  51 mEUR which represent overall sector net profit loss of 4mEUR. 
                                                            
21  Between 2000 and 2009, the total production of unmanufactured tobacco in the EU decreased by 31%, from 
438.7 thousand tonnes annually to 303.8 thousand tonnes annually. The volume of the EU cigarettes market in 
2010 (608.8 billion sticks) declined by 23.3% in comparison to 2000. The market size of RYO tobacco in 2010 
(75.500 tonnes) increased  in comparison to 2000 by 42.2 %. Thus, overall FMC+RYO market decreased by 
19.2 % (assuming that 1g of RYO tobacco corresponds to one cigarette).  
22 Negative effect of the reform was the growth of raw tobacco’s prices which brings significant competitive 
disadvantage of EU tobacco growers in the global market. 
23 The first processors collect the raw tobacco cured by farmers and undertake the first process before selling it 
to the second processors (see also Annex 2), cf. DG AGRI. 
24 Alliance One Int.; Universal Corporation 
25 The second processors subsequently purchase, process, blend, pack, store and ship tobacco to meet each 
specifications of manufacturers of cigarettes and other tobacco products (see Annex 2). 
26 AOI 2011 Annual Report, http://phx.corporate-ir.net//phoenix.zhtml?c=96341&p=irol-reportsannual, accessed 
on 29 February 2012. Recently, the Commission fined the company's subsidiaries in Spain, Italy and Greece for 
operating cartels, but the outcome of the appeal is not yet known.  
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Other upstream suppliers 
Table 2.9 below shows the reduction in revenues and profits of other industries/sectors 
supplying the tobacco manufacturers as a result of decline in the consumption of tobacco 
products. 
Table 2.9: Reduction in revenues and profits of suppliers to FMC/RYO producers 
Reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Tobacco additives           
Revenue loss in sector (mEUR) 6.1 12.1 18.2 24.3 30.3 
Profit loss in sector (mEUR) 0.41 0.83 1.24 1.65 2.06 
Cigarette papers      
Revenue loss in sector (mEUR) 6.1 12.1 18.2 24.3 30.3 
Profit loss in sector (mEUR) 0.41 0.83 1.24 1.65 2.06 
Cigarette packages      
Revenue loss in sector (mEUR) 9.1 18.2 27.3 36.4 45.5 
Profit loss in sector (mEUR) 0.62 1.24 1.86 2.48 3.09 
Cigarette filters / Others      
Revenue loss in sector (mEUR) 13.8 27.6 41.5 55.3 69.1 
Profit loss in sector (mEUR) 0.94 1.88 2.82 3.76 4.70 
Source: own calculation; based on data received from industry 
 
The EU based suppliers of tobacco additives generated an estimated 610 mEUR of revenue 27 
from sales to producers of FMC/RYO in the EU in 2010. The projected decrease of 2% in 
consumption would lead to total revenue losses for the sector of approximately 12.1 mEUR 
which represents an overall sector net profit loss of 0.83 mEUR. Given that the dependence 
of additives/flavours production sector on tobacco industry is rather limited (possibly 
with the exception of some specialised SMEs), the impact of decreasing tobacco consumption 
on revenues and profit losses within the sector would be marginal.  
The EU based suppliers of cigarette fine papers generated revenues of 610 mEUR28 from 
sales to the tobacco industry in the EU in 2010. Sales to tobacco industry often represents 
close to 100% of these suppliers total revenue, but only approximately 50% of the sector 
production is reported as sales within the EU. The projected decrease of 2% in tobacco 
consumption would lead to total revenue losses for the sector of approximately 12.1mEUR 
which represents an overall sector net profit loss of 0.83 mEUR. Similarly to suppliers of 
additives, the 2% decrease in cigarette consumption would have a relatively small impact on 
overall revenues and profits of the cigarette paper industry representing 1% of the profits 
taking into account exports. 
The EU based suppliers of cigarette packages generated revenue of 910 mEUR29 from sales 
to the tobacco industry in EU in 2010. The sales to the tobacco industry represent 
approximately 10% of the sector total revenue. The projected decrease of 2% in cigarettes 
consumption would lead to total revenue reduction for the sector of approximately 18.2 
mEUR which represents an overall sector net profit loss of 1.24 mEUR. Since the dependence 
                                                            
27 Reconciled from the data obtained from additive and cigarette manufacturers 
28 Reconciled from the data obtained from industry - fine paper producers and cigarette manufacturers 
29 Reconciled from the data obtained from industry – ECMA industry association and cigarette manufacturers 
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of cigarette package producers on the tobacco industry is low, the overall impact of a decrease 
in tobacco consumption by 2% on reduction in revenues in the sector will be an 
insignificant 0.2% of total sector turnover. 
It is estimated that other EU based suppliers to tobacco industries including acetate tow / 
cigarette filter producers generated revenues of 1.38 billion EUR30 from sales to the tobacco 
industry in the EU in 2010. The projected decrease of 2% in cigarette consumption would 
lead to total revenue losses for the sector of approximately 27.6 mEUR which represents an 
overall sector net profit loss of 1.88 mEUR. There is insufficient information available on 
how much the industries concerned rely on sales to the tobacco industry located in the EU31, 
but in line with the explanations above it is assumed that the impact on these industries is 
significantly less than the respective decrease in consumption.  
A.5.2.2.3. Impact on wholesalers and retailers 
The reduction in consumption will also affect the downstream distributors of the tobacco 
industry, i.e. wholesalers and retailers (which range from specialist retailers to hypermarkets). 
This section aims at summarizing the expected impacts of reduced consumption on these 
stakeholders.  
Wholesale 
The EU based wholesalers of tobacco products generated revenues of 23.25 billion EUR32 
from sales of FMC and RYO in the EU in 2010. As shown in the table 2.10, the projected 
decrease of 2% in consumption would lead to total revenue losses for the sector of 
approximately 465 mEUR which represents an overall sector net profit loss of 7 mEUR. 
Table 2.10: Reduction in revenues and profits of wholesalers 
Reduction in tobacco consumption Wholesale 
1% 2% 3% 4% 5% 
Revenue loss in sector (mEUR) 232.5 465 697.5 930 1162.5 
Profit loss in sector (mEUR) 3.49 6.98 10.46 13.95 17.44 
Source: Euromonitor; own calculation 
In a number of Member States wholesale activities, formerly part of national tobacco 
monopolies, are operated by large tobacco manufacturers.33 In other MS the wholesalers are 
often involved in the distribution of various product categories, and therefore only part of 
their revenue would be impacted34.  
                                                            
30 Reconciled from the data obtained from industry – GAMA industry association  
31 The acetate tow producers are part of big multinational cooperations which generate only a very small fraction 
of their revenues with acetate tows 
32 Reconciled from the data obtained from industry. Obviously, the wholesalers would have proportionally 
reduced purchasing costs of 18.82 bEUR. In this regard the sector added value is estimated at 4.4 bEUR. 
33 Case No COMP/ M.4424 JT / Gallaher; Case No COMP/ M.4581 Imperial Tobacco  / Altadis. Article 6(2) 
non-opposition 
34 e.g. Cash and carry warehouses, European Tobacco Wholesalers Association 
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Retail 
The turnover generated at retail level from tobacco products (FMCs and RYO) amounted 
to 31.36 bEUR in 2010.35 The table below shows the revenue and profit reductions of the 
retail distributors of tobacco products as a result of declining consumption. The projected 
decrease of 2% in consumption would lead to total revenue loss for the sector of 
approximately 627 mEUR (cooresponding to the sector added value of 162 mEUR) which 
represents an overall sector net profit loss of 9.4 m EUR. 
 
Table 2.11: Reduction in revenues and profits of wholesalers 
Reduction in tobacco consumption 
Retail 
1% 2% 3% 4% 5% 
Revenue loss in sector (mEUR) 313.6 627.2 940.8 1254.4 1568 
Profit loss in sector (mEUR) 4.70 9.41 14.11 18.82 23.52 
Source: Euromonitor; own calculation 
It is evident that the dependence of retailers on turnover generated with tobacco varies quite 
significantly. On the one hand, there are specialist tobacco retailers, which generate a 
significant part of their turnover from tobacco. On the other hand big super markets sell a 
great variety of products and tobacco products only account for a minor share of their 
revenues. Table 2.12 below shows the proportion of sales of tobacco products in the EU 
across the different retail channels and allocates the total revenues at retail level to them. The 
subsequent column shows the impact of declining consumption for each type, if consumption 
decreases by 2%. Similarly to previous sections the net profit margin was applied for each of 
the sectors36. 
  
Table 2.12 : Shares of retail sale of tobacco products in EU and impact on revenue/profit  
Impact of 2% decline in 
consumption (mEUR) Place of sale 
Share of retail 
sales in EU 
(2010) Revenues Profits 
Tobacco specialists 23.8% 149.27 2.24
Newsagent-tobacconists/kiosks 24.7% 154.93 2.33
Supermarkets/discounters 14.6% 91.60 1.37
Hotels/restaurants/bars 1.3% 8.13 0.12
Vending machines 8.6% 53.93 0.81
Small grocery retailers 10.8% 67.73 1.01
Convenience stores 4.9% 30.73 0.46
Forecourt retail / gas stations 8.9% 55.80 0.84
Others 2.4% 15.07 0.23
  100.0% 627.20 9.41 
Source: Matrix report 2012; Euromonitor, own calculation 
 
                                                            
35 Obviously, the wholesalers would have proportionally reduced their purchasing costs in the range of 23.25 
bEUR. In this regard the sector added value is estimated at 8.1 bEUR. 
36 S&P Index 500 Stocks margins by sectors; 3Q/2011 
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The retailers most dependent on selling tobacco products37 generate an aggregated revenue 
from selling tobacco products of 15.2 bEUR, which is almost 50% of the total retail revenues 
from the sales of tobacco products. Assuming that their revenues from tobacco products 
account for between 45-60% of their total revenues38, the projected decrease of 2% in 
cigarettes consumption would lead to revenue losses of 304.2 mEUR, representing 0.9-1.2% 
of their total revenues. Overall the profit reduction for the retailers most dependent on tobacco 
would account for 4.57 mEUR. 
As discussed in more detail in Section 4, money not spent on tobacco products will be 
spent on other products and services. This will also partially benefit retailers specializing in 
tobacco (e.g. bars, newsagents, snacks).  
All other retailers, which are less dependent on tobacco products, generated revenues 
from tobacco products in the region of 16 bEUR. Since these revenues form only a fraction of 
their total revenues, the projected decrease of 2% in cigarettes consumption would influence 
these retailers only in an insignificant manner. 
 
Whilst the general trend in tobacco sales has been downward, the distribution channels 
through which tobacco is sold changed only slightly between 2000-2010. Declining sales in 
cigarettes have affected all retail channels, but to different degrees.39 Furthermore, in recent 
years, the number of very small mixed businesses in the EU have in general been on the 
decline. This has resulted mainly from overall consumer behavior changing (e.g. longer 
working hours and extended shopping hours for supermarkets and major shopping centers). 
Thus, regardless of public policies on tobacco, the continuing decline in profitability of small 
corner stores in EU is likely to lead to concentration of cigarette and tobacco sales by 
larger retailers.  
 
A.5.2.2.4. Input output model 
As explained, money not spent on tobacco is spent on other goods and services (e.g. food, 
cloths, holidays, cinemas among others). This additional expenditure is expected to benefit the 
economic operators concerned (re-distribution effect). In order to fully capture the 
macroeconomic effects, a so-called input/output model was used. Whilst this model is 
explained in more detail in section 4 below (employment), the attached table shows which 
sectors are expected to benefit from a reduction in tobacco consumption and which sectors are 
expected to lose revenues (for more detailed explanations see A5.2.4.1 below). 
                                                            
37 Tobacco specialists, Newsagents-tobacconists/kiosks 
38 Data provided by European Federation of Tobacco Retailers 
39 Over last 10 years, sales have dropped more in specialised stores than in larger supermarkets/hypermarkets or 
discounters (Matrix report 2012).  
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Table 2.13: The impact on output of different sectors associated with a reduction in consumption of  
tobacco by 1%  (in billion EUR) 
Industry 
Monetary impact 




of increase in 
expenditure for 
other goods 
Net effect on 
output 
TOTAL -0.574 0.634 0.059 
Agriculture -0.025 0.017 -0.008 
Mining and petroleum -0.002 0.006 0.005 
Food industries -0.012 0.067 0.054 
Tobacco -0.197 0 -0.196 
Textile -0.002 0.022 0.019 
Wood and wood products -0.003 0.018 0.015 
Paper products and printing -0.018 0.007 -0.011 
Chemical products -0.011 0.014 0.003 
Rubber products -0.003 0.005 0.002 
Metal and non metal products -0.004 0.009 0.005 
Basic metal products -0.004 0.008 0.004 
Machinery -0.005 0.009 0.004 
Transport devices -0.025 0.057 0.033 
Housing and Electricity -0.011 0.07 0.059 
Finance and trade and insurance -0.018 0.018 0 
Wholesale and retail -0.033 0.044 0.011 
Services -0.095 0.136 0.041 
Compensation of employees -0.093 0.108 0.014 
Source: Matrix report 2012 
A.5.2.3. Impact on society and Government budgets  
For the society as a whole, a reduction in tobacco consumption has mostly positive 
implications (improved public health, reduced health care costs and less absenteeism).  
However, it might also have some adverse impacts on budgets (reduction in tax revenues), 
even if in the past a reduction in tobacco consumption has not lead to a decrease of revenues 
and from a macro-economic perspective represents only redistribution of the resources to 
other stakeholders with the society.  
 
This section describes the effects outlined above in more details. It starts with the positive 
effects associated with a reduction in tobacco consumption and then turns to the budgetary 
implications of this reduction. The subsequent section balances both effects and comes to the 
conclusion that the positive effects outweigh the negative effects. In order to cater for the 
benefits and costs that occur in different time periods, social discounting is applied in the last 
part of this Section.  
A.5.2.3.1. Positive impacts of reduced consumption  
The main positive impact of reduced tobacco consumption is that public health is 
significantly improved. People, who do not smoke/stop smoking in time, live significantly 
longer with better health. It is evident that across society and individuals, as well as for their 
families and those close to them, a gained (healthy) life year is a very significant and precious 
value in its own right. This effect will be outlined in the first subsection, which also monetises 
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the value in line with the Commission’s Impact Assessment guidelines to allow for  
comparisons to be made. 
 
Apart from improved public health (i.e. decreased mortality and longer healthy life years), 
reduced tobacco consumption will also lead to lower health care costs and to improved 
productivity due to fewer cases of absenteeism and premature retirements. These impacts 
will be described in the second and third subsections. 
A.5.2.3.1.1. Morbidity and mortality caused by tobacco 
The risks associated with smoking 
From a scientific/medical perspective, it is by now generally acknowledged that smoking 
harms nearly every organ of the human body, causing a broad range of diseases.40 At least 24 
of these smoking induced diseases are fatal, whereas others lead to chronic illnesses. The 
long-term risks of smoking have been extensively quantified in a cohort study of British 
doctors that compared the overall survival of smokers and non-smokers over time. This study 
showed that at least 50% of smokers die prematurely.41 
Another study based on Danish data compared the average lifetime in good health of 
smokers and non-smokers and found that, in addition to the years lost from dying earlier, 
smokers suffer from poor health conditions  for a greater number of years compared to non-
smokers. Men who smoked heavily (defined here as at least 15g of tobacco per day) had 8 
years more of poor health than people who never smoked. Women who smoked heavily had 
an average of 12 years more of poor health, in addition to their earlier loss of life.42  A number 
of studies have also found similar results.43,44,45  
Peto et al46 have estimated that in the EU27 smokers who die in middle age as a result of their 
tobacco consumption lose an average of 22 years of life. Even those who die at age 70 or 
older as a result of their smoking at lose on average 8 years of life. Peto et al estimates that,  
on average, smokers who die as a result of their tobacco consumption die 14 years earlier 
than people who never-smoked. Other studies come to similar conclusions.47  
These findings also allow for a comparison between different risk factors that lead to 
premature mortality, for every 1000 individuals who smoked regularly across all EU countries 
(reference year 2000), 500 will die from smoking related illness, whilst only seven will be 
                                                            
40 US Department of Health and Human Services. The health consequences of smoking: a report 
of the Surgeon General.Washington, Government Printing Office, 2004. 
41 Doll R, Peto R, Boreham J, Sutherland I. (2004). "Mortality in relation to smoking: 50 years' observation on 
male British doctors". BMJ 328 (7455): 1519. 
42 Bronnum-Hansen H, Juel K. Abstention from smoking extends life and compresses morbidity: 
a population based study of health expectancy among smokers and never-smokers in Denmark. Tobacco Control 
2001; 10: 273-278. 
43 Nusselder WJ, Looman CW, Marang-van de Mheen PJ, van de Mheen H, Mackenbach JP. Smoking and the 
compression of morbidity. J Epid Comm Health 2000; 54: 566-574. 
44 Klijs B et al. Obesity, smoking, alcohol consumption and years lived with disability: a Sullivan life table 
approach. BMC Public Health. 2011; 11: 378.  
45 Bronnum-Hansen H, Juel K, Davidsen M, Sorensen J. Impact of selected risk factors on expected lifetime 
without long-standing, limiting illness in Denmark. Prev Med. 2007;45(1):49–53.  
46 Peto R, Lopez AD, Boreham J,Thun M. Mortality from Smoking in Developed Countries 1950-2010. 
2nd Edn. Imperial Cancer Research Fund, World Health. Data updated November 2011. Organization. Oxford, 
Oxford University Press, 
47 http://www.cpinternet.com/~mdmagree/smokers_2006-01-19.html 
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killed in road accidents and only one will be murdered.48 Smoking is generally seen as the 
largest avoidable health threat in Europe and the rest of the world.  
Healthy life years as a value to society 
 
Every civilised society strives to avoid premature death of its citizens and to maintain a 
high level of public health. For example, EU Member States build hospitals and medical 
research centres, finance the education of doctors and nurses, and provide public health 
insurance that reimburses medical treatments, pharmaceuticals and medical devices. Even 
outside the healthcare sector, many measures are introduced to improve public health and/or 
ensure a high level of public health. Some examples of Member State actions, across different 
sectors, that demonstrate these societal efforts towards a high level of public health forcefully 
are the obligation to wear seat belts in cars, the prohibition of dangerous pesticides that could 
potentially enter the food chain and the introduction of legislation that requires the removal of 
asbestos in public buildings.  
 
The underlying reason for all these policies is that Member States governments and societies 
in general attribute a high value to the avoidance of premature death and a high level of public 
health. Life in general and healthy life years in particular are a value in their own right 
and in most constitutions of Western societies the right to live and the right to have access to 
medical treatment is recognised as human right of highest importance. With the same token 
societies do not allow companies to put their profits above public health as repeated scandals 
in health care sector show (e.g. Mediator case in France49). 
 
Traditionally, the question whether a public measure improving public health makes 
sense from an economic perspective is of secondary nature. Nobody seriously raises the 
question whether society should stop medical treatment of people who are no longer part of 
the active workforce or whether citizens should be obliged to wear seat belts. However in 
times of economic crisis it is important to ensure that measures are not only beneficial to 
society but also cost effective. A good example, is the approach of the UK public body NICE, 
which evaluates whether a new medicine should reimbursed based on both its cost and the 
number of healthy life years gained from the treatment.  
The attempt to monetise  
In light of the above, economists have repeatedly attempted to monetise the value of life in 
order to provide regulators with a tool to decide whether certain policy measures are 
beneficial for society (e.g. because the measures are cost-effective). Concretely at least two 
approaches are discussed: (1) the loss of productive capacity (a tangible cost) and (2) the 
psychological effects borne by the deceased and others (an intangible cost).  
 
The first method focuses on the loss of productive capacity. The approach is known as the 
human capital approach. It involves estimating and monetising the loss of the expected 
productive capacity. The second method also looks at the psychological costs of premature 
death/avoidable illness. This approach is also known as the willingness-to-pay approach, in 
which researchers identify how much people would be willing to pay to reduce the risk of 
                                                            




death in a particular period of time. Generally, intangible costs (willingness-to-pay) are more 
difficult to establish than tangible costs, for which conventional markets (market prices) exist.  
 
If regulators merely take into account the human capital approach, the premature deaths of 
people above workforce age could be considered to have no cost/limited costs to society 
since no productive capacity is lost. Indeed, when such an approach is taken, it can be argued 
that some “benefits” accrue to society as a whole from the premature death of old people, 
since certain resources (such as pension payments), which would have be needed to meet the 
needs of the deceased, are now saved. It can thus be concluded that looking only at the 
human capital approach would not be in line with the Europe’s values. 
 
As indicated above, European societies and Member States actions (including the allocation 
of substantial health care resources to the aged) demonstrate that lives of people/healthy life 
years are valuable in their own right, irrespective of whether the persons concerned are 
part of the work force. Thus, while it is important to evaluate the loss of productive capacity, 
it is not appropriate to ignore the social costs of premature deaths. 
 
The analysis method used by the European Union considers the value that is attributed to 
each life year gained, not the value of a lost life itself (which can involve the loss of many 
years of living or just a few months). The values used in the Commission’s impact assessment 
guidelines are based on surveys or observations of the research project ExternE, which 
established a ‘typical’ range of €50,000 to €100,000 for the value of one life year (VOLY). 
The median of estimates of intangible value of the loss of one year’s living (as included in the 
Commission’s Impact Assessment guidelines), is €52,000 irrespective of the age or country of 
residence of the victim.  
 
Table 3.1 shows that premature deaths in the population due to smoking is a very significant 
burden associated with tobacco consumption. In total, almost 700,000 premature deaths (i.e. 
15% of all deaths in the EU for those over 35) can be attributed to smoking, out of almost 5 
million total deaths annually observed in the EU (year 2005).  
 
Table 3.1: Overall estimated mortality attributable to smoking in the EU27 in 2005 
Gender Total mortality Attributable to smoking 
As % of total 
mortality 
Males 2,404,508 522,267 21.7
Females 2,408,625 176,557 7.3
Total 4,813,133 698,824 14.5
  Source: R. Peto, 2011 
 
Expressed in life years, it is calculated that in 2010, about 9.94 million years are lost 
prematurely. Applying the estimate from the ExternE project, the loss to society caused by 
premature deaths associated with smoking thus amounts to a monetised value of 517 


















Loss as % 
of GDP 
(at PPS) 
Austria 132,411 6,885 1.3 244,796 2.8 
Belgium 226,637 11,785 2.3 298,464 3.9 
Bulgaria 179,103 9,313 1.8 78,424 11.9 
Czech Republic 219,861 11,433 2.2 202,557 5.6 
Denmark 157,613 8,196 1.6 159,410 5.1 
Estonia 25,989 1,351 0.3 19,993 6.8 
Finland 65,266 3,394 0.7 144,259 2.4 
France 1,116,577 58,062 11.2 1,639,459 3.5 
Germany 1,563,453 81,300 15.7 2,224,648 3.7 
Greece 206,717 10,749 2.1 249,870 4.3 
Hungary 434,458 22,592 4.4 152,259 14.8 
Ireland 67,451 3,507 0.7 133,871 2.6 
Italy 992,332 51,601 10.0 1,469,877 3.5 
Latvia 48,974 2,547 0.5 27,152 9.4 
Lithuania 66,660 3,466 0.7 42,754 8.1 
Luxembourg 5,582 290 0.1 31,102 0.9 
Malta 4,900 255 0.0 7,978 3.2 
Netherlands 365,121 18,986 3.7 511,825 3.7 
Poland 1,080,437 56,183 10.9 543,816 10.3 
Portugal 130,191 6,770 1.3 199,839 3.4 
Romania 511,757 26,611 5.2 237,224 11.2 
Slovakia 98,134 5,103 1.0 92,359 5.5 
Slovenia 37,966 1,974 0.4 41,781 4.7 
Spain 721,281 37,507 7.3 1,112,893 3.4 
Sweden 122,421 6,366 1.2 260,683 2.4 
Unit. Kingdom 1,355,499 70,486 13.6 1,606,081 4.4 
Total 9,936,789 516,713     4.7 
Source: GHK; 2012 data51, Cyprus excl. 
 
Application of the methodology to the expected reduction of tobacco consumption 
The above methodology can be applied to the expected drop in tobacco consumption. Table 
3.3 shows how the estimated losses to society caused by premature deaths would decrease, if 
tobacco consumption is reduced by 1, 2, 3, 4, or 5%. For example, a 2% decline in 
consumption would result in a net benefit to society of 10.3 bEUR per year.  
Table 3.3: Estimated monetary benefit of decreased mortality  
Premature mortality decrease  
with  different percentage reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Premature mortality cost due to smoking  
(mEUR) 
511,546 506,379 501,212 496,044 490,877
Net benefit (mEUR) 5,167 10,334 15,501 20,669 25,836
Source: GHK 2012, own calculation 
                                                            
50 Gross domestic product adjusted for the size of an economy in terms of population and also for differences in 
price levels across countries 
51 A Study on Liability and The Health Costs of Smoking. GHK, revised report published in June 2012. 
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It is important to underline again that the above approach is merely an attempt by 
economists to express in monetary terms how much society values life in general and 
(healthy) life years in particular. It is a proxy for the fact that people do not wish to die 
prematurely. It is also important to underline again that a good part of the benefits associated 
with reduced tobacco consumption will accrue only in a few years time (e.g. when a drop in 
cancer treatments are observed).  
Implications for social security system  
As indicated above, certain studies, including one study from the tobacco industry which was 
later withdrawn, have argued that smokers subsidise non-smokers' pensions, at least in some 
countries.52 Society would thus benefit from premature deaths caused by smoking. 
In this respect, it is first important to underline that other studies53 have argued that smokers' 
greater disabilities (fewer healthy life years) lead to net pension payments to them. It has also 
been argued in more general terms that the net lifetime costs of smokers are superior for the 
State than the costs for non-smokers, in particular if one includes indirect costs. Evidence 
from Sweden shows that smokers use the social welfare systems more than non-smokers, and 
that smoking leads to net lifetime external costs for men and women currently smoking, and 
even for former male smokers. 
Furthermore it should be noted that people above the official workforce age actively 
participate in the economy, be it as consumer, as investor or as provider of often unpaid 
services, e.g. taking care of children. The pension age in most Member States is also currently 
being increased. It can therefore be expected that the current work force will work much 
longer than in the past, increasing potential productivity losses in the future, in particular 
considering the demographic development of Europe.  
In any event, it is important to underline that the arguments developed in the studies 
mentioned above are contrary to the approach foreseen by the Commission's impact 
assessment guidelines, which attributes a value to each (healthy) life year irrespective of 
the fact whether the person is still an active member of the active work force or not. This is 
due to the fact, as previously mentioned, that life has a value in its own right.  
A.5.2.3.1.2. Health care budget 
Another major benefit for society and Governments is that a reduction in tobacco 
consumption is expected to lead to reduced health care costs.  
The health care costs associated with treating smoking related diseases 
Governments/societies incur very significant costs associated with smoking-related diseases. 
The size of these costs depends on the extent to which healthcare, prevention and public 
health services are covered by public funds. Indirectly, the burden on Governments also 
appears in the form of smoking related disabilities and social benefits payments, lost income 
                                                            
52 Arthur D. Little International Inc. Public finance balance of smoking in the Czech Republic, 1999. 
http://www.mindfully.org/Industry/Philip-Morris-Czech-Study.htm (accessed 15 February 2012). 
53 - Atkinson AB, Skegg JL(1973) Anti-smoking publicity and the demand for tobacco in the UK. The 
Manchester School of Economic and Social Studies 41:265–282. 
- Anneli Taala, Raul Kiivet,b and Teh-Wei Huc (2004); The Economics of Tobacco in Estonia 
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tax and lost contributions to social benefits funds. This section focuses on health care costs, 
whereas the issue of absenteeism is addressed in the next subsection. 
 
With respect to health care costs, it has been well documented through clinical evidence that 
smoking increases the risks of individuals contracting certain diseases requiring health 
treatment. For the purposes of the analysis, the direct costs to European public healthcare 
systems were considered in terms of the estimated amount of healthcare expenditure 
attributable to the treatment of diseases caused by smoking in a given year. Direct costs 
represent the costs of in-patient and out-patient treatment and the cost of medication.  
 
There are six main disease categories that are associated with smoking. This includes 
respiratory and cardiovascular diseases or cancers. In order to estimate the expenditure on 
health attributable to smoking, a standard smoking attributable factor (SAF) for each six 
disease categories was used54. Table 3.4 presents these diseases and the total treatment costs 
per disease that is attributable to smoking.  
 
The calculation on the expenditure is based on the annual EU public healthcare expenditure 
for diseases, which might be caused by smoking and the subsequent attribution of this total 
expenditure to different causes (including smoking) on the basis of available statistical data. 
In conclusion, healthcare expenditure on treating smoking attributable diseases is 
estimated to be around 25 bEUR which corresponds to 2.89% of total healthcare spending 
in the EU27 and 0.22% of GDP.  
 
Table 3.4 EU-wide health care expenditures on treatment of smoking attributable diseases  





Other respiratory diseases 2.662
Upper aerodigestive cancers 1.740
Total 25.300
Source: GHK, 2012 
 
Benefits from a decline in smoking consumption  
Declines in smoking consumption will lead to a reduction in health care costs. The extent of 
the reduction will depend on the success of the envisaged measures.  
 
For certain diseases there will be a time lag before the reduced heath care costs are observed 
(e.g. cancer treatments), whereas for other diseases (e.g. respiratory and cardiovascular) the 
savings will be more immediate. Regarding respiratory diseases many ex-smokers feel 
immediate positive effects when they stop smoking, with smokers frequently suffering from 
coughing, headache, eye irritation, sore throat, sneezing and runny nose, nausea, breathing 
                                                            
54 The estimates of the costs to public healthcare systems of treating smoking attributable diseases are based on 
incidence data and average of per case expenditure based on data from the UK, Germany and the Netherlands 
(data 2008-2010). 
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problems, and irregular heartbeat.55 Lightwood and Glantz estimated that each new non-
smoker as a result of the Californian anti-smoking campaign reduced anticipated medical 
costs associated with acute myocardial infarction and stroke by $47 in the first year and by 
$853 during the next 7 years.  
 
In order to present the figures for one single year (year 5 after transposition), the costs for the 
long term treatments were anticipated. In this light it is expected that the annual net benefit of 
a reduction in tobacco consumption by 2% amounts to 506 million EUR per year. The current 
value of this benefit should be the same or even higher considering the inflation of the health 
care costs above the average. 
 
Table 3.5: Estimated savings in health care expenditures  
Health care expenditures  
with different percentage reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Projected Total EU health care expenditures 
(mEUR) 
19,628 19,430 19,232 19,034 18,836
Net benefit (mEUR) 198 396 594 792 990
Source: GHK, 2012, own calculation 
 
Lifetime costs of smokers and non-smokers  
Smoking is a major health hazard, and since non-smokers are healthier than smokers, it is 
only natural that health care systems spend less money on non-smokers compared to smokers, 
which is confirmed by a number of studies.56,57,58 Not smoking saves money spent on health 
care.59 In each age group, the annual per capita health care costs for smokers are higher than 
for non-smokers and they rise sharply with age. The difference varies according to age group, 
but according to some sources the costs for smokers among 65-to-74-year-olds are as much as 
40 percent higher for men and as much as 25 percent higher for women. 
 
                                                            
55 Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial 
infarction and stroke. Institute for Health Policy Studies, Department of Medicine, University of California, San 
Francisco 94143-0124, USA. Circulation. 1997;96:1089-1096 
56 Paul A Fishman, Zeba M Khan, Ella E Thompson, and Susan J Curry:Health Care Costs among Smokers, 
Former Smokers, and Never Smokers in an HMO 
57 Manning, W. G., et al. (1989). The taxes of sin: Do smokers and drinkers pay their way? Journal of the 
American Medical Association, 261, 1604-1609. 
58 Milbank Q. 1992;70(1):81-125. Cigarette smoking and lifetime medical expenditures. 
59 Despite the fact that the link between the consumption of tobacco products and health cost savings is not 
necessarily linear as smoking and other risky health behaviours, such as drinking alcohol or food disorders, 
could be to some extent substitutable. However there is no evidence that the population of non-smokers is more 
prone to any kind of behaviour linked to increased health risks than smoker's population.   
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Figure 3.1: Average annual health care cost in Netherlands  
 
 
Source: Van Baal et al, 200860   
 
However some recent studies61,62 in this field have argued that the non-smoking population as 
a whole is more expensive than the smoking population because the annual cost per capita 
ignores the differences in longevity between smokers and non-smokers. Non-smokers live 
longer and therefore incur more costs over their lifetime due to diseases not related to 
smoking, particularly in old age, when these costs are the highest. As the differences in life 
expectancy are substantial, more non-smokers live to old age than smokers. In the age group 
of 70 and above, the lower per capita cost of non-smokers is outweighed by the greater 
number of non-smokers requiring treatments of age related, mostly chronic, diseases. 
 
In this context, it is noteworthy that, within a longer evaluation period, the reduction of health 
care costs attributable to reduced smoking gradually decreases. According to this study the 
break-even year, when the initial benefit is balanced by the eventual cost at the society level, 
has been estimated to occur after 26 years of follow-up63. 
  
Ageing is one of the greatest social and economic challenges of the 21st century for European 
societies. The EU strives to help citizens age in good health, and live active and independent 
lives64. Our society is clearly willing to spend money on not only on additional life years but 
also on healthier life years. Therefore, the evaluation of interventions within tobacco control 
policy should not be restricted to a comparison of “total costs”, but it should rather, or at least 
also, look at cost-effectiveness. The analysis reveals the costs per gained life year. In this 
respect it is important to note that in the area of smoking cessation, favourable cost-
                                                            
60 Van Baal et al. Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure 
PLoS Med. 2008 February; 5(2): e29. 
61 The Health Care Costs of Smoking, Jan J. Barendregt, M.A., Luc Bonneux, M.D., and Paul J. van der Maas, 
Ph.D.N Engl J Med 1997; 337:1052-105  
62 van Baal PHM, Polder JJ, de Wit GA, Hoogenveen RT, Feenstra TL, et al. (2008) Lifetime medical costs of 
obesity: Prevention no cure for increasing health expenditure. PLoS Med 5(2): journal.pmed.0050029 
63 Discounting of the projected costs and benefits has a greater impact as the costs become more distant in time 
and brings the “break-even” further into the future.   
64 http://ec.europa.eu/health/ageing/policy/index_en.htm 
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effectiveness results have been shown even if increased medical costs in life-years gained are 
taken into account65.  
 
Thus, even if recent studies are correct when arguing that over their lifetime the total health 
care costs of non-smokers are higher than those of smokers, any intervention leading to 
reduced smoking would beneficial, as it would yield a very high return in health for the 
money invested. An effective antismoking policy is thus cost-effective.66 
 
In conclusion, it is fair to say that a reduction of consumption by 2% would result in savings 
to EU Governments of 506 mEUR per year. Whilst over a longer time period and 
presupposing a very successful tobacco control policy the benefits of smoking cessation are 
expected to reduce/diminish, it is important to underline that tobacco control policy is 
certainly a very cost-effective measure to improve public health. 
A.5.2.3.1.3. Increased productivity 
Smoking also has an important impact on the productivity of the paid workforce. Smoking 
reduces the size of the available workforce as a result of smoking-attributable deaths and 
illnesses causing premature retirement. It also increases the absenteeism resulting from 
smoking-attributable sickness or injury. A reduction in smoking consumption is expected 
to reduce these productivity losses. 
 
Premature retirements and deaths 
Table 3.6 presents estimates of the loss of productivity from premature retirements and 
deaths in the EU which are caused by smoking. The total annual costs for the economy in the 
EU caused by absenteeism due to smoking are 6.1 bEUR. These losses are estimated for the 
paid workforce. The calculations are based on estimates of years lived with disability 
(YLD),67 estimated inactivity due to smoking related diseases (number of people in retirement 
due to smoking) and average labour costs in business economy.68 As with the preceding cost 
estimates for health care, these are net estimates, and show the amount of resources which 
would have been available if there had been no tobacco-attributable productivity losses. 
                                                            
65 David Hoeflmayr, Reiner Hanewinkel. (2008) Do school-based tobacco prevention programmes pay off? The 
cost-effectiveness of the ‘Smoke-free Class Competition’. Public Health 122:1, 34-41. 
66 Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, et al. (2007) Lifestyle 
interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. 
Diabetes Care 30: 128–134. 
van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen HC (2006) Estimating health-adjusted life expectancy 
conditional on risk factors: results for smoking and obesity. Popul Health Metr 4: 14. 
van Baal PH, Feenstra TL, Hoogenveen RT, Ardine de Wit G, Brouwer WB (2007) Unrelated medical care in 
life years gained and the cost utility of primary prevention: in search of a ‘‘perfect’’ cost-utility ratio. Health 
Econ 16: 421–433. 
67 WHO estimates, 2004  
68 Eurostat data, 2009 
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Table 3.6: Estimated number of retirements due to smoking   
Disease category 
Total inactive 










Economic loss due to 
smoking-related 
incapacity 
 (million EUR) 
Lung cancer n.a. 11,482 9,664 359
Upper aerodigest. cancers n.a. 5,694 3,027 109
Other cancers n.a. 153,392 10,617 390
Cardiovascular diseases n.a. 214,922 141,131 3,929
COPD n.a. 235,804 22,560 780
Other respirat. diseases n.a. 156,868 15,127 514
Total 8,017,872 778,162 202,127 6,081
Source: GHK, 2012 
 
Table 3.7 shows how the estimated losses caused by premature retirement and deaths would 
decrease with the different percentage reductions in tobacco consumption. The net annual 
benefits resulting from a 2% decline in consumption are expected to amount to 122 million 
EUR (productivity gains). 
 
 Table 3.7: Estimated productivity losses caused by early retirements due to smoking  
Economic losses (caused by early retirement, deaths)  
with different percentage reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Economic loss form early retirement and 
deaths due to smoking (mEUR) 
6,020 5,959 5,898 5,837 5,776 
Net benefit (mEUR) 61 122 183 244 305 
Source: own calculation 
 
Absenteeism during active work life 
Decreased on-the-job productivity and employee absence because of smoking related diseases 
result in an additional cost factor to employers. 
 
It has been well documented69 that smokers have a higher rate of workplace absenteeism than 
non-smokers. Based on GHK calculations70, an estimated 93 million days were reported as 
being missed by adults in the EU due to smoking-related diseases in 2009. The smoking 
attributable fraction was calculated based on estimates of the number of days lost to disease 
(DLD) suffered by smokers that could be directly attributed to their smoking.  
 
Absenteeism costs were calculated using the “lost wages method” (based on the average 
daily earnings rate for employed persons), the most frequently used method to measure 
                                                            
69 The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General”, 
2006 for a summary of clinical evidence (U.S. Department of Health and Human Services 2006) 
Bush and Wooden (1994) 
70 Eurostat data; calculation based on absenteeism data from 3 countries (AT, NL, DE) during 2007-2010 
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productivity loss71, suggesting productivity loss of € 2.2 billion in the EU from absenteeism 
due to smoking. Table 7 provides a detailed breakdown of smoking attributable absenteeism 
per MS and diagnosis. 
 
 
Table 3.8: Estimated loss from smoking-induced absenteeism in 2009 (mEUR)  
Country Neoplasms Respiratory diseases 
Cardiovascular 
diseases Total 
Austria 3.3 18.3 6.3 28
Belgium 14 60.4 36.5 111
Bulgaria 0.4 2.7 1.2 4
Cyprus 0.2 0.8 0.4 1
Czech Republic 3 18.2 9 30
Denmark 9.5 56.9 35.4 102
Estonia 0.2 1.8 0.6 3
Finland 5 23.1 12.6 41
France 43.5 194.4 105.7 344
Germany 38.6 157.4 132.8 329
Greece 2.9 12.8 6.9 23
Hungary 2.7 18.8 8.2 30
Ireland 2.5 16.4 8.9 28
Italy 25.7 112.7 53.6 192
Latvia 0.3 2.7 0.9 4
Lithuania 0.4 3.4 1.2 5
Luxembourg 0.3 1.3 1 3
Malta 0.1 0.2 0.2 0
Netherlands 30.4 160.4 95.1 286
Poland 9.2 55 29.9 94
Portugal 3.6 13.8 7.5 25
Romania 0.9 7.3 2.5 11
Slovakia 1.2 7.1 3.2 11
Slovenia 1.4 6 3.7 11
Spain 16.7 54.8 29.8 101
Sweden 6.5 37.3 23.6 67
United Kingdom 26.4 158.8 94.2 279
EU 27 total 249 1203 711 2162
Source: GHK, 2011 
 
Table 3.9: Reduction of  loss from smoking-induced absenteeism (mEUR) 
Economic losses due to absenteeism  
with different percentage reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Economic loss from absenteeism due to 
smoking (mEUR) 
2140.4 2118.8 2097.1 2075.5 2053.9 
Net benefit (mEUR) 21.6 43.2 64.9 86.5 108.1 
Source: own calculation 
 
Table 3.9 shows how the estimated losses caused by absenteeism would decrease, if tobacco 
consumption decreased. More specifically, the net annual benefits of 2% decline in 
consumption would result in savings of 43 million EUR. 
                                                            
71 Mattke S. Balakrishnan A. Bergamo G. Newberry SJ. A review of methods to measure health-related 
productivity loss. Am J Managed Care. 2007;13:211–217. 
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Production losses in the household sector 
Smoking-attributable sickness or death causes production losses not only in the paid 
workforce but also in the unpaid household sector. The total economy of a nation consists of 
both market and non-market sectors. The non-market sector uses through an unpaid capacity 
considerable human resources for the production of goods and services which are directly 
consumed by households without going through the market. These activities, though 
productive, are in almost all cases not included in conventional national accounts statistics 
and thus not considered for this analysis. For the purpose of this impact assessment they are 
just mentioned, but not monetised. 
Conclusion 
Smoking causes a loss of national productive capacity in the paid workforce as a result of 
smoking-attributable death and sickness. As a result of a 2% decline in tobacco consumption, 
smoking related productivity losses to the EU economy would decrease by € 165 million 
annually. Taking into account that the retirement age is expected to increase in the years to 
come, this figure is expected to increase significantly, but to maintain a conservative 
approach, the figures have not been amended. 
A.5.2.3.1.4. Conclusion on the advantages 
The overall benefits for Governments and society resulting from a reduction of tobacco 
consumption are summarised in the table below:  
Table 3.10: Overall benefits for Governments and society (in million EUR) 
Different percentage reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Decrease in health care expenditures  253 506 759 1,012 1,265 
Increased productivity 83 165 248 331 413 
     - due to less early retirement / deaths 61 122 183 244 305 
     - due to less absenteeism 22 43 65 87 108 
Decrease in premature mortality costs  5,167 10,334 15,501 20,669 25,836 
Source: own calculation based on the above described analysis 
A.5.2.3.2. Budgetary impact 
Sales of tobacco products allow Member States to generate significant tax revenues. 
Governments collect excise duties, VAT and upon importation customs duties on tobacco 
products.72 For the purpose of this Section, it was considered appropriate to concentrate on the 
excise duties collected. Custom duties are negligible considering minimal market share of 
manufactured tobacco products imported from third countries.  Disregarding VAT appears 
justified as money not spent on tobacco products is expected to be spent on other goods 
and/or services, which in turn generate VAT. From this perspective, a reduction in tobacco 
consumption should be “VAT neutral”.  
Conventional wisdom would suggest that a decline in tobacco consumption will lead to a 
decline in Governments' revenues. Accordingly, tax revenues of Member States would 
                                                            
72 EU legislation allows Member States to exclude customs duties from the basis for calculating the ad valorem 
excise duty on cigarettes. 
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decline when tobacco consumption decreases. However, in reality, Member States' tax 
revenues increased over recent years despite decreasing tobacco consumption. This is due to 
the fact that Member States have introduced higher tax levels over recent  years. This will be 
further explained in this section. 
Table 3.11: EU-27 revenues from excise duty (cigarettes + RYO) in 2010 
Pack of 20 cigarettes 
Member State Weighted 
average retail 
price incl. taxes 
Excise duty 
All duties    
(excise + 
VAT) 
Net retail   
price excl. 
Taxes 
2010   Excise 
duty collected 
incl. RYO        
(mEUR) 
IE 8.47 € 5.23 € 6.65 € 1.82 € 1,160 
UK 6.27 € 4.61 € 5.65 € 0.62 € 10,153 
FR 5.40 € 3.47 € 4.35 € 1.05 € 10,359 
SE 4.97 € 2.81 € 3.80 € 1.17 € 852 
NL 4.73 € 3.12 € 3.88 € 0.86 € 2,407 
DK 4.65 € 2.82 € 3.75 € 0.90 € 1,105 
DE 4.60 € 2.82 € 3.63 € 0.96 € 13,478 
BE 4.53 € 2.69 € 3.48 € 1.05 € 1,987 
FI 4.32 € 2.60 € 3.41 € 0.92 € 691 
IT 4.10 € 2.39 € 3.07 € 1.03 € 10,622 
AT 3.79 € 2.27 € 2.90 € 0.89 € 1,502 
MT 3.76 € 2.33 € 2.90 € 0.86 € 70 
LU 3.60 € 2.06 € 2.53 € 1.07 € 2,099 
PT 3.45 € 2.28 € 2.66 € 0.79 € 1,429 
ES 3.33 € 2.15 € 2.66 € 0.67 € 8,023 
CY 3.27 € 2.11 € 2.54 € 0.73 € 199 
EL 3.13 € 2.04 € 2.62 € 0.51 € 2,913 
CZ 2.78 € 1.65 € 2.12 € 0.66 € 1,616 
SK 2.66 € 1.72 € 2.17 € 0.49 € 614 
SI 2.64 € 1.60 € 2.04 € 0.60 € 391 
RO 2.39 € 1.60 € 1.88 € 0.51 € 1,345 
PL 2.32 € 1.53 € 1.97 € 0.35 € 4,250 
BG 2.25 € 1.55 € 1.93 € 0.32 € 777 
LV 2.21 € 1.46 € 1.86 € 0.36 € 130 
HU 2.21 € 1.34 € 1.78 € 0.43 € 925 
EE 2.21 € 1.49 € 1.86 € 0.34 € 115 
LT 2.16 € 1.30 € 1.68 € 0.48 € 160 
EU 27     79,369 
Source: EC, DG Taxud, 2010 
 
The expected reduction of excise duties applying conventional wisdom 
Revenue from excise duty on the sale of tobacco products in EU was about € 79 billion in 
2010, contributing almost 3% to total Government revenues. Most of these revenues were 
generated by cigarettes (€72 billion). 
Table 3.12: Loss revenues from excise duties 
Excise tax revenues with different percentage 
reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Projected excise tax revenues (mEUR) 78,575 77,781 76,987 76,193 75,399
Decrease in excise tax revenues (mEUR) 794 1,588 2,382 3,176 3,970
Source: DG TAXUD, own calculations 
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As consumption of FMC and RYO is expected to decline, fewer tobacco products will be 
purchased and excise duty will decline (Table 3.12). Applying a linear approach, the 
projected decrease in consumption of 2% would lead to lower excise tax revenues of 1.6 
billion EUR. 
It should be underlined that this is a conservative/worst case scenario as the calculations do 
not take into account that – as a result of measures proposed in PA4b (cross border internet 
sales) and PA5 (measures addressing illicit trade) - certain sales currently occurring in the 
illicit part of the market are expected to return to the licit part of the market. 
Possible tax increases 
The calculations are also a “worst case scenario” for another reason. They do not take into 
account that Member States can react to decreased tax revenues with tax increases. In fact, 
Member States are expected to take action to mitigate the negative impact on public 
budgets caused by lower tobacco consumption, as they have done in the past.  
Table 3.13: Excise duty from tobacco products collected by MS's 
Member State 2002 2003 2004 2005 2007 2008 2009 2010 
AT 1296.9 1328.7 1317.9 1339.7 1446.2 1424.5 1457.6 1502.0 
BE 1255.0 1395.7 1409.4 1425.2 1559.5 1532.0 1529.5 1686.6 
BG         687.4 875.3 901.9 762.9 
CY     142.6 131.1 180.4 191.4 185.1 186.5 
CZ     658.6 827.0 1666.9 1410.6 1375.1 1576.3 
DE 13205.5 13353.0 12544.9 12386.9 12861.9 12260.6 11950.8 11991.6 
DK 923.5 937.2 856.7 894.8 913.9 912.1 935.9 1042.8 
EE     58.7 70.1 96.3 95.9 131.1 110.9 
EL 2126.8 2248.1 2241.5 2257.1 2581.3 2516.2 2566.2 2913.0 
ES 5144.9 5537.1 5836.3 6150.8 7169.7 7371.3 7452.8 7689.6 
FI 535.1 528.1 538.0 544.2 563.7 570.1 614.0 628.6 
FR 8628.6 8828.0 9244.0 9851.0 9380.0 9550.4 9894.5 9393.2 
HU     681.1 675.7 956.8 1000.7 1055.4 787.7 
IE 1121.0 1137.1 1042.9 1067.1 1177.5 1156.6 1201.9 1145.5 
IT 7790.0 7993.0 8636.0 8912.0 9938.3 10256.9 10341.0 10426.4 
LT     62.4 74.4 117.5 197.6 199.0 159.0 
LU 352.0 381.5 458.8 372.4 415.0 439.1 413.2 406.7 
LV     40.5 62.0 105.7 204.8 160.0 126.6 
MT     57.3 60.2 56.7 60.4 62.9 68.2 
NL 1380.3 1439.1 1597.6 1409.4 1717.0 1767.0 1809.0 1869.0 
PL       2408.3 3521.6 3737.6 3856.5 4249.7 
PT 1153.0 1215.2 1016.6 1309.8 1209.2 1276.1 1115.4 1395.6 
RO         918.7 1081.2 1261.5 1345.3 
SE 751.6 740.6 717.6 731.0 823.8 799.3 739.4 798.7 
SI     226.0 247.0 299.6 341.8 362.0 389.1 
SK     188.8 289.6 685.8 388.5 507.3 610.1 
UK 12237.4 11608.9 10813.0 10741.6 11147.7 10232.0 8374.6 9257.4 
EU-25    64238.2 72198.0 71649.8 70453.7 72518.8
EU-xx total 57901.7 58671.3 60387.1 64238.2 72198.0 71649.8 70453.7 72518.8 
Source: EC, annual reports published by DG Taxud 
 
The relatively low price elasticity of cigarette demand implies that a tax increase will in most 
cases secure higher revenues, and which is supported by research in a variety of contexts. In 
developed countries, demand for tobacco products decreases at around half the rate of price 
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increases.73 Therefore, price and/or tax increases normally result in the generation of 
additional revenues. 
The fact that tax revenues of Member States from tobacco have been stable in the past or even 
increasing can also be seen from the table 3.13. While the number of FMC released for 
consumption in the EU 27 (ex RO) declined by 24% between 2002 and 2010, the 
revenues increased by more than 28% in the same period (EU 27, ex RO and BG).74 
Reducing tobacco consumption does therefore not necessarily lead to a negative impact on 
public budgets in form of reduced excise duties (for VAT see above).  
 
A.5.2.3.3. Summary 
Taking into account the four main socio-economic factors (public health, health care 
expenditures, productivity loss and tax revenues), the annual net benefits to the EU would 
amount to 9.4 billion EUR, based on the assumption that smoking consumption will 
decrease by 2% (Table 3.14). The table includes estimates of both true economic benefits (i.e. 
reductions in health care expenditures, productivity losses, and premature mortality) as well 
as changes in excise tax revenues collected by Governments. Reductions in excise tax 
revenues do not, however, represent an actual benefit to society as a whole but rather a 
transfer of resources from one sector of society to another (i.e. from consumers to the state, or 
vice versa). A reduction in excise tax revenues (which is moreover very unlikely, see 
explanation above) does not thus constitute a true cost to society. However, it still represents a 
significant economic effect for the government and therefore it is included in the summary 
table below.  
Table 3.14: Overview of costs and benefits from the societal and Governmental perspective (mEUR) 
Different percentage reduction in tobacco consumption 
  1% 2% 3% 4% 5% 
Decrease in excise tax revenues75 -794 -1,588 -2,382 -3,176 -3,970
Decrease in health care expenditures  253 506 759 1,012 1,265
Decrease of productivity loss  83 165 248 331 413
     - due to early retirement / deaths 61 122 183 244 305
     - due to absenteeism 22 43 65 87 108
Decrease in premature mortality costs  5,167 10,334 15,501 20,669 25,836
Overall net benefit 4,709 9,417 14,126 18,836 23,544
Source: own calculations 
A.5.2.3.4. Social discounting 
Discounting is used to allow comparisons between benefits and costs that occur in different 
time periods by expressing their values in present terms. In the analysis above, it is assumed 
that the costs and benefits of the policies occur simultaneously and their relative values do not 
change over time. All amounts are expressed in the present value, e.g. changes of the health 
care costs are calculated from the actual present values and are thus in principle expressed in 
                                                            
73 Curbing the Epidemic:  Governments and the Economics of Tobacco Control, World Bank Development in 
Practice series.  1999.  Washington DC. 
74 Calculation, based on unpublished data, provided by DG TAXUD 
75 Disregarding measures taken against illicit trade and possibility to increase tax levels. 
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current prices.76 Therefore, in order to calculate the future value of current health care costs in 
year 5 after the implementation of the revised TPD (using the appropriate discount rate), the 
current cost would need to be increased to accommodate for inflation in the health care sector. 
This figure would then subsequently need to be discounted back to the present value, using a 
general inflation rate. For these reasons, the basic calculations are non-discounted. However, 
in order to account for individual or social rates of time preference, present values of the 
future benefits and costs can be calculated by employing the appropriate social discount rates.    
The discount rate is not likely to affect the present value of the benefits and costs for those 
cases in which costs and benefits of a policy occur simultaneously and their relative values do 
not change over time. On the other hand, social discounting is applied in order to compare 
benefits and costs that occur at different times based on the rate at which society is willing to 
make such trade-offs. Discounting may substantially affect the present values of costs and 
benefits when there is a significant difference in the timing of realisation of costs and benefits. 
As this might be the case in tobacco control policies, which usually deliver some of their 
expected benefits with a certain time delay, three scenarios have been developed. The table 
below gives an overview of the scenarios in terms of time delays for two major benefits (i.e. 
decrease in morbidity induced costs and mortality).  
Table 3.15 Alternative scenarios of time delays for morbidity and mortality benefits 
Scenario 1 
All the costs and benefits realised in year 5 are plainly discounted to the net 
present value. 
Scenario 2 
All the costs and benefits are discounted for the period of 5 years except the 
benefits from reduced premature mortality which are discounted for the period of 
25 years77 
Scenario 3 
The costs from decrease in excise tax revenues are discounted for 5 years, the 
benefits from decrease in health care costs and productivity loss are discounted 
for 10 years and the benefits from reduced premature mortality are discounted 




Considering that costs and benefits can be represented as changes in consumption profiles 
over time, discounting should be based on the rate at which society is willing to postpone 
consumption today for consumption in the future. Thus, the rate at which society is willing to 
trade current for future consumption, or the social rate of time preference, is the appropriate 
discounting concept79.  One common approach to estimating the social rate of time preference 
is to approximate it from the interest rates for long-term, risk-free assets such as 
                                                            
76 Assuming their nominal increasse in line with general inflation rate.  
77 While the evidence suggest that the health consequences of smoking occur in relatively short period, the 
change in mortality rates is usually observed two decades later.  
Lopez AD, Collishaw NE, Piha T.A descriptive model of the cigarette epidemic in developed countries. 
Tobacco Control 1994; 3: 242-247.www.who.int/tobacco/statistics/country_profiles/en/Introduction.pdf 
78 As incidence of some smoking related diseases increases with age, it can be argued that the social  benefits of 
smoking cessation could be observed with additional delay if only the youngest population would be responsive 
to the proposed measures. 
79 EPA, Guidelines for Preparing Economic Analyses, December 2010. 
http://yosemite.epa.gov/ee/epa/eerm.nsf/vwAN/EE-0568-06.pdf/$file/EE-0568-06.pdf 
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government bonds. The rationale behind this approach is that this market rate reflects how 
individuals discount future consumption and Government should value policy-related 
consumption changes as individuals do. In other words, the social rate of discount should 
equal the consumption rate of interest.  
The overall net benefit of reduction in tobacco consumption by 1% for different scenarios and 
for various discount rates is calculated in table 3.16. The interests of the long term 
government bonds of Germany, UK and France fluctuate in the range of 2-3%.80 We 
approximate the social rate of time preference at the level of 3%, which is for the purposes of 
our analysis a rather conservative assumption. 
Considering the social discount rate corresponding with market interest rates of long term 
risk-free governmental bonds issued by major Member States, the annual net overall 
discounted benefit arising from a reduction in tobacco consumption by 2% would amount to  
4.0 bEUR under the most likely scenario, i.e when decrease in tax revenues and health 
care/absenteeism savings are observed during the 5 years after implementation, while on 
average the benefits from reduced premature mortality accrue only in 25 years.  
Table 3.16: Net present values of future benefits and costs (corresponding with 1% decrease in 
consumption) for different scenarios and discount rates 
Discount rate 
Overall benefits 
1% 2% 3% 4% 5% 
Non-discounted 4,709 4,709 4,709 4,709 4,709 
Scenario 1 4,471 4,250 4,038 3,834 3,638 
Scenario 2 3,578 2,700 2,016 1,486 1,077 
Scenario 3 3,000 1,857 1,092 584 245 
Source: own calculation 
The conservative scenario 3 can cater for sensitivity analysis and even with the highest 
considered discount rate the cost/benefit ratio remains positive, with a corresponding net 
present benefit of 0.49 bEUR. 
A.5.2.4. Impact of the reduction in consumption on employment  
A.5.2.4.1. Input-output model 
 
In order to evaluate how the reduction in consumption impacts on employment, the so called 
input-output model81 was used. Input-output analysis is a means of examining relationships 
within an economy, both between businesses and between businesses and final consumers. 
The analysis captures all monetary market transactions for consumption in a given time 
period. The resulting mathematical formula allows the examination of the effect of a change 
in one or several economic activities on the entire economy. The core of the analysis is the 
                                                            
80 Rates as of May 2012; www.bloomberg.com/markets/rates-bonds/government-bonds;  
81 I-O analysis is a well-established method for estimating economy-wide effects from a change in demand from one 
particular industry (Beyer et al, 2000). Conceptually, the I-O model estimates the direct and indirect effects associated 




creation of input-output tables. These tables describe the flow of goods and services in the 
economy in a matrix form.  
 
The World Bank recommends the input/output model as one of the preferred methodologies 
for estimating economy-wide effects from a change in demand from one particular industry while 
acknowledging its limitations, including the static nature of the model. For example, it does 
not account for technological development leading to increased production in a certain 
industry sector without increased the employment. Cigarette manufacturing is highly 
automatized, and numerous examples have shown that jobs in cigarette manufacturing have 
fallen dramatically as a result of upgrading to new more capital-intensive technology, even 
with increases in production levels.82  Conversely, service oriented industries are more work 
intensive and employment levels follow to a larger sector output. 
 
Three different matrices are used for a standard input-output model. The inter-industry 
transaction matrix describes the flow of goods and services between all individual sectors of 
an economy in a given year. The direct requirement matrix indicates the requirements for a 
particular industry to produce an average unit output. The total requirement matrix indicates 
the total requirements of all industries necessary for that industry to deliver a unit of output to 
final demand. 
 




Source: Matrix 2012 
 
The model assumes that money not spent on tobacco is spent on other goods and services 
according to consumers’ existing (average) expenditure patterns. To simulate the change in 
employment from a reduction of tobacco consumption, the amount of expenditure released 
from tobacco spending is distributed according to an assumed expenditure pattern and then 
applied to the static input/output (I/O) model. The model contains interdependencies or 
relationships between industry sectors in the economy and is used to simulate the impact of an 
external policy change (i.e. change of which the consequence is a reduction of tobacco 
consumption) on outputs and employment of each sector of the economy (Figure 4.1).  
Calculations 
If consumers forgo tobacco products they will spend the money they would have spent on 
tobacco products on other goods and services (for example on food, beverages, clothing, 
cinemas, and hotels). These sectors will therefore see an increase in demand for their 
products/services and thus increase their expenditure on inputs. This has a knock-on effect in 
all associated industries. The overall impact on the economy of a reduction in tobacco 
                                                            
82 http://ec.europa.eu/health/archive/ph_determinants/life_style/tobacco/documents/world_bank_en.pdf 
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consumption is therefore the net effect on employment due to both reduced 




Table 4.1: Increased spending on other products as a result of a reduction in tobacco consumption (mEUR, 2010) 
Spending 
pattern of a 
recent ex-
smoker 
Increase in consumption of non-tobacco products 
with different reductions in tobacco consumption 
Expenditure categories 
  
  1% 2% 3% 4% 5% 
Food products and beverages 22.90% 43.1 86.2 129.3 172.4 215.5
Clothing; furs 7.80% 14.7 29.4 44.1 58.8 73.5
Housing, electrical energy, gas, 
steam and hot water  24.40% 46 92 138 184 230
Furniture; other manufactured 
goods n.e.c. 6.50% 12.2 24.4 36.6 48.8 61
Health and social services 5.60% 10.5 21 31.5 42 52.5
Motor vehicles, trailers and semi-
trailers 6.10% 11.6 23.2 34.8 46.4 58
Other transport equipment 6.10% 11.6 23.2 34.8 46.4 58
Post and telecommunication 
services 2.50% 4.7 9.4 14.1 18.8 23.5
Recreational, cultural and 
sporting services 6.10% 11.5 23 34.5 46 57.5
Education services 0.70% 1.4 2.8 4.2 5.6 7
Hotel and restaurant services 5.70% 10.7 21.4 32.1 42.8 53.5
Other services 5.60% 10.5 21 31.5 42 52.5
Total 100% 188.5 377.0 565.5 754.0 942.6 
Source: Matrix report 2011; data on spending pattern by York (1995) 
 
As stated in Section 2, the EU-27 tobacco market at retail level including taxes is worth 
130.6 bEUR.83 Thus, a 1% reduction in tobacco consumption would mean 1.3 bEUR less 
spent on tobacco. However in order to establish the impact on the economic stakeholders it is 
essential to remove the part of the turnover associated with taxes not least as it is assumed that 
Member States might use the possibility to increase the tax rates to maintain the revenues 
(VAT and excise duties).84 Additionally, the distribution margin of wholesalers and retailers 
cannot be attributed to the tobacco manufacturers (in total 40%). In this light, the calculations 
are based on the assumption that the tobacco industry experiences reduced revenues of about 
188 mEUR for each per cent of reduced consumption.  
 
                                                            
83 The value of the domestic tobacco market is based on the value of consumed cigarettes and roll your own 
tobacco. A large proportion of this comprises tax payments. 
84 It is true that once consumers forgo tobacco products, they will save and consequently spend total amount of 
money including taxes. However, similarly the governments would use/spend/redistribute the taxes which 
ultimately will end up in the economy.   
For the purpose of this impact assessment it was considered that - on a weighted average basis - taxes (excise + 
VAT) account for 77.4% of the final retail price across the EU-27; DG Taxud data + VAT rates in MS 
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Table 4.1 shows how consumers are expected to spend the money they save on tobacco. 
Like in previous sections, the presentation is based on different scenarios from a drop in 
consumption of 1 to 5%, i.e. between 188 to 942 mEUR. The table outlines corresponding 
increases in expenditure by sector due to a reduction in tobacco consumption.  
 
The York study provides the most extensive insight into actual spending patterns of recent ex-
smokers and shows how they spend their additional money (not spent on tobacco) on day to 
day products such as food and beverage, clothing, recreational activities, restaurants, and 
other services. Considering the fact that spending patterns have probably further evolved since 
1995, the impact of the various spending patterns on the overall results of the model was 
tested using several different scenarios of expenditure patterns, i.e. for general consumer 
(Eurostat data, 2009), for recent ex-smoker adjusted85 and for consumers with a hypothetical 
spending pattern86. Table 4.2 shows how the net impact on output and employment changes 
for the different spending scenarios. The sensitivity analysis confirms that the choice of 
spending patterns in the sensitivity testing do not significantly alter the outcomes of the 
overall analysis.  
 































Ex-smoker - 290 + 320 +30 -1,426 + 1,984 +558 
General 
consumer 
- 290 +310 +20 -1,425 + 2,002 +577 
Ex-smoker 
adjusted 
- 290 +340 +50 -1,430 + 2,237 +807 
Hypothetical 
scenario 
- 290 +310 +20 -1,433 + 2,413 +980 
Source: Matrix report, 2012 
 
The above change in the pattern of consumption will cause a corresponding change in the 
pattern of production (input-output model used) which is shown in tables 4.3 and 4.4. It 
demonstrates that a 188 mEUR reduction in tobacco consumption results overall in 575 
mEUR reduction in production in the economy87, whilst the corresponding increase in 
consumption of other goods and services amounts to 634 mEUR (net positive effect: around 
59,4 million EUR). The impact on overall production in the economy due to a reduction in 





                                                            
85 The spending patterns for the York study had a significant percentage allocated to housing, electricity,  and 
healthcare. To test the impact of this distribution, the spending pattern was adjusted to remove these categories 
86 The hypothetical spending pattern was based on assuming consumers would spend their additional money only on 
day to day products, i.e. food and beverages, clothing, recreational activities, restaurants, and other services 
87 The fact that 188 million EUR loss to the tobacco industry generates a 575 million EUR loss overall is due to 
the fact that the input/output model accounts for direct and indirect effects. 
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Table 4.3: Production patterns (mEUR, 2010 prices) 
Different percentage of reduction in tobacco consumption   
1% 2% 3% 4% 5% 
Monetary impact of reduction 
in tobacco consumption -575.0 -1150.0 -1725.0 -1725.0 -2875.0
Monetary impact of increase in 
expenditure for other goods 634.4 1268.7 1903.1 1903.1 3171.9
Net effect on output 59.4 118.9 179.6 239.0 298.5
Source: Matrix report 2012; I-O model calculations 
 
The fact that spending on non-tobacco goods and services results in an increase in net 
production is partially explained by the fact that the tobacco sectors are less input intensive88.  
A.5.2.4.2. Impact on employment 
The impact on employment levels is estimated by applying the employment-output ratios for 
different industries to the changes in production in each industry. The employment-output 
ratio provides an estimate of the value of each employee within an industry. It is calculated by 
taking the total market value for each industry across EU-27 and dividing by the total number 
of employees in that industry across EU-27.  
 
Table 4.4 below shows the change in employment in each industry associated with a 1% 
reduction in tobacco consumption. It demonstrates that the reduction in production caused by 
the fall in tobacco consumption will result in a loss of 2,854 jobs. The corresponding increase 
in consumption on non-tobacco products results in a gain of 3,972 jobs. The impact on 
employment due to a reduction in tobacco consumption by 1% is thus equivalent to an 
increase of 1,118 jobs. When comparing production and employment together it is clear that 
the relationship between production and employment is not linear. The analysis shows that a 
small gain in production within non-tobacco sectors results in a larger gain in employment. 
This observation is explained by the fact that non-tobacco sectors which have an increase in 
production are associated with smaller employment output ratios (i.e. are less capital and 
more labour intensive).  
 
As explained above, the economy will adjust over time, and broad-scale long-term impacts 
are unlikely. In this respect, it is important to recall that tobacco consumption will not 
decrease overnight, but over a longer period of time. By the same token the additional 
expenditure in other sectors will only be felt over time.  
 
 
                                                            
88 The value added of an industry refers to things such as fixed capital and operating surplus. It would be 
expected that industries such as tobacco which are heavily dependent on machinery would invest more in items 
such as fixed capital.  In comparison industries which are less machinery dependent most likely rely more on raw 
inputs such as agriculture to produce food and beverage products.  Within the I-O model industries which are 
less input intensive result in smaller multipliers. As the non-tobacco sectors are more input intensive than the 
tobacco industry, spending on these goods results in larger multipliers generating an output gain.  
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Net effect on 
employment 
Agriculture -24.8 16.9 -7.9 -589.8 399.2 -190.6
Mining and 
petroleum -1.8 6.4 4.6 -8.4 33.6 25.8
Food industries -12.1 66.6 54.5 -67.2 366.9 299.7
Tobacco90 -196.6 0.2 -196.5 -731.9 0.6 -731.3
Textile -2.3 21.6 19.3 -22.6 280.4 258.4
Leather products -0.5 0.9 0.5 -3.9 7.1 3.9
Wood and wood 
products -3.3 18.0 14.7 -32.3 206.7 174.4
Paper products and 
printing -17.9 7.2 -10.7 -68.5 27.8 -40.7
Chemical products -11.2 14.4 3.3 -17.4 21.3 3.9
Rubber products -3.3 5.0 1.7 -20.7 31.0 11.0
Metal and  non 
metal products -4.1 9.1 5.0 -16.2 35.5 18.7
Basic metal 
products -4.0 7.9 3.9 -29.7 59.4 29.1
Machinery -5.4 9.2 3.9 -28.4 48.5 20.0
Transport devices -24.5 57.3 32.8 -138.9 288.1 149.9
Miscellaneous -1.5 2.9 1.4 -28.4 60.7 32.3
Electricity -11.0 70.2 59.2 -36.8 214.5 177.7
Construction and 
maintenance -10.3 13.4 3.0 -97.5 127.3 29.1
Finance and trade 
and insurance -18.0 17.8 -0.1 -98.8 98.2 -1.3
Wholesale and 
retailing -33.2 44.3 11.1 -355.3 432.2 76.9
Services -95.2 136.4 41.3 -436.7 1204.1 767.4
Private households 
with empl. persons -0.5 0.6 0.1 -25.2 29.1 3.9
TOTAL -575.0 634.4 +59.4 -2854 3972 +1118 
Source: Matrix report 2011 
 
As can be expected, the tobacco, agriculture, and pulp/paper industry are the most 
negatively affected by a reduction in tobacco consumption. It is estimated that within these 
industries 731, 191, and 41 jobs are lost respectively, with possible short- to medium-term 
economic disruption in areas that would bear the highest share of adverse employment 
impacts.   
 
However, the loss of jobs in these industries is offset by an increase in employment in a 
variety of industries such as food products and beverages, clothing and furs, furniture, 
                                                            
89 The changes associated with a 2% reduction in tobacco consumption are proportionally higher. 
90 The I-O model estimates the direct and indirect effects associated with a change in demand for a particular 
industry The combination of the direct and indirect effect is known as the I-O multiplier. The I-O multipliers 
used in the analysis are derived from the Eurostat input-output matrix (Eurostat, 2007). The I-O multiplier for 
tobacco products sector equals to 1.043.  
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electrical energy, gas, steam and hot water, health and social work services, hotel and 
restaurant services and other services. For example, it is estimated the other services, food 
and beverage, and textiles will see an increase in employment of 767, 300, and 258 jobs 
respectively. The changes associated with a 2% reduction in tobacco consumption are 
proportionally higher. 
 
A.5.2.4.3. Redistribution and regional effects 
Overall, as shown in the analysis, a reduction in tobacco use will have a positive effect on the 
total output and employment in the EU. However, reducing tobacco consumption might lead 
to a change in employment among different sectors and regions. Job losses might occur in (1) 
those sectors immediately associated with tobacco production, such as tobacco farming and 
processing, manufacturing, paper products and printing, wholesale and retail services, or in 
(2) those regions dependent on tobacco growing and manufacturing. However, these losses 
are generally outweighed by increases in employment in all other industries or in non-tobacco 
dependent regions. For any country or region, the estimated net change of employment 
depends on specific assumptions and the structure of the economy. 
 
Production and processing of tobacco takes place in 12 EU Member States. The main 
tobacco farmers within the EU are Italy, Bulgaria, Poland, Spain, and Greece. These 
countries, together with France, produce over 90% of the total EU production of 
unmanufactured tobacco. It is thus estimated that the loss of 1178 jobs in agriculture sector 
due to a 2% decrease in tobacco consumption would be the jobs of tobacco farmers located in 
the above-mentioned countries. This corresponds to a reduction of 1.4% of the workforce 
currently working in this sector91. The regions specialised in growing burley, oriental or dark 
varieties are located in Bulgaria (all regions producing tobacco), southern Poland (Lubelskie, 
Lodzkie, Mazowieckie, Podlaskie), Northern Greece (Macedonia and Thrace), Italy (Tuscany, 
Campania, Lazio), but also France, Romania and Spain. In most of these regions tobacco 
growers are small farmers and tobacco consists of their main revenue. Virginia is mainly 
grown in Italy (Veneto, Umbria), Spain (Extremadura), southern Poland, Bulgaria, France and 
Hungary.92 Compared to the previous restructuring of the sector, the impact is considered 
small, although non-negligible in some areas. Between 2005 and 2006, partially as a result of 
the discontinuation of direct subsidies for growing tobacco, the production of raw tobacco in 
EU25 dropped from 345,600 to 232,400 tonnes.93 
 
In 2009, there were overall 48.500 persons employed in the manufacturing of tobacco 
products in the EU. The main tobacco manufacturers are located in Germany (27% of 
tobacco employment), Poland (17%), Bulgaria (11%), UK (10%), France, Spain and 
Netherlands (8-9%). It is thus estimated that a 2% decrease in tobacco consumption will 
ultimately lead to the loss of 1462 jobs in manufacturing sector mainly affecting the countries 
listed above. However, the overview of employment trends in Germany, France and UK 
indicates that employment is not to the same extent directly linked to falls in sales in all 
countries. Furthermore, in order to tackle the challenge of falling sales, there has been a 
fundamental restructuring of tobacco companies over the past ten years94. Some relocations of 
                                                            
91 Euromonitor; 84228 persons employed in sector  
92 DG AGRI, January 2012 as cited by Matrix 2012 
93 Evaluation des measures de la PAC relatives au secteur du tabac brut, COGEA, August 2009  
94 Euromonitor data, Matrix report 2012 
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manufacturing premises have also taken place, as shown in the case study below while other 
two case studies with examples of such restructuring are given in Annex 2. 
 
It can be concluded that further market developments would clearly affect tobacco companies 
in different countries in different ways and thus the exact impact of further falls in tobacco 
sales on costs, profits and employment within the tobacco manufacturing sector will differe 
from country to country.  
In 2009, there were 45,900 individuals employed in the wholesale of tobacco products95 and  
according to the European retailer association (CEDT), there are almost 990,000 retail 
premises selling tobacco in the EU, with around 230,000 of these specialised shops which 
typically generate 45-50% of their turnover from tobacco.96  In total, retailers generate 7.84 
bEUR added value which would correspond to maximum of 600,000 FTE's97 assuming the 
average salary in the sector98 and neglecting any other costs (housing/rent, energies, furniture, 
communication, transportation etc.). The I/O model predicts that the indirect impact of a 2% 
decrease in tobacco consumption will ultimately result in the loss of 710 jobs in the wholesale 
and retail sector of tobacco, representing a 0.11% decline.  
A.5.2.4.4. Conclusion  
Table 4.4 below shows the impact on overall economic production and employment 
associated with reduction in tobacco consumption between 1-5%. Overall, the net impact on 
employment is positive, i.e. the reduction in tobacco consumption is likely to result in an 
increase in employment. This is due to the fact that, although a reduction in tobacco 
consumption leads to job losses in the production of tobacco, this is more than compensated 
by the gain in employment in sectors producing goods and services purchased by former 
smokers.  
 
Table 4.5: The impact on production/employment associated with a reduction in consumption between 1-5%  
Reduction in tobacco 
consumption (%) 
Employment impact 
of reduction in 
tobacco expenditure 
Employment impact 
of increase in 
expenditure for other 
goods 
Net effect on 
employment 
1% -2854 3972 1118 
2% -5708 7943 2235 
3% -8562 11915 3353 
4% -11416 15886 4470 
5% -14270 19858 5588 
Source: Matrix 2012, own calculation 
 
In any event it is very important to underline that it is  the tobacco industry itself which is 
responsible for more lost jobs in a given country's domestic tobacco industry than the most 
successful tobacco control policies. Industry induced job losses derive among other from 
                                                            
95 Eurostat 2010. Bulgarian farmers represent 50% of the EU tobacco farmers, followed by Poland and Greece 
(both 17%) 
96 Tobacco Retailers Figures. CEDT (Confédération Européenne des Détaillants en Tabac). sent to DG SANCO 
in January 2012 
97 Full Time Equivalents 
98 12879 EUR, Eurostat 2010 
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(1) mechanisation of tobacco production plants, in which technology replaces factory 
workers; and (2) purchase of imported tobaccos, replacing domestically grown tobaccos 
raised by local farmers. 
 
